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THESIS ABSTRACT 
THE CONTRIBUTION OF MUSCULOSKELETAL DISORDERS AND MULTIMORBIDITY TO 
HEALTH-RELATED JOB LOSS AMONG OLDER WORKING-AGE ADULTS:  A POPULATION-
BASED STUDY  
BACKGROUND: Employment is the most important source of financial income and material 
well-being and therefore is the main driver of the social gradient in physical health, mental 
health, and mortality. In addition, good employment fulfils psychosocial needs and is 
fundamental for an individual’s social status, societal participation, and identity. However, 
work participation is known to fall steeply after the age of 50 in women and 55 in men. In 
the EU, musculoskeletal disorders (MSDs) account for 50% of all absences from work lasting 
3 days or longer and for 60% of all permanent work incapacity. However, in those aged over 
50, MSDs also commonly co-occur with other health conditions, in what is known as 
multimorbidity.  
AIMS: the overarching aims of this thesis are to investigate, among older working-aged 
people, a) the impact of common comorbid health conditions on work outcomes in people 
with MSDs, and b) the common patterns of multimorbidity and their contribution to health-
related job loss. 
METHODS: Chapter four is a systematic review of the impact of comorbidity on work 
outcomes in people with musculoskeletal disease. The chapters that follow describe results 
from a nested matched case-control study of working-age participants, over the age of fifty. 
Health and Employment After Fifty (HEAF) study participants with health-related job loss 
(HRJL) were matched 1:1 to working control participants for age, sex, and GP practice. 
Participants’ health diagnoses at the time of HRJL were extracted using retrospective data 
from the Clinical Practice Research Datalink (CPRD). Chapter five describes a cohort of older 
workers with HRJL (case participants) for their known demographic, lifestyle, occupational, 
and health factors. Chapter six compares case participants to working controls for CPRD-
defined health disorders to assess their association with HRJL. Chapter seven uses cluster 
analysis to describe common patterns of multimorbidity across the total study sample. In 
Chapter eight, these prominent clusters of health disorders were explored for their 
association with HRJL. Finally, in Chapter nine, multivariable conditional logistic models 
were constructed using purposeful selection to explore the population attributable fraction 
of HRJL for CPRD-defined health disorders. 
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CONCLUSIONS: Results supported the primary importance of common mental health 
problems and musculoskeletal disorders for health-related job loss in the older working-age 
population. However, multimorbidity (classified as two or more CPRD-defined health 
disorders) was strongly associated with HRJL and accounted for a significantly greater 
proportion of HRJL than any individual health disorder. Multimorbidity clusters formed by 
co-occurring musculoskeletal disorders and mental health problems appeared to have a 
particularly strong impact on HRJL.  
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Chapter 1- Introduction 
1.1 Work, ageing, and health 
1.1.1 The ageing UK population  
The population of the United Kingdom is getting older. Currently, 18% of the population is 
aged 65 years and older, with 2.4% aged 85 years and older.(1) In populations with high 
fertility and death rates, the traditional “population pyramid” actually resembles a pyramid 
shape, with larger numbers of youth at the bottom and fewer people reaching advanced 
age. In the UK however, the population pyramid flattens out at the bottom and broadens at 
the top, see Figure 1.(2) This reflects a combination of low national birth rates, particularly 
in the 1970’s and early 2000s, and improvements in healthcare and lifestyle that have led 
to longer lifespans.(3) The successful lengthening of the average lifespan comes with 
economic challenges since the working-age group produce labour to support those who 
have retired (both in terms of care provided and taxes-rendered); and the ratio of working-
age to retired is decreasing. In 2016 in the UK, there were as many as 285 persons aged 
over 65 years per 1000 working-age persons (16 – 64 years).(3) 
Figure 1: Population pyramid (by age and sex) for UK, England and Wales, Scotland and 
Northern Ireland: mid-2016, Office for National Statistics. Total population 65,648,054.(2) 
Public sector information licensed for use under the Open Government Licence v3.0. 
                          (2) 
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1.1.2 Encouraging work to older ages: the ageing workforce 
In order to address this population shift, member countries of the Organisation for 
Economic Co-operation and Development (OECD) have applied several changes in policy to 
encourage people to stay in work to a later age and to offset the fall in labour growth.(4) 
For example, the age at which public and private pensions can be claimed has been raised 
and governments have sought to address the employment disadvantages that result from 
age-discrimination due to negative age stereotypes. However, clear cases of age-
discrimination are hard to find and measure.(5) In the UK, policy changes have included 
increasing state pension age, abolishing mandatory retirement ages, and legislation to 
remove age and disability discrimination in the workplace.(6)  
As well as governmental intervention, other individual incentives to work until later in life 
are taking effect. Higher costs, taxation, and reduced return on savings and pensions have 
resulted in an increase in the numbers of people intending to work until later in life and the 
proportion of people working beyond the traditional retirement age.(6) In the UK, between 
2004 – 10, the estimated average age of labour force withdrawal increased from 63.8 years 
to 64.6 years in men, and from 61.2 years to 62.3 years in women.(7)  
Encouraging people to work until later in life is a complicated solution as it increases the 
overall age of the workforce. As the age of the workforce increases, the prevalence of 
health problems rises concomitantly, along with rates of adverse work outcomes such as 
sickness absence and work disability.  
1.1.3 Work disability in the UK 
Under the Equality Act (2010), disability is defined as having a physical or mental 
impairment that has a “substantial” or “long-term” negative effect on a person’s ability to 
do normal daily activities.(8) Similarly, work disability can be defined as having a physical or 
mental impairment that has a substantial or long-term negative impact on a person’s ability 
to carry out the employee-role. However, work disability is not consistently defined. In the 
literature, work disability may be broadly classified by self-report, can sometimes include 
evidence of sickness absences, and sometimes requires that a person is certified work-
disabled and receiving some kind of financial support.(9–14) While work disability has been 
used as an umbrella term for all health-related adverse work outcomes, it usually refers to 
a person who is no longer employed.   
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The cost of reduced work participation can be high for the individual, employer and society. 
Productivity loss, sickness absence, and time and resources dedicated to poor health in 
work, amount to £9 billion in costs, per year, for the employer, while the government pays 
an additional £13 billion per year on sickness-related benefits.(15) These figures featured in 
Dame Carol Black’s influential review of sickness absence in health and work in 2008,(16) 
and are now likely to be an underestimate as, between 2013 – 2016, the number of 
disabled people of working age increased by over 400,000 taking the total to greater than 7 
million.(17) In 2014, the UK was ranked first for new work disability claims of all OECD 
countries (see Figure 2).(18)  
Figure 2: New disability benefit claims per 1,000 of the working-age population. (18) 
 
1.1.4 The relationship between age and work disability 
As people age, they are more likely to become work disabled,(19–41) especially over the 
age of 50.(19) One systematic review concluded that age is related to work disability 
independently of diagnosed health problems.(42) This is likely because age correlates with 
multiple other health, lifestyle, and demographic risk factors for work disability. For 
example, reaction times and attention broadly decrease with age(43) and older people 
have fewer physical reserves.(44) Older people will generally have had chronic diseases for 
longer and, if the disease is progressive, will have more severe disease and a greater 
number of complications. In addition to health-related mechanisms, societal factors are 
impactful - including the exclusion of the elderly from the labour market due to 
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The median rate of work participation falls steeply after the age of 50 in women and 55 in 
men and, among the working-age population, people over 50 account for the majority of 
work loss (see Figure 3).(45) As a result, the UK government is particularly interested in 
working-age people over 50 in its efforts to support people to remain in work. 
Understanding the health and demographic causes of work loss in this cohort holds most 
promise for developing targeted policy and healthcare interventions to support a longer 
working life. However, few UK-based studies of health-related job loss amongst the older 
working-age group have been conducted. To address this important research gap, people 
with health-related job loss between 50 - 64 years of age form the main focus of this thesis. 
Figure 3: Participation rates over the life cycle in a) men and b) women in the UK. 
Participation rates at each age between 1984 and 2010. Based on data for the three 
months to June between 1992 and 2010 and the three months to May between 1984 and 













                                       
                                                                                                                                             (46)
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1.1.5 Is work good for your health? 
The effort to encourage people to work till later in life raises ethical issues, since work may 
be detrimental to health in some cases. This was particularly captured by the recent high-
profile case of Stephen Smith who was mistakenly deemed “fit to work” despite his severe 
weight loss and chronic obstructive pulmonary disease (COPD), see Figure 4. In 2006, the 
Department for Work and Pensions conducted an independent review of scientific evidence 
to answer the question: “is work good for your health and well-being?”(47) It focussed on 
adults of working age, with a special interest in the health-conditions that account for two-
thirds of sickness absence and long-term incapacity: mental health problems, 
musculoskeletal disorders, and cardio-respiratory conditions.(48)  
Figure 4: Getting it wrong – the story of Stephen Smith, aged 64, weighing six-stone with 
severe COPD, who was deemed “fit to work” by the Department of Work and Pensions 
(DWP). Front page Liverpool Echo, February 4th, 2019.(49) 
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This review found that employment is the most important source of financial income and 
material well-being and therefore is the main driver of the social gradient in physical health, 
mental health, and mortality.(48) This is a key argument for the benefits of work for health. 
People who have low socioeconomic status endure many health disadvantages. For 
example, there is consistent evidence of higher prevalence of common mental health 
disorders among people with lower social status, regardless of measures of mental disorder 
or social class used.(50) Moreover, low income level, poor educational attainment, and 
neighbourhood low socioeconomic factors have been consistently associated with 
cardiovascular disease.(51) The financial gains that come with working may help to offset 
these disadvantages. Good employment additionally fulfils psychosocial needs and is 
fundamental for an individual’s social status, societal participation, and identity.(52) 
While work appears to be good for health in general, in some cases physical or psychosocial 
aspects of work could pose mental or physical health-hazards. For example, heavy physical 
work, such as construction work, is associated with lower back disorders,(53) and work 
around asbestos has led to cases of pleural plaques, bronchogenic carcinoma, and 
mesothelioma.(54) In addition, high work demands (increasing workload, long hours, time 
pressures) combined with low overall control (low decision authority, low skill discretion, 
low work-time control) may lead to the development of common mental health problems 
such as depression and anxiety.(55) 
Unemployment, on the other hand, is clearly associated with higher mortality, poorer 
general health, longstanding illnesses, psychological morbidity, higher rates of healthcare 
consultations, higher number of drug prescriptions, and more hospital admissions for the 
unemployed individual.(48) Unemployment also appears to be devastating for the family. In 
the UK in 2004, children in families where neither parents were working were 2.5 times 
more likely to have emotional disorders compared to children in families where one parent 
was working, and three times more likely compared to children with both parents 
working.(56) Additionally, one cross-sectional study (n=10,317) found that children in 
families where neither parents had worked in the prior 6 months were more likely to have 
psychosomatic symptoms (OR 1.67 95%CI 1.16 to 2.40), chronic illness (OR 1.35 95%CI 1.00 
to 1.84), and low wellbeing (OR: 1.47 95%CI 1.12 to 1.94).(57) Families without a working 
member are also much more likely to remain in a state of poverty.(58) 
Re-employment appears to improve self-esteem, general health, and mental health and 
leads to reduced psychological or psychiatric morbidity.(48) This evidence of “reversibility 
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of effect” supports the hypothesis that work independently promotes health. One study 
found improvements in general distress, anxiety, and depression after re-employment were 
particularly strong among those of a lower social class.(59) Similarly, in another study, 
moving off social security benefits and into work improved income, mental health, and 
quality of life outcomes.(48)   
Of course, interpreting all these findings can be challenging since the health of the 
employed and ill health of the unemployed may in part reflect a health-selection effect, 
whereby a person’s initial health status later influences their work status. The problem of 
using broad group effects to make inferences about the individual (known as the 
“ecological fallacy”) is another danger as the beneficial effects of work, identified at the 
population level, may not capture the severity and clinical features of an individual’s health 
disorders, the nature and quality of their work, and their social context.  
So is work good for a person with pre-existing illness? The consensus is that work for sick or 
disabled people, in general, can help to aid recovery and can be therapeutic, resulting in 
better health outcomes, quality of life, wellbeing, and reduced risk of long-term work 
disability. Moreover, much can be said for avoiding the pernicious effects of unemployment 
including deteriorating mental and physical health, the loss of independence, and reduced 
participation in society.(48) It should be noted that this consensus amounts to a summary 
of policy statements and guidance which lean heavily on evidence about the apparent 
positive effects of work in general and the clear detrimental effects of worklessness in 
general. In truth, there is little direct evidence about the physical or mental health benefits 
of employment for sick, disabled, or older people.  
Of the existing evidence, one study on rehabilitation of people with musculoskeletal 
disorders who were on sick leave (full or partial) at baseline (n=91) found that participants 
who reduced their sick leave level had significantly lower pain intensity and frequency 
scores; lower disability, anxiety and depression scores; and higher reported quality of life at 
5-year follow up than those who increased or maintained their sick leave.(60) For 
musculoskeletal disorders, evidence has also shown returning to work is usually safe and 
does not require full recovery.(61,62) Similarly, most employees with chronic diseases 
continue to work.(63) At the very least, results like these suggest that work is not harmful 
for many people with sickness or disability, and given the known benefits of work, this 
population should be supported to remain in work wherever desired and possible.  
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Unfortunately, the disability-employment gap (calculated as the difference in employment 
rate between people with and without Equality-Act-defined disability) has barely changed 
in more than a decade: an average of 31.1 percentage points between the disabled and 
non-disabled since 2008.(64) In recognition of the likely beneficial impact of work upon 
health and wellbeing, and the apparent stagnation of work opportunities for people with 
disability, there has been a push for work to be considered a health outcome from 
organisations both inside and outside of government.(65,66)   
To close this disability-employment gap, a range of interventions may be effective such as 
stepped-support for people who are at risk of work disability, or early intervention 
following sickness absence or work loss.(67,68) Such interventions can be costly and 
economically impossible to offer to everyone with a health condition. Therefore, a targeted 
approach is needed that focusses on commonly occurring and disabling health conditions in 
the working-age population between 50 – 65 years old (the highest risk age-group). In this 
cohort, musculoskeletal disorders (MSDs) are key as they are both highly prevalent and, 
along with mental health disorders, are the leading cause of work disability. MSDs 
therefore form a focus of this thesis. I give an overview of the major MSD groups below, 
along with their relationship to work outcomes.  
1.2 Musculoskeletal disorders  
1.2.1 Clinical features and epidemiology 
MSDs include inflammatory rheumatic diseases, such as rheumatoid arthritis and 
spondyloarthritis; degenerative conditions, such as osteoarthritis; fragility disorders, such 
as osteoporosis; regional pain syndromes, such as low back pain and neck pain; and 
widespread pain disorders, such as fibromyalgia. MSDs are common throughout the life 
course but become increasingly common at older ages (in particular, low back pain and 
osteoarthritis).  
MSDs are markedly heterogeneous, ranging from highly disabling but fortunately less 
common conditions such as rheumatoid arthritis, ankylosing spondylitis, and systemic lupus 
erythematosus through to considerably more common but generally less disabling 
conditions such as low back pain and osteoarthritis. At older ages, osteoporosis also causes 
a substantial burden by increasing the risk of low-trauma fractures.(69)  
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1.2.2 Osteoarthritis  
Osteoarthritis is both the most common type of arthritis and the leading cause of physical 
disability in older adults.(70) This condition occurs as a result of the deterioration of 
cartilage, the protective smooth connective tissue that covers the articulating surfaces of 
our joints. Once the cartilage has degenerated and worn away, this leaves underlying bony 
structures to rub on one another causing friction and symptoms of pain, aching, and 
stiffness. The condition is progressive and the development of bone spurs and osteophytes 
can occur within the joint which can worsen symptoms. The pathogenesis of osteoarthritis 
has traditionally been described as “wear and tear” of the joint over time, however more 
recent research has implicated a more dynamic disease process involving joint 
inflammation and synovitis.(71) 
Diagnosis of osteoarthritis is often made on the basis of radiographic changes such as 
osteophytes, joint space narrowing, and sclerosis on x-ray of the joint, see Figure 5. 
However, substantial discordance may exist between those who report joint pain and those 
who have radiographic changes. For example, in one systematic review the proportion of 
participants over the age of 50 with knee pain who had radiographically defined 
osteoarthritis ranged from 15 – 76%, and similarly the proportion of participants with 
radiographic changes who had pain ranged from 15 – 81%.(72) Osteoarthritis is often 
reported as “symptomatic osteoarthritis,” which indicates the presence of symptoms as 
well as radiographic evidence, and “radiographic osteoarthritis” which only indicates 
radiographic signs, and may not require clinical management if asymptomatic.(73)  
Osteoarthritis is common. However, estimates of prevalence vary greatly depending on the 
definition used (as well as by age, sex, and region studied).(74) In the UK, one third of 
people over the age of 45 have sought treatment for osteoarthritis, a total of 8.75 
million.(75) The commonest regions affected by osteoarthritis are the knee and hip. In the 
UK, approximately 20% and 8% of people have sought treatment for osteoarthritis of the 
knee and hip, respectively. Less common are osteoarthritis of the foot and ankle and 
osteoarthritis of the hands and wrist which affect 7% and 6% of those over the age of 45. Of 
course, many people may also have osteoarthritis in two or more regions of the body 
known as multi-site or “generalised” osteoarthritis. In total, an estimated 1.76 million 
people (7% of those over the age of 45) have sought treatment for multi-site 
osteoarthritis.(75) 
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The risk factors for osteoarthritis are multifaceted. Firstly, there are a range of factors that 
make an individual susceptible, including older age, female sex, obesity, genetics and 
ethnicity, diet, and bone metabolism. At the level of the joint, repetitive joint use, load 
bearing, highly physical occupations, and prior injury may predispose to later development 
of osteoarthritis.(73) These factors may affect OA risk to a varying degree, for example, the 
risk of knee osteoarthritis is two times greater for men whose jobs required both carrying 
and kneeling/squatting in mid-life,(76) and those who are overweight or obese are nearly 
three times more likely to develop knee osteoarthritis than those of normal weight.(73) In 
the UK among those between the ages 45 – 64, approximately a third of women, compared 
to a quarter of men, have sought treatment for osteoarthritis.(75) 
Figure 5: The radiographic features of knee osteoarthritis, including joint space 









    
(77) 
1.2.3 Inflammatory arthritis 
Inflammatory rheumatic disorders or inflammatory arthritis, classifies a group of conditions 
characterised by inflammation of the joints and sometimes other tissues. Most 
inflammatory arthritis is autoimmune, affecting the synovium, and leading to destruction of 
the bones and joint. The most common kinds of inflammatory arthritis are rheumatoid 
arthritis and spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis, 
however a range of other conditions are also described and include juvenile idiopathic 
arthritis and systemic lupus erythematosus. Gout is also a type of inflammatory arthritis; 
however, it is not autoimmune and is described separately, below. Symptoms of 
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inflammatory arthritis include pain, warmth, swelling and tenderness around the joint as 
well as morning stiffness (>1 hour). In addition, systemic symptoms may be apparent and, 
depending on the type of inflammatory arthritis, may include skin rashes, scleritis, and 
vasculitis.(78) 
Rheumatoid arthritis is commonly diagnosed using a set of criteria that take into account 
the number and site of involved joints, symptom duration, serological evidence (e.g. 
rheumatoid factor positive), and inflammatory markers (erythrocyte sedimentation rate 
and C-reactive protein).(79) Spondyloarthritis is split into axial types, such as ankylosing 
spondylitis, and peripheral types, such as psoriatic arthritis.  Axial spondyloarthritis is 
mainly diagnosed based on three or more months of symptomatic inflammatory back pain 
in a person younger than 45, with either evidence of sacroiliitis on imaging or an HLA-B27 
positive blood test in combination with other features of spondyloarthritis. Peripheral 
spondyloarthritis is diagnosed using a combination of joint-based signs and broader clinical 
features. For example, psoriasis with arthritis and positive family history of 
spondyloarthritis would be sufficient for a diagnosis of psoriatic arthritis.(80) 
Other than gout, rheumatoid arthritis is the most common kind of inflammatory arthritis 
affecting an estimated 400,000 people across the UK. This is followed by ankylosing 
spondylitis which affects approximately 200,000 people.(81) The occurrence and severity of 
rheumatoid arthritis is genetically influenced and is more common among women to a ratio 
of 2-3:1. Lifestyle factors such as smoking can also affect the development and course of 
this disease. Ankylosing spondylitis, the most common kind of axial spondyloarthritis, is 
more common in young men in whom it is most likely to start in late teens or early 20’s. 
Once again this condition is genetically influenced and most patients have the HLA-B27 
gene.(82) Psoriatic arthritis, the most common kind of peripheral spondyloarthritis, is 
common among people with psoriasis (around 6 – 41% of this group), and a family history is 
a risk factor, which also suggests a strong genetic component.(83) 
1.2.4 Gout 
Gout is a crystal arthropathy that is due to hyperuricaemia and deposition and build-up of 
urate crystals in peripheral joints and soft tissues. Clinically, this presents with severely 
painful acute synovitis which significantly impacts on function in acute attacks. Recurrent 
attacks occur in untreated gout and each attack may last for weeks before resolving. This 
can eventually lead to joint damage and deformity if uncontrolled.(84) Gout most 
commonly affects the first toe, ankle, knee, fingers, wrist and elbow joints.  
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The criteria for gout diagnosis involves the occurrence of peripheral joint or bursal swelling, 
pain or tenderness, and the presence of urate monohydrate crystals in synovial fluid or 
tophus analysis.(85) Urate lowering treatment can prevent the formation of urate crystals 
and dissolve away existing crystals, meaning recurrent acute attacks and joint damage can 
be avoided with effective treatment.(86) 
Gout is the most common kind of inflammatory arthritis, affecting around 4.5 million 
people in the UK (2.49% prevalence).(87) Hyperuricaemia is the key causal factor in 
developing gout and is linked to dietary factors (such as purine rich foods, alcohol, and 
fructose/sugar sweetened soft drinks), obesity, renal disease, and various medications such 
as diuretics and aspirin.(88) 
1.2.5 Widespread pain syndromes 
Chronic widespread pain is common in the population and characterised by long-lasting 
pain, in multiple sites often with additional symptoms such as fatigue and psychological 
distress.(89) A small proportion of those with chronic widespread pain will also have 
fibromyalgia syndrome, a complex neurosensory disorder characterised by a history of 
diffuse and persistent musculoskeletal pain, in conjunction with numerous discrete tender 
points elicited on clinical examination.(90,91) Additional symptoms such as fatigue, sleep 
disturbances, depression, and headache may also be apparent in this syndrome.(91,92) The 
cause of fibromyalgia is unclear, it is theorised that low-grade systemic inflammation could 
modify pain regulation, leading to increased pain sensitivity.(93) Alternatively, it has been 
suggested that psychological stress, perhaps caused by chronic disease, may play a role in 
generalisation of pain.(94,95)  
The American College of Rheumatology (ACR) classifies widespread pain as having pain in 
the left and right side of the body, pain above and below the wrist, and axial skeletal pain 
for at least three months. In addition to this, for a diagnosis of fibromyalgia, participants 
traditionally had to feel pain on palpation for 11, or more, of 18 potential tender point 
sites.(96) 
Chronic widespread pain affects approximately 10 – 11% of the UK population while 
fibromyalgia has a prevalence of around 1-5%.(97,98) Both conditions are strongly 
associated with female gender(99) and increasing age.(100)  
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1.2.6 Regional pain, cumulative trauma disorders, and work-related 
musculoskeletal disorders 
This section describes common musculoskeletal disorders which can be associated with 
certain work activities, including tendon inflammations, inflammation of the surrounding 
tissue (tenosynovitis, epicondylitis, bursitis), cumulative trauma disorders, and regional 
pain syndromes not attributable to known pathology, such as low back pain. These 
musculoskeletal conditions are common (see Figure 6) and have been associated with work 
factors such as rapid pace, repetitive motion actions; heavy lifting and forceful exertions; 
non-neutral body positions; regional or whole body vibrations; insufficient recovery time; 
and psychosocial factors related to job strain (high work demands and low control).(101) 
Specifically, higher-risk careers have been found to include nursing, mining, food 
processing, and heavy and light manufacturing.(102)  
Figure 6: Cigna infographic showing the incidence of musculoskeletal disorders 
exacerbated by work in the UK (2011/2012)(103) 
 
Upper limb conditions include tendon-related disorders, such as de Quervain’s disease and 
trigger finger; nerve-related disorders, such as carpal tunnel syndrome; muscle-related 
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problems, such as tension neck syndrome, myalgia and muscle sprain/strains; circulatory 
problems such as Raynaud’s syndrome; osteoarthritis; and bursa-related disorders.(104) 
These disorders are fairly common in UK general practice with an annual incidence of 25 
first-time presentations with an upper limb disorder per 1000 person-years. Rate of 
presentation with upper limb disorders increases up to 45 years of age and then stays 
constant.(105) Along with the broadly higher-risk careers mentioned above, occupations in 
which the hands and arms are used intensively can be at increased risk for the development 
of upper limb disorders. These include clerical and administrative work, postal service, 
cleaning, and packaging.(102) However, non-work factors are also associated.  
Neck musculoskeletal disorders can include neck strain, neck injuries, such as whiplash, 
degenerative disc disease and neurological pain from a pinched nerve or herniated disc. 
The most common neck MSD is non-specific neck pain. In one UK-based cross-sectional 
study, among the working age (16 – 64 years old), self-reported neck pain had a one-week 
period prevalence of 19.6% while self-reported neck pain in the prior year was as high as 
33.7%.(106) Repetitive work involving continuous hand or arm movements affecting the 
muscles of the shoulder or neck, and extreme working postures leading to prolonged static 
loads on the neck musculature are thought to raise the risk of developing these 
conditions.(107) There is a higher risk of neck pain among women and risk peaks around 
age 35 – 49 years, after which the risk decreases.(108)  
Regional back pain mostly refers to low back pain, which is usually idiopathic (85 – 95%) but 
may also be caused by injury, fracture, or degenerative changes in the back such as 
degenerative disc disease and osteoarthritis.(109) Back pain is common, an estimated 10 
million people in England and Scotland report persistent back pain at any one time (around 
17% prevalence).(110) Age is a risk factor with the prevalence of back pain increasing until 
ages 60 – 65 years and physical demands at work such as manual handling, bending, 
twisting, and whole-body vibration have been associated. For instance, one study found a 
prevalence of low back pain of 39% in male manual workers but only 18.3% in male 
sedentary workers.(111) Some employees appear particularly susceptible to back and lower 
limb disorders including, drivers, warehouse workers, baggage handlers, nurses, support 
workers, and operators of cranes and large machinery.(102) Low back pain is also 
associated with a number of psychosocial factors such as stress, anxiety, depression, job 
dissatisfaction, poor work relationships/support, and work monotony.(112)  
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Lower limb pain is mostly captured by hip pain and knee pain, which are largely caused by 
osteoarthritis in older adults, and are discussed above.(113)  
1.3 Musculoskeletal disorders and work  
People with MSDs are less likely to be employed than people in good health, and are more 
likely to retire early.(114) In one systematic review and meta-analysis, MSDs were 
associated with double the risk of disability pension (RR 2.23 95%CI 1.93 to 2.59).(115) In 
the European Union and the United States, MSDs account for a higher proportion of 
sickness absence from work than any other health condition.(116,117)  
Likewise, in the UK, MSDs are common and work-disruptive. One in eight of the working-
age population reports having an MSD and the employment rate for people with MSDs is 
59.7% compared with 73% in the general population.(118,119) In 2013, more days of 
sickness absence were attributed to back, neck and muscle pain than any other cause, 
which accounted for 30.6 million days of sickness absence (23% of all UK working days 
lost).(120) In addition, MSDs are responsible for a third of all UK long-term sickness 
absences; these have a poor long-term career prognosis and are particularly expensive for 
the individual and society.(120) Finally, in the UK, MSDs have the third lowest rate of full-
time paid work (see Figure 7) and are the third highest-reported reason for being 
permanently sick or disabled, after mental health problems or a recent cancer 
experience.(121,122)  
A synthesis of qualitative research on the experience of work in people with chronic 
musculoskeletal pain in the UK, found that people with musculoskeletal pain struggled to 
affirm themselves as good workers; struggled balancing life and work in the face of 
unpredictable symptoms; and sensed that their work colleagues didn’t believe their 
symptoms, all of which had an adverse effect on their working life. Additionally, it was felt 
that the system did not facilitate return to work among those who fell out of 
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Osteoarthritis is independently associated with an increased risk of work disability. In one 
recent longitudinal study, people with osteoarthritis had a 90% higher hazard of health-
related job loss compared with non-osteoarthritis controls matched for age and sex, and 
after adjustment for BMI, number of chronic conditions, income, marital status, and degree 
of work stress (aHR: 1.90 95%CI 1.36 to 3.23).(124) Over one year, knee osteoarthritis has 
been found to have an approximately two-fold increased risk of one or more episodes of 
sick leave, and about 40 – 50% increased risk of requiring disability pension as compared 
with the general population (RR 1.54 95% 1.48 to 1.60 in women, 1.36 95%CI 1.28 to 1.43 in 
men).(125) One population-based cross-sectional study found a very strong association 
between hip osteoarthritis and needing to reduce or change work for health reasons, 
adjusting for age, sex, other conditions and socioeconomic status (aOR: 8.0 95%CI 4.6 to 
14.1). This was a notably stronger relationship than found for those with knee osteoarthritis 
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Risk of disability among people with osteoarthritis has been found to increase with age, 
lower attained education, being non-married, and presence of comorbidity. In one study of 
people with osteoarthritis younger than 65 years old, arthritis itself was found to explain 
less than one third of work disability after adjusting for these factors.(127) Disease-specific 
factors associated with an increased risk of disability in osteoarthritis included number of 
regions affected, duration of arthritis, and being underweight (BMI <20) or overweight (BMI 
≥ 30).(128) Certain physical occupations have also been associated with disability due to 
osteoarthritis, particularly in weight bearing joints such as the hip. For example, compared 
to professional workers in one study, the hazard of disability retirement due to hip 
osteoarthritis was found to be much higher among male construction workers, electricians, 
and plumbers (HR 15.2 95%CI 7.5 to 30.8) and female professional drivers (HR 15.2 95%CI 
7.5 to 30.8).(129) 
1.3.2 Inflammatory arthritis 
Rates of unemployment due to ill health or disability are high in participants with 
inflammatory rheumatic disorders: At baseline in the British Society for Rheumatology 
Biologics Registers (BSRBR), 49%, 41%, and 39% of rheumatoid arthritis, ankylosing 
spondylitis, and psoriatic arthritis patients were work disabled, respectively (self-reported 
and defined as not working due to ill health/disability).(130) Following first symptoms of 
rheumatoid arthritis, there is an estimated 80% chance (95%CI 78 – 82%) of remaining in 
work at two years, and an estimated 68% chance (95%CI 65% - 71%) of remaining in work at 
five years.(131) In Dutch patients with ankylosing spondylitis 13% had left the labour force 
by 5 years and 21% by 10 years, with risk for withdrawal 3.1 times higher (95%CI 2.5 to 3.7) 
than the general population.(11) In psoriatic arthritis, an estimated 22 – 23% left the 
workforce specifically as a result of their condition.(132)  
Similarly, as among people with osteoarthritis, older age, physical job demands, low level of 
education attainment, and low functional capacity predict work disability in rheumatoid 
arthritis. Older age, manual work, lower social class, and worse function were predictive in 
ankylosing spondylitis.(133) In psoriatic arthritis, longer disease duration, manual work, low 
education level, worse physical function, and female sex have been associated with work 
disability.(132) 
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1.3.3 Gout 
Rates of work disability among patients with gout are under-reported. However, there is 
some evidence to show that employees with gout take approximately 3 more days of 
sickness absence per year than employees without gout.(134) In a study among participants 
with chronic gout refractory to therapy, working participants reported a mean 25.1 days of 
work lost due to gout per year.(135) 
1.3.4 Widespread pain 
Fibromyalgia and, to a lesser extent, widespread pain conditions are strong predictors of 
work disability. One study compared fibromyalgia to widespread pain controls and general 
population controls. The prevalence of self-reported work disability was 31% among those 
with fibromyalgia (26.0% receiving disability pension), 10.5% among the widespread pain 
group (with 9.2% receiving disability pension) and 3% among the general population 
controls (2.2% receiving disability pension). A recent systematic review found that 
fibromyalgia symptom severity, and physically demanding jobs and work tasks were 
associated with higher risks of work disability, while perceived support of managers and 
colleagues helped people with fibromyalgia to manage the risk of work overload.(136) 
The number of musculoskeletal pain sites is a known modifier of the impact of MSDs upon 
work. Multi-site musculoskeletal pain has been associated with an increased risk of low 
work ability,(137) sickness absence,(138,139) restrictions/limitations at work,(138) and 
work disability.(140–142) One longitudinal study examined the interaction between 
concomitant upper- and lower-body musculoskeletal pain and occupational exposures in 
relation to permanent work disability: Compared to people with low occupational 
mechanical stress and no pain, low mechanical exposures and combined pain had an 
adjusted hazard ratio of (HR 3.35 95%CI 1.74 to 6.45), high mechanical exposures and 
combined pain was associated with a higher relative hazard of permanent work disability 
(HR 4.59 95%CI 2.36-8.94).(143) 
1.3.5 Regional pain 
Low back pain is the leading cause of long-term disability worldwide.(144) In the UK, it is 
responsible for approximately 12.5% of all sick days (the largest single cause of absence 
from work in 1988 – 89)(145) and is responsible for an estimated £10 billion of indirect 
costs to the UK economy each year.(146) In 2004 – 05, people with work-related low back 
disorders took an average of 17.4 (95%CI 13.5 to 21.3) days off work due to their condition.  
47 | P a g e  
 
In the UK, musculoskeletal pain of the upper limbs or neck caused an estimated 4.7 million 
(95%CI 3.5 to 6.0 million) working days lost in 2004 – 05, amounting to an estimated 21.7 
(95%CI 16.3 to 27.0) working days off annually for people with these conditions.(147)  
Fewer working-age people have lower limb musculoskeletal disorders, however, of around 
1 million people suffering a work-related disorder (i.e. a condition that is caused or made 
worse by work), approximately 18% reported MSDs mainly affecting the lower limb.(148) 
These conditions can be highly disabling, particularly affecting mobility, and in 2004 – 05 
people with MSDs affecting the lower limb took an average of 26.4 (95%CI 18.6 to 34.5) 
days off work, per person, due to this health problem.(148)  
Older age, delay between injury and first medical treatment, female gender, higher 
surrounding unemployment rate, and work related factors such as smaller firm size, and 
working in construction or logging was associated with prolonged work disability in US one 
study of workplace injuries.(149) 
1.4 Multimorbidity 
The co-existence of at least two different long-term health conditions in the same individual 
has been variously defined in the literature as “multimorbidity” or “comorbidity” but with a 
lack of clear consensus about the use of these definitions.(150) “Multimorbidity” is a broad 
term for the co-occurrence of multiple health problems in one person. The term 
“comorbidity” is generally used for any additional health disorder(s) occurring in an 
individual with an existing index health disorder. Importantly, these terms usually include 
long-term mental, as well as physical, health disorders.  
The component health disorders used to classify multimorbidity are also inconsistent in the 
literature. For example, studies include: co-occurring long term conditions only; co-
occurring long term conditions or acute conditions; or co-occurring long term conditions, 
acute conditions, or health-related risk factors.(150,151) Studies may also use completely 
different checklists of specific disorders to comprise a multimorbidity score. These 
difficulties with classification cause a particular problem when trying to summarise or 
compare prevalence estimates of multimorbidity.(152) 
Reported levels of multimorbidity are especially high in the population of interest for this 
thesis, the older working-age between 50-65 years old. A UK based epidemiological study 
found that prevalence of multimorbidity correlates strongly with increasing age and was 
approximately 30-50% in those 50 – 65 years old (see Figure 8).(153) Therefore, to study 
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the impact and contribution of MSDs to health-related job loss among older workers, it is 
also important to consider the number and type of co-occurring health problems, i.e. the 
surrounding multimorbidity.  
Figure 8: Number of chronic disorders by age-group.(153) 
 
1.5 The relationship between musculoskeletal disorders and multimorbidity 
Multimorbidity can occur for a number of reasons.(154) Firstly, the existing high prevalence 
of certain conditions mean that the likelihood of co-occurrence together in one person, by 
chance alone, is high, particularly for conditions which become more common with 
increasing age. For example, osteoarthritis and asthma may commonly co-occur but have 
no known etiological association. Shared risk factors between conditions can also increase 
the likelihood of clustering. For example, obesity increases the risk of developing both 
osteoarthritis and type 2 diabetes.(155,156) Finally, sometimes a pathogenic link between 
conditions means the risk of another developing is greater. For example, there is a known 
causal pathway between rheumatoid arthritis and cardiovascular disease.(157) Below, I will 
outline how these three mechanisms of multimorbidity relate to the common co-
occurrence of MSDs and multimorbidity. 
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1.5.1 MSDs and multimorbidity are both highly prevalent  
Due to their high prevalence, MSDs have higher odds of co-occurring with other long-term 
conditions, and therefore forming a component disorder in multimorbidity. In the European 
Union, chronic musculoskeletal pain is experienced by an estimated 100 million 
people;(117) back pain, has a mean estimated 1-year prevalence of 38%, worldwide;(158) 
and across the UK, an estimated 8.75 million people have sought treatment for 
osteoarthritis, the equivalent to a third of all people over 45 years of age.(75)  
Similarly, evidence shows an endemic high prevalence of multimorbidity itself. In the 
European Union, there are an estimated 50 million people with multimorbidity and this 
number is expected to grow as the population ages.(159) Longitudinal evidence from 
various other countries also suggests that the number of people with multimorbidity is 
growing.(160–162) According to one estimate in England, by 2018, there will be 2.9 million 
people living with multimorbidity, as compared with 1.9 million in 2008.(162)  
1.5.2 MSDs and multimorbidity share important risk factors 
Many important risk factors for common MSDs show striking overlap with risk factors for 
multimorbidity, even where the definition of multimorbidity has not included MSDs. For 
example, age and female gender are two of the most important non-modifiable risk factors 
for MSDs (although this may not be true for specific conditions).(163) Likewise, there is a 
greater risk of multimorbidity among women as compared with men(164,165) and 
multimorbidity is also associated with increasing age.(152,164) The majority of people aged 
over 65 years are multimorbid;(153) for example, in Scotland, the estimated prevalence of 
multimorbidity was 64.9% amongst those aged 65-84 years and increased to 81.5% among 
those aged 85 years or over (see Figure 8).(153)  
Modifiable risk factors such as physical inactivity and obesity are important in osteoarthritis 
and other regional pain syndromes, including low back pain.(155) Smoking is the main 
modifiable risk factor for inflammatory arthritis and lifestyle risk factors for osteoporosis 
include smoking, poor nutrition and low physical activity.(166) Multimorbidity has a 
similarly clear association with obesity,(167–171) and, while evidence about other 
modifiable risk factors for multimorbidity is scarce, there are parallels with those for MSDs. 
For instance, smoking,(169) physical activity in elderly males,(172) and nutrition(173) have 
been linked to multimorbidity in recent publications.  
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Social deprivation is associated with an increased likelihood of reporting chronic painful 
conditions, including arthritis and back pain.(174) For example, among English people of 
working age (45-64 years), the reported prevalence of arthritis was found to be more than 
double (21.5%) that observed in the least deprived areas (10.6%).(121) Multimorbidity also 
shows a strong association with social deprivation (see Figure 9);(152,153,164,165) people 
in the most deprived areas develop multimorbidity on average 10–15 years earlier than 
those living in the least deprived areas.(153) In particular, a higher risk of multimorbidity 
including a mental health condition has been demonstrated among people in the most 
deprived areas (11% versus 5.9% respectively).(153)  
Figure 9: The prevalence of multimorbidity by age and socioeconomic status. On the 
socioeconomic scale, 1 is the most affluent and 10 is the most deprived.(153) 
 
1.5.3 MSDs and long-term conditions may cause and exacerbate one another 
Lastly, sometimes there are direct causal relationships between MSDs and other long-term 
conditions. For example, people with rheumatoid arthritis are at increased risk of 
developing several comorbid diseases including cardiovascular disease and osteoporosis 
because of shared aetiological pathways. In the UK, findings from the Early Rheumatoid 
Arthritis Study (ERAS) reported a 27.5% and 15.1% 15-year cumulative incidence of 
cardiovascular disease and osteoporosis in people with rheumatoid arthritis, 
respectively.(175)  
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People with poor musculoskeletal health also carry a greater burden of mental health 
problems. MSDs, like many long-term conditions, are associated with an increased risk of 
mood, anxiety and substance use disorders. The association is even stronger in those with 
back pain or fibromyalgia.(176,177) Musculoskeletal disorders and mental health have a 
complex and reciprocal relationship, each exacerbating, or potentially causing, the other. 
Living with persistent pain can lead to depression and anxiety. Conversely, psychological 
distress and depression worsen the experience and reporting of pain.(178) A cycle can 
therefore develop, with ever-worsening pain and low mood leading to social withdrawal 
and isolation. People with mental health conditions may also delay seeking treatment, and 
clinicians may underestimate physical symptoms, attributing these to an individual’s mental 
health condition.(179)  
1.5.4 MSDs and multimorbidity frequently occur together 
A combination of the factors discussed above explains the high prevalence of 
musculoskeletal disorders found alongside other long-term conditions as part of 
multimorbidity. For example, it has been shown that among English primary care patients 
(> 45 years of age) reporting living with a major long-term condition, almost a third also 
have a musculoskeletal condition.(121) Moreover, among those aged > 65 years, almost 
half of those with a heart, lung, or mental health problem also had an MSD (see Figure 
10).(121) In the most deprived populations, painful conditions, such as osteoarthritis and 
back pain, are the most common multimorbidity among those already living with heart 
disease, diabetes, chronic obstructive pulmonary disease (COPD) or cancer.(153)  
The converse is also true: people with an MSD have been shown to be more likely to have 
at least one other long-term condition. For example, according to the results of one study, 
four out of five people with osteoarthritis had at least one other long-term condition such 
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Figure 10: Prevalence of musculoskeletal disorders among English people a) aged 45 years 
and over and b) aged 65 years and over, reporting other long-term conditions.(121,122) 
 
 
In order to visualise the relationship between MSDs and multimorbidity, and recognising 
the varying multimorbidity criteria used in the literature, a recent cross-sectional study 
used three definitions to define the prevalence of multimorbidity in working-age 
Australians. Two multimorbidity thresholds (i.e. minimum of 2+ or 3+ conditions) were 
compared, as well as three definitions of multimorbidity from three sources: a survey-
based definition from the Australian National Health Survey; a policy-based definition from 
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the Australian National Health Priority Areas; and a research definition from a well-cited 
systematic review. They found that irrespective of how multimorbidity is defined, 
musculoskeletal disorders are a near-ubiquitous feature of multimorbidity (see Figure 
11).(181) 
Figure 11: Overlap between Australian populations with musculoskeletal disorders and 
multimorbidity as defined by different definitions and thresholds. A- total working-age 
sample population; B- sub-sample with at least one condition; C- sub-sample with 
multimorbidity; D- sub-sample with any musculoskeletal condition; E- musculoskeletal 
sub-sample considered multimorbid. Lowe et al. reproduced with permission from BioMed 
Central.(181) 
 
1.6 MSDs and multimorbidity exacerbate one another 
Beside the fact that MSDs and multimorbidity commonly co-occur, there is also strong 
evidence that MSDs and multimorbidity interact to exacerbate the health- and treatment- 
burden on patients, as outlined below. 
1.6.1 MSDs and multimorbidity interact to worsen health-burden 
Morbidities tend to accrue in individuals. For example, as the number of physical 
comorbidities increase, so too does the likelihood of developing a mental health 
problem.(153) This accumulation of pathologies contributes to the complex and numerous 
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needs of people with multimorbidity. People with multimorbidity are less able to perform 
everyday tasks due to functional decline(182) and have worsened quality of life and health 
outcomes than those with one index condition.(183) For instance, across a range of index 
diseases, the presence of a comorbidity is consistently shown to increase mortality rates 
when compared to the index disease alone.(183)  
MSDs play an important role in worsening the health-impacts of multimorbidity. They are 
the third largest cause of disability adjusted life years (DALYs) and the largest single cause 
of years lived with disability (YLD).(184) Pain is also a very common feature of most MSDs. 
For example, 78% of people with arthritis surveyed by Arthritis Research UK reported that 
they experience pain most days, with 57% experiencing pain every day.(185) Activities of 
daily living (ADLs or instrumental ADLs) such as bathing, dressing, getting out of bed or a 
chair, completing housework, preparing meals and shopping are frequently affected by the 
pain, along with other common MSD symptoms, such as stiffness, restricted mobility and 
impaired physical functioning.(186) People often need to make adaptations to their home 
to enable them to cope. Moreover, symptoms of MSDs, particularly those with an 
inflammatory cause, tend to fluctuate in severity over time so that their effects are 
unpredictable.(187–189) The pain, distress and functional limitations caused by MSDs 
greatly reduce independence and quality of life, and impair an individual’s ability to 
participate in family, social and working life.(166) Arthritis and back pain, in particular, are 
amongst the most common causes of reduced health-related quality of life in the individual 
and, because of their high prevalence, the wider population.(165,178)  
Self-reported Quality of Life (QoL) scores can be used to understand the personal impact of 
long-term conditions and to show the contribution of specific diseases to poor health in 
multimorbidity. In a national English survey, people living with one or more non-
musculoskeletal long-term conditions reported substantially poorer quality of life than 
those without a long-term condition (QoL score 0.79 vs 0.90, respectively). However, 
quality of life was even more significantly reduced among those who had arthritis or back 
pain as part of their multimorbidity (QoL score 0.71). Notably, the impact of 
musculoskeletal disorders was significant enough that living with arthritis or back pain 
resulted in impaired quality of life irrespective of whether arthritis or back pain were the 
only condition (QoL score 0.68) or were one among multimorbidity (QoL score 0.71) (see 
Figure 12). This suggests that MSDs disproportionately reduce quality of life in 
multimorbidity, when compared to other long-term health disorders.(121)  
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Figure 12: Average Quality of Life scores for people aged 45 years and over who live with 
long-term conditions (LTCs). Long-term conditions are defined as conditions that cannot 
be cured but are controlled by medication and/or other treatment/therapies.(121,122)  
 
1.6.2 MSDs and multimorbidity interact to worsen treatment-burden  
Despite the proven effectiveness of many individual therapies commonly used in long term 
conditions, each additional therapy carries a ‘treatment burden.’ Treatment burden is a 
concept that encapsulates the physical effects of treatment, financial losses, and the 
psychosocial effects of time demands and dependence on others for assistance.(190) 
Predictably, the effects of treatment burden increase for a person receiving multiple 
treatments for multiple health problems. For example, a review of five UK disease-based 
clinical guidelines concluded that implementation of all individual disease best practice 
recommendations for a person with multimorbidity would result in polypharmacy.(191) 
Instead, recent clinical guidance recommends a person-centred approach to 
multimorbidity, prioritising treatments that improve quality of life while minimising overall 
treatment burden.(192) 
MSDs can contribute significantly to the overall number of treatments a person receives. 
The management of MSDs aims to improve quality of life by reducing joint pain and 
stiffness, limiting progression of joint damage and maintaining or restoring functional 
ability,(193) but achieving this can necessitate the use of a range of interventions. This 
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Additionally, drug therapies for MSDs may include topical or oral medication to ease joint 
pain and stiffness, and reduce inflammation. Amongst those severely affected, surgery may 
be required for people living in constant pain from arthritis, for example, osteoarthritis is 
responsible for over 90% of initial hip and knee joint replacements.(194,195)  
1.6.3 MSDs and multimorbidity interact to impair self-management, leading to 
health and social decline 
People with multiple long-term conditions are often required to carry out numerous tasks 
to maintain their health and administer their healthcare. This includes managing different 
tablets to be taken at specific times of day, or week, or only occasionally, keeping stock of 
their pills, creams, inhalers and injections, requesting repeat prescriptions on time, and 
visiting the pharmacy to collect items. Monitoring of treatment effectiveness with regular 
blood tests or physical tests (e.g. blood pressure measurement) may be required, and this 
may necessitate additional visits to the GP, or to the hospital, or may require an additional 
burden placed upon the individual (e.g. self-monitoring of blood glucose in diabetes 
mellitus).(190) As health systems are largely configured to treat individual diseases rather 
than support those living with multimorbidity,(153) managing multiple long-term 
conditions may require the attention of an array of separate health and care professionals 
at home, in the community and in hospitals. The time and effort required to remember and 
attend these appointments (including travel time and car parking or negotiating with 
hospital transport) contributes to the treatment burden.(190)  
Having a musculoskeletal condition as part of multimorbidity makes all these activities 
more difficult. The Centres for Disease Control and Prevention’s (CDC) Arthritis Program in 
the USA has identified nine functional limitations that people with arthritis report as being 
‘very difficult’ or that they ‘cannot do,’ including grasping small objects, lifting or carrying, 
prolonged sitting or standing, walking ¼ mile, climbing stairs, and stooping, bending or 
kneeling.(196) As a result, comorbid arthritis or back pain substantially restrict the function 
and daily activities of people living with cardiovascular disease, diabetes and respiratory 
disease.(197) In addition, the unpredictable fluctuations in symptom severity that are a 
frequent feature of musculoskeletal disorders restrict mobility and can make attending 
hospital or GP appointments and planning ahead difficult, directly limiting people’s ability 
to manage their health.  
Therefore, for a person who is just managing despite their multiple long-term conditions, 
developing arthritis can take away their ability to cope with, or afford, treatment. This may 
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prevent effective self-management for other long-term conditions, which could then 
worsen. For example, people with painful osteoarthritis alongside their other long-term 
conditions have been shown to have increased risk of needing hospital admission.(198) 
Therefore, the co-occurrence of multimorbidity and an MSD may be a “tipping point”, 
depriving people of their ability to maintain their health and independence, leading to a 
spiral of decline. 
1.7 MSDs, multimorbidity, and the workforce  
Musculoskeletal disorders and their impact upon work in the older working-age population 
has primarily been studied without consideration of the presence of co-occurring health 
disorders, or with only simple adjustment for presence or absence of comorbidity. This has 
left an important research gap since the overlap between MSDs and multimorbidity is 
significant and likely to be impactful, as outlined above. In addition, health disorders co-
occurring with MSDs may interact in different ways to impact a person’s ability to stay 
employed.  
Multimorbidity-focused and work-focused research are two emerging fields which have 
both seen an increase in interest over recent years (see Figure 13). However, literature 
focused on both multimorbidity and work outcomes is scarce. Of the existing literature, it 
has been shown that the type of co-occurring long-term conditions, and not only the crude 
number of long-term conditions, is important for work outcomes.(199) However, there 
appears to be little research considering  common patterns of co-occurring health disorders 
and the association of these common health disorder groups with work outcomes.  
Given the recognised individual impact of MSDs on work outcomes, and their strong 
relationship with multimorbidity, it is likely that MSDs disproportionately contribute to the 
overall impact of multimorbidity upon work. To illustrate this, one recent cross-sectional 
study of a Dutch household survey among people of working age (18 – 65 years) showed 
that the effect of multimorbidity upon work disability, sickness absence, and 
unemployment, is significantly amplified when MSDs are included in the classification of 
multimorbidity.(200) However, these results have yet to be replicated in a study of the 
older working-age population in the UK. 
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Figure 13: Number of search results by year, from Pubmed using the following search 
terms a) “multimorbidity” and b) “work disability” 
a) “multimorbidity” 
 
b) “work disability” 
 
1.8 Summary 
There is a movement to encourage people to continue work to older ages. Of particular 
interest are the age group 50 – 65 years old in whom work participation drops off steeply in 
the UK. Much of this work loss appears to be health-related due to the proliferation of 
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among people with chronic health disorders, as it has advantages for personal finance, 
quality of life, mood, sense of identity, and for the health of the whole family. Therefore, 
people with chronic health problems who want to remain in work should be supported to 
do so. However, interventions to support work participation require person-centred, co-
ordinated care involving healthcare professionals, patients, and employers. These can be 
expensive and time consuming. Targeting high-risk disease groups is therefore economically 
advantageous.  
MSDs appear to be a key causal disease group for work disability; however, since they 
frequently co-occur with other health conditions in the older working-age population, 
research that explores the relationship between comorbidity and adverse work outcomes 
in musculoskeletal populations is needed. As MSDs are highly prevalent, such research 
would help to identify important sub-groups that are high-risk for poor work outcomes 
among the MSD population.  
In addition, the impact of multimorbidity, in general, upon a person’s ability to stay in work 
is also not well understood or characterised in the older working-age population. In 
exploring the relationship between multimorbidity and poor work outcomes, it is important 
to go beyond a crude count of the number of comorbid conditions to classifying 
multimorbidity, as the type of co-occurring conditions, not just the number, is likely to be 
important.   
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Chapter 2 - Aims and Objectives 
2.1 Research aims  
Therefore, the overarching aims of this thesis are to investigate, among older working-aged 
people, a) the impact of common comorbid health conditions on work outcomes in people 
with MSDs, and b) the common patterns of multimorbidity and their contribution to health-
related job loss. 
2.2 Research objectives  
1. To systematically review evidence for the impact of comorbidity upon work outcomes 
among people with musculoskeletal disorders 
Among a sample of older workers (50 – 65 years old)  
2. To describe a representative sample of participants with health-related job loss for 
their demographic factors, lifestyle factors, and health disorders 
3. To explore the association between demographic factors, lifestyle factors, and health 
disorders and the occurrence of health-related job loss  
4. To describe patterns of multimorbidity and which health disorders commonly co-
present  
5. To explore the association between common patterns of multimorbidity and the 
occurrence of health-related job loss 
6. To explore the relationship between musculoskeletal disorders, with and without 
comorbidity, and health-related job loss 
7. To estimate the population attributable fraction of health disorders and multimorbidity 
for health-related job loss in the English older working-age population 
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Chapter 3 – Methods  
3.1 Introduction 
In this chapter, the study population are introduced, and data collection and broad 
methodological techniques which will be used are discussed. This includes methods used 
for obtaining data relating to study participants’ demographics and employment history 
and for estimating clinical disease burden and multimorbidity. In addition, the main 
statistical techniques applied in this thesis are described. Other methodological techniques 
relevant only to specific research questions will be detailed within their respective 
chapters.   
3.2 The study population and data sources 
One population of study participants, and two sources of primary data were explored in this 
thesis. Study participants were from the Health and Employment After Fifty (HEAF) study, 
which is a prospective cohort of a representative sample of primary care patients, in 
England. These participants were recruited from 24 selected GP practices between 2013 
and 2014 and provided data from postal questionnaires and their electronic clinical records. 
As part of the HEAF study, participants received a baseline questionnaire which contained 
items relating to demographics, employment, and health. Participants also gave written 
consent that their clinical records, pharmaceutical and diagnostic information could be 
accessed from the Clinical Practice Research Datalink (CPRD).(201) These data sources will 
be described in more detail in the following sections.  
3.3 Ethical approval 
The HEAF study received ethical approval from National Research Ethics Service Committee 
North West-Liverpool East. While no ethical approval is required for research using CPRD 
primary care data with selected established data-linkages, proposed studies with patient 
involvement require separate ethical approval, for example, where CPRD data is being 
linked to questionnaire responses. The HEAF study link to CPRD data received ethical 
approval from the Independent Scientific Advisory Committee of the Clinical Practice 
Research Datalink.  
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3.4 The HEAF study 
3.4.1 Background 
The HEAF study is a large prospective cohort study recruiting older working-age adults, 
between 50 – 64 years of age, from primary care settings (GP practices).(201) The HEAF 
cohort was established in 2013 Professor Keith Palmer and Professor Karen Walker-Bone 
based at the Medical Research Council Lifecourse Epidemiology Unit (MRC-LEU) in 
Southampton. The cohort was set up to examine the relationship between work, health and 
wellbeing, particularly: i) to assess the health benefits and risks of remaining in work to 
older ages; and ii) to assess how health itself impacts on employment outcomes, such as 
job-loss and sickness absence using prospective follow up of these participants. The 
sampling frame comprised the registers of 24 general practices (GPs) across England. These 
practices responded to an advert inviting CPRD-contributing practices to take part in the 
study. GPs were based in England to allow later linkage with other English based databases 
such as the Hospital Episode Statistics. Although there was no requirement that the 
distribution of included participants’ occupations be nationally representative, GPs 
contributing to the sampling frame did provide a broad geographical spread which allowed 
recruitment from the North, Midlands, and South of England (see Figure 14). This was 
advantageous since rates of population work participation, types of health disorders, and 
interactions with healthcare are likely to differ between regions.(201)  
A full-time team of clinical, database, and information managers, data entry and 
administrative staff, and statisticians oversee the continued running of the HEAF study as 
well as the initial processing of HEAF study participant data. This takes place in the MRC-
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Figure 14. location of GP practices participating in the HEAF study.(201) 
 
3.4.2 Eligibility and contacting participants in the HEAF study 
Eligible participants were registered at one of the participating GPs and were born between 
1948 and 1962, in order to recruit from the target age band of 50 – 64 years of age. General 
practitioners, in the participating practices, were asked to review the list of eligible 
participants and exclude those patients whom they considered would be inappropriate to 
approach, e.g. because of recent bereavement or terminal illness. Initially, the participating 
practices mailed a single invitation to the study, without reminder. Participants’ contact 
details were not given to researchers unless the participants gave this information 
voluntarily to the team by returning the baseline questionnaire and signed consent form to 
the MRC-LEU. The consent form also gave an opportunity for participants to give or decline 
access to their CPRD data. Those who declined CPRD linkage were not included in this 
thesis.(201) 
66 | P a g e  
 
3.4.3 The HEAF baseline questionnaire 
Although the HEAF study is a prospective study, with annual questionnaire follow up, data 
used in this thesis was derived from the initial HEAF baseline questionnaire, distributed in 
2013 – 2014. As mentioned, this questionnaire contained detailed information about 
employment, health and wellbeing. The cover page and an example of one of the data 
entry forms is displayed in Figure 15, below. Of the items that were relevant to this thesis, 
participants responded to questions about their date of birth, gender, ethnicity, marital 
status, education, employment status, and occupation. The work of this thesis mostly 
depended on CPRD records to define health exposures. However, the HEAF baseline 
questionnaire was also used to extract information about a participant’s smoking habits. 
These questionnaire-derived variables are described in more detail below. 
3.4.4 Data cleaning 
HEAF participant data was extracted and cleaned by the MRC-LEU team in Southampton 
before being used for research. Following the return of the study questionnaires by post, 
information was independently extracted into an electronic database by two data entry 
personnel. To minimise the risk of transcription error, any disagreements were highlighted 
and compared to the original questionnaire entry for accuracy. Following extraction, 
electronic participant data was cleaned. Initially, the dataset was cleaned of any remaining 
formatting or transcription errors by a database manager. Following this, a statistician 
looked for any incongruent data patterns across individual participants, for example, in the 
case of a participant who initially described himself as unemployed but went on to describe 
the qualities of his current job. For events such as these, an investigation of the original 
questionnaire was once again performed to derive the most likely meaning. Where 
erroneous data was unreconcilable, the information was not used for research. Once these 
processes were complete, electronic data was available for my use.  
3.4.5 Variables derived from the HEAF baseline questionnaire for this thesis 
For the main demographic variables, participants reported both their date of birth and the 
date of questionnaire completion; age was therefore derived by calculating the number of 
years between these two dates. Participants indicated their sex as being either “male” or 
“female” and their ethnicity as being one of the following categories: “White”, “Black-
Caribbean”, “Black-African”, “Black-other”, “Indian”, “Pakistani”, “Bangladeshi”, “Chinese”, 
or “other”, which could be specified in a free text space. Additionally, participants indicated 
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their marital status and could specify one of the following categories: “married”, “single”, 
“civil partnership”, “widowed”, or “divorced”.  
To derive information about level of education, participants were asked to indicate whether 
they had any of the following qualifications: “O levels/GCSEs”, “A levels”, “vocational 
training certificates”, “university degree(s) or HND” (Higher National Diploma), or “higher 
professional qualifications”. From these responses I could derive a person’s highest 
qualification level. For analysis, these categories could be viewed at different levels of 
resolution. For example, there were few participants for whom A-level was the highest 
qualification level, likely because people completed their A-levels with a view to entering 
higher education. Therefore, I combined O level/GCSE and A level categories to form a 
“high school and sixth form” level of qualifications. In addition, I observed that many HEAF 
participants had indicated obtaining higher professional qualifications but not university 
degree level qualifications. This suggests that the “higher professional qualifications” were 
unlikely to be masters or PhD-level qualifications. I therefore considered university level 
qualifications the highest strata of education, followed by vocational and higher 
professional qualifications, then high school and sixth form, and finally, no qualifications.  
Figure 15. Cover page and page one (of 15) from the HEAF study baseline questionnaire. 
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Study participants also responded to questions about employment status and occupation, 
indicating their current employment status as either “employed”, “self-employed”, 
“unemployed”, or “retired”. Participants who stated that they were currently in paid work 
gave their job title and indicated the industry in which they worked. Likewise, participants 
who were not currently in paid work indicated the job title of their last paid occupation and 
the date at which they left this job. These participants were also asked whether they left 
work because of a health problem and could respond “no, not at all”, “yes, a health 
problem was the main reason for leaving”, or “yes, a health problem was part of the reason 
for leaving”. For those who considered a health problem to be a factor in their leaving 
work, an additional question about the type of health problem was asked, and response 
options included: “a problem with your back, neck, arm, shoulder or leg”, “a mental health 
problem or stress”, “a problem with your heart or lungs”, or “another type of health 
problem.” 
Lastly, the HEAF questionnaire included participant’s smoking history. Participants were 
asked: if they had ever smoked regularly; how old they were when they first started 
smoking regularly; whether they still smoked regularly; and, if no, their age when they last 
smoked regularly. Using this information, and the participant’s date of birth, I could derive 
a person’s smoking status at any point in time prior to the baseline questionnaire.  
3.4.6 Deriving classifications of work and socioeconomic class from a participant’s 
self-reported job title in HEAF 
3.4.6.1 The Standard Occupational Classification system 
The Standard Occupational Classification 2010 system (SOC-10) is a commonly used UK-
based system, developed by the Office of National Statistics (ONS).(202) In the HEAF study, 
this system was used to group jobs according to their skill specialisation and skill level. 
Firstly, the SOC-10 four-digit codes split occupations into major, sub-major, minor, and unit 
occupation groups based on specialisation type. For example, the SOC-10 code 2112 
corresponds to: major category 2 (professional occupations); sub-major category 1 (science, 
research, engineering and technology professionals); minor category 1 (natural and social 
science professionals and unit occupation group); and unit category 2 (biological scientists 
and biochemists). The SOC-10 separation of occupations by the major specialisation groups 
is outlined in Table 1, below.(202) 
 
69 | P a g e  
 
Table 1: General nature of qualifications, training and experience for occupations in SOC-
10 major groups as described in “Standard Occupational Classification 2010: Volume 1 
Structure and descriptions of unit groups” (202) 
Code Major SOC-10 group  General nature of qualifications, training, and experience 
required for occupations in the major group 
1 Managers, directors and 
senior officials 
A significant amount of knowledge and experience of the 
production processes and service requirements associated with 
the efficient functioning of organisations and businesses. 
2 Professional 
occupations 
A degree or equivalent qualification, with some occupations 
requiring postgraduate qualifications and/or a formal period of 
experience-related training. 
3 Associate professional 
and technical 
occupations 
An associated high-level vocational qualification, often involving a 
substantial period of full-time training or further study. Some 
additional task-related training is usually provided through a 
formal period of induction. 
4 Administrative and 
secretarial occupations 
A good standard of general education.  Certain occupations will 
require further additional vocational training to a well-defined 
standard (e.g. office skills). 
5 Skilled trades 
occupations 
A substantial period of training, often provided by means of a 
work-based training programme. 
6 Caring, leisure and 
other service 
occupations 
A good standard of general education. Certain occupations will 
require further additional vocational training, often provided by 
means of a work-based training programme. 
7 Sales and customer 
service occupations 
A general education and a programme of work-based training 
related to Sales procedures. Some occupations require additional 
specific technical knowledge but are included in this major group 
because the primary task involves selling. 
8 Process, plant and 
machine operatives 
The knowledge and experience necessary to operate vehicles and 
other mobile and stationary machinery, to operate and monitor 
industrial plant and equipment, to assemble products from 
component parts according to strict rules and procedures and 
subject assembled parts to routine tests. Most occupations in this 
major group will specify a minimum standard of competence for 
associated tasks and will have a related period of formal training. 
9 Elementary occupations Occupations classified at this level will usually require a minimum 
general level of education (i.e. that which is acquired by the end of 
the period of compulsory education). Some occupations at this 
level will also have short periods of work-related training in areas 
such as health and safety, food hygiene, and customer service 
requirements. 
The sub-major specialisation categories of SOC-10 have also been arranged by skill level, 
which was defined in relation to the content of, and time taken to attain, qualifications, 
training, and work experience to be able to perform the work. The first skill level comprises 
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occupations suitable for a person who had completed compulsory education and requiring 
only short periods of work-related training, for example cleaning and catering assistants; 
the second skill level includes occupations of a similar level of education but involving 
longer work-related training or experience, such as driving, caring, or secretarial work; the 
third level contains occupations that normally involve a knowledge base requiring 
qualifications at a sub-degree level and potentially a long period of work experience; and 
the fourth skill level includes “professional” occupations that usually require degree-level 
education or an equivalent period of work experience.(202) The separation of sub-major 
specialisation groups by skill level can be observed in Table 2, below.  
Table 2: the sub-major groups of SOC-10, by skill level. as described in “Standard 
Occupational Classification 2010: Volume 1 Structure and descriptions of unit groups” 
(202) 
Skill level Code Sub-major group of SOC-10 
Level 4 11 Corporate managers and directors 
21 Science, research, engineering and technology 
professionals 
22 Health professionals 
23 Teaching and educational professionals 
24 Business, media and public service professionals 
Level 3 12 Other managers and proprietors 
31 Science, engineering and technology associate 
professionals 
32 Health and social care associate professionals 
33 Protective service occupations 
34 Culture, media and sports occupations 
35 Business and public service associate professionals 
51 Skilled agricultural and related trades 
52 Skilled metal, electrical and electronic trades 
53 Skilled construction and building trades 
54 Textiles, printing and other skilled trades 
Level 2 41 Administrative occupations 
42 Secretarial and related occupations 
61 Caring personal service occupations 
62 Leisure, travel and related personal service occupations 
71 Sales occupations 
72 Customer service occupations 
81 Process, plant and machine operatives 
82 Transport and mobile machine drivers and operatives 
Level 1 91 Elementary trades and related occupations 
92 Elementary administration and service occupations 
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3.4.6.2 Assigning SOC-10 occupational classifications in HEAF 
Each participant included in HEAF was assigned a four-digit SOC-10 code, based on their 
reported job title and industry. These codes were assigned by two personnel using the 
Computer Assisted Structured Coding Tool (CASCOT), a computer programme which 
facilitates the conversion of text information to standard classifications.(203) CASCOT 
automatically assigned a SOC-10 code to each participant’s self-reported job title along with 
a percentage score representing the certainty of the match between the given job title and 
the specific SOC-10 category. The Warwick Institute for Employment Research recommends 
an optimal match certainty threshold of 64%, above which text can be automatically 
assigned to occupational codes by CASCOT.(204) Therefore, initially, all participant’s 
occupations were automatically assigned SOC-10 codes, then those codes to which CASCOT 
had assigned a match certainty greater than 64% kept their assigned SOC-10 codes. Finally, 
those with match certainty lower than 64% were manually reviewed by two HEAF study 
personnel for accuracy. Those job titles for which the automatically assigned SOC-10 code 
appeared inappropriate were manually reassigned new SOC-10 codes using the most likely 
alternative occupational code.  
3.4.6.3 Defining socioeconomic status using the National Statistics Socio-economic 
Classification 
The SOC-10 information was mapped onto the National Statistics Socio-economic 
Classification (NS-SEC) which is also a UK-based classification system developed by the 
ONS.(205) The NS-SEC organises occupations into socioeconomic strata by considering 
aspects of a person’s labour market situations and work situations. “Labour market 
situations” relates to source of income, economic security, and prospects of economic 
advancement, while “work situations” refers to a person’s location in authority structures 
at work and their degree of autonomy/control at work. As such, SOC-10 codes can be 
arranged into a socio-economic hierarchical classification system with never worked and 
long-term unemployed at the bottom, and employers in large establishments at the top.  
The NS-SEC can be derived from SOC-10 using a full (gold-standard), reduced, or simplified 
method. Since the HEAF questionnaire did not collect information about a participant’s 
supervisory roles or whether the employing organisation employed 25 or more employees, 
I used the simplified method, which relies entirely on a participants SOC-10 code and has 
been found to correctly allocate 88% of participants, compared with the full method.(205) 
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3.4.6.4 Deciding on an appropriate level of resolution for the NS-SEC  
In the NS-SEC, there are as many as 14 possible socioeconomic strata including: employers 
in large establishments; higher managerial occupations; higher professional occupations; 
lower professional and higher technical occupations; lower managerial occupations; higher 
supervisory occupations; intermediate occupations; employers in small establishments; 
own account workers; lower supervisory occupations; lower technical occupations; semi-
routine occupations; routine occupations; and never worked or long-term unemployed. 
Depending on the requirements of the researcher, different resolutions of the NS-SEC are 
possible ranging from a 14- to three-category system, see Table 3.(206,207) Insufficient 
information about the size of the employing organisation was available from HEAF, so it 
was not possible to distinguish employers in large establishments from higher managerial 
occupations in the 14 tier classification. Therefore, the nine-level NS-SEC categorisation 
which combined employers in large establishments with higher managerial occupations in 
the top socio-economic stratum was used and retained a high degree of detail, overall. 















































































































































3.5 The Clinical Practice Research Datalink 
Other than the data retrieved from the HEAF study questionnaire, the primary source of 
health data for this thesis was the CPRD. 
3.5.1 Background 
While electronic health records have existed since the 1970s, it wasn’t until the 1980s that 
electronic medical record systems were being introduced among individual UK general 
practices. Particularly, the work of two general practitioners was influential. First was Dr 
James Read who pioneered a hierarchical coding system for clinical events, ushering in the 
use of the comprehensive, intuitive and eponymous “Read codes.” In 1988, the Royal 
College of General Practitioners (RCGP) and the British Medical Association (BMA) 
recommended the adoption of these codes nationally, which were used by almost all GPs in 
the UK since the mid-1990s.(208) They remain the standard vocabulary for clinicians to 
record clinical findings and procedures, across health and social care IT systems, to this 
day.(209)  
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Also in the 1980s, Dr Alan Dean, with a team of software developers, formed the VAMP 
Health company to produce a computer-based tool for recording electronic routine medical 
information, in order to replace the paper records historically used by general practitioners. 
The Clinical Practice Research Datalink (CPRD) was the eventual result of this work, and was 
established in London, in 1987. Originally, the smaller Value Added Medical Products 
(VAMP) dataset, this became the larger General Practice Research Datalink in 1993, before 
eventually growing to become the CPRD in 2012.(210) It is now one of the largest databases 
of longitudinal primary care medical records in the world and has been collecting data for 
over 30 years. Currently, this not-for-profit service is primarily government-funded through 
the National Institute for Health Research (NIHR) and the Medicines and Healthcare 
products Regulatory Agency (MHRA).(211) The main purpose of the CPRD is to offer high 
quality primary-care clinical data to support retrospective and prospective public health 
and clinical studies.(212)  
3.5.2 Size and representativeness of CPRD  
Approximately one in 10 general practices across England, Wales, Scotland, and Northern 
Ireland have contributed deidentified data to CPRD. This includes over 1,200 UK primary 
care practices and data from 35 million patients, with 10 million patients currently 
registered and active; although the number of patients and general practices has varied 
since the establishment of CPRD.(212) As of 2014, there were 674 contributing practices 
covering approximately 6.9% of the UK population, and participants were found to be 
broadly representative of the general population in terms of age, sex, and ethnicity. The 









75 | P a g e  
 
Figure 16: Distribution of 674 CPRD practices by region in England, and in Wales, Scotland 
and Northern Ireland. Note: practices mapped are those contributing up to standard data 
to the dataset on 2 July 2013, based on the January 2014 dataset build.(211) 
 
3.5.3 Available data from the CPRD 
A complete electronic record of a patient’s primary care events is captured in real time by 
practice staff for the duration of a general practice’s participation in CPRD and a patient’s 
registration at a contributing general practice. Although it is possible for a patient to opt 
out of sharing information from their health record, this rarely occurs.  
CPRD captures routine information on all care events that a GP has recorded as part of their 
usual clinical care, these include: demographic data (e.g. age, sex, and patient registration 
date); clinical diagnoses and symptoms (e.g. heart failure or painful knee); assessment of 
lifestyle and risk factors (such as BMI recordings, smoking, and alcohol intake); prescribed 
drugs and vaccinations (issued at a primary care level); laboratory and diagnostic testing 
(e.g. HbA1c); and referrals to hospital and secondary care (e.g. referrals to mental health 
crisis teams).(212) General practitioners and other health care professionals will code these 
data using the Read code system and British National Formulary (BNF) codes for 
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prescription data. At the same time, linkage to other secondary care data sources (for 
example, Hospital Episode Statistics (HES) and mortality data from the ONS) is possible and 
data is date-stamped so that the time of event/diagnosis can be retrieved.(212) 
The data is suitable for longitudinal analysis as at least 20 years of follow up is available for 
25% of contributing patients. CPRD-supported clinical research requires that patients 
consent to the use of their data for CPRD, then CPRD agree to share this anonymised data if 
and ethics approval and payment of licence and administration fees allow.   
3.5.4 Quality of CPRD data 
The quality of CPRD data is variable across time and somewhat dependent upon the 
participating general practice and practitioner. However, CPRD undertakes internal data-
quality assessments both at the patient and practice level.(213) “Unacceptable” patients 
are those for whom there is non-contiguous follow up or poor data recording (e.g. missing 
vital information such as first registration date, or errors such as age >115 years). Across 
CPRD approximately 11.89% of patients are unacceptable, 10.44% of whom are temporary 
patients, with only 1.45% unacceptable due to inconsistent data.(213) “Up to date” GP 
practices are those which record a minimum of 95% of prescribing events and patient-
consultations. Practices are routinely validated by internal checks and sent a validation 
report after submission of data. These checks look at completeness of prescribing, 
demographic, registration, referrals, and cause of death data. Practices not meeting CPRD 
standards are removed from the database.(214) Possibly because of these quality 
assessments, the recording of most clinical events has improved over time, although large 
inter-practice variation in data quality remains.(215) 
Other factors affect the quality of recorded clinical data in CPRD. For instance, since 2004, 
English general practices also began to participate in the Quality and Outcomes Framework 
(QOF) which is a voluntary annual incentive programme, requiring GP practices to record 
several indicators of quality of care in return for financial reward. For example, a practice 
may be scored based on the percentage of patients with asthma between the age of 14-20 
years old who have had their smoking status recorded in the last 12 months; or the 
percentage of patients with a diagnosis of heart failure who have had their heart failure 
confirmed using an echocardiogram.(216) Following the introduction of QOF, the 
completeness in recording of many variables improved.(211) 
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CPRD has shown a high positive predictive value for certain clinical diagnoses and incidence 
figures derived from CPRD appear to be comparable to other UK-based data sources.(211) 
However, few studies reporting validation outcomes have reported sensitivity and 
specificity outcomes for CPRD diagnostic data. This may be a limitation as the absence of a 
Read code for a particular disease is usually interpreted as the absence of the disease itself. 
However, diseases may be missed, such as those diagnosed in secondary care which have 
to be transcribed into the patient’s primary care record. There are also no standard 
definitions for clinical diseases in CPRD and miscoding is possible, particularly for poorly 
defined conditions. To combat this, researchers use lists of possible Read codes for a 
particular disease of interest with selective algorithms to improve internal validation 
wherever possible.(211)  
3.5.5 Deidentification of CPRD data 
The NHS is the single provider of healthcare in the United Kingdom. As all participating 
CPRD practices are under the NHS this means that each individual patient contributing data 
has a unique patient identifying number, the NHS number. This is a trusted identifier that 
can be used for valid linkage of health data from various sources. The NHS number is used 
to produce an “encrypted linker key,” this is performed by a third party (NHS Digital) and 
CPRD does not receive or distribute patient-identifiable data. Instead, patients are ascribed 
a new unique CPRD number. Using such identifiers CPRD data can be linked to 
questionnaire data for observational research, as was implemented for the HEAF 
study.(212)  
3.5.6 Structure of CPRD data 
Data in the CPRD can be separated into clinical, referral, immunization, test, and therapy 
data. When an entry of data to a patient’s clinical record occurs, this is considered a 
“consultation,” which is recorded against practice, patient, and staff pseudo-identifiers. 
Within a consultation, “events” can be recorded which can include demographic 
information, drug prescriptions, clinical diagnoses and symptoms, hospital admissions and 
the clinical outcome of hospital admissions, referrals to specialist care, provided 
preventative care, diagnostic and monitoring tests, immunisations, and details of death. 
Each event is recorded with an associated date. Figure 17 below gives a conceptual diagram 
of CPRD data.(211)  
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Figure 17: the structure of the CPRD dataset. Patients consult with practice staff, where 





3.5.7 Request and retrieval of CPRD data 
There over 96,000 codes corresponding to “events” in the entire Read code hierarchical 
classification system. In this system, codes are organised into broader diagnostic categories 
such as “N: Musculoskeletal and connective tissue diseases” and within those, narrower 
divisions of clinical diagnostic codes such as “N211: rotator cuff syndrome” or related 
symptomatic codes such as “N131: chronic/recurrent neck pain.” Similarly, BNF prescription 
codes contain broad categories (such as “10.3: Drugs for the relief of soft-tissue 
inflammation”) and specific codes relating to drug names, doses, and formulations. Given 
that it was possible to request an unmanageable amount of CPRD data for study 
participants, it was desirable to refine the request according to HEAF study research 
objectives.(201) To achieve this, members of the HEAF research team searched CPRD 
disease and drug code dictionaries to compile a list of relevant codes, which were 
requested from CPRD. The following items of CPRD data were prioritised: 
• All hospital admissions, including discharge diagnoses and procedures 
• All GP consultations for: musculoskeletal disorders (MSDs); mental health 
problems; cardiovascular problems; asthma; chronic obstructive pulmonary 
disorder (COPD); diabetes; and epilepsy 
• All prescriptions related to these health problems 
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• All injuries likely to be occupational 
• Frequency of GP consultations for all reasons combined 
• Records of height, weight, BMI, smoking habits, and alcohol consumption 
10,825 BNF codes and 11,316 Read codes relating to the above items were requested from 
CPRD. If these events had been previously coded in the electronic clinical record of HEAF 
study participants, data were returned to the research team. For example, if a study 
participant had been diagnosed with COPD and the event was coded, this information 
would have been returned along with the date of diagnosis and a unique identification 
number for linkage with questionnaire data.  
3.5.8 Development of health disorder variables using CPRD codes 
The returned CPRD data were already grouped by body system (e.g. musculoskeletal, 
mental health, cardiovascular), however no further grouping had been performed. Two 
researchers with medical training (myself and Professor Keith Palmer) independently went 
through the clinical codes and assigned them into disease groups. Codes were grouped into 
the smallest possible distinct disorders or events. For example, two codes were found 
relating to people who had had a heart transplant: “other transplantation of heart”; and 
“other transplant of heart NOS.” These were grouped together to form a heart transplant 
category. Read codes were excluded from further analysis if 1) they were considered too 
vague, or not relating to clinically recognised health problems, for example “Sibling 
Jealousy,” 2) they referred to a health problem that had not been requested from CPRD (as 
these codes would be unlikely to capture all participants in the study sample with the 
specific health problem). For example, Table 4 lists the excluded musculoskeletal Read 
codes; a full list of excluded codes is available in Table 1, Appendix. In the event of 
disagreements between the two researchers a third clinician was sought out to adjudicate 
(Dr Nicola Goodson or Prof. Karen Walker-Bone).  
Once codes were organized into health problem groups at the highest possible degree of 
resolution, distinct groups were combined into larger clinical disorder groups where 
appropriate. This was desirable in order to increase the available statistical power for 
analysis. However, maintaining a high resolution of the clinical disease groups was also 
desirable, since clinical disease groups become less meaningful as they become less 
distinct. The grouping process is outlined, below.  
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Table 4: Excluded musculoskeletal Read codes 
Body system Excluded Read codes 
Musculoskeletal 
disorders 
Acute rheumatic fever 
O/E - knee joint abnormal 
O/E - shoulder joint abnormal 
H/O: rheumatic fever 
O/E - finger joint abnormal 
O/E - wrist joint abnormal 
O/E - elbow joint abnormal 
O/E - joint abnormal 
O/E - neck joint abnormal 
O/E - toe joint abnormal 
O/E - hip joint abnormal 
O/E - hand joint abnormal 
Rheumatoid factor 
Back X-ray 
Adverse reaction to analgesics, antipyretics, antirheumatics 
[D]Head and neck symptoms 
O/E - ankle joint abnormal 
[X]Cervicogenic headache 
 
3.5.8.1 Musculoskeletal disorders 
At the end of categorisation, 51 distinct musculoskeletal disorder sub-groups were 
identified.  These included: 1) rheumatoid arthritis 2) inflammatory arthritis or juvenile 
arthritis 3) probable osteoarthritis (OA) unclear site 4) OA back 5) OA neck 6) OA shoulder 
and elbow 7) OA hip 8) OA knee 9) OA lower limb, not specified or other than hip or knee 
10) OA back or neck, not specified (NS) 11) OA hand, wrist, digits 12) OA pelvis 13) crystal 
arthritis 14) infective arthritis/arthropathy 15) NS disorder of joints 16) back pain 17) 
discogenic/nerve root pain 18) spinal surgery 19) neck pain 20) hip pain 21) knee pain 22) 
lower limb pain unspecified or other than hip or knee 23) knee bursitis 24)  knee joint 
swelling or effusion 25) widespread pain 26) connective tissue disease 27) shoulder pain 28) 
elbow pain 29) wrist/hand or forearm pain 30) specific disorders of the shoulder & shoulder 
girdle (not OA) 31) specific disorders of the elbow (not OA) 32) specific disorders of 
forearm, hand, wrist or digits (not OA) 33) shoulder surgery & other procedures 34) 
procedures relating to elbow 35) procedures relating to wrist 36) other procedures upper 
limb (not shoulder) 37) upper limb pain not specified 38) non -specific sprain/injury group 
39) neck injury 40) back injury 41) shoulder/upper limb injury 42) hip injury 43) knee injury 
(including ligament tears) 44) other lower limb injury 45) specific disorder that does not fit 
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anywhere 46) arthroplasty of hip 47) other hip procedures 48) arthroplasty of knee 49) 
other knee procedures 50) other musculoskeletal referral codes 51) ‘rheumatism’ NS. See 
Table 2, Appendix, for a description of the specific Read codes that comprised these groups. 
These sub-groups were arranged into related broader groups, see Figure 18.  
Figure 18: Concept map showing related groups of musculoskeletal disorders 
 
Of the chronic musculoskeletal disorders identified, by far the most prevalent condition was 
osteoarthritis. The low prevalence of the other chronic musculoskeletal disorders, such as 
inflammatory rheumatic disorders, limited the power available for undertaking a subgroup 
analysis of these conditions. Therefore, all chronic musculoskeletal disorders were grouped 
together for analysis including all osteoarthritis, inflammatory arthritis, and chronic tissue 
disease groups. Crystal arthropathies were also considered chronic musculoskeletal 
disorders, providing that the person was still being treated for the condition at the point of 
analysis.  
Many other musculoskeletal code groups referred to musculoskeletal pain conditions, or 
short-term musculoskeletal injuries, for example back pain or knee injury. These groups 
were combined to form a broad musculoskeletal pain group. Unlike chronic 
musculoskeletal disorders, these conditions may be short-term or heal completely. 
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Therefore, for these musculoskeletal codes, the proximity in time to the work outcome of 
interest was important.  
Four sub-groups were considered too non-specific to classify the presence of a 
musculoskeletal pain or chronic musculoskeletal disorder and these subgroups were 
dropped from any further analysis in this thesis. These included, “procedures relating to the 
elbow”, “procedures relating to the wrist”, “procedures relating to the upper limb (not 
shoulder)”, and “other musculoskeletal referral codes”. See Table 5, below, for the final 
grouping of musculoskeletal code sub-groups for analysis. 







Inflammatory arthritis/juvenile arthritis 
Probable osteoarthritis (OA) unclear site 
OA back 
OA neck 
OA shoulder and elbow 
OA hip 
OA knee 
OA lower limb, not specified or other than hip or knee 
OA back or neck, not specified 
OA hand, wrist, digits 
OA pelvis 
Crystal arthritis 
Connective tissue disease 
Arthroplasty of hip 











Lower limb pain unspecified or other than hip or knee 
Knee bursitis 
Knee joint swelling or effusion 
Widespread pain 
Shoulder pain 
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Elbow pain 
Wrist/hand or forearm pain 
Specific disorders of the shoulder & shoulder girdle (not 
OA) 
Specific disorders of the elbow (not OA) 
Specific disorders of forearm, hand, wrist or digits (not OA) 
Shoulder surgery & other procedures 
Upper limb pain not specified 
Non -specific sprain/injury group 
Neck injury 
Back injury 
Shoulder/upper limb injury 
Hip injury 
Knee injury (including ligament tears) 
Other lower limb injury 
Specific disorder that does not fit anywhere 
Other hip procedures 
Other knee procedures 
‘Rheumatism’ NS 
 
3.5.8.2 Mental health disorders  
At the end of categorisation, 22 different mental health disorder sub-groups were 
identified.  These included: 1) disorders usually first diagnosed in infancy, childhood, or 
adolescence 2) delirium, dementia, and amnestic and other cognitive disorders 3) mental 
disorders due to a general medical condition not elsewhere classified 4) substance-related 
disorders 5) schizophrenia and other psychotic disorders 6) mood disorders or depressive 
disorders 7) bipolar disorders 8) anxiety disorders 9) somatoform disorders 10) factitious 
disorders 11) dissociative disorders 12) sexual and gender identity disorders 13) eating 
disorders 14) sleep disorders 15) impulse-control disorders, not elsewhere classified 16) 
adjustment disorders 17) personality disorders (axis II) 18) self-harm, suicidal actions, or 
ideations 19) referral to a support service 20) under the psychiatrist’s team 21) crisis 
admission, section, on a severe mental health register 22) symptoms of psychological 
distress (with no diagnosis specified). See Table 3, Appendix, for the specific Read codes 
that comprised these distinct groups. I arranged these sub-groups into related broader 
groups, see Figure 19. 
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Figure 19: Concept map showing related groups of mental health problems 
 
Mental health disorder sub-groups referring to disorders usually diagnosed at the primary-
care level were grouped together: these included adjustment disorders, somatoform 
conditions, and mood disorders (anxiety and depression). This was considered appropriate, 
since a person presenting with anxiety or depression in general practice may be coded as 
having a mood disorder or an adjustment disorder, which may depend as much on the 
general practitioner as on the participant’s clinical history. 
Sleep disorders were also considered separately for analysis, since there was a greater 
possibility that these had manifested because of some other organic cause. For example, 
sleep apnoea or pain are common causes of sleep disturbance.  
Disorders for which diagnosis and care required psychiatric oversight were grouped 
together, these included the following subgroups: schizophrenia and other psychotic 
disorders, bipolar disorders, dissociative disorders, sexual and gender identity disorders, 
eating disorders, impulse-control disorders not elsewhere classified, and personality 
disorders (Axis II). These sub-groups also described disorders that were relatively rare, and 
therefore there was incentive to combine into one group in order to allow enough power 
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for analysis. However, clinical features were more heterogeneous between sub-groups in 
this case.  
Lastly, certain subgroups indicated a history of a severe mental health problems and were 
combined for the purposes of this study. These included: self-harm, suicidal actions or 
ideations; under the psychiatrist’s team; crisis admission, section, on a severe mental 
health register.  
At this stage, certain subgroups were excluded from further analysis. These included: 
“disorders usually first diagnosed in infancy, childhood, or adolescence”, which included 
several Read codes relating to speech disorders such as stammering; “Substance-related 
disorders” which contained one code relating to alcohol withdrawal-induced seizure; 
“delirium, dementia, amnestic and other cognitive disorders”, “Referral to a support 
service”, “symptoms of psychological distress” for which Read codes did not define a 
clinically distinct health problem; and “mental disorders due to a general medical condition 
not elsewhere classified”, for which the underlying cause was not described. In addition, 
the study sample contained no participants with “Factitious disorders”. See Table 6, below, 
for the final grouping of mental health problem code groups for analysis. 
Table 6: Mental health problems sub-groups arranged into broader groups for analysis 
Broad mental health problem group  Mental health problem sub-groups 
Primary-care-level mental health 
problems 
Mood disorders or Depressive disorders 
Anxiety disorders  
Somatoform disorders 
Adjustment disorders 
Sleep disorders Sleep disorders 
Psychiatric-care-level mental health 
problems 
Schizophrenia and other psychotic disorders 
Bipolar disorders 
Dissociative disorders 
Sexual and gender identity disorders 
Eating disorders 
Impulse-Control Disorders Not Elsewhere Classified  
Personality disorders (Axis II)  
Severe mental health problems Self-harm, suicidal actions or ideations 
Under the psychiatrist’s team 
Crisis admission, section, on a severe mental health 
register 
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3.5.8.3 Cardiovascular disorders 
At the end of categorisation, 28 different cardiovascular sub-groups were identified. These 
were 1) myocardial infarction or unstable angina 2) myocardial ischaemia, atherosclerosis, 
or angina 3) cardiology and vascular investigations 4) coronary angioplasty, bypass, or stent 
5) non-specific cardiovascular problem 6) pulmonary embolism 7) referrals, cardiac clinic 
follow up, cardiovascular surgeon, GP with cardiovascular interest and other cardiovascular 
follow up and monitoring codes 8) heart failure 9) probable or possible heart failure 10) 
diseases of the endocardium and valves 11) arrythmia other than AF 12) cardiomyopathies 
13) pericardial diseases 14) possible and probable acute coronary syndrome 15) non-
coronary vascular, atherosclerotic, and peripheral arterial disease 16) aneurysms (all body) 
17) heart transplant 19) hypertension 20) deep vein thrombosis 21) stroke or 
cerebrovascular disease 22) cardiac arrest or cardiopulmonary resuscitation 23) superficial 
vein thrombus 24) atrial fibrillation or supraventricular tachycardia 25) ectopics 26) 
arrhythmia requiring cardioversion, ablation, or a pacemaker 27) non-coronary vascular 
atherosclerotic events, occlusions, or cardiovascular surgery 28) secondary hypertension 
including gestational hypertension and pre-eclampsia 29) transient ischaemic attack (TIA) 
30) other non-superficial venous occlusions. See Table 4, Appendix, for the specific Read 
codes that comprised these distinct groups. I arranged these sub-groups into their related 
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Figure 20: Concept map showing related groups of cardiovascular disorders 
 
Using the generated sub-groups it was possible to create several clinically distinct but 
broader cardiovascular variables. An ischaemic heart disease variable was constructed 
using angina and myocardial infarction-related subgroups as well as a sub-group referring 
to cardiac surgery for these problems. It was also possible to define severe ischaemic heart 
disease using one sub-group relating to acute coronary syndrome events. A heart failure 
variable was defined using two sub-groups containing heart failure specific codes and heart 
transplant codes. Structural heart disease was comprised of two sub-groups relating to 
diagnoses of cardiomyopathy and diseases of the endocardium and valves. An arrhythmia 
variable brought together sub-groups containing diagnostic codes for supraventricular 
tachycardias and surgical procedures to treat cardiac arrhythmias. Hypertension was 
defined using only one sub-group of hypertension specific diagnostic codes. A venous 
thrombosis variable was comprised of two sub-groups containing pulmonary embolism and 
deep vein thrombosis codes. A peripheral atherosclerosis variable was defined using two 
sub-groups containing diagnostic codes relating to peripheral atherosclerotic disease and 
related events. Lastly, Stroke and TIA groups were combined for analysis to form a 
cerebrovascular accident variable. However, it was noted that the clinical sequela of stroke 
and TIA may be dramatically different. Since TIAs, by nature, leave no residual damage, 
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their occurrence may primarily impact work if occurring in proximity to the adverse work 
outcome of interest. 
At this stage, certain subgroups were excluded from further analysis. These included: 
“cardiology or vascular investigations”, “non-specific cardiovascular problems”, “referrals 
or follow up in cardiac clinic and other cardiac monitoring” which did not define distinct 
cardiovascular disorders. “probable/possible heart failure” which was excluded since more 
specific heart failure sub-groups were available; “pericardial diseases” which described 
uncommon short term cardiovascular disorders; “possible/probable acute coronary 
syndrome” for which no codes were identified in the study sample; “aneurysms” for which 
only one study participant reported a rupture code;  “cardiac arrest, cardiopulmonary 
resuscitation” which may be as a result of underlying non-cardiovascular causes; 
“superficial vein thrombus” which contained codes relating to relatively benign disorders 
such as thrombophlebitis; “ectopics” which contained codes relating to benign cardiac 
arrhythmias which may occur in health individuals; “secondary hypertension including 
gestational/pre-eclampsia” which described typically transient conditions, in younger 
populations, often followed by pre-planned maternity leave from paid employment; and 
“venous occlusions” which was a heterogenous group of other venous thrombotic events. 
See Table 7, below, for the final grouping of cardiovascular code groups for analysis. 
Table 7: Cardiovascular disorder sub-groups arranged into broader groups for analysis 
Broad cardiovascular disorder group  Cardiovascular disorder sub-groups 
Ischaemic heart disease Myocardial infarction/unstable angina 
Myocardial ischaemia/atherosclerosis/angina 
Coronary angioplasty/bypass/stent 
Severe ischaemic heart disease Myocardial infarction/unstable angina 
Heart failure Heart failure 
Heart transplant 
Structural heart disease Diseases of the endocardium and valves 
Cardiomyopathies 
Arrhythmias Arrhythmia other than AF or treated 
AF, SVT 
Arrhythmia requiring cardioversion/ablation/pacemaker 
Hypertension Hypertension 
Venous thromboembolism Pulmonary embolism 
DVT 
Peripheral Atherosclerosis Vascular atherosclerotic events/occlusions/surgery 
(non-coronary) 
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Vascular/atherosclerotic/peripheral arterial disease 
(non-coronary) 
Cerebrovascular accident TIA 
Stoke/CVA 
 
3.5.8.4 Asthma, COPD, Diabetes, and Epilepsy 
Following categorisation, six respiratory subgroups were identified. These included 1) 
asthma or probable asthma 2) severe asthma 3) acute bronchitis 4) chronic bronchitis 5) 
bronchitis NOS 6) COPD or emphysema. Two subgroups relating to epilepsy were identified, 
these included 1) epilepsy 2) fit/seizure (non-specific). Four subgroups relating to diabetes 
were identified, these included 1) diabetes 2) diabetes with eye involvement 3) diabetes 
with indicators of poor control 4) diabetes with other complications. See Table 5, Appendix, 
for the specific Read codes that comprised these groups. I arranged these sub-groups into 
their related broader groups, see Figure 21. 
Figure 21: Concept map showing related groups of respiratory, diabetes, and epilepsy 
codes 
 
An asthma variable was constructed using the “asthma or probable asthma” sub-group. In 
addition, I defined severe asthma using the “severe asthma” sub-group which contained 
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Read codes indicating more debilitating disease, for example “Emergency admission, 
asthma.” A COPD variable was constructed using two sub-groups which contained 
diagnostic codes for COPD, emphysema, and chronic bronchitis. A diabetes variable was 
constructed from one sub-group containing general diabetes codes. It was also possible to 
identify poorly controlled diabetes using three subgroups containing Read codes for 
diabetic eye disease, diabetic complications, and other indicators of poor diabetic control, 
for example “diabetes mellitus with ketoacidosis”. An epilepsy variable was defined using a 
sub-group of epilepsy-specific codes and a sub-group containing fit or seizure events. While 
fit or seizure codes were often specific to epilepsy, certain codes could have described fits 
or seizures with other underlying causes. 
At this stage, certain sub-groups were excluded from further analysis. These were “acute 
bronchitis”, and “bronchitis non-specific” which were removed as they were non-specific to 
COPD.  Of the respiratory conditions, only COPD- and Asthma-related codes had been 
requested from CPRD, therefore, codes pertaining to other respiratory conditions were 
excluded, since they were not adequately measured. See Table 8, below, for the final 
grouping of these health problem code groups for analysis. 
Table 8: Other health disorders arranged into broader groups for analysis 
Broad health disorder group  Health disorder sub-groups 
Respiratory disorders 
Asthma 1 Asthma or probable asthma 
Severe Asthma 2 Severe asthma 
COPD 4 Chronic bronchitis 
6 COPD or emphysema 
Diabetes 
Diabetes 1 Diabetes 
Diabetes with complications 2 Eye involvement 
3 Poor control 
4 Other complication 
Epilepsy 
Epilepsy  1 Epilepsy 
2 Fit or seizure (non-specific) 
 
3.5.8.5 History of heavy alcohol intake 
CPRD also contained clinical codes relating to a history of heavy alcohol intake. Following 
separation of these codes from other alcohol and lifestyle-related Read codes, two 
subgroups were identified. These included 1) codes pertaining to heavy alcoholism, for 
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example, “hazardous alcohol use” or “replaces meals with drinks” 2) codes relating to 
previous alcoholism e.g. “ex-heavy drinker – (7-9u/day)” and “ex-very heavy drinker” – 
(>9u/day). A “history of heavy alcohol intake” variable was constructed using these sub-
groups. See Table 6, Appendix, for the specific Read codes that comprised these sub-
groups.  
3.6 Study design and methods  
3.6.1 Outcome of interest 
This thesis primarily focusses on one work outcome: health-related job loss (HRJL). As 
described above, participants who were not currently in paid work were asked whether 
they left work because of a health problem and could respond “no, not at all”, “yes, a 
health problem was the main reason for leaving”, or “yes, a health problem was part of the 
reason for leaving”. In general, HRJL was defined as job loss in which a health problem was 
either part of or the main reason for leaving. However, some sensitivity analysis was 
undertaken to explore the differences between those who answered that a health problem 
was “part of the reason” and those who answered that health was “the main reason” for 
job loss.  
3.6.2 Methods- case control 
A matched retrospective case-control study design was used for this observational, 
epidemiological study. Briefly, this investigative design involves the selection of cases 
(participants with a certain disease or health outcome of interest) and matches them with 
control participants who are similar in many respects, but do not have the outcome of 
interest. Cases and controls are matched for important confounding factors associated with 
both the exposures being studied and the outcome of interest.  Following matching, cases 
and controls can be compared for the presence of certain exposures that, if unevenly 
distributed across groups, may constitute evidence of association.  
3.6.3 Time period covered by this study  
CPRD data were linked to data from the HEAF baseline questionnaire. This supplied clinical 
diagnostic information covering the time period prior to HEAF study participant’s 
completion of the questionnaire, between 2013 – 2014 (see Figure 22). For cases, it was 
important to know if any CPRD-defined health disorders had occurred prior to the 
occurrence of HRJL. Likewise, for working controls, it was important to know whether any 
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CPRD-defined health disorders had occurred prior to the point of HRJL of their matched 
controls. Proximity to the work outcome of interest was also important. For example, in the 
case of chronic health problems like osteoarthritis, a diagnosis could be made any time 
prior to the index date, since these conditions do not resolve. For shorter-term conditions, 
it was imperative that there was evidence of a recent clinical event in the year prior to job 
loss.  
Figure 22: Data used in this thesis and the time period covered (red square) 
 
3.6.4 Case definition  
Cases were participants of the HEAF study who reported that they had HRJL, as defined 
above. Since HEAF participants had variable retrospective CPRD coverage, it was necessary 
that retrospective CPRD data extended back prior to a case’s HRJL. Therefore, cases were 
included in the present study if they had CPRD coverage for a minimum of a year prior to 
the date of their health-related job loss. Cases were those who reported HRJL at HEAF 
baseline, however, a HEAF participant who had previously stopped work for a health 
reason, but were subsequently reemployed before HEAF baseline, would not be identified 
as a case for the current study.  
3.6.5 Matching Controls 
Control participants were selected from the remaining HEAF study participants who did not 
report that they had experienced HRJL. Good comparability between cases and controls is 
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the primary issue in the design of a case-control study, besides accuracy and completeness 
of the data. The controls do not need to be generalizable to the broader population of 
people without health-related job loss. Rather, they must represent, as closely as possible, 
their cases, but without being matched for the exposure under study or the outcome of 
interest.(217) Below is a discussion of the process of selecting confounding factors to match 
for. 
The first, and most well-known, assumption of matching is that the proposed confounder is 
associated with both the exposure and the outcome of interest.(218–220) However, 
inappropriately matching for an intermediate variable between the exposure and the 
outcome on the causal pathway could threaten a study’s validity. For example, matching 
based on number of GP consultations when considering the relationship between 
multimorbidity and work disability would be to adjust for the downstream effect of the 
health problem itself and may obscure any observable statistical association. Strength of 
association also appears to be important and it is recommended that the matched variable 
must have a strong, or at least moderate, association with both the exposure of interest 
and the outcome of interest.(219) 
In selecting matching variables, several possible confounding factors were identified, 
including: age(19–41), gender(19,21–24,28,30,31,33,39,41,132), education(19–
24,28,32,36,132,221–224), low socioeconomic status or social class(21–23,32,40,222,225–
230), types of work(19–21,24–28,30,33,35,40,132,136,222,224,226,231,232), regional 
differences(21,23,221,223,233,234), ethnicity(21–23,32), and marital status(21,23–25). 
However, it was not practically possible to match for each of these exposures as the more 
specific the criteria, the greater the risk of over-matching and the less likely that enough 
controls can be found for analysis.  Therefore, a trade-off was necessary, and controls were 
matched for both important and common confounders. Any remaining important 
confounders were statistically adjusted for in later analysis.   
Cases were matched to control participants for age. Age is an important non-modifiable risk 
factor for of work disability,(19–41) and increasing age is also known to correlate with 
multimorbidity.(153) Apart from health-associations, the relationship between age and 
reduced work participation is likely to be driven by increasing availability of options such as 
early retirement or other factors such as age discrimination in employment. Therefore, it 
was desirable to adjust for the effect of age in analysis. Since participants of HEAF were 
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recruited within a narrow age band (50 – 65 years old) it was possible to match cases to 
controls to within one year of age.  
Gender has been shown to drive the risk of certain health disorders such as mental health 
problems and cardiovascular disease.(235,236) Female gender was also associated with risk 
of work disability across a variety of health problems in the literature.(19,21–
24,28,30,31,33,39,41,132) The strength of this association is debatable and the large 
number of women available for most research studies means that small effects can often 
be detected as statistically significant. I could not rule out the important role played by 
gender, and since many male and female participants were available for matching, little 
was lost by controlling for this common variable. Therefore, cases were matched to 
controls for gender.  
There were sufficient participants within each general practice to make matching by 
general practice possible. This would allow adjustment for a participant’s local levels of 
deprivation as well as accounting for factors such as regional job market, since most people 
live near to their general practice. Local levels of deprivation are related to an individual’s 
socioeconomic status, which is a strong driver of health(153) and work disability in the 
literature.(21–23,32,40,222,225–230) Regional differences also appear to be important 
influencers of health(237,238) and work disability.(21,23,221,223,233,234) As such, cases 
and controls were matched by GP practice.   
3.6.6 Control definition 
In summary, therefore, control participants were selected from the remaining HEAF study 
participants who had not reported HRJL in the HEAF baseline questionnaire. Matched 
controls were required to be at risk of HRJL at the point of observation, i.e. were working 
when their matched case experienced HRJL. Therefore, HEAF participants who had been 
retired or unemployed at the time of a case’s HRJL were ruled out as controls; this was 
possible as HEAF study participants reported the date at which they had stopped working 
for any reason. As described, control participants were also matched for three key 
confounding factors: age, sex, and GP practice. All control participants were within 1 year of 
age of their matched cases, of the same sex, and from the same GP practice. Finally, control 
participants were included in the present study if they had CPRD coverage for a minimum 
of a year prior to the date of health-related job loss of their matched case.  
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3.6.7 Sample size 
Of the total number of participants in the HEAF study (n=8,134), 494 HEAF participants with 
HRJL met eligibility criteria and were included as case participants. These were matched 1:1 
with eligible control participants. Therefore, in total, 988 participants were included in the 
thesis study sample, see Figure 23.  
Figure 23: Flowchart of the study populations included in this thesis 
 
3.7 Using and validating CPRD-defined health exposures in analysis 
In their current format, CPRD-defined health disorder variables were unsuitable for 
analysis. This was primarily because it was not yet clear whether the health problem had 
occurred prior to the HRJL event. CPRD offers time-stamped data on drugs prescriptions 
and diagnoses, meaning that it was possible to determine whether exposure preceded the 
event of health-related job loss. CPRD-defined health disorders were therefore limited to 
those that had occurred prior to the date of a case’s HRJL, or, for control participants, the 
date of the matched case’s HRJL.  
Although high positive predictive values of CPRD diagnoses have been reported in the 
literature,(239) there are numerous ways in which a diagnostic Read code can be 
misapplied or misspelled by a general practitioner, leading to measurement error. I 
therefore reviewed studies identified by one well-cited systematic review of studies 
reporting validation outcomes for CPRD/GPRD-defined health disorders.(239) Included 
studies used a variety of methods to validate this data including internal validation methods 
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(e.g. manual review of computerised records, sensitivity analysis) or external methods 
(comparison of rates/prevalence with other studies, questionnaire or record request sent 
to GP). Many of these studies also employed algorithms that made use of a combination of 
clinical diagnostic codes and pharmaceutical data, although clinical referral codes and 
investigative codes were sometimes also used. A discussion of this literature and 
comparison with the algorithms used in this thesis for defining health disorders follows.  
3.7.1 Musculoskeletal disorders  
3.7.1.1 Chronic musculoskeletal disorders 
Numerous studies reporting validation outcomes for CPRD-defined diagnoses measured 
chronic musculoskeletal disorders using disease-specific Read codes and sometimes other 
criteria, see Table 9. Most studies used diagnostic Read codes and required no further 
evidence, specifically these were studies of musculoskeletal disorders,(240) rheumatoid 
arthritis,(241,242) osteoarthritis,(243) childhood-onset arthritis,(244) hip and knee 
arthroplasty,(245–247) systemic lupus erythematosus, (248) and gout populations.(249) For 
inflammatory rheumatic disorders, some studies required one or more further pieces of 
evidence, such as multiple disease codes for RA, codes suggesting systemic involvement, 
evidence of fulfilled diagnostic criteria in clinical notes, or specific drug treatments (e.g. 
disease modifying anti-rheumatic drugs or the prescription of anti-inflammatory 
drugs).(250–254) One study in gout required a concomitant prescription of allopurinol, 
colchicine, probenecid, indomethacin, or other non-steroidal anti-inflammatory agent.(254) 
The studies that applied strict criteria were mostly of inflammatory rheumatic conditions.  
For chronic musculoskeletal disorders I chose to be inclusive for the following reasons: In 
primary care, inflammatory rheumatic disorders contribute to a small percentage of the 
overall number of people with chronic musculoskeletal disorders, which is mostly 
comprised of people with osteoarthritis. For the work of this thesis, it was also not 
necessary to distinguish certain types of inflammatory rheumatic disorder from other 
similar diseases, such as was necessary for the rheumatoid arthritis research papers. Lastly, 
the prevalence of musculoskeletal disorders has been reported as underestimated by CPRD 
when compared to other general practice databases.(240) 
Gout can be considered a chronic condition;(255) however, a person may fully recover from 
gout and no longer need to think about it, or they may require regular treatment to 
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manage this condition. It was therefore necessary to distinguish people for whom gout 
appears to be a problem that could be affecting their work.  
People with chronic musculoskeletal disorders were therefore defined as:  
1. Participants with a diagnostic code for chronic musculoskeletal disorders, 
excluding gout, diagnosed any time prior to HRJL. 
OR 
2. Participants with a diagnostic code for gout diagnosed in the year prior to HRJL 
OR 
3. Participants with a diagnostic code for gout received more than a year prior to 
HRJL, who were receiving treatments for gout in the year prior to HRJL.   
3.7.1.2 Musculoskeletal pain  
Fewer studies reporting validation outcomes for the use of CPRD data in musculoskeletal 
pain disorders were identified. Some examples included papers studying carpal tunnel 
syndrome(256) and polymyalgia rheumatica.(257) Geoghegan et al. accepted any carpal 
tunnel diagnostic code that had occurred in the observation period,(256) whereas Smeeth 
et al required that polymyalgia rheumatica codes have concomitant codes showing two 
prescriptions for oral corticosteroid use over six months.(257) See Table 9, below.  
In defining the musculoskeletal pain group, the exact diagnosis of the musculoskeletal pain 
was considered less important than the experience of musculoskeletal pain within a time 
frame that might influence a person’s risk of HRJL. Restriction of the musculoskeletal pain 
group to only those who were prescribed pain medications was a possibility. However, pain 
is managed in a variety of ways such as massage, CBT, or alternative medicines. 
Alternatively, participants could be taking over the counter pain medication which is not 
observed in CPRD. Since musculoskeletal pain conditions may be short-lasting, codes that 
occurred in the prior year were considered.  
People with recent musculoskeletal pain were therefore defined as: 
 Participants with a diagnostic code for musculoskeletal pain, received in the year 
prior to HRJL 
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Table 9: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for musculoskeletal disorders 
Health 
problem 
Populations studied Criteria used  
Chronic MSD Musculoskeletal disorders (240) 
Rheumatoid arthritis (241,242) 
Osteoarthritis (243) 
Childhood-onset arthritis (244) 
Hip and knee arthroplasty (245–247) 
Systemic lupus erythematosus (248) 
Gout (249) 
Disease-specific Read codes with no 
further evidence required 
Systemic lupus erythematosus 
(250,251) 
Rheumatoid arthritis (252,253) 
 
Disease-specific Read codes AND 
one or more pieces of evidence, such 
as:  
- Evidence of systemic 
involvement 
- Multiple disease codes 
- Written evidence of fulfilled 
diagnostic criteria 
- Drug prescriptions (e.g. 
disease modifying anti-
rheumatic drugs or 
prescriptions for anti-
inflammatory drugs) 
Gout (254) Disease-specific Read codes AND 
evidence of treatment with 
allopurinol, colchicine, probenecid, 
indomethacin, or other non-steroidal 
anti-inflammatory agent. 
MSD pain Carpal tunnel syndrome (256) 
 
Disease-specific Read codes with no 
further evidence required 
Polymyalgia rheumatica (257) Disease-specific Read codes AND 
two prescriptions for oral 
corticosteroid use over six months 
 
3.7.2 Cardiovascular disease 
3.7.2.1 Ischaemic heart disease 
In the literature, some studies reported validation outcomes for CPRD-defined ischaemic 
heart disease, defined using CPRD read codes alone. They searched for codes indicating 
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ischaemic heart disease or surgery indicating heart disease.(258,259) This simpler approach 
yielded a high positive predictive value for myocardial ischaemia codes, which was greater 
than 90% when compared to hospital-discharge letters.(259) Other studies were more 
careful, favouring a combination of diagnostic codes and one extra item of evidence, for 
example hospital discharge letters, symptomatic codes, evidence of raised troponin, or 
treatment with fibrinolytic or antiplatelet drugs for the diagnosis of myocardial 
infarction.(260–263) In a prevalence study for the Office of National Statistics, a similar 
approach was used for ischaemic heart disease where the definition was the presence of a 
diagnostic code for the disease in combination with treatment with aspirin or a drug in BNF 
Chapter 2 (cardiovascular system).(264) 
Although CPRD Read codes for myocardial infarction were found to have high positive 
predictive value when used alone, prescription data for drugs used in cardiovascular 
disorders was readily available from CPRD and participants with known ischaemic heart 
disease would be expected to be receiving medication. It was therefore required that 
participants with Read codes relating to ischaemic heart disease should also have received 
a prescription from the BNF chapters relating to treatments used in lipid control or 
atherosclerotic disease. Since ischaemic heart disease is generally a long-standing 
condition, these codes could occur any time prior to HRJL. 
People with ischaemic heart disease were therefore defined as: 
Participants who had received a diagnostic code for ischaemic heart disease and a 
prescription for treatments used in lipid control or atherosclerotic disease, prior to HRJL. 
People with severe ischaemic heart disease were defined as: 
Participants who had received a diagnostic code for myocardial infarction or unstable 
angina and a prescription for treatments used in lipid control or atherosclerotic disease, 
prior to HRJL. 
3.7.2.2 Heart failure 
Among studies reporting validation outcomes, a couple defined heart failure using CPRD 
read codes alone, i.e. searching for codes indicating heart failure such as “cardiac failure”, 
“left ventricular failure.”(265,266) In one study, these codes were found to have a high 
positive predictive value with 83.4% of the cases confirmed by the patient’s general 
practitioner.(266) One ONS prevalence study required a combination of diagnostic codes 
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for heart failure with a prescription for either a diuretic or ACE-inhibitor in the same 
year.(267) 
Participants with heart failure would be expected to be receiving drug therapy. Therefore, 
to improve validity, participants with heart failure were required to have received drugs 
used in BNF chapters relating to the treatment of heart failure. Participants who had a 
history of heart transplant were clinically distinct from the broader group of participants 
with heart failure, however since these were rare, they were grouped with the other heart 
failure participants. Since heart failure is a chronic condition, these codes could occur any 
time prior to HRJL. 
People with heart failure were defined as: 
Participants who had received a diagnostic code for heart failure and a prescription for 
treatments used in heart failure, prior to HRJL. 
3.7.2.3 Hypertension 
Only one study reporting validation outcomes studied hypertension classified using CPRD 
data. This was an ONS study that classified hypertension using a combination of 
hypertension-specific diagnostic codes with a prescription for hypertension related-drugs in 
the year of analysis.(268)  
In this thesis, in concordance with the ONS study, a person with hypertension was required 
to have both diagnostic codes for hypertension and to have been treated with drugs used in 
hypertension. Again, it was reasonable to assume that people with recognised hypertension 
would have received drug treatment for this problem. Since hypertension is generally a 
chronic condition, these codes could occur any time prior to HRJL. 
People with hypertension were defined as: 
Participants who had received a diagnostic code for hypertension and a prescription for 
treatments used in hypertension, prior to HRJL. 
3.7.2.4 Structural heart disease  
Structural heart disease included people with diseases of the endocardium and valves, and 
cardiomyopathies. This was a heterogeneous group of rarer conditions. In the literature, 
two studies reporting validation outcomes defined valvular disease using CPRD Read codes 
in addition to one other item of evidence, for example echocardiography, heart 
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catheterisation, or clinical examination codes. They searched for codes indicating valvular 
disease such as “valve regurgitation” or “valve incompetence,” and confirmed the diagnosis 
if there was also further documented evidence of the diagnosis.(269,270) 
Access to hospital records to help validate the read codes for structural heart disease was 
not possible for this thesis. In addition, none of the drug prescriptions were disease-specific 
enough to restrict the classification of structural heart disease. Finally, these conditions 
were rare and likely to be important on the individual level, so it was desirable to err on the 
side of inclusivity. Since these structural heart problems are generally chronic, codes were 
permitted to occur any time prior to HRJL. 
People with structural heart disease were defined as: 
Participants who had received a diagnostic code for structural heart disease prior to HRJL. 
3.7.2.5 Arrhythmias 
Multiple studies reporting validation outcomes for CPRD-defined cardiac arrhythmia were 
identified. The majority of these studies also confirmed the diagnosis using hospital 
records, questionnaires sent to the GP, or death certificates.(271–275) One study found 
that CPRD codes for ventricular arrhythmias alone had a positive predictive value of 80% (4 
of 5), with the remainder unclear because of poorly written notes.(258) Another article 
studying atrial fibrillation (AF) (paroxysmal or chronic) sought GP validation and found that 
AF codes had an accuracy of 93.4%.(274) Similarly, 95.9% of CPRD AF codes were GP-
confirmed in another study.(275) 
It was not possible to write to the general practitioners to validate disease codes in this 
thesis. However, given the reported high positive predictive values of these codes, it was 
considered valid to use them alone. While I had access to data about antiarrhythmic drug 
prescriptions, certain arrhythmias may be controlled using non-medical means such as 
cardioversion and, therefore, arrythmia codes were not validated based on concurrent drug 
treatment. Cardiac arrhythmias may be brief or short-lasting, so only codes that occurred in 
the prior year were considered. 
People with cardiac arrythmias were defined as: 
Participants who had received a diagnostic code for cardiac arrythmia in the year prior to 
HRJL. 
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3.7.2.6 Venous thromboembolic disease 
In the literature, multiple studies reporting validation outcomes for CPRD-defined venous 
thromboembolism (VTE) were identified. Most also required a confirmation of this 
diagnosis using one further item of evidence. For example, Meier et al. looked into hospital 
records and death certificates for confirmation of PE, and required ultrasound or venogram 
confirmation of DVT.(276) Other identified studies reinforced the diagnosis of VTE with 
evidence of anti-coagulation prescription.(277–280) One study looked at codes for hospital 
admission for PE or DVT and found that around 96% of the codes could be confirmed by 
writing to the GP.(281) Another study showed that for 99% of read code diagnoses of VTE 
the GP confirmed hospitalisation and 83% also had confirmatory evidence of venogram, 
doppler ultrasound, or VQ scan.(279) 
For this thesis people with deep vein thrombosis were grouped with pulmonary embolism. 
These describe two clinically distinct groups of patients with potentially very divergent 
clinical presentations. However, the survivor bias inherent in this retrospective study would 
mean that anyone who had died from pulmonary embolism would not have been included 
in this study. Therefore, the expected low prevalence of pulmonary embolism in this 
sample suggested combination with deep vein thrombosis would be expedient. Since 
pulmonary embolism is also a clinical sequela of DVT, this also seemed appropriate. Once 
again it was not possible to write to the general practitioners to validate VTE codes in this 
study, however VTE codes were required to co-occur with evidence of anti-coagulation 
drug prescriptions. Since VTE codes in this study are likely to describe deep vein thrombosis 
or pulmonary embolism with full recovery, CPRD-defined VTE was considered a short-term 
condition. As such, codes were restricted to those used for analysis that occurred in the 
prior year. 
 People with venous thromboembolic disease were defined as: 
Participants who had received a diagnostic code for venous thromboembolic disease and a 
prescription for treatments used in anticoagulation, in the year prior to HRJL. 
3.7.2.7 Peripheral arterial disease (PAD) 
No studies reporting validation outcomes that used CPRD to identify peripheral arterial 
disease were identified. However, since prescription data was available showing whether a 
person had received treatments for lipid control or anti-coagulation, I validated peripheral 
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arterial disease codes using this information. Since these health disorders are generally 
chronic, codes were included that occurred at any time prior to HRJL. 
People with peripheral arterial disease were defined as: 
Participants who had received a diagnostic code for peripheral arterial disease and a 
prescription for treatments used in lipid control, atherosclerotic disease, or anticoagulation 
therapy, prior to HRJL. 
Table 10: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for cardiovascular disorders 
Health problem Populations studied Criteria used  
Ischaemic heart 
disease 
Ischaemic heart disease 
(258,259) 
Myocardial infarction (259) 
Disease-specific Read codes with no 
further evidence required 
Ischaemic heart disease (264) 
 
Disease-specific Read codes AND 
evidence of treatment with aspirin 
or a drug in BNF Chapter 2 
Myocardial infarction (260–
263) 
Disease-specific Read codes AND 
one or more pieces of evidence, 
such as:  
- Hospital discharge letters 
- Symptomatic Read codes 
- Raised troponin 
- Treatment with fibrinolytic 
or antiplatelet drugs 
Heart failure  Heart failure (265,266) Disease-specific Read codes with no 
further evidence required 
Heart failure (267) Disease-specific Read codes AND 
prescription for either a diuretic or 
ace-inhibitor in the same year 
Hypertension Hypertension (268) Disease-specific Read codes AND 
prescription for a hypertension-
related drug in the same year 
Structural heart 
disease 
Valvular disease (269,270) Disease-specific Read codes AND 
one or more pieces of evidence, 
such as: 
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- Echocardiography 
- Heart catheterisation 
- Clinical examination 
Arrhythmias Cardiac arrhythmias (272,273) 
Ventricular arrhythmias 
(258,271) 
Atrial fibrillation (274,275) 
Disease-specific Read codes with no 






Disease-specific Read codes AND 
treatment with an anti-coagulant  
Venous thromboembolism 
(276,281) 
Disease-specific Read codes AND 
one or more pieces of evidence, 
such as: 
- Doppler 
- Ventilation perfusion scan 
- Angiography 




No studies identified No studies identified 
 
3.7.3 Mental health problems 
3.7.3.1 Primary-care-level mental health problems 
There was one study reporting validation outcomes and using CPRD codes to analyse the 
prevalence of mental health problems and drug addiction.(282) This study used disease 
codes with no other form of evidence.  
While it was possible to use prescription data to classify mental health problem exposures, 
a participant may choose other options for the treatment of mood disorders such as CBT, 
counselling, or even hypnosis. Therefore, in this thesis, prescriptions related to mental 
health problems were not used to validate the disease codes. Mental health problems may 
also improve and are often short term. For this reason, mental health codes that had 
occurred in the year prior to health-related job loss were included. In addition, a person 
may have been diagnosed for a mental health problem earlier but be continuing 
medication, such as selective serotonin reuptake inhibitors (SSRIs), to control symptoms. 
These participants were also included in analysis. 
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People with primary care level mental health problems were defined as: 
Participants who had received a diagnostic code for a primary-care-level mental health 
problem in the year prior to HRJL. 
OR 
Participants who had received a diagnostic code for a primary-care-level mental health 
problem earlier than a year prior to HRJL and received a prescription code for treatments 
used in mood disorders or treatments used in insomnia and anxiety, in the year prior to 
HRJL. 
3.7.3.2 Sleep disorders 
No studies reporting validation outcomes for the use of CPRD codes to classify sleep 
disorders were identified. Similarly to primary-care-level mental health problems, 
prescription data can be used to validate sleep disorder diagnostic codes, although a 
participant may choose other non-pharmacological options for treatment. Sleep disorders 
may also improve and are often short term. For this reason, sleep disorder codes that had 
occurred in the year prior to health-related job loss were included. In addition, a person 
may have been diagnosed for a sleep disorder earlier but may still be receiving medication, 
such as zolpidem, to control symptoms. These participants were also included in analysis. 
People with primary care level mental health problems were defined as: 
Participants who had received a diagnostic code for a sleep disorder in the year prior to 
HRJL. 
OR 
Participants who had received a diagnostic code for a sleep disorder earlier than a year prior 
to HRJL and received a prescription code for treatments used in mood disorders or 
treatments used in insomnia and anxiety, in the year prior to HRJL. 
3.7.3.3 Psychiatric care diagnosed mental health problems 
Several studies that used CPRD-derived diagnostic codes to classify psychotic disorders, 
including schizophrenia, were identified. Howard et al, in three studies, included 
participants with CPRD codes for a psychotic disorder or had prescription codes for lithium 
or a neuroleptic or antipsychotic drug.(283–285) In the diagnosis of schizophrenia, some 
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studies required only the relevant CPRD disease codes.(286–288) One study reported the 
diagnostic accuracy of CPRD-defined schizophrenia, comparing to case notes to see 
whether such patients met International Classification of Disease criteria(289) and the 
Diagnostic and Statistical Manual of the American Psychiatric Association.(290) The 
sensitivity and positive predictive value of schizophrenia diagnostic codes was found to be 
88% (95%CI 62 to 98%) and 71% (95%CI 48% to 88%), respectively. For non-organic 
psychosis, sensitivity and positive predictive value was 91% (95%CI 74% to 97%) and 91% 
(95%CI 74% to 98%), respectively.(287) No other research studying the use of CPRD for 
bipolar disorders, dissociative disorders, sexual and gender identity disorders, eating 
disorders, impulse control disorders, or personality disorders were identified. 
Since identified studies reported high diagnostic accuracy for CPRD-defined schizophrenia, 
it was considered acceptable to use schizophrenia codes alone, with no further evidence 
required. Diagnostic codes for longer lasting psychiatric disorders, such as personality 
disorders or sexual and gender identity disorders were also used alone. For these 
conditions, a participant was permitted to receive a diagnostic code any time prior to 
health-related job loss. Other psychiatric conditions such as dissociative disorders, eating 
disorders, impulse-control disorders, bipolar disorders, and psychosis were conditions that 
could completely resolve. For these conditions, a participant was required to also have 
evidence of a continuing mental health problem into the year prior to health-related job 
loss.  
People with psychiatric-care-level mental health problems were defined as: 
Participants who had received a diagnostic code for schizophrenia, personality disorders, or 
sexual and gender identity disorders, prior to HRJL. 
OR 
Participants who had received a diagnostic code for dissociative disorders, eating disorders, 
impulse-control disorders, bipolar disorders, and psychosis in the year prior to HRJL  
OR 
Participants who had received a diagnostic code for dissociative disorders, eating disorders, 
impulse-control disorders, bipolar disorders, and psychosis earlier than a year prior to HRJL 
and received a prescription for treatments used in mood disorders, treatments used in 
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mania and hypomania, treatments used in psychoses, or treatments used in insomnia and 
anxiety, in the year prior to HRJL. 
3.7.3.4 Severe mental health disorders 
In the literature, several studies reporting validation outcomes for CPRD-defined suicide 
and self-harm were identified. Two studies used diagnostic codes for suicide with no 
further evidence required.(291,292) Two other studies used diagnostic codes for suicide or 
self-harm combined with a review of the GP notes or death certificates.(293,294)  
In this thesis, severe mental health problems included codes relating to self-harm, suicidal 
actions or ideations and refers to people with crisis admission, section, on a severe mental 
health register or under psychiatric care. It was considered that such events were unlikely 
to be misclassified; therefore, any code relating to these events was included in analysis. 
These codes represent serious life events which may have fallout for years to come. 
Therefore, I was interested the occurrence of these codes any time prior to HRJL.  
People with psychiatric-care-level mental health problems were defined as: 
Participants who had received a diagnostic code for a severe mental health event prior to 
HRJL 
Table 11: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for mental health problems 




Mental health problems in 
general practice (282) 
Disease-specific Read codes with 
no further evidence required 
Sleep disorders No studies identified No studies identified 
Psychiatric-care-
level mental health 
problems 
Schizophrenia (286–288) Disease-specific Read codes with 
no further evidence  
Schizophrenia (283–285) Disease-specific Read codes AND 
prescriptions for a neuroleptic, 
antipsychotic or lithium 
Severe mental 
health problems 
Suicide and self-harm 
(291,292) 
 
Disease-specific Read codes with 
no further evidence 
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Suicide and self-harm 
(293,294) 
 
Disease-specific Read codes AND 
a review of the GP notes or death 
certificates 
 
3.7.4 Neurological disorders: epilepsy and cerebrovascular accident 
3.7.4.1 Epilepsy 
In the literature, studies reporting validation outcomes for CPRD-defined epilepsy used a 
combination of diagnostic codes with epilepsy-specific drug codes.(295–297) Epilepsy is a 
condition with a relatively specific and sensitive set of drugs for which it is treated. This 
makes the use of prescription data ideal, as a person is unlikely to have epilepsy if they are 
not also being managed by an epilepsy drug, see NICE guidelines for diagnosed 
epilepsy.(298) As such, in this thesis, epilepsy codes were only included for analysis if they 
occurred with concomitant epilepsy-specific prescriptions. The use of fit and seizure codes 
was more complicated: in clinical practice, a diagnosis of epilepsy is made carefully, and 
may not be made for some time following a seizure, as long-term treatment with epilepsy 
drugs has considerable consequences for the patient. Therefore, participants with fits and 
seizures who were later diagnosed with epilepsy (even after HRJL) were also included.  
People with epilepsy were defined as: 
Participants who had received a diagnostic code for epilepsy prior to HRJL and had ever 
received a prescription for treatments used in epilepsy 
OR 
Participants who had received a diagnostic code for fits or seizures prior to HRJL, and had 
ever received a diagnostic code for epilepsy and a prescription for treatments used in 
epilepsy 
3.7.4.2 Cerebrovascular accident 
Several studies reporting validation outcomes used CPRD data to classify stroke and TIA. In 
several studies these clinical codes were used with one further piece of evidence, such as 
the use of antiplatelet drugs, new epilepsy, hospitalisation discharge letters and referrals, 
or neuroimaging results.(299–303) Other studies combined TIA and stroke codes to form a 
cerebrovascular accident (CVA) group.(258,304) Importantly, one study found the 
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diagnostic accuracy of TIA and stroke diagnostic codes was quite low: overall agreement 
between stroke and TIA codes and hospital specialist notes was 66%. This was largely due 
to misdiagnosis between strokes and TIA codes. However, if the two groups were merged 
to form CVA, agreement increased to 80%. 
In accordance with the methods outlined in the literature, I reinforced diagnostic codes for 
these conditions with one further piece of evidence: participants were also required to 
have been prescribed antiplatelet drugs. Since TIA is a condition from which full recovery is 
expected, these codes were restricted to those that had occurred in the year prior to HRJL. 
In consideration of the disparity between GP diagnosis of stroke/TIA and specialist 
diagnosis of stroke/TIA in the literature, I also merged these two groups to form a CVA 
group for analysis.  
People with CVA were defined as: 
Participants who had received a diagnostic code for stroke prior to HRJL and had ever 
received a prescription for antiplatelet treatment 
OR 
Participants who had received a diagnostic code for TIA and received a prescription for 
antiplatelet treatment in the year prior to HRJL 
Table 12: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for neurological disorders 
Health problem Populations studied Criteria used  
Epilepsy Epilepsy (295–297) Disease-specific Read codes with 





Disease-specific Read codes with 
no further evidence required 
Stroke or TIA (299–303) 
 
Disease-specific Read codes AND 
one or more pieces of evidence, 
such as: 
- Antiplatelet drug 
treatment 
- New diagnostic epilepsy 
code 
- Hospitalisation 




3.7.5 Respiratory disorders: asthma and COPD 
3.7.5.1 Asthma 
A few studies were identified in the literature that reported validation outcomes and used 
CPRD diagnostic codes for asthma in their analysis. Two studies used the asthma codes 
alone,(305,306) while another required both asthma codes and prescription codes.(307) 
Two studies reported good agreement between CPRD and other databases or coding 
systems for asthma, with or without the use of prescription data.(305,307) 
The use of prescription inhalers in asthma is ubiquitous enough that a person who was not 
prescribed such medication would have a doubtful diagnosis of asthma. It was also 
desirable to exclude participants with a previous diagnosis of asthma but who had not 
needed treatment for some time (e.g. over a year).  
People with asthma were defined as: 
Participants who had received a diagnostic code for asthma prior to HRJL and had received 
a prescription for treatments used in asthma or COPD in the year prior to HRJL 
People with severe asthma were defined as:  
Participants who had received a diagnostic code for severe asthma prior to HRJL and had 
received a prescription for treatments used in asthma or COPD in the year prior to HRJL 
3.7.5.2 COPD 
In the literature, one study of CPRD-defined COPD used diagnostic codes alone in analysis 
and found similar prevalence rates to those found in the Morbidity Survey in General 
Practice.(307) Other identified studies used a combination of disease codes and 
prescription data.(307–309) Soriano et al. used a system of COPD prescriptions to devise a 
severity ladder: those on at least two prescriptions of inhaled or oral bronchodilators, 
xanthines, cromones, steroids, or combinations were considered as having moderate COPD; 
those on oxygen or nebulised therapy were considered as having severe COPD; while 
everyone else was defined as having mild COPD.(309) When comparing COPD diagnosis to 
GP-recorded diagnosis, the positive predictive value was surprisingly low: one study 
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reported that only 57.8% of cases were confirmed by the GP. This appeared to be because 
the remaining participants had had asthma which was erroneously coded as COPD.(309) 
The expected number of people with diagnosed COPD in this working-age study sample was 
likely to be very low and therefore I did not attempt to derive the severity of COPD using 
prescription codes. However, given the low diagnostic accuracy of COPD Read codes 
reported in one study, COPD disease codes were restricted to those that occurred prior to 
HRJL alongside prescriptions for COPD treatments in the year prior to HRJL. In interpreting 
analysis using asthma and COPD variables, it was also important to remain mindful of 
possible misdiagnosis between these two conditions in study participants.   
People with COPD were defined as: 
Participants who had received a diagnostic code for COPD prior to HRJL and had received a 
prescription for treatments used in asthma or COPD in the year prior to HRJL 
Table 13: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for asthma and COPD 
Health 
problem 
Populations studied Criteria used  
Asthma Asthma (305,306) Disease-specific Read codes with 
no further evidence required 
Asthma (307) Disease-specific Read codes AND 
prescriptions for asthma drugs 
COPD COPD (307) 
 
Disease-specific Read codes with 
no further evidence required 
COPD (307–309) Disease-specific Read codes AND 
two prescriptions for COPD drugs 
 
3.7.6 Endocrine disorders 
3.7.6.1 Diabetes 
The use of CPRD-derived disease codes for diabetes varied significantly in the literature. 
Two studies were identified that used disease codes alone,(310,311) one study that 
required a combination of disease codes and prescription codes,(312) and three studies 
that based identification of diabetes solely on the basis of treatment with diabetic drugs in 
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the past 12 months.(313–315) Additionally, several studies split by type 1 or type 2 diabetes 
using an algorithm which took into account age at diagnosis and type of 
treatment.(266,303,316–318)  
For the work of this thesis, the distinction between type 1 and type 2 diabetes was not as 
important as whether diabetes was well-managed and whether there were complications. 
Severe diabetic problems would be likely to have a greater impact on work. Moreover, to 
restrict diabetes codes based on diabetic prescriptions would be to exclude many people 
managing their diabetes without drugs. Since diabetes is a chronic condition, codes were 
included that had occurred prior to the point of health-related job loss.  
People with diabetes were defined as: 
Participants who had received a diagnostic code for diabetes or severe diabetes prior to 
HRJL  
People with severe diabetes were defined as:                                   
Participants who had received a diagnostic code for severe diabetes prior to HRJL  
Table 14: Identified research studies reporting validation outcomes and using CPRD/GPRD 
criteria for diabetes 
Health 
problem 
Populations studied Criteria used  
Diabetes Diabetes (310,311) Disease-specific Read codes with 
no further evidence required 
Diabetes (312) Disease-specific Read codes AND 
prescription for diabetes 
Diabetes (313–315) Diabetes treatment in the prior 
12 months 
Type 1 and type 2 diabetes 
(266,303,316–318) 
Type 1 and type 2 diabetes were 
distinguished using an algorithm 
that separated diabetes based on 
age at diagnosis and type of 
treatment (e.g. treated with 
insulin and <35 years old at 
diagnosis = type 1 diabetes) 
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3.8 Statistics  
This section describes the statistical methods used throughout the thesis and how they will 
be applied to answer the research objectives. This includes a discussion of the use of 
descriptive statistics, conditional logistic regression, and cluster analysis. Statistical analyses 
were performed using STATA-13.  
3.8.1 Descriptive statistics 
Percentages were used to describe proportions for categorical data. For measures of 
central tendency and scatter, means and standard deviations were used for continuous 
data, and medians and interquartile ranges for ordinal data and skewed continuous data. 
The Wilcoxon rank-sum test, also known as the Mann-Whitney U test was used to compare 
independent sample, continuous variables between groups. This test was used where data 
was not normally distributed and tested the null hypothesis that a randomly selected value 
from one group is equally likely to be larger or smaller than a randomly selected value from 
a second group. Since independence is a requirement, this test was run on unmatched data 
only. 
The chi-squared test was used for categorical data, to determine whether differences in 
proportions were statistically significant. Where expected values in cells of the generated 
contingency table were below 5, Fisher’s exact test was used instead.  
3.8.2 Conditional logistic regression 
Logistic regression analysis is a commonly used statistical approach in which a logistic 
function is used to predict the probability of a categorical dependent variable (outcome of 
interest) using a set of explanatory variables (exposures of interest). Binomial logistic 
regression is used to predict the probability of a binary dependent variable (outcomes 
where only two values are possible) e.g. living vs dead or diabetes vs no diabetes. While in 
linear regression a straight line is used to describe the relationship between one or several 
explanatory variables and a continuous outcome, in logistic regression it is not possible to 
apply a linear equation to predict probabilities. Instead, the log odds of the event of 
interest are predicted, which may follow a linear relationship with the explanatory variables 
of interest and therefore can be predicted using a linear equation. The coefficients (beta 
values) produced by the logistic model describe the relationships between the explanatory 
variables of interest and the log odds of the event of interest. By exponentiating these 
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coefficients, it is possible to calculate odds ratios (OR) which are a measure of the 
association between the variables of interest and the outcome of interest.  
Conditional logistic regression is a specialised version of logistic regression that takes case 
and control matched pairs into account. In this kind of analysis, cases are compared to their 
matched controls for a certain set of explanatory variables. Interestingly, this analysis 
predicts (or “retrodicts”) how the value of the explanatory variables of interest vary based 
on the fixed value of the outcome of interest. The coefficients (and thus odds ratios) 
produced by this model can be interpreted the same as for a logistic regression, except that 
all observed associations are independent of the variables for which case and control 
participants were matched. Using the proposed case control analysis above as an example, 
this means conditional logistic regression analysis will account for age, gender, and GP 
practice in this thesis.  
Matched case control studies are advantageous as they require fewer study participants 
than regular case control studies to achieve sufficient statistical power. Matching for known 
confounding factors means that further statistical adjustment is not required for the 
variables used in the matching process. However, once matched for, such variables cannot 
be examined for their association with the outcome of interest in regression analysis.  
In this thesis, conditional logistic regression was used to assess the association between 
demographic, lifestyle, and health-related exposures and the occurrence of HRJL. As 
described above, the number of variables on which a participant can be matched is limited 
as the greater the number of matching variables the less likely suitable controls can be 
found for analysis. However, other factors may confound the relationship between a health 
exposure and HRJL, and, where appropriate, these were statistically adjusted for as co-
variables in multivariable logistic regression analysis.  
To make appropriate adjustment in multivariable analysis there should be strong reason to 
believe a variable is associated with both the exposure and outcome of interest. Adjusting 
for a factor that is associated with the exposure of interest alone, or the outcome of 
interest alone, constitutes an unnecessary adjustment leading to reduced precision in 
estimating effect. If a factor is associated with both the exposure and outcome of interest 
one must also be careful that it is not a mediator between the exposure and outcome: 
adjustment for a mediating variable amounts to an over-adjustment which may lead to 
underestimates of true effect.(319) Throughout the thesis, I considered potential 
confounding factors for their association with the outcome of interest (HRJL) and the 
115 | P a g e  
 
exposure under study, before their use in multivariable conditional logistic regression 
analysis.  
3.8.3 Cluster analysis 
Cluster analysis is used to describe common groupings, or patterns, of variables in a study 
population. In this thesis, cluster analysis was used to define common groups of health 
disorders among study participants with multimorbidity. Several methodological 
considerations are required for planning cluster analysis. In the first stage, the variables on 
which to base the cluster analysis are selected and it is important that these variables 
characterise the phenomenon under study. For example, age does not constitute a useful 
cluster-defining variable for multimorbidity as it does not characterise multimorbidity well. 
Instead, variables describing distinct health disorders are appropriate.  
Cluster analysis groups individuals based on their mathematical “similarity” for selected 
variables. In practice, there are several techniques that can be used to describe the degree 
of similarity. One approach used involves correlation between groups, where large values 
of Pearson’s correlation statistic r, for example, may indicate strong similarity between two 
individuals for certain variables and initiate their clustering together. However, in the 
literature, geometric distances are more commonly used for cluster analysis. Similarity 
statistics are derived from these geometric distances with higher values representing 
greater levels of similarity. There are multiple similarity statistics that use geometric 
distances and their selection depends upon the objectives of the research and the data 
available.(320) In this thesis, the clustering of health disorders among participants with 
multimorbidity was described, and clustered variables were all binary (since the participant 
either had the disorder or did not). In this situation, an appropriate similarity measure is the 
Jaccard coefficient.(321) This coefficient is advantageous as it’s easily understood and 
defines similarity between two individuals using a count-based algorithm which considers 
the proportion of variables that are present in two individuals over those that are present 
in both or only in one person, J = M11 / M01 + M10 + M11, see Figure 24. For the purposes of 
this thesis, it was also advantageous because it did not lend weight to negative matches 
(i.e. grouping participants based on diseases that they did not have), as for most study 
participants many CPRD-defined disorders will not be present. The Jaccard coefficient 
contrasts with the simple matching coefficient, for example, that lends weight to negative 
matches, including M00 in its numerator and denominator SMC = M11 + M00/ M01 + M10 + 
M11 + M00.  
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Figure 24: binary variables used in calculating the Jaccard similarity coefficient and the 













Cluster analyses can take hierarchical or non-hierarchical approaches. Non-hierarchical 
cluster analysis requires the user to pre-specify the number of clusters they wish to 
examine. The algorithm (k-mean or k-median) assigns each participant or observation to 
one of the cluster seeds with the nearest mean or median similarity. Non-hierarchical 
cluster analysis is useful in that the results are less susceptible to outliers and as it can 
analyse extremely large datasets. However, this method can be susceptible to high 
variability in output, depending on the number of clusters that have been specified. 
Therefore, non-hierarchical methods tend to be used when analyses are less explorative 
and when the researcher has validated information about the underlying structure of the 
data that will help them to select an appropriate number of cluster points. A more 
explorative approach was undertaken in this thesis since patterns of multimorbidity had not 
yet been described in the older working-age population, and it was preferable to be led by 
the available data. In addition, to visualise how health disorder clusters merged at different 
levels of similarity was only possible with the use of a generated dendrogram in hierarchical 
cluster analysis.  
Hierarchical methods include agglomerative and divisive methods. In agglomerative cluster 
analysis participants start the process as individuals that are subsequently clustered one by 
one based on their similarity to other groups of participants, so that eventually all 
participants form one cluster. The opposite process happens in divisive methods where 
participants start in one cluster and are separated out by an individual’s dissimilarity to 
other members of that cluster. In this process, all individuals end up on their own or in a 
group of identical participants for the variables specified. For the purposes of this work, 
analysis was performed in STATA-13, which takes an agglomerative approach to 
hierarchical cluster analysis, since the computational time required for divisive methods is 
greater.(322) 
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Similarity measures, such as the Jaccard coefficient, may be employed in different 
clustering algorithms, which decide which groups of individuals should be grouped together 
at each step in the clustering solution. Some of the more well-known methods include: 
• Single linkage: which computes dissimilarity as the dissimilarity between the most 
similar pair of observations between two groups. This technique has low resistance 
to measurement error and outliers and tends to form unbalanced clusters where 
members have little in common and are mostly grouped together based on 
intermediate observations.(323,324)  
• Complete linkage: which is like single linkage except it uses the furthest pair of 
observations between two clusters to calculate dissimilarity. This technique is less 
sensitive to outliers but tends to clump observations into many tight compact 
clusters which are resistant to merging.(324)  
• Average linkage: uses the average dissimilarity between two clusters and therefore 
has properties intermediate between single and complete linkage. These 
algorithms are commonly used, reasonably robust, and produce more stable 
dendrograms.(324,325)  
• Wards linkage: uses the similarity between two clusters based on the minimum 
increase in the error of sum of squares within the clusters, summed over all 
variables.(324) Wards method is strongly biased towards producing clusters with 
similar numbers of participants and groups that are multivariate normal. This 
method is appropriate in situations when it is reasonable to assume that clusters 
should be of similar sizes. 
I used average-linkage algorithms to cluster since these produced a more stable solution 
and because finding clusters of similar sizes was not a necessity for the purposes of this 
thesis.  
During hierarchical cluster analysis, the researcher must consider at what point clusters are 
most meaningful i.e. when individuals within each cluster are similar enough for their 
selected characteristics but the total number of clusters is also small enough to allow for 
intelligible comparison. This process is facilitated by the production of a tree-like 
dendrogram which allows the researcher to observe the overall similarity measure (the 
average within-cluster distance) at each point in the stepwise process. For the purposes of 
this thesis, I observed points at which there were large leaps in the within-cluster 
dissimilarity between cluster steps, reflecting the algorithm’s “reluctance” to join two 
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clusters together, as occurs when there appears to be substantial inter-cluster differences. 
This is visualised by long drawn out vertical lines on the generated dendrogram. When such 
leaps were visible, the process was stopped, and the comparative disease and demographic 
profiles of the developed clusters were examined.  To compliment this process, I used the 
variance ratio criterion, or pseudo F-statistic, which was calculated to suggest the optimum 
number of clusters.(326) When the F-statistic was similar at different stop points, the 
dendrogram was observed to make a final decision regarding number of clusters.  
As part of this process, outlying clusters were identified and described. Such clusters were 
usually composed of few or single individuals with marked differences to the majority (e.g. 
participants with rarer disorders or unusual pairings). Outlying clusters were defined as 
those composed of less than 10 participants and were discarded from further analysis.  
3.8.4 Statistical power calculations 
For the analyses conducted in this thesis, recruitment had already occurred, and the 
number of participants was set. Therefore, I estimated the statistical power available for 
planned analyses using the available sample size. Statistical power describes the probability 
of finding a statistically significant effect (rejecting the null hypothesis) if there is an effect 
to be found (the alternative hypothesis is true). In other words, the higher the statistical 
power the lower the chance of committing a type II error. In this section, for a range of 
planned analyses, I considered the minimum detectable odds ratio that could be achieved 
with a statistical power of 80%. To calculate statistical power, a well-cited method for 
matched case-control studies using 1:1 matching was applied (Schlesselman 
1982).(327,328) This method required information about the number of case participants 
available (maximum 498 for this thesis), the number of controls per case (1:1 for all 
analyses), the alpha significance level (set by convention at 5%), and, lastly, the likely 
prevalence of the exposure of interest among control participants – which was estimated 
using previously reported prevalence figures in a comparable population and age group.  
Since this thesis employed a novel classification system to define health exposures, the 
prevalence of these exposures could not be estimated from pre-existing publications using 
the same classification system. Instead, I used prevalence figures from the Age UK Almanac 
of disease profiles in later life.(329) This paper used a sample representative of the English 
population, born before 1954, from a complete dataset of GP practices participating in 
CPRD. As such, it provided UK-based and similarly sourced reference figures for disease 
prevalence. However, it should be emphasised that power calculations performed using 
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these figures were estimates only, since the prevalence study retrieved additional 
diagnostic information from HES data and was likely to have used different Read codes to 
classify health exposures. In addition, prevalence figures were not available for ages below 
60-64 years, meaning the estimated prevalence of certain conditions may have been 
slightly higher than in this sample for some age-associated health problems. 
Using the Age UK prevalence figures, I considered the statistical power available to 
complete the main aims of this thesis. Firstly, I considered the statistical power to assess 
the association between HRJL and the major musculoskeletal, mental health, 
cardiovascular, neurological, and endocrine disorders studied in this thesis. Then, I 
considered the statistical power available to assess the relationship between 
multimorbidity and HRJL. 
Age UK reported the prevalence of osteoarthritis to be 17.1% among those aged 60-64 
years. Osteoarthritis is the most common musculoskeletal disorder in this age group and 
the major contributor to chronic musculoskeletal disorders. Therefore, for chronic MSDs 
and HRJL, a conservative estimate was made, using this prevalence figure, that the total 
sample size in this thesis was sufficient to detect a minimum association of 1.56 OR at a 
statistical power of 80%.  
Age UK reported the prevalence of diagnosed depressive disorders to be 22.3% and the 
prevalence of severe mental health problems to be 1.9% among those aged 60-64 years 
old. Depressive disorders are the most common mental health problems diagnosed in 
primary care, therefore, a conservative estimate was made that the total sample size in this 
thesis was sufficient to detect a significant association between HRJL and primary care-level 
mental health problems, at a minimum OR of 1.50 and a statistical power of 80%. In 
addition, the sample size was sufficient to detect a minimum OR of 2.7 for severe mental 
health problems, according to the Age UK figures.  
Concerning cardiovascular disorders, Age UK reported the prevalence of ischaemic heart 
disease to be 7.6%, heart failure to be 1.4%, and hypertension to be 32.4% among those 
aged 60-64 years old. At a statistical power of 80%, the total sample size in this thesis was 
sufficient to detect an association between these exposures and HRJL at a minimum OR of 
1.81 for ischaemic heart disease, a minimum OR of 3.1 for heart failure, and a minimum OR 
of 1.45 for hypertension. The remaining cardiovascular conditions (structural heart disease, 
cardiac arrhythmias, venous thrombus and peripheral atherosclerosis) represented a mix of 
rarer diagnoses for which it was harder to find UK- and age-specific reference values. Since 
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these conditions are rarer it may be difficult to detect a significant association with HRJL 
using the available sample size, unless the strength of association is large.  
Age UK reported the prevalence of asthma to be 11.7% and of COPD to be 4.8% among 
those aged 60-64 years old. At a statistical power of 80%, the total sample size in this thesis 
was sufficient to detect an association between these respiratory exposures and HRJL at a 
minimum OR of 1.66 for asthma, and a minimum OR of 2.03 for COPD, according to the Age 
UK figures. 
Age UK reported the prevalence of stroke to be 2.8% and of epilepsy to be 1.8% among 
those aged 60-64 years old. At a statistical power of 80%, the total sample size in this thesis 
was sufficient to detect an association between these neurological exposures and HRJL at a 
minimum OR of 2.40 for stroke, and a minimum OR of 2.82 for epilepsy, according to the 
prevalence figures reported by Age UK. 
Age UK reported the prevalence of diabetes to be 10.6% among those aged 60 – 64 years 
old. Therefore, at a statistical power of 80%, the total sample size in this thesis was 
sufficient to detect an association between diabetes and HRJL at a minimum OR of 1.69.  
Next, I considered what statistical power was available to assess the association between 
multimorbidity and HRJL. Age UK looked at 22 conditions (hypertension, atrial fibrillation, 
coronary heart disease, heart failure, stroke, dementia, depression, epilepsy, mental health, 
asthma, COPD, diabetes, hypothyroidism, chronic kidney disease, cancer in the past 5 years, 
anaemia, osteoporosis, falls, fragility fractures, incontinence and skin ulcers). They found 
that the prevalence of participants with no morbidity, one morbidity, two morbidities, 
three morbidities, four morbidities, or five morbidities were 38.1%, 31.1%, 17.3%, 8.0%, 
3.3% and 2.2% respectively, among those aged 60 – 64 years. Although the Age UK 
classification of multimorbidity could not be replicated here, these prevalence figures were 
used as rough estimates. At a statistical power of 80%, the total sample size in this thesis 
was sufficient to detect an association between multimorbidity and HRJL at a minimum OR 
of 1.55 for two morbidities, OR of 1.79 for three morbidities, OR of 2.28 for four 
morbidities, and OR of 2.60 for five morbidities, according to the prevalence figures 
reported by Age UK. 
Based on the power calculations above, it appeared that statistical power was sufficient to 
observe, at minimum, a small to moderate association with HRL for the majority of health 
exposures of interest in this thesis. However, for subgroup analyses, it was recognised that 
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the overall number of case-control pairs available would drop, meaning reduced statistical 
power. Using depression as an example, if the association between depression and HRJL 
was considered, and analysis was restricted to male participants only in order to look for 
effect modification by gender, the number of available case-control pairs would drop to 220 
instead of 494. In this case, at the prevalence of depression reported by Age UK (22.3%) and 
a statistical power of 80%, the sample size was still sufficient to detect a minimum OR of 
1.82 (a weak association) among men. However, for rarer conditions, for example stroke, 
using the prevalence of stroke reported by Age UK (2.8%) at a statistical power of 80%, the 
sample size was only sufficient to detect a strong association (minimum OR 3.35) among 
men. This drop in power was appreciated when interpreting results from subgroup analysis. 
It must be stressed that where effect estimates suggested an important relationship, but 
analysis was underpowered to show a statistically significant result, this was not 
interpreted as evidence of no association.  
3.9 Summary 
3.9.1 Data sources 
• Data was derived from two sources for this thesis: 
o The baseline HEAF study questionnaire, which was a postal questionnaire 
including items relating to date of birth, gender, ethnicity, marital status, 
education, employment status, and occupation (responses collected 2013 – 
2014). 
o The CPRD, which was an electronic medical record system used to derive 
retrospective primary-care clinical data in the form of date-stamped 
diagnostic “Read” codes and BNF prescription codes (CPRD data was 
available from a participant’s initial registration at a CPRD-contributing GP 
practice to the point of completion of the HEAF baseline questionnaire). 
o As only CPRD-contributing GP practices were recruited to the HEAF study, it 
was possible to link questionnaire data to CPRD data for all HEAF study 
participants.  
3.9.2 Study design and participants 
• A matched retrospective case-control study design was used, involving the 
selection of “cases” (with the outcome of interest) and matched “controls” 
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(participants who are similar for important confounders, but do not have the 
outcome of interest). These are defined below: 
o Cases were participants of HEAF who were unemployed at baseline and 
reported that a health problem was “part of the reason” or “the main 
reason” reason for dropping out of work. Cases were included if they had 
CPRD coverage for a minimum of a year prior to the date of their health-
related job loss (HRJL). 
o Control participants were participants of HEAF who did not report HRJL at 
baseline. Controls were employed when their matched case participant 
experienced HRJL. All control participants were within 1 year of age of their 
matched cases, of the same sex, and from the same GP practice. Control 
participants were included if they had CPRD coverage for a minimum of a 
year prior to the date of HRJL of their matched case. 
3.9.3 Categorising CPRD-defined health exposures  
• Returned CPRD data grouped initially by body system. Two researchers with 
medical training independently organised the clinical codes into disease groups. 
Codes were grouped into distinct disorders or events.  
• Read codes were excluded from further analysis if:  
o non-specific or not relating to clinically recognised health problems  
o referring to a health problem that had not been requested from CPRD.  
• Distinct groups were combined into larger clinical groups when: 
o Clinical conditions were similar enough  
o When existing groups were likely to be too small for meaningful analysis  
3.9.4 Use of CPRD-defined health exposures in analysis 
• Use of CPRD diagnostic codes were restricted based on the date at which they 
occurred: 
o Codes for chronic or long-lasting disorders were used if they occurred any 
time prior to the date of HRJL 
o Codes for short-term or probable short-term disorders were used if there 
were evidence of them occurring in the year prior to HRJL 
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• Where appropriate for certain clinical conditions, use of CPRD diagnostic codes 
were restricted based on BNF prescription codes, if: 
o available pharmaceutical codes were for drugs used in that clinical 
condition 
o all people with that clinical condition would be expected to have been 
prescribed a drug in the specified drug class  
3.9.5 CPRD-defined health exposures  
• The following CPRD-defined health exposures were explored in this thesis: 
o Chronic musculoskeletal disorders 
o Musculoskeletal pain disorders 
o Ischaemic heart disease 
o Heart failure 
o Hypertension 
o Structural heart disease 
o Cardiac arrythmias 
o Venous thromboembolic disease 
o Peripheral arterial disease 
o Primary-care-level mental health problems 
o Psychiatric-care-level mental health problems 
o Severe mental health problems 
o Epilepsy 






• For descriptive analysis, percentages were used to describe proportions for 
categorical data; means and standard deviations were used for continuous data; 
and medians and interquartile ranges were used for ordinal data and skewed 
continuous data. 
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• Wilcoxon rank-sum test was used to compare non-parametric independent 
continuous variables between groups. The chi-squared test was used for categorical 
data to assess differences in proportions. Where expected values in a cell of the 
generated contingency table were below 5, Fisher’s exact test was used for 
categorical data. 
• Conditional logistic regression analysis was used to study the association between 
independent exposures of interest and HRJL, taking into account case and control 
matched pairs and thereby controlling for age, gender, and GP practice.  
• Cluster analysis was used to describe common groups, or patterns, of co-occurring 
CPRD-defined health problems in study participants with multimorbidity.  
• Power calculations, based on prevalence figures reported by the Age UK almanac of 
disease profiles, estimated that statistical power was sufficient to observe a small 
to moderate association with HRJL for the majority of health exposures of interest. 
However, for subgroup analysis, the overall number of case-control pairs was fewer 
and statistical power was reduced, meaning power was only sufficient to detect a 
strong association for rarer conditions.  
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Chapter 4: How does comorbidity 
impact work outcomes in 
musculoskeletal disease? a systematic 
review 
4.1 Introduction  
In this chapter, the first research objective (see Chapter 2) is addressed: to systematically 
review evidence for the impact of comorbidity upon work outcomes among people with 
musculoskeletal disorders. Throughout this review, people with MSDs and no known 
comorbidities comprised the reference group. Only two other systematic reviews on the 
topic were identified: one reviewed the effect of co-presenting mental health problems on 
return to work and sickness absence in a low back pain population; the other, the effect of 
depression on return-to-work rates in MSD populations.(330,331) To my knowledge, this is 
the first review to consider impact of all reported comorbidities on work, and the first to 
consider all major employment outcomes, according to their definitions in the identified 
literature, including: work disability; sickness absence; unemployment; job loss; return-to-
work time; and productivity loss. 
4.2 Methods 
A broad systematic review was performed in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA).(332) Cochrane library, 
MEDLINE, Psychinfo, PubMed, and Web of Science were searched independently by two 
reviewers on 12/12/2018 applying important search terms in the following algorithm: 
(((disease* or illness* or disorder* or health or pain) AND (musculoskeletal or rheum*)) OR 
(osteo* or arthrit* or spondyl* or rheum* or frail*)) AND (employ* or work or job* or 
productivity) AND (comorbid* or multimorbid*). Similar terms were accounted for by using 
the wildcard function. The protocol was registered in PROSPERO in advance of completion 
of this work (registration number CRD42016038756). 
Studies were included if they: (1) were published in the English language; (2) compared 
patients with an MSD and comorbidity to MSD alone as the reference group; (3) reported 
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adjusted measures of association between comorbidity and work outcomes (there was no 
requirement for a study to adjust for any specific covariable); (4) report measures of error 
or report enough information to impute or calculate confidence intervals; and (5) were 
available in full text. Comorbidity was defined as a co-presenting long-term health 
condition in a person with an MSD, excluding those for which the long-term conditions 
could be sequelae or complication of their index MSD condition. The additional impact of 
comorbidity over and above that of having an MSD alone was the focus of this review. Fully 
published papers were included only, since it was not possible to critically appraise study 
methods from the abstract alone. Reviews, comments, and editorials were excluded. It was 
accepted that included studies may define work outcomes of interest in different ways. 
However, for the purposes of this review, the work outcomes of interest were broadly 
categorised as in Table 15, below. 
Table 15: Categorisation of included work outcomes  
Work outcome Definition 
Work disability Work outcomes included those in which participants described 
themselves as unable to work due to health problems; where 
certified or official disability was apparent; or participants 
were receiving disability pension 
Return to work 
following disability 
Work outcomes included those in which previously disabled or 
out-of-work participants with health problems were assessed 
for return to employment, or time taken to return to work 
Sickness absence 
(absenteeism) 
Work outcomes included those which described absence from 
work over a matter of hours or days in an employed individual, 
with no indication of the receipt of disability pension 
Reduced productivity 
and presenteeism 
Work outcomes included those which included some 
assessment of impaired productivity at work e.g. working 
longer hours, reduced output, and longer breaks. 
Presenteeism refers to reduced productivity as a direct result, 
or in part, due to a health problem  
Employment status 
and job loss 
Work outcomes included those which assessed odds of being 
unemployed (or employed). Job loss referred to loss of 
employment for any reason, while health-related job loss is 
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that which is as a direct result, or in part, due to a health 
problem 
Work transition Included changing work or type of work for any reason 
 
Data were extracted from the included papers into predefined tabulated summaries. These 
data included: study design; classification used for the index condition and comorbidity; 
important characteristics of the study population (number (n) and average age/gender); 
definition of the work outcome(s) considered; factors used in statistical adjustment for final 
analysis; and measure of association (see Tables 7 – 12, Appendix). Risk of bias was 
assessed using three versions of the Newcastle-Ottawa Scale (NOS) for case-control studies, 
cohort studies, and an adapted version for cross-sectional studies.(333) In assessment of 
quality, studies were judged based on three broad categories: risk of selection bias, 
comparability of the exposed and non-exposed groups, and quality of measurement of the 
exposure and outcome variables.  Studies could score up to nine points for cohort studies 
or case control studies, and ten points for cross-sectional studies. Studies were also rated 
downwards for quality if they had not adjusted or stratified for age, gender, or 
socioeconomic status (education was also accepted as a proxy for socioeconomic status) as 
a minimum in their final analyses (see Tables 13 – 15, Appendix).  
Given the highly variable MSD populations and classifications of comorbidity observed 
across included studies, it was not appropriate to attempt meta-analysis. Therefore, a 
narrative summary of the evidence was completed, and results were displayed graphically 
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The search strategy identified 1801 publications, the titles and abstracts of which were 
screened for inclusion. The full text of 172 articles were retrieved, of which 39 studies met 
the pre-stated inclusion criteria (see flowchart, Figure 25).(9–13,199,334–366) Common 
reasons for exclusion were: no work outcomes of interest reported; abstract alone or no 
full text published; no exposure of interest studied (i.e. comorbidities); no population of 
interest (i.e. musculoskeletal disorders); inappropriate study design, such as review articles; 
and inappropriate reference group (which must be MSD alone to outline the additional risk 
posed by comorbidities). Some excluded studies examined the exposure of multiple 
comorbid MSDs (e.g. back pain and neck pain). However, it was not clear if these articles 
were reporting true comorbid diseases, or simply additional musculoskeletal manifestations 
arising from a single index condition.  
Twenty cohort studies were included,(10,11,343–357,359,360,362) 18 cross-sectional 
studies,(9,12,13,199,334–341,358,361,363–366) and one case-control study.(342) These 
papers were entirely from developed nations, including 11 from the USA, 
(10,12,199,334,338,339,345,346,348,350,365), ten from Netherlands, 
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(9,11,340,341,347,349,354,361,362,364) six from Canada,(13,334,337,344,356,358) three 
from Australia,(343,352,363), two from Denmark,(357,360) and one each from 
Norway,(359) Sweden,(351) Germany,(336) Argentina,(342) Switzerland,(355) and UK.(353)  
Classification of musculoskeletal disorders 
The MSD study populations varied, and included: non-specific musculoskeletal disorder 
(MSD), musculoskeletal pain, or rheumatism,(337,340,360,364) back pain and/or neck 
pain,(350,358,364) knee pain or knee arthroplasty,(343,347,363) inflammatory rheumatic 
disorders (IRDs),(336,354) rheumatoid arthritis (RA),(339,341,349,351,357) ankylosing 
spondylitis (AS),(9–11,342,362), spondyloarthritis (SpA),(361) psoriatic arthritis (PsA),(334) 
systemic lupus erythematous (SLE),(338,344) scleroderma,(13) arthritis non-
specific,(12,199,352,358,365) osteoarthritis (OA),(353) occupational muscular injury,(346) 
whiplash,(356) and spinal surgery, discectomy, or disc disorders.(345,348,355,359,366) 
The classifications used for these MSDs were heterogeneous and varied according to the 
disorder considered. For example, the presence of non-specific musculoskeletal disorders, 
musculoskeletal pain, osteoarthritis, or non-specific arthritis, was usually self-reported and 
determined through the use of a questionnaire or structured 
interview.(12,199,337,340,352,353,356,358,360,364,365) However, for disorders that are 
primarily managed by specialists, e.g. inflammatory rheumatic disorders, the majority met 
pre-specified clinical criteria, often assessed by a rheumatologist.(9–
11,13,334,336,338,339,341,342,344,347,349,351,354,355,359,361,362) In some studies, 
the presence of an MSD was derived through the use of electronic medical coding, for 
example, from administrative insurance databases.(336,345,349,357,364,366) Included 
studies and the classifications used for their MSD populations are outlined below, see Table 
16.  
Table 16: Classifications used for each musculoskeletal disorder 
Included 
study 
MSD classification used in study 




Rheumatism- survey interview data (self-report). Participants indicated they had 
experienced rheumatism or inflammation of joints in past 12m and had been 
treated for the condition by a healthcare professional or if medication had been 
prescribed.  





Musculoskeletal disorders – online questionnaire (self-report). Presence of 
diseases was assessed using the Work Ability Index,(367) in which participants 
were asked to indicate across a list of 13 broad disease categories whether they 
currently had a health disorder which had been diagnosed by a physician 
(yes/no). Specific musculoskeletal disorders included: disorder of the upper back 
or cervical spine; disorder of the lower back; pain radiating from the back into the 
leg (sciatica); musculoskeletal disorder affecting the limbs (hands, feet); 
rheumatoid arthritis; other musculoskeletal disorder. Participants were classified 
as having an MSD if they indicated any of the above.  
Melkevik 
(2018) (360) 
Musculoskeletal pain – survey questionnaires (self-report). Participants were 
asked to rate the average levels of musculoskeletal pain in low back, 
neck/shoulders and knees over the last three months. The response scale ranged 
from 0 to 9: 0 was “no pain” and 9 was “worst imaginable pain.” A drawing from 
the Nordic Questionnaire defined the three respective body part regions.(368) A 
cut-off of 3 points on each scale was used to indicate whether participants had 
substantial levels of pain in the low back, in the neck/shoulders, or in the knees. 
Munce 
(2007) (337) 
Chronic pain condition – survey questionnaire (self-report). Participants reported 
that they had a chronic pain condition, diagnosed by a health care professional 
and present for at least 6 months. Included chronic pain conditions were: 
fibromyalgia, arthritis, rheumatism, back problems and migraine. 
Back pain and/or neck pain 
Buist-
Bouwman 
(2005) (364)  
Chronic back trouble- survey interview data (self-report). Participants indicated 
they had experienced chronic back trouble in the past 12m and had been treated 
for the condition by a healthcare professional or medication had been prescribed.  
Nordin  
(2002) (364) 
Non-specific low back pain (NSLBP) – data obtained from occupational health 
administrative clinical records held by two utility and transportation companies. 
Clinical data was held as ICD-9 codes. NSLBP included the following ICD-9 codes 
after an index visit to the occupational health physician: lumbago (724.2) and 
sprains of the lumbosacroiliac region (846.0–3/8–9, 847.2–3). To prevent 
inclusion of specific back pain, analysis was limited to those cases in which the 
primary diagnosis was “sprains and strains of the lumbo-sacroiliac region.” 
Csupak 
(2018) (358) 
Back problems – survey interview data (self-report). Participants were asked to 
report back problems (excluding fibromyalgia and arthritis) diagnosed by a health 
professional that lasted (or were expected to last) for at least 6 months.  
Knee pain or knee arthroplasty 
Agaliotis 
(2013) (343)  
Knee Pain – participants reported knee symptoms for more than 6 months, had 
knee pain or were taking non-steroidal anti-inflammatory drugs or analgesia for 
knee pain on most days of the past month and rated their knee pain ≥4 out of 10 
for most days of the past week. A symptomatically eligible knee needed to 
demonstrate medial tibio-femoral joint space narrowing on X-ray but retain more 
than 2 mm joint space. 
Agaliotis 
(2017) (363) 
Knee Pain – defined as for Agaliotis (2013), above.  




Participants had received a total knee arthroplasty at one of two Dutch hospitals 
Inflammatory rheumatic disorders (IRDs) 
Lowe (2004) 
(336)  
Participants with inflammatory rheumatic disorders from a rheumatology 
outpatient clinic, diagnosed by their physicians according to ACR 1987 criteria for 
RA,(369) Tan et al criteria for SLE,(370) and using ICD-10 codes for other 
inflammatory rheumatic disorders.  
de Buck 
(2006) (354) 
Rheumatologist diagnosed RA, AS, SLE, or scleroderma. RA according to the 
American Rheumatism Association (ARA) classification criteria (Arnett et al. 
1988);(369) AS according to the modified New York classification criteria (Van der 
Linden et al. 1984),(371) reactive arthritis or psoriatic arthritis; systemic lupus 
erythematosus (SLE) according to the ARA classification criteria (Tan et al. 




Rheumatologist diagnosed RA according to the ARA criteria, 1987.(369) 
Hansen 
(2016) (357) 
Patients with RA identified through the nationwide DANBIO Registry(372) and the 
Danish National Patient Registry (NPR).(373) Rheumatoid arthritis was identified 
using the following codes from the ICD-8 and ICD-10: 712.19 (Syndroma Felty), 
712.39 (Arthritis rheumatoides alia et non specificata), 712.59 (Fibrositis 
rheumatoides chronica nodularis), DM05 (Arthritis rheumatoides seropositiva), 
and DM06 (Arthritis rheumatoides alia). 
Manders 
(2014) (349) 
Rheumatoid arthritis data from the biologic register of the Dutch Rheumatoid 
Arthritis Monitoring (DREAM) project.(374) Participants were diagnosed 
according to the 1987 ACR classification criteria,(369) had moderate to high 




Participants starting treatment with their first TNF-inhibitor from the Swedish 
Rheumatology Quality Register.(375) A national register comprising the Swedish 
biologics register (Anti-Rheumatic Treatment In Sweden (ARTIS), covering 87–
95% of all biologics-treated patients with RA in Sweden, and the register for 




Rheumatoid arthritis patients diagnosed according to the 1987 American College 
of Rheumatology classification criteria.(369) 
Ankylosing spondylitis  
Boonen 
(2001) (11) 
Patients selected from the nationwide Dutch Standard Diagnosis Register of 
Rheumatic Diseases (SDR).(376) Selected patients had to have definite 
rheumatologist-diagnosed ankylosing spondylitis. 
Castillo-Ortiz 
(2016) (9) 
Rheumatologist-diagnosed patients with ankylosing spondylitis recruited from a 
rheumatology outpatient clinics. 
Marengo 
(2008) (342) 
Patients attending a rheumatology clinic diagnosed according to the modified 
New York criteria for ankylosing spondylitis, 1984.(371) 




Patients attending a rheumatology clinic diagnosed according to the modified 
New York criteria for ankylosing spondylitis, 1984.(371) 
Webers 
(2018) (362) 





Patients with a clinical diagnosis of spondyloarthritis, either axial or peripheral, 




Patients recruited from a psoriatic arthritis clinic with a rheumatologist-
confirmed diagnosis of PsA (99% fulfilling CASPAR criteria).(378) 
Systemic lupus erythematosus 
Dhanhani 
(2009) (344) 
Patients diagnosed with SLE according to the ACR classification criteria (Tan et al, 
1982),(370) with the presence of at least 4 criteria or the presence of 3 criteria 
and evidence of SLE on tissue biopsy sample, who joined the University of 
Toronto Lupus Clinic and Registry. Patients were limited to those who were seen 
within 1 year of their diagnosis.  
Panopalis 
(2007) (338) 
All participants met at least 4 of the 11 ACR revised criteria for the classification 
of SLE.(370) after chart review by a rheumatologist or a registered nurse working 




Study subjects consisted of those enrolled in the Canadian Scleroderma Research 
Group Registry (CSRG).(379) Patients must have a diagnosis of scleroderma made 




Arthritis – survey interview data (self-report). Participants reported arthritis 
(excluding fibromyalgia) diagnosed by a health professional that lasted (or was 
expected to last) for at least 6 months.  
Joshi (2015) 
(365) 
Arthritis – telephone interview data (self-report). Patients responded ‘‘yes’’ to 
the question, ‘‘Have you been told by a doctor, nurse, or other health 
professional that you have some form of arthritis, rheumatoid arthritis, gout, 
lupus, or fibromyalgia?’’  
Kessler 
(2001) (199) 
Arthritis – telephone interview and self-administered questionnaire data (self-
report). Arthritis was assessed by a standard checklist (of several chronic 
conditions) preceded by the question, “In the past 12 months, have you 
experienced or been treated for any of the following?” 
Kessler 
(2003) (335) 
Arthritis – defined as in Kessler (2001), above.  
Schofield 
(2014) (352) 
Arthritis – survey data (self-report). People who reported having ‘arthritis and 




Arthritis – interview survey data (self-report). Each self-reported condition was 
assigned an ICD-9 code. Respondents with “arthritis” had ICD-9 diagnostic codes 
for rheumatoid arthritis, juvenile rheumatoid arthritis, other forms of 
inflammatory arthritis, osteoarthritis, ankylosing spondylitis and other forms of 
spondylosis, or rheumatism. 





Osteoarthritis – postal questionnaire data (self-report). “Osteoarthritis” was 
defined as hip, knee or foot pain for 1 day or more during the past year. 
Occupational muscular injury 
Brede (2013) 
(346) 
Occupational musculoskeletal injury - referred to a rehabilitation centre after an 
occupational musculoskeletal injury and enrolled in the treatment program. 
Participants were work disabled as a result of their injury for at least 4 months 




Whiplash – postal questionnaire data (self-report). To be classified as whiplash, a 
claimant had to be injured in an automotive collision, not have been hospitalized 
for more than 2 days, and answered ‘yes’ to the two following questions: “Did the 
accident cause neck/shoulder pain?” and “Have you felt neck/shoulder or 
reduced/painful neck movement pain since the accident?” 
Spinal surgery, discectomy, or disc disorders 
Anderson 
(2016) (345) 
Participants were identified through a workers’ compensation claims from the 
Ohio Bureau of Workers’ Compensation administrative database. ICD-9 codes 
were used to identify patients who underwent anterior, posterior, or 360° lumbar 
fusion for spondylolisthesis. 
Kausto 
(2017) (366) 
Participants were identified through the Sickness Insurance Register and Hospital 
Discharge Register administrative databases in Finland. ICD-10 codes were used 
to identify patients with intervertebral disc disorders (ICD-10 M51). 
Schade 
(1999) (355) 
Patients with a symptomatic disc herniation undergoing lumbar discectomy. 
Patients were selected for an automated percutaneous lumbar discectomy only if 
they presented with a contained disc protrusion exhibiting a concordant 
(positive) pain response on provocative discography. Discography was analysed 
by two independent radiologists.  
Lee (2017) 
(348) 
Patients with spinal surgery (including, disk herniation, stenosis, 
spondylolisthesis, degenerative scoliosis, and traumatic injuries) were identified 
from the electronic medical records derived from two University “institutions.” 
Furunes 
(2018) (359) 
Participants had low back pain as the main symptom for at least 1 year, Oswestry 
Disability Index score ≥ 30, had conservative treatment for ≥ 6 months without 
sufficient effect, and degenerative changes in the intervertebral disc L4/L5 and/or 
L5/S1. Degenerative disc and chronic low back pain was treated with lumbar total 
disc replacement at one of five Norwegian University Hospitals.  
 
Classification of work outcomes 
In order of frequency, the most commonly reported work outcomes across the literature 
were categorised as work disability or disability pension,(9–13,336,338,339,344,351,357) 
return to work after disability,(345–348,350,351,355,356,366) sickness 
absence,(335,337,340,341,353,364) employment status or job 
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loss,(338,341,342,349,352,354,361) presenteeism or reduced 
productivity,(334,335,343,361,365) and work transitions.(363) The classification of these 
work outcomes was also not consistent, as outlined in Table 17, and summarised below.  
As described in earlier chapters, work disability can be defined as having a physical or 
mental impairment that has a substantial or long-term negative impact on a person’s ability 
to carry out the employee-role, and usually refers to a person who is no longer employed as 
a result of poor health. In this review, work disability outcomes were classified as those in 
which participants described themselves as unable to work due to health problems, where 
certified or official disability was apparent, or participants were receiving disability pension. 
Among the included studies, work disability was generally self-reported. In some studies, 
participants were asked whether they had any “official” or certified work disability, or if 
they were in receipt of a disability pension.(9–11,339) Other studies simply asked whether 
there was a health problem that prevented participants from working.(12,338,358) Some 
studies grouped sickness absence along with more permanent disability.(13,336,351) In one 
study, work disability was limited to that caused by the index disease (ankylosing 
spondylitis).(11) 
Studies reporting return to work following a period of work disability, considered the 
relative time taken to return to work, or whether the participant had returned to 
employment at a certain point on follow up. The follow-up period varied and ranged from 1 
to 2 years. Frequently, data was derived from electronic administrative databases, such as 
those used for insurance, (345,348,351,356,364,366) in others return to work was self-
reported.(346,347,355) In addition, studies had differing criteria for what constituted a 
“return to work” for example, one required that participants had sustained work for at least 
6 months,(345) while another older study simply asked participants if they had returned to 
‘any’ work.(355) 
Sickness absence was self-reported in included studies.(199,337,340,341,361,362,364) 
Participants were generally asked about recent days of sick leave taken from work. 
However, the length of time over which participants were asked to recall sickness absence 
varied from 7 days,(337,341,361) to the past month,(199) to the past year.(340,364) In 
analysis, some studies considered any full days of absence from work in the past 
week,(337) or even year,(340) as having had “sick leave,” others analysed the total number 
of days of sickness absence,(199,364) while others calculated total hours missing from work 
in the past week.(341,361)  
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Some studies estimated productivity losses, presenteeism, or perceived work limitations as 
a result of health problems; these were self-reported. Presenteeism was defined using the 
validated Work Productivity and Activity Impairment (WPAI) questionnaire in two 
studies.(343,361) Two studies used other validated questionnaires to measure health-
associated productivity losses combined with the amount of time absent from work due to 
sickness for an overall work limitations score.(199,334) Over different time scales, the 
remaining three studies recorded single questionnaire items about whether the participant 
felt they had experienced significant work restriction or limitation.(199,361,365) For one of 
these studies the question did not specify that the work restriction was due to a health 
problem,(353) for another the question specified work restriction was as a result of 
“arthritis or joint symptoms”.(365)  
Studies reporting employment status were generally more homogeneous in their 
measurement of this outcome, which was self-reported in all cases. Participants were asked 
whether they were currently employed, a question that implied paid employment. In 
analysis, some studies used “current employment”,(338,341,359,361) others 
“unemployment”(342,352) for the outcome of interest. 
Job loss was self-reported and comprised one study that defined job loss as being 
unemployed or on disability pension at 1 year follow up,(354) and another that classified it 
as stopping work participation after 2 years of treatment (patients who had paid work or 
did voluntary work were defined as working in this study).(349)  
Lastly, one study also reported “work transitions” in the prior 6 months using a validated 
questionnaire.(363) The Work Transitions Scale summarised information about a 
participant’s loss of work hours, and changes in work hours, and changes in type of work 
performed as a direct result of knee problems.  
Table 17: Classifications used for each reported work outcome 




Work disability- questionnaire data (self-report). Participants were asked if they 
were not working because of “official work disability due to disease.” 
Ward (2001) 
(10) 
Work disability- questionnaire data (self-report). Patients were asked whether they 
received payments for work disability, their current work status, and dates of 
retirement or permanent work disability (if applicable). Participants were analysed 
for permanent work disability and for receipt of disability payments, separately.  




AS-related work disability – questionnaire data (self-report). Defined as officially 
recognised inability to perform paid work because of ankylosing spondylitis. 
Csupak 
(2018)(358) 
Permanent work disability. Questionnaire data (self-report). Participants were 
asked whether they had permanent inability to work. 
Abraido-Lanza 
(2006) (12) 
Work disability- interview survey data (self-report). Participants were asked 
whether any health problem or condition prevents them from working in a job or a 
business, or limits the type or amount of work that they can perform. 
Hudson (2009) 
(13) 
Work disability- questionnaire (self-report). Those considered work disabled were 
of working age and stated “I am currently disabled or on sick leave.” 
Lowe (2004) 
(336) 
Work disability – questionnaire (self-report) with validation by insurance 
statements for participants claiming to be on disability pension: Patients were 
classified “work-disabled” if: 1) formerly employed, currently receiving temporary 
or permanent disability pension, 2) employed (full-time or part-time) with a sick 
leave of at least 4 weeks, or 3) unemployed and unable to do their usual activities 
for at least 4 weeks because of medical illness.  
Panopalis 
(2007) (338) 
Unable to work – telephone interview (self-report). Participants stated their 
employment status as “unable to work.” 
Callahan (1992) 
(339) 
Work disability- questionnaire (self-report). Participants indicated if they were 
receiving work disability payments.  
Olofsson (2017) 
(351) 
Time until work disability (long-term sickness absence). Data from linked health 
insurance databases. Among working participants, defined as time to lose 15 days 
of 30 with sick leave or disability pension over follow up (maximum 3 years). 
Hansen (2016) 
(357) 
Work disability (long-term sickness absence). Linked data from the Danish (public) 
Register of Evaluation of Marginalization (DREAM) register,(374) which provides 
weekly information on social transfer payments for all residents in Denmark. Long-
term sickness absence was defined as ≥3 weeks of receiving sickness absence 
benefits more than one year after diagnosis with RA.   
Return to work after disability 
Anderson 
(2016) (345) 
Return to work – data derived from workers compensation database. Participants 
were classified as returning to work if they returned within 2 years after lumbar 
fusion and remained working for more than 6 months. 
Brede (2013) 
(346) 
Failure to retain work at 12 months – structured interview (self-report). To be 
classified “working” at 1 year, participants were employed full- or part-time, either 
at full or light-duty. Participants who returned to work after discharge but did not 
maintain employment at the 1-year evaluation and patients who did not return to 




Return to work after at least 2 years follow up following total knee arthroplasty – 
questionnaire (self-report). Patients responding affirmatively to the question “I 




Return to work – data from electronic medical records. Defined as return to full 
employment within 1 year of spinal surgery and still working on last follow up 
(follow-up for at least 2 years after surgery). 
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Nordin  (2002) 
(364) 
Time to return to work – data obtained from administratively maintained 
occupational health records. Following work disability, worker was followed up 
over time to determine the point at which the employee first returned to 
unrestricted, full duty. This period defined the duration of work disability (episode 
duration). First return to regular duty was the outcome of interest. 
Olofsson (2017) 
(351) 
Time to return to work. Data from linked health insurance databases. Return to 
work was defined as (for patients with no work ability at baseline) the time taken 
to achieve ≤15 net days with sick leave or disability pension out of 30, over 
(maximum) three year follow up.  
Schade (1999) 
(355) 
Return to work at 2 years. Questionnaire (self-report). Participants reported if they 
had returned to ‘any’ work.   
Cote (2001) 
(356) 
Time to insurance claim closure (for whiplash). Linked data derived from two 
insurance company administrative databases. Time-to-claim-closure was defined 
as the period extending from the collision date to the date of final compensation 
payment made by the insurer to a claimant or, for permanent benefits, the date of 
final agreement between the insurer and the claimant. The decision to close a 
claim corresponds to the end of treatment, the attainment of maximal medical 
improvement, or the termination of income replacement benefits. 
Kausto (2017) 
(366) 
Time to sustained return to work– data derived from sickness insurance databases. 
Sickness absence period was started from the initial day of work absence until the 
end of the compensation period. Sustained return to work was defined as the end 
of the sickness benefit period that was not followed by a recurrent sickness 




Absenteeism in the past week. Questionnaire data (self-report). Participants were 
asked whether they were unable to work in the past week (which was distinct from 
permanently being unable to work).  
Kessler (2003) 
(335) 
Number of work loss days – questionnaire (self-report). Participants were asked 
“how many days out of the past 30 were you totally unable to work or carry out 
your normal activities” because of problems with physical or mental health.  
Melkevik 
(2018)(360) 
Any sickness-absence for four consecutive weeks or more during the 550 days 
following study entry. 
Munce (2007) 
(337) 
Absenteeism in the past week. Survey questionnaire data (self-report). 
Absenteeism was defined as a positive response to the questions “you were absent 
from your job or business in the last week” and the “main reason for not working 
last week” was due to “illness/disability.”  
van den Berg 
(2017) (340) 
Sickness absence in the year prior. Online questionnaire (self-report). Employees 
were asked to indicate on a 5-point scale how many days of sick leave that they 
had during the past year. Sick leave was defined as anyone with 1–365 days of sick 




Absenteeism. Work Productivity and Activity Impairment questionnaire (self-
report). Outcome was percentage of working hours absent during the prior 7 days.  




Number of work-loss days over the last year. Survey interview data (self-report). 
Participants were asked “how many days in the past year were you unable to work 




Absenteeism. Work Productivity and Activity Impairment questionnaire (self-
report).(380) Percentage of working hours absent during the prior 7 days. 
Webers 
(2018)(362) 
AS-related sick leave over 6 years follow up. Questionnaire data (self-report). Study 
recorded sick leave without a minimum duration, since last clinic visit (every 2 
months during the first 2 years of follow-up, and annually till 6 years). 
Reduced productivity, presenteeism, and work limitation 
Kennedy (2014) 
(334) 
Work limitations. Work Limitations Questionnaire (WLQ) (self-report).(381) 
Patients completed the 25-item self-administered WLQ as well as the WLQ 2-
Question Time Loss Module; the latter asks patients to quantify the number of full 
and partial workdays missed during the past two weeks due to health concerns. 
The questions of the 25-item WLQ were grouped into four subscales that address 
time, physical, mental-interpersonal, and output demands, respectively. Scores 
ranging from 0 to 100 were calculated for each subscale, with higher scores 
corresponding to greater work limitation and productivity loss. An overall WLQ 
Productivity Score was calculated and expressed as the percentage loss in 
productivity associated with illness. Patients were assigned to one of four levels of 
work impairment based on productivity scores, where normal corresponds to <5% 
productivity loss, mild impairment 5–10.9%, moderate impairment 11–16.9%, and 
severe impairment ≥17% work productivity loss. Outcome was risk of moderate-
severe work impairment. 
Kessler (2001) 
(199) 
Work impairment days – questionnaire (self-report).  Participants were asked 
about 30-day prevalence of work-loss days and work cut-back days (i.e. how many 
days out of the past 30 were  participants “totally unable to work or carry out your 
normal household work activities because of your physical health or mental 
health”; and how many additional days out of the past 30 were participants able to 
work but had to “cut back on work or how much you got done because of your 
physical health or mental health”).  Information on work-loss and work cut-back 
days was combined into a summary measure of work-impairment days on a scale 
on which a work-cut-back day was counted as one-half of a work-loss day. 
Kessler (2003) 
(344) 
Number of work cut back days – questionnaire (self-report). Participants were 
asked the number of days out of the past 30 when they were able to work “but had 
to cut back on what (they) did or did not get as much done as usual” because of 
problems with their physical or mental health. 
Agaliotis (2013) 
(343) 
Presenteeism. Questionnaire data derived from the Work Productivity and Activity 
Impairment Questionnaire (WPAI). Participants were asked “Your knee problems 
may affect your ability to work or perform daily activities. Please estimate your 
capacity for each day from 0% (unable to do usual work/activities) to 100% (fully 
functioning in usual role).” This index was dichotomised as “exposed to 
presenteeism” (participants who scored an average of 99.99% and below) vs those 
not exposed (100%). 




Work limitation – telephone interview data (self-report). Participants were asked 
“Do arthritis or joint symptoms now affect whether you work, the type of work you 
do, or the amount of work you do?’’ 
Nikiphorou 
(2018)(361) 
Presenteeism. Work Productivity and Activity Impairment (WPAI) questionnaire 
(self-report). (380) Outcome was percentage of impairment while at work during 
the prior 7 days. 
Wilkie (2013) 
(353) 
Work restriction- one item from the Keele Assessment of Participation (KAP) 
questionnaire(382): ‘‘During the past 4 weeks, if you work, have you taken part in 
paid or voluntary work as and when you have wanted?’’- Three year onset of work 
restriction was defined as moving from no restriction at baseline (all/most of the 




Employment at follow up (minimum 3 years). Structured interview (self-report). 
Work status was categorised as employed (part time or full time) or unemployed. 
Panopalis 
(2007) (338) 
Current employment. Interview survey data (self-report). Employment status: 
Participants were asked about their work situation for both the year of diagnosis 
and the current year (i.e. in the last week). Participants were employed if they 
reported that they had a job (whether or not they were at work in the last week) or 




Current employment. Work Productivity and Activity Impairment (WPAI) 
questionnaire (self-report).(380) Participants were asked their current employment 
status (employed vs. not employed).  
Marengo (2008) 
(342) 
Current unemployment. Questionnaire (self-report). Participants could respond 
they were employed, unemployed, retired, or pensioner.  
Schofield (2014) 
(352) 
Not being in the labour force. Survey data (self-report). Categories included labour 
force participation, employment restrictions, or retirement. 
Nikiphorou 
(2018)(361) 
Current employment. Work Productivity and Activity Impairment (WPAI) 
questionnaire (self-report).(380) Participants were asked their current employment 
status (employed vs. not employed). 
Job loss 
de Buck (2006) 
(354) 
Job loss. Interview or questionnaire (self-report). Job loss was defined as receiving 
a full work disability pension or being unemployed in a person employed at 
baseline after 2 year follow up.  
Manders (2014) 
(349) 
Stopping work participation after 2 years of treatment. Structured interview (self-
report). At the start and after 2 years, patients indicated whether they had paid 
work, did voluntary work, received a retirement pension, or received a work 
disability allowance. Patients who had paid work or did voluntary work were 




Work transitions in past 6 months. Work Transitions Scale (self-report). Work 
Transitions Scale was a 10-item scale evaluating three categories of work 
transitions due to knee problems, including: 1) occasional loss of work hours or 
work interruptions, 2) change in the type or nature of work, or 3) permanent 
changes of work hours. Each question required a no/yes response. A score of one 
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was given for each ‘‘yes’’ response. Scores were summed for a total range of 0 to 
10; a higher score indicated more work changes.  
 
Classification of comorbidity 
Table 18, below, shows the criteria by which comorbidity was defined and the method of 
attainment. Data on comorbidities was usually drawn from self-report (interview survey or 
questionnaire), however some comorbidity data was drawn from electronic health records 
or other administrative databases,(9,348,350,357,362,366) or involved physician (e.g. 
rheumatologist or occupational health physician) history taking or 
assessment.(334,339,349,359,361) Validated comorbidity scores or indexes were used in 
nine studies (including the Self-Administered Comorbidity Questionnaire, the Functional 
Comorbidity Index, and the Rheumatoid Disease Comorbidity 
Index).(9,13,334,341,343,353,361–363) Other studies used pre-defined checklists of 
important conditions but it was unclear if these lists had been validated previously or by 
what criteria a co-presenting disease would be considered for 
inclusion.(11,12,199,349,350,352,353,357,365,366) Several studies did not give sufficient 
information about the comorbidities considered and the classifications used. 
(10,11,199,339,342,348,353,359,365) For example, one older study relied on a 
rheumatologist definition of number of comorbidities with no standardised checklist 
described;(339) another gave no details at all regarding how presence of comorbidity was 
assessed or classified.(359)  
Study quality 
The methodological quality of the included studies was rated from 3 to 8 stars, using the 
NOS criteria (Table 13 – 15, Appendix), with most studies moderately well reported and 
conducted (mean quality was 6.2). In most cases, the participants with comorbidity were 
selected from the same cohort as the non-exposed participants. Some studies did not 
adjust the final analyses for one of age, sex, or socioeconomic status and were marked 
down accordingly.(11,199,335–337,342,343,347,348,350–352,354–357,364) However, in 
most cases, analysis was adjusted, or stratified, for age and gender as a minimum. Some 
studies did not provide enough information about the representativeness of their 
populations, or the reliability of the databases from which information was 
drawn.(9,10,338,340,342–345,347–349,352,353,359,360,363) Another common limitation 
of this literature was that most work outcomes were self-reported. Similarly, in most cases, 
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the health exposures were self-reported with no validation or confirmation using more 
objective data from test results or medical records.(9–11,13,199,334–337,339–344,346–
348,353–355,359,360,362–365) Studies were also frequently marked down for failing to 
compare characteristics of study participants and non-participants; failure to maintain at 
least 80% of their baseline population for follow up; or for failing to report about the 
quantity of missing data.(9,13,199,334,336–342,344–346,348–351,353,356,357,361,364–
366) 
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Table 18: Classifications of comorbidity used in included studies 
Included 
study 














No Included conditions were defined as any chronic impairment or departure 
from normal health with onset 1-3 months from the date of the interview, 
such as chronic disorders of the digestive, genitourinary, nervous, endocrine, 
circulatory, respiratory systems, or other chronic conditions (specific examples 
included glaucoma, ulcers, diseases of the prostate, multiple sclerosis, 











Questionnaire recorded the presence of 12 current medical conditions: high 
blood pressure, heart disease, lung disease, diabetes, ulcer or stomach 
disease, kidney disease, liver disease, anaemia or other blood problems, 
cancer, depression, back pain, and rheumatoid arthritis. Additional scores are 
given if the participant reported receiving treatment and if this condition 
limited activities. The scores range from 0 to 36 points, where a higher score 
indicates more comorbidity. The comorbidity score was further categorized 


















No Comorbidity was assessed using a list of 19 comorbid conditions. No further 
information given. 





disc and low 














A questionnaire recorded the presence of 12 current medical conditions: high 
blood pressure, heart disease, lung disease, diabetes, ulcer or stomach 
disease, kidney disease, liver disease, anaemia or other blood problems, 
cancer, depression, back pain, and rheumatoid arthritis. Additional scores are 














No Number of chronic conditions was computed by adding up the chronic 








No Comorbid conditions were assessed as those with entitlement to special 
reimbursements (due to diabetes, rheumatoid arthritis, asthma/COPD or 











Included conditions were: arthritis (rheumatoid and osteoarthritis), 
osteoporosis, asthma, COPD, acute respiratory distress syndrome, or 
emphysema, angina,  congestive heart failure (or heart disease), heart attack 
(myocardial infarct),  neurological disease (such as multiple sclerosis or 
Parkinson’s), stroke or TIA,  peripheral arterial disease, diabetes (types I and 
II), upper gastrointestinal disease (ulcer, hernia, reflux), depression, anxiety or 
panic disorders, visual impairment (such as cataracts, glaucoma, macular 
degeneration), hearing Impairment (very hard of hearing, even with hearing 
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aids), degenerative disc disease (back disease, spinal stenosis, or severe 










In the a self-administered questionnaire, “In the past 12 months, have you 
experienced or been treated for any of the following?” was asked for: asthma, 
bronchitis, or emphysema; tuberculosis; other lung problems; arthritis, 
rheumatism, or other bone or joint diseases; sciatica, lumbago, recurring 
backache; persistent skin trouble (e.g. eczema); thyroid disease; hay fever; 
recurring stomach trouble, indigestion, or diarrhoea; urinary or bladder 
problems; being constipated all or most of the time; gall bladder trouble; 
persistent foot trouble (e.g. bunions, ingrown toenails); trouble with varicose 
veins requiring medical treatment; AIDs or HIV infection; lupus or other 
autoimmune disorders; persistent trouble with your gums or mouth; 
persistent trouble with teeth; high blood pressure or hypertension; anxiety, 
depression, or some other emotional disorder; alcohol or drug problems; 
migraine headaches; chronic sleeping problems; diabetes; multiple sclerosis, 
epilepsy, or other neurological disorders; stroke; ulcer; hernia or rupture; piles 
or haemorrhoids; swallowing problems.   
Lee (2017) 
(348) 
Spinal Surgery Electronic 
medical records 
No A patient was positive for comorbidity status if a “significant medical 







appears to be 
self-report but 
unclear 
No The following comorbidities were included: cardiovascular disease, diabetes 








No Participants were asked about comorbid diseases “cardiovascular, respiratory, 
gastrointestinal, traumatic, neuropsychiatric, etc.” but no information was 
given regarding checklists or questionnaires used.  













Pulmonary disease, myocardial infarction, other heart disease, stroke, 
hypertension, diabetes, fracture, ulcer, other gastrointestinal, and depression 
were used to compute the Rheumatic Disease Comorbidity Index (RDCI), a 




low back pain 
(NSLBP) 





No The evaluating physician defined comorbidity as any secondary diagnoses to 
NSLBP assigned at the index visit. To facilitate the analysis, comorbid 
conditions were classified on the basis of 10 different body systems according 
to the ICD-9 classification scheme: “neoplasms”; “endocrine, nutritional, 
metabolic diseases and immunity disorders”; “mental disorders”; “diseases of 
the nervous system and sense organs”; “diseases of the circulatory system”; 
“diseases of the respiratory system”; “diseases of the digestive system”; 
“diseases of the musculoskeletal system and connective tissue”; “symptoms, 
signs, and ill-defined conditions”; and “injury or poisoning.” Other categories 














No Computer assisted disease grouping by ICD codes, these were separated into 
the groups used by the Australian Beureau of Statistics (ABS): deformities of 
the joints/limbs, back problems, repetitive strain injury/occupational overuse 
syndrome, synovitis/tenosynovitis, other soft tissue/muscle disorders, 
osteoporosis, other acquired deformities of the musculoskeletal system and 
connective tissue, other disorders of the musculoskeletal system, and 
connective tissue. Due to low record numbers in the survey for conditions 
comorbid with arthritis, the following conditions were grouped together to 
form an ‘other conditions’ group: certain infectious and parasitic diseases, 
diseases of the blood and blood-forming organs, Alzheimer’s disease, certain 
conditions originating in the perinatal period, congenital malformations, 
deformations and chromosomal abnormalities, and a group that the ABS 
originally called ‘other conditions’. 













Physician-confirmed ischaemic cardiovascular disease (myocardial infarction, 
stroke), cancer (colon, skin, lung, breast and uterus in women, prostate in 
men, and lymphoma), gastrointestinal diseases (diverticulitis, ulcers), 
infections (hepatitis), lung disease (COPD and asthma) and psychiatric 
disorders (depression) were used to compute the Rheumatic Disease 







No Study asked for the presence of any comorbid medical condition, no further 











Pulmonary disease, myocardial infarction, other heart disease, stroke, 
hypertension, diabetes, fracture, ulcer, other gastrointestinal, and depression 
are used to compute the Rheumatic Disease Comorbidity Index (RDCI), a 





No Study asked about the presence of any comorbid medical condition, no further 








No Number of comorbid conditions-determined by rheumatologist. No further 














The presence of extra-articular manifestations (uveitis, psoriasis, and 
inflammatory bowel disease [IBD]) and of comorbidities was retrieved from 
medical records. Using this data the Rheumatic Disease Comorbidity Index 
(RDCI) was calculated (range 0–9), representing the weighted sum score of 
common comorbidities including lung disease, diabetes mellitus, 
hypertension, myocardial infarction, stroke, other heart disease, cancer, 
fracture [spine, hip, or leg], gastrointestinal ulcer, other gastrointestinal 
problems, and depression. 













No 18 groups of chronic, somatic comorbidities were considered (cancer, thyroid 
diseases, diabetes, other endocrine, nutritional and metabolic diseases, 
obesity, neurological diseases, chronic diseases of the ears, hypertension, 
chronic pulmonary diseases including asthma, cardiac disease, stroke, 
inflammatory bowel disease, diseases of the liver, diseases of the skin, kidney 
diseases, gynecological diseases, and transplantations) and 4 groups of 
psychiatric comorbidities (dementia, substance abuse, anxiety, and 
depression). These comorbidities were selected by an expert panel prior to 
data analysis. 
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4.3.1 Do comorbidities worsen work outcomes in MSDs? 
Twenty published studies (9 cohort, 10 cross-sectional, 1 case-control), explored the 
association between presence of comorbidity, or number of comorbid conditions, and risk 
of adverse employment outcomes.(9–13,199,334,339,341–343,348–
350,352,353,357,363,365,366) Results from studies where confidence intervals were 
reported, or could be imputed, are shown in Figure 26.  
Work disability and disability pension 
The association between comorbidity and various classifications of work disability was 
reported in seven studies amongst AS, RA, arthritis, and scleroderma populations.(9–
13,339,357) For six of these studies a statistically significant increased odds or hazard of 
work disability was observed, see Table 19, below. One older study (Callahan 1992), in RA, 
showed no significant association between number of comorbidities and a participant’s 
self-reported receipt of disability payments, although it was very unclear what definition 
was used for comorbidity.(339) One study among people with AS, found that presence of 
comorbidity strongly increased the rate of self-reported disability certification/payment (HR 
4.07 95%CI 1.23 to 13.43), but was underpowered to detect an effect for permanent work 
disability (HR 2.62 95%CI 0.58 to 11.86).(10)  
Table 19: Summary of included studies reporting the impact of comorbidity upon work 
disability 
Study  MSD 
population 






Arthritis Number of 
comorbidities 
Health problem 
preventing work in a 
job or limiting type or 
amount of work that 
can be performed. 









inability to perform 
paid work due to AS 











Not working because of 
official work disability 
due to disease 
OR 2.2 (1.2 to 4.0) 









Receipt of work 
disability payments 








Greater than 3 weeks 
of receiving sickness 
absence benefits 
payments first year 
after RA diagnosis 








Greater than 3 weeks 
of receiving sickness 
absence benefits 
payments one year 
after diagnosis with RA 








Currently disabled or 
on sick leave 







Receipt of disability 
payments 









HR 2.62 (0.58 to 11.86) 
*confidence intervals imputed using reported p-value and point estimates  
Return to work 
The impact of comorbidity upon return to work was reported in three studies, summarised 
in Table 20. (348,350,366) Two studies among spinal surgery and non-specific low back pain 
populations found a statistically significant impact of comorbidity upon return to work after 
work disability.(348,350) Presence of comorbidity was associated with a reduced likelihood 
of full employment one year after surgery,(OR 0.19 95%CI 0.04 to 0.85)(348) and a greater 
time taken to return to full work duty (HR 1.31 95%CI 1.12 to 1.52).(350) Another study 
amongst those with disc disorders found no significant impact of comorbidity among men 
or women (HR 0.93 95%CI 0.71 to 1.23),(366) although a narrow definition of comorbidity 
was used, as participants were only counted as having a comorbidity if they were receiving 
special reimbursements as a result of four selected conditions.  
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Table 20: Summary of included studies reporting the impact of comorbidity upon return to 
work 
Study  MSD 
population 










Return to sustained 
work (30 days) following 
sickness absence 









Return to sustained 
work (30 days) following 
sickness absence 







Return to full 
employment within one 
year of surgery and still 
working at 2 years 
follow up 




low back pain 
Number of 
comorbidities 
Time to first return to 
unrestricted full work 
duty following disability 
HR 1.31 (1.12 to 1.52) 
 Sickness absence 
Four studies considered the impact of comorbidity upon sickness absence among 
participants with MSDs.(199,341,361,362) All of these studies found comorbidity was 
associated with increased odds, or rates, of sickness absence (OR 1.18 95%CI 1.04 to 1.34; 
OR 1.44 95%CI 1.25 to 1.68; OR 1.52 95%CI 1.00 to 2.29; beta coefficient: 4.0 95%CI 0.3 to 
7.7) see Table 21. In one study a comorbidity disease score was not associated with AS-
related sick leave among those with high educational attainment (OR 1.58 95%CI 0.34 to 
7.38), however, estimated effect sizes were similar to those for people with low 
educational attainment and the study may have been underpowered to show a statistically 
significant effect for this sub-group.  
Table 21: Summary of included studies reporting the impact of comorbidity upon sickness 
absence 





Arthritis Three or more 
comorbidities 
Days out of the 
past 30 unable to 
work or carry out 
Beta coefficient 4.0 
(0.28 to 7.7)* 
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normal activities 
as a result of 
physical or 








absent over past 
7 days 












absent over past 
7 days 











Index score  
AS-related sick 
leave days over 6 
years 











Index score  
AS-related sick 
leave days over 6 
years 
OR 1.52 (1.00 to 2.29) 
*confidence intervals calculated using reported standard error  
Reduced productivity and presenteeism  
Of five reporting studies,(334,343,353,361,365) two found a significant association between 
comorbidity and presenteeism or reduced productivity (OR: 2.31 95%CI 1.19 to 4.5; OR 1.42 
95%CI 1.26 to 1.61).(334,361) Although non-significant, the effect estimates reported by 
Agaliotis et al., among people with knee pain, were in the range described by Kennedy et al. 
and Nikiphorou et al. One study among participants with arthritis found a non-significant 
and almost non-existent effect of number of comorbidities upon arthritis-specific impaired 
working, type of work, or amount of work. This study used a very broad work outcome 
(only partially including aspects of productivity loss) and also relied on patients to define 
the number of comorbidities, with no use of a checklist or validated score as in the other 
studies.(365) In another study, the presence of one to four comorbidities was not 
significantly associated with three-year onset of work restriction, as defined by not taking 
part in paid or voluntary work as and when desired. Once again, a very broad work 
outcome was used, and this study gave insufficient information about how comorbidities 
were assessed.(353) See Table 22, below.  
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Table 22: Summary of included studies reporting the impact of comorbidity upon reduced 
productivity and presenteeism  






Knee pain  Self-Administered 
Comorbidity 
Questionnaire 
(One to three 
comorbidities) 
Work Productivity and 
Activity Impairment 
(presenteeism score) 





Knee pain  Self-Administered 
Comorbidity 
Questionnaire 
(four or more 
comorbidities) 
Work Productivity and 
Activity Impairment 
(presenteeism score) 










working, type of work, 
or the amount of 
work.  










(productivity score)  




Spondyloarthritis Rheumatic Disease 
Comorbidity Index 
score 
Work Productivity and 
Activity Impairment 
(presenteeism score) 





Osteoarthritis Presence of one to 
four comorbidities 
Not taking part in paid 
or voluntary work as 
and when wanted 
over past 4 weeks, 
over 3 years follow up.   
OR 1.28 (0.81 to 
2.02) 
Employment status and job loss  
Six studies reported the impact of comorbidity upon employment status or job 
loss.(341,342,349,352,359,361) Five of these studies reported a statistically significant 
association between comorbidity and unemployment or job loss, see Table 
23.(341,349,352,359,361) A non-significant finding was reported in one case-control study 
of people with AS, although confidence intervals were very wide (OR: 2.5 95%CI 0.23 to 
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26.5).(342) Interestingly, Van der Zee-neuen et al. found that the impact of comorbidity on 
current employment was statistically significant only across countries with high GDP, 
however the direction and size of effect estimates was not very different when compared 
to data from all countries (OR 0.89 vs OR 0.93, respectively).(341)  
Table 23: Summary of included studies reporting the impact of comorbidity upon 
employment status or job loss 












(minimum 3 year) 










2 years (defined 
as paid or 
voluntary work) 


































OR 1.73 (1.06 to 2.86)   
Schofield 
(2014)(352) 




























OR 0.89 (0.81 to 0.97) 






*confidence intervals imputed using reported p-value and point estimates  
Work transition 
One study, among participants with knee pain, reported the impact of number of 
comorbidities (defined using the Self-administered Comorbidity Questionnaire) upon work 
transition.(363) This was defined using a Work Transitions Scale, which was a composite 
score capturing loss of work hours, interruptions to work, or changes in the type or nature 
of work over the previous 6 months. Compared to having no comorbidities, having one to 
three comorbidities had a non-significant 3.49-fold increased odds of work transition 
(95%CI 0.84 to 14.46). While four or more comorbidities was associated with a 4.44-fold 
increased odds of work transition (95%CI 1.02 to 19.32).(363) 
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Figure 26: Impact of comorbidity on adverse work outcomes amongst people with MSDs. 
Chart is colour-coded by category of work outcome: work disability or disability pension 
(black), return to work (blue), sickness absence (green), productivity loss or presenteeism 







































Effect size (95%CI), logarithmic scale 
Hansen (2016), RA, WD, HR (<1 year after RA diagnosis)
Hansen (2016), RA, WD, HR (>1 year after RA diagnosis)
ABRAI´DO-LANZA (2006), arthritis, WD, OR
Boonen (2001), AS, WD, OR
Hudson (2009), scleroderma, WD, OR
Ward (2001), AS, WD, HR
Ward (2001), AS, DR, HR
Castillo-Ortiz (2016), AS, WD, HR
Callahan (1992), RA, WD, OR
Kausto (2017), disc disorders, RTW, HR (men)
Kausto (2017), disc disorders, RTW, HR (women)
Nordin (2002), NSLBP, RTW, HR
Lee (2017), spine surgery, RTW, OR
Nikiphorou (2018), SpA, SA, OR
Van de Zee-Neuen (2017), RA, SA, OR
Webers (2018), AS, SA, OR (more educated)
Webers (2018), AS, SA, OR (less educated)
Joshi (2015), arthritis, Pres, OR
Nikiphorou (2018), SpA, Pres, OR
Wilkie (2013), AS, Pres, HR
Agaliotis (2013), Knee pain, Pres, OR (1-3 comorbidities)
Agaliotis (2013), Knee pain, Pres, OR (≥4 comorbidities)
Kennedy (2014), PsA, Pres, OR
Nikiphorou (2018), SpA, UE, OR
Van de Zee-Neuen (2017), RA, UE, OR
Schofield (2014), arthritis, UE, OR (1 comorbidity)
Schofield (2014), arthritis, UE, OR (2 comorbidities)
Schofield (2014), arthritis, UE, OR (≥3 comorbidities)
Manders (2014), RA, JL, OR
Marengo (2008), AS, UE, OR
Furunes (2018), disc disorders, UE, OR
Agaliotis (2017), knee pain, WT, OR (1-3 comorbidities)
Agaliotis (2017), knee pain, WT, OR (≥4 comorbidities)
Association of comorbidity with poor work outcomes amongst people
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4.3.2 Psychiatric disease comorbidity 
Seventeen published studies (10 cohort, 7 cross-sectional), explored the association 
between psychiatric comorbidity and work outcomes among people with MSDs.(336–
338,345,346,351–358,360,364–366) Results from included studies that also reported 
confidence intervals, or where confidence intervals could be imputed, are shown in Figure 
27. 
Work disability and disability pension 
Five included studies reported the effect of mental health comorbidity on work 
disability.(336,338,351,357,358) All studies reported a statistically significant effect, see 
Table 24. Comorbid depression, or depressive symptoms, were significantly associated with 
development of work disability in two studies among inflammatory rheumatic disorders 
and lupus populations (OR 1.6 95%CI 1.1 to 2.3 and OR 1.7 95%CI 1.15 to 2.54, 
respectively).(336,338) One study reported comorbid anxiety disorders were associated 
with work disability in back pain and arthritis cohorts (OR 4.26 95%CI 2.06 to 8.81; OR 5.38 
95%CI 2.44 to 11.84, respectively).(358) Diagnosed depression or anxiety was associated 
with a 1.67-fold hazard (95%CI 1.15 to 2.54) of long-term sickness absence/disability 
benefits among participants with rheumatoid arthritis.(351) Finally, one study found 
comorbid psychiatric disorders increased the rate of >3 weeks sickness absence with 
benefits following diagnosis with rheumatoid arthritis, both after short- and long-term 
follow up (HR 1.9 95%CI 1.8 to 2.0 and HR 1.9 95%CI 1.8 to 2.0, respectively). 
Table 24: Summary of included studies reporting the impact of psychiatric comorbidity on 
work disability 
Study  MSD 
population 








to work  




Back pain Generalised 
anxiety disorder 
Permanent inability 
to work  










benefits >3 weeks 
during year after RA 
diagnosis 
HR 2.2 (2.0 to 
2.5) 










benefits >3 weeks 
more than one year 
after RA diagnosis 












pension, or sick leave 
of at least 4 weeks, 
or unemployed for at 
least 4 weeks due to 
health problems.  









Loss of 15 days of 30 
with sick leave or 
disability pension 
over follow up 
(maximum 3 years) 













Inability to work OR 1.71 (1.15 to 
2.54) 
Return to work  
Six studies considered the impact of psychiatric comorbidity upon return to work after 
disability, which are summarised in Table 25, below.(345,346,351,355,356,366)  
Time to return to work after disability due to whiplash and discectomy was significantly 
increased with comorbid depression (HR 0.63 95%CI 0.51 to 0.77; HR 0.64 95%CI 0.54 to 
0.75; and beta coefficient: 0.43 95%CI 0.12 to 0.74).(355,356) One study, in which effect 
estimates could not be estimated, found that no participants with depression (n=29/686) 
returned to work following surgery for spondylolisthesis.(345) In contrast, one study did not 
find a significant association between depressive symptoms or major depressive disorders 
and time to return to work after completing rehabilitation for occupational musculoskeletal 
injury (OR 1.06 95%CI 0.77 to 1.45; and OR 1.21 95%CI 0.89 to 1.64, respectively).(346)  
Two studies considered comorbid psychiatric disorders other than depression.(351,366) In 
one study, purchase of antidepressants or hospitalisation due to mental health disorders 
was associated with reduced rate of return to work after intervertebral disc disorder-
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related work disability, both in men and women (HR: men 0.82 95%CI 0.74 to 0.91; women 
0.86 95%CI 0.82 to 0.9).(366) Finally, Olofsson et al. reported participants with depression 
or anxiety had a lower rate of sustained return to work among those not working at 
baseline with rheumatoid arthritis, but this did not reach statistical significance (HR 0.62 
95%CI 0.37 to 1.03).(351) 
Table 25: Summary of included studies reporting the impact of psychiatric comorbidity on 
return to work following disability 
Study  MSD 
population 













months) return to 
work within 2 
years 
No subjects with 
depression returned to 
work following fusion 











Failure to retain 
work at 12 
months 











Failure to retain 
work at 12 
months 














Rate of claim 
closure (insurance 
dataset 1) 















Rate of claim 
closure (insurance 
dataset 2) 
HR 0.636 (0.537 to 
0.753) 












due to mental 
disorders 
Time to return to 
sustained work 
(end of sickness 
benefit period 
with no recurrent 
sickness absence 
for 30 days) 











due to mental 
disorders 
Time to return to 
sustained work 
(end of sickness 
benefit period 
with no recurrent 
sickness absence 
for 30 days) 









Time to regain 
>15 days of 30 
















Return to “any” 
work at 2 years 
follow up 
Beta coefficient 0.43 
(0.12 to 0.74)* 
*confidence intervals calculated using reported standard error  
Sickness absence 
Five included studies considered the association between psychiatric comorbidities and 
sickness absence from work, see Table 26, below.(335,337,358,360,364) Psychiatric 
comorbidities were significantly associated with sickness absence in three of these 
studies.(335,337,364) Of these, a comorbid major depressive event was associated with 
increased absenteeism in the prior week for participants with chronic pain conditions (RR 
2.9 95%CI 2.8 to 2.9).(337) Comorbid mental disorders among participants with arthritis 
was associated with a mean difference of 2.3 sick leave days extra in the past 30 (95%CI 0.7 
to 3.9). Finally, Buist-Bouwman et al. found anxiety, mood disorder, or substance misuse 
disorder in past 12 months was associated with significantly increased number of sickness 
absence days over the past year among those with chronic back trouble, but not 
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rheumatism (beta coefficient 10.4 95%CI 4.1 to 16.7; and beta coefficient 1.7 95%CI -4.8 to 
8.2, respectively).  
Two studies did not find a statistically significant impact.(358,360) One study among 
participants with musculoskeletal pain at 1 to 3 locations (in the low back, in the 
neck/shoulders, or in the knees) found a medium or high depressive symptom score had no 
observable, or consistent, impact on rate of long-term sickness absence over follow 
up.(360) Csupak et al. found no statistically significant relationship between generalised 
anxiety disorder (diagnosed in the past 12 months) and absenteeism in the prior week for 
back pain and arthritis participants (OR 1.48 95%CI 0.61 to 3.64; and OR 1.90 95%CI 0.67 to 
5.36, respectively). 










Rheumatism Anxiety, mood 
disorder, or substance 
misuse disorder in 





Number of days 
unable to work 
due to mental 
health problems 




past 12 months) 
Beta coefficient 







disorder, or substance 
misuse disorder in 





Number of days 
unable to work 
due to mental 
health problems 




past 12 months) 
Beta coefficient 










work in the past 
week  
OR 1.90 (0.67 to 
5.36) 










work in the past 
week 










Statistical Manual, 3rd 
edition, revised) 
Number of days 
unable to work 
out of past 30   
Mean difference 










multiplied by 10: 0 – 
12.99 low, 13 – 20.99 




weeks or more 



















multiplied by 10: 0 – 
12.99 low, 13 – 20.99 




weeks or more 



















multiplied by 10: 0 – 
12.99 low, 13 – 20.99 




weeks or more 









1.31 (0.87 to 
1.98) 












work in the last 
week, mainly 
due to illness or 
disability.  
RR 2.9 (2.8 to 
2.9) 
*confidence intervals calculated using reported standard error  
Presenteeism and productivity loss 
Three studies considered the impact of psychiatric comorbidity on work outcomes that 
included an assessment of productivity loss among people with MSDs; see Table 
27.(335,353,365) Joshi et al. found that arthritic patients with diagnosed depressive 
disorders were more likely to report their arthritis/joint symptoms were currently affecting 
whether they worked, the type of work, or the amount of work they were producing (OR 
1.51 95%CI 1.41 to 1.60).(365) Kessler et al. considered role impairment, an overall 
measure of the number of days lost in the last 30, or with reduced productivity as a result 
of health problems. This study found, on average, 2.6 more days of role impairment among 
people with arthritis and comorbid mental health problems (95%CI 1.0 to 4.2).(335) Finally, 
among participants with lower limb pain in the prior year (classified as osteoarthritis), 
comorbid depression, but not anxiety, was significantly associated with not taking part in 
paid or voluntary work as and when desired over the prior 4 weeks (OR 2.11 95%CI 1.13 to 
3.95).(353) 
Table 27: Summary of included studies reporting the impact of psychiatric comorbidity on 
presenteeism and productivity loss 
Study  MSD 
population 












currently affect whether 
working, type of work, or 
the amount of work. 
OR 1.51 (1.41 to 1.60) 
















Role impairment score 
taking into account work 
loss days and number of 
days out of the past 30, 
when able to work but 
needed to cut back on 
what (they) did or did 
not get as much done as 
usual because of 
problems with physical 
or mental health. 
Mean difference 2.6 











Not taking part in paid or 
voluntary work as and 
when wanted over past 
4 weeks, for 3 years 
follow up.   











Not taking part in paid or 
voluntary work as and 
when wanted over past 
4 weeks, for 3 years 
follow up.   
OR 2.11 (1.13 to 3.95) 
*confidence intervals calculated using reported standard error  
Employment status and job loss 
Three studies considered the relationship between comorbid mental health problems and 
employment status among MSD populations; see Table 28.(338,352,354) Among an SLE 
cohort, comorbid depression was significantly associated with reduced odds of 
employment (OR 0.64 95%CI 0.44 to 0.94),(338) and comorbid mental health disorders and 
comorbid mood disorders were associated with unemployment amongst arthritis patients 
(OR: 3.46 95%CI 1.92 to 6.23 and OR 5.42 95%CI 2.61 to 11.26, respectively).(352) Finally, 
among participants with inflammatory rheumatic disorders, a 1.18-fold increased risk of job 
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Table 28: Summary of included studies reporting the impact of psychiatric comorbidity on 
employment status and job loss 
Study  MSD 
population 











Depression (HADS) Job loss after 2 
year follow up  




























Arthritis Diagnosed mental 
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Figure 27: Impact of psychiatric comorbidity upon work participation in people with 
MSDs. Chart is colour-coded by category of work outcome: work disability or disability 
pension (black), return to work (blue), sickness absence (green), productivity loss or 
presenteeism (purple), unemployment or job loss (orange), work transition (red). See 






































Effect estimate (95%CI), logarithmic scale
Hansen (2016), RA, psych, WD, HR (< 1 year after RA diagnosis)
Hansen (2016), RA, psych, WD, HR (> 1 year after RA diagnosis)
Csupak (2018), arthritis, anx, WD, OR
Csupak (2018), back pain, anx, WD, OR
Olofsson (2017), RA, dep/anx WD, HR
Panopalis (2007), SLE, dep, WD, OR
Lowe (2004), IRD, dep, WD, OR
Kausto (2017), disc disorder, psych, RTW, HR (men)
Kausto (2017), disc disorder, psych, RTW, HR (women)
Cote (2001), whiplash, dep, RTW, HR (cohort 1)
Cote (2001), whiplash, dep, RTW, HR (cohort 2)
Brede (2012), MS injury, dep, RTW, OR
Brede (2012), MS injury, m.dep, RTW, OR
Olofsson (2017), RA, dep/anx, RTW, HR
Munce (2007), chronic pain, dep, SA, RR
Melkevik (2018), MS pain (1 location), dep, SA, HR
Melkevik (2018), MS pain (2 locations), dep, SA, HR
Melkevik (2018), MS pain (3 locations), dep, SA, HR
Csupak (2018), arthritis, anx, SA, OR
Csupak (2018), back pain anx, SA, OR
Joshi (2015), arthritis, dep, Pres, OR
Wilkie (2013), OA, dep, Pres, OR
Wilkie (2013), OA, anx, Pres, OR
Schofield (2014), arthritis, mood, UE, OR
Schofield (2014), arthritis, MHP, UE, OR
Panopalis (2007), SLE, dep, UE, OR
De Buck (2006), IRD, dep, JL, OR
Association of psychiatric comorbidity with poor work outcomes
amongst people with MSDs 
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4.3.3 Cardio-metabolic comorbidity  
Seven included studies (four cohort, three cross-sectional) explored the association 
between cardiovascular comorbidities and work outcomes in MSD populations (see Table 
29 below).(340,344,347,351–353,365) 
Work disability and disability pension  
Among a cohort with lupus, comorbid hypertension was associated with an increased risk 
of being unemployed due to disability (self-reported) (OR 2.23 95%CI 1.16 to 4.32).(344) 
However, among working participants with rheumatoid arthritis, comorbid hypertension 
was not significantly associated with time to significant (>15 days) sick leave/disability 
pension over follow up (HR: 1.25 95%CI 0.85 to 1.85).(351) 
Return to work 
Among participants with rheumatoid arthritis (with 90 days of sick leave and disability 
pension at baseline - prior to biologic therapy) hypertension was also not associated with 
time to achieve >15 days without sick leave or disability pension over follow up (HR 0.9 
95%CI 0.56 to 1.45).(351)  
In another study, obesity (BMI ≥ 30.0) was significantly associated with failure to return to 
work within 2 years following knee arthroplasty (OR 2.8 95%CI 1.1 to 7.1).(347) 
Sickness absence 
Obesity (BMI ≥ 30.0) was also associated with any absenteeism (1–365 days of sick leave 
from work) in the year prior amongst those with self-reported musculoskeletal disorders in 
one cross sectional study (OR 1.37 95%CI 1.1 to 1.71).(340)  
Presenteeism and reduced productivity 
Being obese was associated with whether participants with arthritis felt arthritis/joint 
symptoms were currently affecting whether they worked, the type of work, or the amount 
of work they were performing (OR 1.07 95%CI 1.01 to 1,14).(365) In another study amongst 
people with lower limb “osteoarthritis” (defined as hip, knee, or foot pain for 1 day or more 
during the past year) obesity was not significantly associated with not taking part in paid or 
voluntary work as and when desired over the prior 4 weeks (OR 1.36 95%CI 0.74 to 
2.52).(353) 
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Unemployment 
Heart disease, hypertension, and other diseases of the circulatory system were all 
independently and significantly associated with unemployment (being out of the labour 
force) in one study of arthritis patients. In this study, the strength of association was 
relatively high for these conditions (OR 4.31 95%CI 1.94 to 9.55; OR 2.44 95%CI 1.55 to 
3.83; and OR 6.95 95%CI 2.76 to 17.51, respectively).(352) 
Table 29: Summary of included studies reporting the impact of cardiovascular comorbidity 
on various work outcomes 
Study  MSD 
population 









Hypertension Being unemployed due 
to disability 




Arthritis Obesity Arthritis/joint 
symptoms currently 
affect whether 
working, type of work, 
or the amount of work 






Obesity Return to work after at 
least 2 years follow up 
following total knee 
arthroplasty 






Hypertension Time to regain >15 
days of 30 without sick 
leave or disability 
pension over follow up 
(maximum 3 years) 






Hypertension Loss of 15 days of 30 
with sick leave or 
disability pension over 
follow up (maximum 3 
years) 







being in the labour 
force) 
OR 4.31 (1.94 to 9.55) 





Arthritis Hypertension Unemployment (not 
being in the labour 
force)  










being in the labour 
force) 








Obesity 1–365 days of sick 
leave in the prior year. 







Obesity Occurrence of not 
taking part in paid or 
voluntary work as and 
when wanted over past 
4 weeks (3 years follow 
up).   
OR 1.36 (0.74 to 2.52) 
 
4.3.4 Diabetes comorbidity 
Only, two studies (2 cohort, 1 cross-sectional), explored the association between diabetes 
and risk of adverse work outcomes (see Table 30).(344,352) Diabetes was significantly 
associated with unemployment among people with arthritis (OR 2.55 95%CI 1.29 to 
5.02),(352) but not with self-reported unemployment due to disability in another study 
amongst participants with SLE (OR 1.00 95%CI 0.41 to 2.44).(344)   
Table 30: Summary of included studies reporting the impact of diabetes comorbidity on 
work outcomes 
Study  MSD 
population 









Diabetes Being unemployed 
due to disability 





Arthritis Diabetes Unemployment (not 
being in the labour 
force) 
OR 2.55 (1.29 to 
5.02) 
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4.3.5 Respiratory disease comorbidity 
Only one cross-sectional study explored the association between respiratory diseases and 
unemployment status in arthritis patients (see Table 31). Both asthma and general 
respiratory diseases were significantly associated with being unemployed (OR 2.46 95%CI 
1.37 to 4.42; and OR 3.16 95%CI 1.35 to 7.43, respectively).(352) 
Table 31: Summary of included studies reporting the impact of respiratory comorbidity on 
work outcomes 
Study  MSD 
population 






Arthritis Asthma Unemployment (not 
being in the labour 
force) 









being in the labour 
force) 
OR 3.16 (1.35 to 
7.43) 
 
4.3.6 Other comorbidities  
Two studies reported work outcomes associated with other comorbidities among people 
with MSDs (see Table 32). One paper amongst those with lower limb “osteoarthritis” 
(defined as hip, knee, or foot pain for 1 day or more during the past year) did not find 
cognitive impairment was a significantly associated with not taking part in paid or voluntary 
work as and when desired over the prior 4 weeks (OR 1.09 95%CI 0.67 to 1.75).(353) 
Another cross-sectional study among people with arthritis reported unemployment was 
associated with comorbid diseases of the eye and adnexa (OR 3.86 95%CI 1.13 to 13.14), 
comorbid skin and subcutaneous tissue disease (OR 3.75 95%CI 1.31 to 10.72), comorbid 
digestive system disorders (OR 3.63 95%CI 1.91 to 6.89), and nervous system disorders (OR 
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Table 32: Summary of included studies reporting the impact of “other” comorbidity on 
work outcomes 
Study  MSD 
population 






Arthritis  Diseases of the eye 
and adnexa 
Unemployment 
(not being in the 
labour force) 









(not being in the 
labour force) 





Arthritis Diseases of the 
digestive system 
Unemployment 
(not being in the 
labour force) 





Arthritis Diseases of the 
nervous system 
Unemployment 
(not being in the 
labour force) 










(not being in the 
labour force) 








(not being in the 
labour force) 





Arthritis Diseases of the 
genitourinary system 
Unemployment 
(not being in the 
labour force) 





Arthritis “Other” comorbidity Unemployment 
(not being in the 
labour force) 










>0 on Cognitive and 
Alertness behaviour 
subscale of the 
Functional 
Limitations Profile) 
Occurrence of not 
taking part in paid 
or voluntary work 
as and when 
wanted over past 
4 weeks (3 years 
follow up).   
OR 1.09 (0.67 to 
1.75) 
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4.4 Discussion 
The presence of comorbidity was found to have a detrimental effect on work among people 
with MSDs. The majority of included studies showed comorbid health disorders were 
significantly associated with adverse work outcomes across various MSD populations 
(populations with an existing high risk of poor work outcomes).(9–13,199,334,341,348–
350,352,357,359,361–363) Of the five studies that did not observe significant findings: two 
used very broad and unvalidated indicators of work restriction and reduced 
productivity;(353,365) one was underpowered with only 15 events and wide confidence 
intervals;(342) another found that comorbidity was not significantly associated with work 
disability when disease severity factors such as joint count, radiographic score and 
functional status (ADL) were adjusted for.(339) It is possible that by adjusting for activities 
of daily living (ADL), this study was adjusting for a mediating variable, since increased 
comorbidity could lead to functional impairment, followed by reduced ability to remain in 
work. 
Effect size estimates ranged from small/non-significant (e.g. OR 1.01) to large and 
significant (e.g. OR 3.68) for odds, or risk, of adverse work outcomes. However, the 
direction of effect was very consistent (see Figure 26). The possible reasons for this 
variability are discussed below and include the measurement of comorbidity used, the 
measurement of work outcomes, and the underlying musculoskeletal populations studied.  
Comorbidity was commonly classified by counting the number of known comorbidities, 
(12,339,350,365) or, by dichotomising to the presence or absence of comorbidity. 
(10,11,199,342,348,349,353,357,359,366) Comorbidity may be described by an extensive 
array of possible disease combinations, each with varied effect on health and function. 
Therefore, even measuring comorbidity by number of health disorders may be over-
simplistic and dilute power to detect the true impact of certain specific comorbidities on 
work. In addition, classification of comorbidity was heterogeneous, drawing on different 
selections of health disorders, often with no justification for the health disorders selected. 
Some studies did make use of validated comorbidity checklists, however these checklists 
were validated against health outcomes (including health care utilisation, medical records, 
all-cause mortality, and physical functioning) not work outcomes. (9,13,334,341,343,361–
363) An agreed systematic approach to recording comorbidity burden should be 
encouraged to allow better comparison between studies, and the use of validated 
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checklists can facilitate this. However, I am unaware of any comorbidity/multimorbidity 
score or checklist which has been validated against important work outcomes. 
Work outcome measures were also heterogeneous, capturing different aspects of ability to 
remain and thrive in work. In 2016, the OMERACT (Outcome Measures in Rheumatology) 
worker productivity group produced consensus-based guidance for the standardisation of 
work and productivity outcome measures in rheumatology research. The following 
absenteeism and productivity loss measures were recommended: WALS (Workplace 
Activity Limitations Scale), WLQ PDmod (Work Limitations Questionnaire with modified 
physical demands scale), WAI (Work Ability Index), WPS (Arthritis-specific Work 
Productivity Survey), and WPAI (Work Productivity and Activity Impairment 
questionnaire).(383) Of the included studies in this review, only six used the recommended 
questionnaires (or items from these questionnaires).(334,340,341,343,361) As described 
above, the use of such validated questionnaires can facilitate consistency and comparability 
across research. Another advantage, over the use of a single closed questions, is that 
responses from these questionnaires can be graded to assess severity of work impairment. 
However, even the use of validated questionnaires does not guarantee that the data will be 
analysed in a consistent manner. For example, in Agaliotis (2013), WPAI presenteeism was 
dichotomised to those “exposed to presenteeism” (participants who scored an average of 
99.99% and below) vs those not exposed (100%).(343)  
OMERACT recommended the use of questionnaires focussed on the short-term or “usual” 
work ability of participants who are currently employed. In this review, many studies 
focussed on other adverse employment events, such as being unable to work for a health 
reason;(9,11–13,336,338,358) return to work following a period of long-term sickness 
absence;(345–348,351,355,356,364,366) or the receipt of disability 
pension.(10,336,339,351,357) For these work outcomes, there are also challenges for 
consistency in reporting. For example, the follow-up period to assess return to work varied; 
appropriate length of follow up may depend on the cause of disability. Additionally, 
assessment of the presence of “official” work disability, or the receipt of disability pension, 
may have different legal classifications depending on the national social security system. In 
the UK, there are several kinds of disability benefits which may be awarded as a result of 
temporary or permanent inability to work, and may be paid to persons who are still 
working.(384) 
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Some studies reported work outcomes that were not health-specific. For example, 
employment status,(338,341,342,352,359,361) job loss,(349,354) and not taking part in 
paid or voluntary work as and when desired.(353) The obvious problem with these work 
outcomes is that it is unclear whether they have occurred specifically as a result of a health 
issue, or for some other reason which may be related to health (for example, lower 
educational attainment). However, for many important comorbid exposures such as heart 
disease, diabetes, and asthma these were the only work outcomes that were reported.(352)  
Finally, variability in the effect sizes reported may reflect differences in the underlying 
musculoskeletal population studied. The reference group of interest was people with 
musculoskeletal disorders and no comorbidities, however, most included studies were 
restricted to sub-populations of specific musculoskeletal disease groups such as SLE and 
rheumatoid arthritis; conditions with their own specific characteristics, demographics, and 
risk of adverse work outcomes. Effect sizes for the impact of comorbidity may therefore 
vary depending on the existing level of risk in the underlying musculoskeletal population.  
However, there were consistent trends. For example, as mentioned above, comorbidity was 
significantly associated with adverse work outcomes across various MSD populations, and 
effect estimates suggested a negative influence on work-health in all cases. Specifically, 
there was consistent evidence to suggest that psychiatric comorbidities had a detrimental 
impact on work. A significant effect was reported in 16 of 18 reporting studies, which 
included eight cross-sectional studies (NOS mean quality 6.5/10, range 5 – 8),(335–
338,358,364–366) and eight cohort studies (NOS mean quality 6.1/9, range 5 – 7).(345,351–
357) However, work restriction was not associated with comorbid anxiety in one 
study.(353) This study used a very broad definition of work restriction, which was not 
health specific and may have failed to discriminate those with significant work restriction 
(‘‘During the past 4 weeks, if you work, have you taken part in paid or voluntary work as 
and when you have wanted?”). Another study did not find that major depressive event, or 
moderate depressive symptoms, were related to ability to remain in active work 12 months 
after occupational MSD injury.(346) In this case, the reasoning behind the multivariable 
adjustments were unclear and appeared to include multiple measures of depression in the 
same statistical model. Finally, one study did not find depression (Major Depression 
Inventory- mean score) among people with self-reported musculoskeletal pain was 
associated with onset of prolonged sickness absence, although depression symptoms rather 
than clinically diagnosed depression was assessed here.(360)  
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A few studies reported that mental and musculoskeletal comorbidity had a multiplying, not 
just additive, impact upon work ability and sickness absence.(335,357,364,385) In other 
words, mental health problems may have a synergistic relationship with musculoskeletal 
disorders whereby the combined effect on work-health is greater than would be expected 
from the individual effects of each disease alone. The impact of comorbid mental health 
problems may be broad, for example, depression has been found to be detrimental for 
home, work, and social relationships, morbidity and even all-cause mortality in patients 
with chronic medical disorders.(386,387) The development of a psychiatric comorbidity 
may therefore initiate precipitous deterioration in the ability to remain working among 
people with MSDs.  
There was little evidence on the impact of other comorbid health disorders for work 
outcomes in MSDs. Comorbid diabetes was associated with unemployment in arthritis in 
one study,(352) but was not associated with work disability in a lupus population.(344) One 
study showed comorbid heart disease, vascular disease, asthma, “other respiratory 
diseases,” diseases of the digestive system, diseases of the eye and adnexa, diseases of the 
skin, injury and poisoning were associated with unemployment in arthritis.(352) But no 
health-specific work outcomes were reported. More research is required to understand the 
role of a broader range of comorbid health disorders on work outcomes, particularly for 
cardiometabolic disorders which are highly prevalent among people with MSDs.(388,389) 
Health risk factors, such as hypertension and obesity, are frequently not included in the 
definition of comorbidity.(150) However, in this review, two studies linked hypertension to 
risk of being unemployed due to disability, or just unemployed, in MSDs (one amongst SLE 
and one amongst arthritic participants, respectively).(344,352) In addition, comorbid 
obesity was associated with sickness absence in the prior year,(340) no return to work 
following knee arthroplasty,(347) and whether arthritis/joint symptoms were affecting 
work status, type of work, or the amount of work produced,(365) amongst MSD and 
arthritis populations. The mechanism of effect in each of these cases is unclear. These 
health risk factors are associated with a range of other, possibly unmeasured, 
cardiovascular disorders and may be indicators of greater musculoskeletal disease severity 
through known inflammatory pathways.(390) Obesity can also mechanically exacerbate 
underlying arthritis symptoms.(391)  
The limitations of this evidence base have been described in detail above. One further 
limitation included the fact that the MSD populations studied were not necessarily 
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representative of the MSDs most frequently seen in UK populations. For instance, more 
evidence is needed from the two most prevalent MSD populations: osteoarthritis and low 
back pain. Some publication bias towards diseases with more expensive and novel 
treatments (i.e. inflammatory rheumatic disorders) was apparent. As a result, while the 
methodological quality of the included studies was relatively strong the use of this review 
to draw conclusions about the general MSD population may be hampered by indirectness.  
Weaknesses of the review methodology include the broad search strategy. Papers that did 
not include the words comorbidity or multimorbidity (and derivatives) in their titles, 
abstracts or keywords would not have been identified. Therefore, studies that focused only 
on the relationship between two diseases (for example, depression and rheumatoid 
arthritis) without using the terms co- or multi-morbid may have been missed. I hoped to 
mitigate this risk by performing thorough citation checks of the included studies, since 
running the search with multiple specific disease terms would have resulted in an 
unmanageable number of references.  
Across studies included in this systematic review, important trends have been highlighted, 
showing the relationship between comorbidities, and specifically psychiatric comorbidities, 
and adverse work outcomes among people with MSDs. Additionally, this review has 
highlighted several research areas which have not been sufficiently addressed. For 
example, the impact of non-psychiatric comorbidities upon work outcomes among people 
with MSDs is still unclear. This is particularly important for cardiovascular comorbidities 
which are common, and therefore naturally likely to co-occur with MSDs. Secondly, this 
review highlighted poor consistency in the measurement of work outcomes, and in the 
measurement of comorbidity (or multimorbidity) itself. The development and use of 
validated measures for comorbidity exposures and work outcomes will be necessary for 
future research.  
4.5 Conclusion 
This review draws conclusions from a heterogeneous evidence base. Varying populations, 
outcome definitions, analysis and study design can make interpretation difficult but, even 
so, trends were identified. Compared to having a musculoskeletal disorder alone, 
comorbidity, and specifically comorbid mental health problems, were associated with 
multiple adverse work outcomes across different MSD populations. Impact is likely to 
depend on the type of comorbid condition and its severity. However, while psychiatric 
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comorbidities were well reported, further research is required to study other important 
comorbid diseases that may be predictive of poor work ability in MSDs.   
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Chapter 5- describing “case” 
participants with HRJL  
5.1 Introduction 
This chapter describes the primary population of interest in this thesis: people who 
reported that they had stopped working mainly or partly because of a health problem 
(those with HRJL, the “cases”) on the baseline questionnaire of the Health and Employment 
After Fifty (HEAF) study, see Figure 28. This population are described for the following 
characteristics: their socio-demographic factors; details of the last job worked prior to HRJL; 
age when stopped working; and the health-cause of job loss as indicated by questionnaire 
responses. Next, their CPRD-defined health disorders are presented, along with the more 
specific health disorder sub-groups that contributed to these variables (see Chapter 3). 
Finally, case participants are stratified by gender, their age at the time of HRJL, and whether 
they reported a health problem was mainly or partly responsible for the job loss, to look for 
any important differences between these sub-groups. 
Figure 28: The cohort described in this chapter, as indicated by the red square 
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5.2 Methods 
A descriptive analysis of participants with premature exit from work due to health was 
undertaken. Case participants were described for demographic factors, previous work, 
social class, factors relating to lifestyle, and lastly for CPRD-defined health problems. The 
classifications used to define these variables are outlined in Chapter 3. When describing 
CPRD-defined health disorders, each disease variable was considered in detail to see which 
constituent disease codes were prevalent. For example, among cases with a chronic MSD, 
the proportion due to osteoarthritis, inflammatory arthritis, or connective tissue diseases 
was described. This higher definition description of disease groups was conducted in order 
to gain a greater understanding of the common diseases contributing to the main health 
exposures under study in this thesis and, in turn, to aid interpretation of results going 
forwards.  
Among case participants, there were certain sub-groups of interest. To date, few studies of 
the determinants of early exit from work due to health have explored the effect of gender. 
Therefore, male and female cases were compared for their demographic, lifestyle, and 
health-related factors to look for important differences. Case participants also differed for 
the age at which they left work. In the UK, the 50 – 60-year-old age band are of particular 
economic interest, since they are the most common HRJL group and still a considerable 
distance from state pension retirement age. Descriptive analysis was therefore stratified by 
those under the age of 50, those 50 to <60 years old, and those older than 60 at the time of 
HRJL. Finally, as outlined in chapter 3, case participants could respond that a health 
problem had been the “main reason” or “part of the reason” for their job loss. I looked for 
important differences in demographic, lifestyle, and health-related factors, between these 
sub-groups, in order to ascertain whether sensitivity analysis by “type” of HRJL is necessary 
in later chapters.  
Statistical analyses were performed using Stata-13. Participants with HRJL were described 
using simple statistics such as percentages for categorical data, means and standard 
deviations for continuous data, and medians and interquartile ranges for non-gaussian 
continuous variables.  
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5.3 Results 
5.3.1 Describing all participants with HRJL 
5.3.1.4 Demographic factors 
Case participants were vast-majority white (98.2%). 19.8% had attained a university-level 
education, 39.7% had vocational or professional-level qualifications, 18.4% had high school 
qualifications, and 22.1% had no qualifications. Most case participants were married 
(67.2%), 9.8% were single, 18.1% were divorced and 4.9% were widowed. See Table 33. 
Table 33: Distribution of demographic factors among cases 
Variable Number of cases (%)1 
Ethnicity (non-white) 9 (1.8) 
Ethnicity (white) 485 (98.2) 
University degree 98 (19.8) 
Vocational 196 (39.7) 
High school qualifications 91 (18.4) 
No qualifications 109 (22.1) 
Married/Civil partnership 330 (67.2) 
Single 48 (9.8) 
Divorced 89 (18.1) 
Widowed 24 (4.9) 
  1. data on relationship status was missing for three case participants  
5.3.1.5 Occupations  
Cases were grouped for their previous occupations using the SOC-10 classification system 
(see Chapter 3). The distribution of major SOC-10 occupational groups can be found in 
Table 34 below. Most cases were either in professional (20.0%), administrative (15.6%), 
elementary (12.8%), or skilled trade (10.7%) work, which together accounted for over half 
of the jobs lost. This was closely followed by caring, leisure, and service occupations (9.5%), 
associate professional and technical occupations (8.9%), sales and customer service 
occupations (7.1%), process, plant and machine operatives (7.1%), and finally managers, 
directors, and senior officials (6.7%).  
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Table 34: Strata of SOC-10 major occupational groups for previous employment among 
cases 
Variable Number of 
cases (%)1 
Managers, directors and senior officials 33 (6.7) 
Professional occupations 99 (20.0) 
Associate professional and technical occupations 44 (8.9) 
Administrative and secretarial occupations 77 (15.6) 
Skilled trades occupations 53 (10.7) 
Caring, leisure, and other service occupations 47 (9.5) 
Sales and customer service occupations 35 (7.1) 
Process, plant and machine operatives 35 (7.1) 
Elementary occupations 63 (12.8) 
  1. data on SOC-10 occupational class was missing for eight case participants 
The SOC-10 sub-major categories provide a greater level of detail. The frequency of these 
occupational sub-groups among case participants are outlined in Table 35 and are 
visualised in Figure 29. Teaching (9.7%), administration (13.2%), and elementary 
administration (10.7%) accounted for approximately one third of all jobs lost due to poor 
health. Other common previous careers among cases included: caring personal service 
occupations (6.9%); sales occupations (6.1%); and health professional occupations (5.7%). 
By the SOC-10 classification of skill level, almost a quarter of all cases had worked in the 
highest skill category (23.6%), 22.6% in level 3, 39.3% in level 2, and 12.6% in the lowest 
skill group.  
Table 35: Strata of SOC-10 sub-major occupational groups among cases 
Variable Skill level Number of cases 
(%)1 
Corporate managers and directors Level 4 18 (3.6) 
Science, research, engineering, and technology 
professionals 
9 (1.8) 
Health professionals 28 (5.7) 
Teaching and educational professionals 48 (9.7) 
Business, media and public service professionals 14 (2.8) 
Other managers and proprietors Level 3 15 (3.0) 
Science, engineering, and technology associate 
professionals 
9 (1.8) 
Health and social care associate professionals 10 (2.0) 
Protective service occupations 7 (1.4) 
Culture, media, and sports occupations 3 (0.6) 
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Business and public service associate 
professionals 
15 (3.0) 
Skilled agricultural and related trades 9 (1.8) 
Skilled metal, electrical and electronic trades 16 (3.2) 
Skilled construction and building trades 15 (3.0) 
Textiles, printing, and other skilled trades 13 (2.6) 
Administrative occupations Level 2 65 (13.2) 
Secretarial and related occupations 12 (2.4) 
Caring personal service occupations 34 (6.9) 
Leisure, travel and related personal service 
occupations 
13 (2.6) 
Sales occupations 30 (6.1) 
Customer service occupations 5 (1.0) 
Process, plant and machine operatives 16 (3.2) 
Transport and mobile machine drivers and 
operatives 
19 (3.9) 
Elementary trade and related occupations Level 1 10 (2.0) 
Elementary administration and service 
occupations 
53 (10.7) 
   1. data on SOC-10 occupational class was missing for eight case participants 
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Figure 29: Occupation spread among case participants 
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5.3.1.6 Socio-economic class 
The SOC-10 occupational categories could be used to classify socio-economic status 
according to the NS-SEC simplified criteria, see Chapter 3. Table 36 shows the distribution 
of three-level and eight-level NS-SEC socioeconomic class among case participants. Using 
the broader three-level socio-economic categories, 32.4% were in the higher managerial 
class, 26.7% in the intermediate class, and 39.3% in the routine and manual class.  
Table 36: Strata of NS-SEC, 8-level, and 3-level criteria, among cases 









160 (32.4) Higher professional occupations 30 (6.2) 







Small employers and own account workers 31 (6.4) 




194 (39.3) Semi-routine occupations 110 (22.3) 
Routine occupations 58 (11.7) 
1. data on NS-SEC occupational class was missing for eight case participants 
5.3.1.7 Lifestyle  
Among case participants, approximately half were ever-smokers, of whom 16.6% were 
current smokers and 33.8% were ex-smokers. A history of heavy alcohol intake was 
indicated in 3.6%. See Table 37, below.  
Table 37: Distribution of lifestyle factors among case participants 
Variable Number of cases 
(%) 
Smoking 
Never smokers 245 (49.6) 
Ex-smokers 167 (33.8) 
Current smokers 82 (16.6) 
Heavy drinking 
No history of heavy drinking 476 (96.4) 
History of heavy drinking 18 (3.6) 
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5.3.1.8 Patient-reported health causes of job loss 
As described in Chapter 3, in the HEAF baseline questionnaire participants with HRJL also 
classified the health problem that led to their job loss according to a few possible 
categories. Among case participants, 44.2% reported that leaving work was at least partially 
because of “a problem with their back, neck, arm, shoulder, or leg”; 35.4% because of 
“mental health disorders or stress”; 13.2% because of “a problem with the heart or lungs”; 
and 35.9% because of “another type of health problem”. See Figure 30.  
Figure 30: Self-reported health causes of job loss among case participants 
 
 
5.3.1.9 Musculoskeletal disorders 
Clinical data from study participants’ CPRD records were considered. Chronic MSDs were 
identified in 136 (27.5%) case participants prior to their HRJL. Of these cases, 61.8% 
considered “a problem with their back, neck, arm, shoulder, or leg” to be a contributing 
factor to their job loss.  
A large majority of cases with chronic MSDs had a diagnosis of osteoarthritis (OA) (n=114, 
83.8%) which was largely probable OA unclear site (58.1%) or OA knee (18.4%). Other than 
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OA, 10.3% had rheumatoid arthritis, 17.7% had another kind of inflammatory arthritis, 7.4% 
had gout, and 4.4% had connective tissue disease. See Table 38, below.  
Table 38: CPRD-defined health disorders contributing to the chronic MSD variable, among 
case participants 
Variable No. of cases with 
HRJL and chronic 
MSD (%) 
Rheumatoid arthritis 14 (10.3) 
Other inflammatory arthritis 24 (17.7) 
Probable osteoarthritis unclear site 79 (58.1) 
OA back 9 (6.6) 
OA neck 19 (14.0) 
OA shoulder and elbow 1 (0.7) 
OA hip 7 (5.2) 
OA knee 25 (18.4) 
OA lower limb, not specified  3 (2.2) 
OA back or neck, not specified 2 (1.5) 
OA hand, wrist, digits 3 (2.2) 
Gout 10 (7.4) 
Connective tissue disease 6 (4.4) 
Arthroplasty of the hip 10 (7.4) 
Arthroplasty of the knee 8 (5.9) 
Probable OA (combined OA groups) 114 (83.8) 
 
Recent musculoskeletal pain, in the year prior to HRJL, was identified in 153 (31.0%) case 
participants. Among these cases, 61.8% said “a problem with their back, neck, arm, 
shoulder, or leg” had contributed to their job loss.  
Over one third (n=65, 42.5%) of cases with recent MSD pain had presented with back pain. 
Other common problems included knee pain (21.6%), shoulder pain (13.1%), and 
widespread pain (10.5%). Of the body region-specific MSD pain codes, there were 40 
participants with upper limb pain (26.1%), 84 participants with recent back and spine pain 
(54.9%), and 50 with recent lower limb pain (32.7%). See Table 39, below.  
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Table 39: CPRD-defined health disorders contributing to the recent MSD pain variable, 
among case participants 
Variable No. of cases with 
HRJL and recent 
MSD pain (%) 
Disorder of joints, non-specific 19 (12.4) 
Back pain 65 (42.5) 
Discogenic/nerve root pain 10 (6.5) 
Neck pain 14 (9.2) 
Hip pain 13 (8.5) 
Knee pain 33 (21.6) 
Lower limb pain unspecified 4 (2.6) 
Knee bursitis 1 (0.7) 
Knee joint swelling or effusion 3 (2.0) 
Widespread pain 16 (10.5) 
Shoulder pain 20 (13.1) 
Elbow pain 1 (0.7) 
Wrist/hand or forearm pain 5 (3.3) 
Specific disorders of the shoulder or 
shoulder girdle  
6 (3.9) 
Specific disorders of the elbow  12 (7.8) 
Shoulder surgery and other procedures 2 (1.3) 
Non-specific sprain/injury 1 (0.7) 
Neck injury 1 (0.7) 
Back injury 2 (1.3) 
Shoulder/upper limb injury 1 (0.7) 
Other lower limb injury 1 (0.7) 
Other specific disorders 3 (2.0) 
Other knee procedures (not 
arthroplasty) 
4 (2.6) 
Rheumatism, non-specific 12 (7.8) 
 
5.3.1.10 Mental health problems  
Among those with HRJL, 140 participants (28.3%) had a recent mental health problem 
(MHP). This included 129 participants with a primary-care-level MHP (26.1%), eight 
participants with a psychiatric-care-level MHP (1.6%), and 37 participants with a sleep 
disorder (7.5%). A history of severe mental health problems was also present in 37 
participants (7.5%). Case participants ascribed their HRJL to “mental health problem or 
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stress” in 59.4% with a recent primary care level MHP, 46.0% with a recent sleep disorder, 
62.5% with a psychiatric care-level MHP, and 62.2% with history of a severe MHP.  
The majority of case participants with recent primary care-level MHPs had mood or 
depressive disorders (83.0%) or anxiety disorders (31.8%). There were few case participants 
with psychiatric care-level MHPs, of whom five (62.5%) had a diagnosis of schizophrenia 
and three (37.5%) bipolar disorder. Of case participants with a history of severe mental 
health problems, there were 67.6% who had been under psychiatric care, 27.0% with a 
history of crisis admission, section, or being on a severe mental health register, and 21.6% 
with a history of self-harm, suicidal actions, or ideations. See Table 40. 
Table 40: CPRD-defined health disorders contributing to MHP variables, among case 
participants 
Variable No. of cases with HRJL and 
MHPs (%) 
Primary care-level mental health problems 
Mood or depressive disorders 107 (83.0) 
Anxiety disorders 41 (31.8) 
Somatoform disorders 3 (2.3) 
Adjustment disorders 14 (10.9) 
Sleep disorders 
Sleep disorders 37 (100.0) 
Psychiatric care-level mental health problems 
Schizophrenia and other psychotic disorders 5 (62.5) 
Sexual and gender identity disorders 1 (12.5) 
Bipolar disorders 3 (37.5) 
Severe mental health problems 
Self-harm, suicidal actions, or ideations 8 (21.6) 
Under the psychiatric team 25 (67.6) 




5.3.1.11 Cardiovascular disease  
Among case participants, there were 44 with heart failure (8.9%), 30 with ischaemic heart 
disease (6.1%), 133 with hypertension (26.9%), one with venous thromboembolism (0.2%), 
11 with peripheral atherosclerosis (2.2%), seven with cardiac arrhythmia (1.4%), and seven 
with structural heart disease (1.4%). When asked, 54.6% with heart failure, 63.3% of 
participants with ischaemic heart disease, 17.4% of participants with hypertension, none 
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with venous thromboembolism (of one participant), 27.3% of participants with peripheral 
arterial disease, and 100.0% of seven participants with cardiac arrythmia stated that “a 
problem with the heart or lungs” had contributed to their job loss. 
The majority of case participants with ischaemic heart disease had myocardial ischaemia, 
atherosclerosis, or angina (86.7%), 40.0% had myocardial infarction or unstable angina, and 
36.7% had a coronary angioplasty, bypass, or stent. Case participants with structural heart 
disease included four participants (57.1%) with diseases of the endocardium and valves and 
three participants (42.9%) with cardiomyopathies. Cases with recent cardiac arrythmias 
included five participants (71.4%) with atrial fibrillation or supraventricular tachycardia, two 
participants (28.6%) with arrythmias requiring cardioversion, ablation, or a pacemaker 
(0.4%) and two participants (28.6%) with other arrythmias. Cases with venous 
thromboembolism included only one participant who had a pulmonary embolism (0.2%). 
Lastly, cases with peripheral atherosclerosis included seven participants (63.6%) with a 
diagnosis of peripheral atherosclerotic disease and five participants (45.5%) with vascular 
atherosclerotic events, occlusions, or vascular surgery. See Table 41, below.  
Table 41: CPRD-defined health disorders contributing to cardiovascular disease variables, 
among case participants 
Variable No. of cases with 
HRJL and CV 
disorder (%) 
Ischaemic heart disease 
Myocardial infarction and unstable angina 12 (40.0) 
Myocardial ischaemia, atherosclerosis, and angina 26 (86.7) 
Coronary angioplasty, bypass, and stent 11 (36.7) 
Heart failure 
Heart failure 44 (100.0) 
Structural heart disease 
Diseases of the endocardium and valves 4 (57.1) 
Cardiomyopathies 3 (42.9) 
Hypertension 
Hypertension 133 (100.0) 
Cardia arrhythmias 
Arrythmia other than atrial fibrillation 2 (28.6) 
Atrial fibrillation and supraventricular tachycardia 5 (71.4) 
Arrythmia requiring cardioversion, ablation or a pacemaker 2 (28.6) 
Venous thromboembolic disease  
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Pulmonary embolism 1 (100.0) 
Peripheral arterial disease 
Vascular atherosclerotic events, occlusions, and non-coronary surgery 5 (45.5) 
Peripheral arterial disease 7 (63.6) 
 
5.3.1.12 Respiratory disorders 
There were 47 case participants with asthma (9.5%), and 15 with COPD (3.0%). In 
questionnaire responses 21.3% of the participants with asthma, and 66.7% of the 
participants with COPD indicated “a problem with the heart or lungs” had contributed to 
their job loss. 
Participants with asthma included 93.6% with asthma or probable asthma codes and only 
three participants (6.4%) with specific indicators of severe asthma (e.g. emergency hospital 
admissions for asthma). Participants with COPD had all received COPD or emphysema 
specific diagnostic codes, two participants (13.3%) were also diagnosed with chronic 
bronchitis. See Table 42, below.  
Table 42: CPRD-defined health disorders contributing to respiratory disorder variables, 
among case participants 
Variable No. of cases with HRJL 
and respiratory disorder 
(%) 
Asthma 
Asthma or probable asthma 44 (93.6) 
Severe asthma 3 (6.4) 
COPD 
Chronic bronchitis 2 (13.3) 
COPD or emphysema 15 (100.0) 
 
5.3.1.13 Neurological disorders 
There were 17 case participants (3.4%) with CVA prior to job loss, and seven participants 
(1.4%) with epilepsy. Of these, 64.7% with CVA, and 28.6% with epilepsy indicated “another 
type of health condition” had contributed to their HRJL, possibly referring to their epilepsy 
or CVA. 
Participants with CVA were all diagnosed with stroke, of which three participants (17.6%) 
also had a diagnosis of recent TIA. Six participants (85.7%) with epilepsy had specific 
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epilepsy-related codes while five had a fit or seizure before job loss and also epilepsy-
specific codes any time prior to the baseline of the HEAF study. See Table 43.  
Table 43: CPRD-defined health disorders contributing to neurological disorder variables, 
among case participants 
Variable No. of cases with HRJL and 
neurological disorder (%) 
Cerebrovascular accident 
TIA 3 (17.6) 
Stroke 17 (100.0) 
Epilepsy 
Epilepsy 6 (85.7) 
Fit/seizure  5 (71.4) 
 
5.3.1.14 Diabetes 
There were 60 case participants with diabetes (12.2%). Of these, 50.0% indicated “another 
type of health condition” had contributed to their HRJL, possibly referring to their diabetes. 
All diabetic case participants had diabetes-specific codes prior to HRJL. Additionally, 53.3% 
had indicators of poor diabetes control (e.g. diabetic ketoacidosis), 23.7% had diabetic eye 
complications, and three participants (5.0%) had another type of diabetic complication. See 
Table 44. 
Table 44: CPRD-defined health disorders contributing to diabetes variable, among case 
participants 
Variable Total with HRJL 
and diabetes, 60 
(12.15%) 
Diabetes  60 (100.0) 
Eye involvement 16 (26.7) 
Poor control 32 (53.3) 
Other complication 3 (5.0) 
 
5.3.2 Describing cases by gender 
5.3.1.15 Demographic factors 
Male and female case participants were similar for the median age at which they left work, 
and for their ethnicity. A greater proportion of female cases than male appeared to have 
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left education after attaining a high school qualification (21,9% vs 14.1%) and more men 
than women after attaining vocational level qualifications (43.6% vs 36.5%), however 
similar proportions had no qualifications or were educated to university level. Finally, male 
cases were more frequently single than female cases (13.2% vs 7.0%, respectively). See 
Table 45, below.  
Table 45: Distribution of demographic factors among case participants, by gender 
Variable No. of men with HRJL 
(%) 
No. of women with 
HRJL (%) 
Age at HRJL, y (IQR) 58.56 (53.66 – 61.23) 57.86 (53.27 – 60.39) 
Ethnicity (non-white) 4 (1.8) 5 (1.8) 
Ethnicity (white) 216 (98.2) 269 (98.2) 
University degree 45 (20.5) 53 (19.3) 
Vocational 96 (43.6) 100 (36.5) 
High school qualifications 31 (14.1) 60 (21.9) 
No qualifications 48 (21.8) 61 (22.3) 
Married/Civil partnership 145 (66.2) 185 (68.0) 
Single 29 (13.2) 19 (7.0) 
Divorced 37 (16.9) 52 (19.1) 
Widowed 8 (3.7) 16 (5.9) 
 
5.3.1.16 Occupations  
Across SOC-10 major occupational categories, considerably more female than male cases 
were working in administration (21.2% vs 8.6%); caring, leisure, and service occupations 
(14.2% vs 3.6%); sales and customer service occupations (10.2% vs 3.2%); and in 
professional occupations (23.0% vs 16.4%). While proportionally more men than women 
were in skilled trade occupations (21.4% vs 2.2%); working as process, plant, and machine 
operatives (14.1% vs 1.5%); and in professional and technical occupations (11.4% vs 6.9%). 
See Table 46, below. 
Table 46: Strata of SOC-10 major occupational groups among case participants, by 
gender. 
Variable No. of men 




Managers, directors and senior officials 10 (4.6) 23 (8.4) 
Professional occupations 36 (16.4) 63 (23.0) 
Associate professional and technical occupations 25 (11.4) 19 (6.9) 
Administrative and secretarial occupations 19 (8.6) 58 (21.2) 
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Skilled trades occupations 47 (21.4) 6 (2.2) 
Caring, leisure, and other service occupations 8 (3.6) 39 (14.2) 
Sales and customer service occupations 7 (3.2) 28 (10.2) 
Process, plant and machine operatives 31 (14.1) 4 (1.5) 
Elementary occupations 35 (15.9) 28 (10.2) 
 
Observing the occupations in finer detail using the SOC-10 sub-major categories, female 
cases, more frequently than male, had been working as health professionals (9.5% vs 0.9%), 
in administrative occupations (17.2% vs 8.2%), secretarial and related occupations (4.0% vs 
0.5%), caring and personal service occupations (10.6% vs 2.3%), or sales occupations (9.1% 
vs 2.3%). Male cases, more commonly than female, previously worked in protective service 
occupations (2.7% vs 0.4%), skilled agricultural and related trades (3.6% vs 0.4%), skilled 
metal, electrical and electronic trades (7.3% vs 0.0%), skilled construction and building 
trades (6.4% vs 0.4%), as process, plant and machine operatives (5.5% vs 1.5%), transport 
and mobile machine drivers and operatives (8.6% vs 0.0%), or in elementary trade and 
related occupations (3.6% vs 0.7%). See Figure 31, below, and Table 16, Appendix.  
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Figure 31: Occupation spread among cases, by gender 
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5.3.1.17 Socio-economic class 
Using the broad three-level NS-SEC system, 26.8% of male cases and 36.9% of female had 
previously worked in managerial class occupations, 29.1% and 24.8% were in intermediate 
class occupations, and 43.2% and 36.1% were in routine and manual class work, 
respectively. See Table 47, below.   
Table 47: Three-level strata of NS-SEC, among case participants, by gender 
Variable No. of men with 
HRJL (%) 
No. of women with 
HRJL (%) 
Higher managerial class 59 (26.8) 101 (36.9) 
Intermediate class 64 (29.1) 68 (24.8) 
Routine and manual class 95 (43.2) 99 (36.1) 
 
5.3.1.18 Lifestyle  
Among case participants, 43.6% of men and 54.4% of women had never smoked. The 
proportion of current smokers was similar between men and women (15.9% vs 17.2%), 
although ex-smoking was more common among men (40.5% vs 28.5%). 5.5% of male cases 
and 2.2% of female cases had a history of heavy alcohol consumption. See Table 48, below.  
Table 48: Distribution of lifestyle factors among case participants, by gender. 







Never smokers 96 (43.6) 149 (54.4) 
Ex-smokers 89 (40.5) 78 (28.5) 
Current smokers 35 (15.9) 47 (17.2) 
Heavy drinking 
History of heavy drinking 12 (5.5) 6 (2.2) 
 
5.3.1.19 Musculoskeletal disorders 
Among case participants, 25.0% of men and 29.6% of women had CPRD-defined chronic 
MSDs. Recent musculoskeletal pain occurred in a similar proportion of men and women 
(30.0% and 31.8%, respectively). See Table 49, below.  
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Table 49: Frequency of musculoskeletal disorder variables, among case participants, by 
gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
Chronic MSD 55 (25.0%) 81 (29.6%) 
Recent MSD pain 66 (30.0%) 87 (31.8%) 
 
5.3.1.20 Mental Health Problems  
Among case participants, primary care-level MHPs (30.3% vs 20.9%) and sleep disorders 
(9.1% vs 5.5%) occurred more frequently among women than men. However, psychiatric 
care-level MHPs were similarly uncommon in men (1.8%) and women (1.5%). A history of 
severe MHPs was present in 8.2% of men and 6.9% of women. See Table 50, below.   
Table 50: Frequency of mental health problem variables, among case participants, by 
gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
Primary care-level MHPs 46 (20.9) 83 (30.3) 
Sleep disorders 12 (5.5) 25 (9.1) 
Psychiatric care-level MHPs 4 (1.8) 4 (1.5) 
Severe MHPS 18 (8.2) 19 (6.9) 
 
5.3.1.21 Cardiovascular disease 
Most of the cardiovascular disorders were found in male, rather than female, cases. 
Specifically, 10.5% of men and 2.6% of women had ischaemic heart disease; 13.2% of men 
and 5.5% of women had heart failure, 3.2% of men and 0.0% of women had structural heart 
disease; 31.4% of men and 23.4% of women had hypertension; 2.7% of men and 0.4% of 
women had cardiac arrythmias, 0.0% of men and 0.4% of women had venous 
thromboembolic disease; and 4.1% of men and 0.7% of women had thromboembolic 
disease. See Table 51, below. 
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Table 51: Frequency of cardiovascular problem variables, among case participants, by 
gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
Ischaemic heart disease 23 (10.5) 7 (2.6) 
Severe ischaemic heart disease 8 (3.6) 4 (1.5) 
Heart failure 29 (13.2) 15 (5.5) 
Structural heart disease 7 (3.2) 0 (0.0) 
Hypertension 69 (31.4) 64 (23.4) 
Cardiac arrythmias 6 (2.7) 1 (0.4) 
Venous thromboembolic disease 0 (0.0) 1 (0.4) 
Peripheral atherosclerosis 9 (4.1) 2 (0.7) 
 
5.3.1.22 Respiratory disorders 
Among case participants, a similar proportion of men and women were diagnosed with 
asthma (8.2% and 10.6%, respectively). Indicators of severe asthma were relatively rare 
(0.5% and 0.7%, respectively). COPD was slightly more common among men than women 
(4.6% vs 1.8%). See Table 52, below. 
Table 52: Frequency of respiratory disorder variables, among case participants, by gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
Asthma 18 (8.2) 29 (10.6) 
Severe asthma  1 (0.5) 2 (0.7) 
COPD 10 (4.6) 5 (1.8) 
 
5.3.1.23 Neurological disorders 
Among case participants, CVA was found in 4.6% of men and 2.6% of women.  Epilepsy was 
rare, reported in 1.8% of men and 1.1% of women. See Table 53, below. 
Table 53: Frequency of neurological disorder variables, among case participants, by 
gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
CVA 10 (4.6) 7 (2.6) 
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Epilepsy 4 (1.8) 3 (1.1) 
 
5.3.1.24 Diabetes 
Among case participants, a greater proportion of men than women had diabetes (17.7% vs 
7.7%). Indicators of poor diabetes control also occurred more commonly among the men 
(11.8% and 4.0%, respectively). See Table 54, below.  
Table 54: Frequency of diabetes variables, among case participants, by gender 
Variable No. of men with 
HRJL (%) 
No. of women 
with HRJL (%) 
Diabetes 39 (17.7) 21 (7.7) 
Diabetes with poor control 26 (11.8) 11 (4.0) 
 
5.3.3 Describing cases by age at HRJL 
The time that elapsed between when a case experienced HRJL and their eventual entry into 
the HEAF study varied. Figure 32 shows a density plot of case participants and time, in 
years, between their job loss and later recruitment into the HEAF study.   
Figure 32: Density plot of the time from HRJL to enrolling in HEAF. 
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Figure 32 shows a skewed distribution, with median time since HRJL of 2.98 years and mean 
of 4.18 years. The interquartile range was 1.26 – 5.87 years, showing that most case 
participants had experienced job loss within the past 6 years.  
Age at HRJL varied correspondingly, Figure 33 is a histogram plot displaying the ages of 
participants at the point of HRJL. Once again there was a skewed distribution, with the 
median age at HRJL 58.21 years (IQR 53.36 – 60.89 years), and the mean 56.65 years. The 
youngest participant was 34.46 years old at the time of job loss and the oldest 65.58 years 
old.  
Figure 33: Histogram of participant ages, in years, at the time of HRJL 
 
Case participants were stratified into the following age bands: those who exited work 
earlier than age 50 (13.0%), those who exited work over the age of 50 but prior to 60 years 
old (53.4%), and those who were older than 60 (33.6%). See Table 55, below. 
Table 55: Distribution of age at HRJL among cases 
Age at HRJL Number of cases (%) 
<50 years old 64 (13.0) 
50 to <60 years old 264 (53.4) 
>60 years old 166 (33.6) 
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5.3.1.25 Demographic factors 
The three age-groups of HRJL were similar for distribution of gender and ethnicity. 
Compared to the other age-bands, single relationship status was more common among 
cases that left work between 50 – 60 years of age (13.0%) and being married was less 
common in this group (64.5%). A higher proportion of participants with university-level 
education were in the age 50 – 60 age band (25.8%). Vocational-level education was more 
prevalent among those who left work >60 years of age and having attained no 
qualifications was most prevalent in the group with HRJL earlier than 50. See Table 56, 
below. 
Table 56: Distribution of demographic factors among case participants, by age at HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ 
years old (%) 
Male 29 (45.3) 111 (42.1) 80 (48.2) 
Female 35 (54.7) 153 (58.0) 86 (51.8) 
Ethnicity (non-white) 3 (4.7) 2 (0.8) 4 (2.4) 
Ethnicity (white) 61 (95.3) 262 (99.2) 162 (97.6) 
University degree 9 (14.1) 68 (25.8) 21 (12.7) 
Vocational 20 (31.3) 93 (35.2) 83 (50.0) 
High school qualifications 16 (25.0) 47 (17.8) 28 (16.9) 
No qualifications 19 (29.7) 56 (21.2) 34 (20.5) 
Married/Civil partnership 45 (71.4) 169 (64.5) 116 (69.9) 
Single 4 (6.4) 34 (13.0) 10 (6.0) 
Divorced 10 (15.9) 46 (17.6) 33 (19.9) 
Widowed 4 (6.4) 13 (5.00) 7 (4.2) 
 
5.3.1.26 Occupations  
Across SOC-10 major occupational categories, there were few obvious patterns (see Table 
57, below). However, a larger proportion of participants who left work prior to age 50 were 
working sales and customer service jobs (10.9%) and elementary occupations (25.0%) 
compared to the other two age groups. Cases who worked administrative and secretarial 
occupations featured more commonly among those who fell out of work at older ages 
(7.8%, 16.3%, and 17.5%, respectively). Again, few obvious patterns were observed using 
the SOC-10 sub-major categories. However, administrative occupations were increasingly 
prevalent at the older age bands (7.8%, 12.9%, and 15.7%, respectively); while sales 
200 | P a g e  
 
occupations (10.9%, 5.7%, and 4.8%, respectively) and elementary administration and 
service occupations (20.3%, 9.5%, and 9.0%, respectively) were more prevalent among 
those who fell out of work at earlier ages. See Table 17, Appendix.  
Table 57: Strata of SOC-10 major occupational groups among case participants, by age at 
HRJL 
SOC-10 major occupational group HRJL <50 
years old (%) 
HRJL 50 to 
<60 years (%) 
HRJL 60+ 
years old (%) 
Managers, directors and senior officials 5 (7.8) 20 (7.6) 8 (4.8) 
Professional occupations 10 (15.6) 58 (22.0) 31 (18.7) 
Associate professional and technical occupations 3 (4.7) 28 (10.6) 13 (7.8) 
Administrative and secretarial occupations 5 (7.8) 43 (16.3) 29 (17.5) 
Skilled trades occupations 7 (10.9) 24 (9.1) 22 (13.3) 
Caring, leisure, and other service occupations 5 (7.8) 26 (9.9) 16 (9.6) 
Sales and customer service occupations 7 (10.9) 18 (6.8) 10 (6.0) 
Process, plant and machine operatives 4 (6.3) 15 (5.7) 16 (9.6) 
Elementary occupations 16 (25.0) 29 (11.0) 18 (10.8) 
 
5.3.1.27 Socio-economic class 
Using the broad three-level NS-SEC system, for those who left work earlier than age 50, 
25.8% had previously worked in managerial class occupations, 21.0% in intermediate class 
occupations, and 53.2% in routine and manual class work. Of those who left work aged 50 - 
<60 years old, 36.4% previously worked in managerial class occupations, 25.3% in 
intermediate class, and 37.3% in routine class occupations. Of those who left work later 
than 60 years old, 30.1% previously worked in managerial class occupations, 32.5% in 
intermediate class, and 37.4% in routine class occupations. Socio-economic class defined 
using the three-level NS-SEC system, by age-band at HRJL, can be found in Table 58, below.  
Table 58: Strata of NS-SEC, 8-levels and 3-levels, among case participants, by age at HRJL 
NS-SEC, three-level HRJL <50 years 
old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ years 
old (%) 
Higher managerial class 16 (25.8) 95 (36.4) 49 (30.1) 
Intermediate class 13 (21.0) 66 (25.3) 53 (32.5) 
Routine and manual class 33 (53.2) 100 (37.3) 61 (37.4) 
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5.3.1.28 Lifestyle  
Among case participants, the proportion of ever-smokers was similar across all three age-
bands. However, ex-smokers were more common among those who left work at a later age 
(18.8%, 31.4%, and 43.4%, respectively) and current smokers were more common among 
those who left work at an earlier age (34.4%, 16.7%, and 9.6%, respectively). The 
proportion of participants with a known history of heavy alcohol consumption was similar 
across all age bands. See Table 59, below.  
Table 59: Distribution of lifestyle factors among case participants, by age at HRJL 
Variable HRJL <50 
years old (%) 




years old (%) 
Smoking 
Never smokers 30 (46.9) 137 (51.9) 78 (47.0) 
Ex-smokers 12 (18.8) 83 (31.4) 72 (43.4) 
Current smokers 22 (34.4) 44 (16.7) 16 (9.6) 
Heavy drinking 
History of heavy drinking 2 (3.1) 10 (3.8) 6 (3.6) 
5.3.1.29 Musculoskeletal disorders 
Chronic MSDs were increasingly prevalent among cases who left work at a later age (14.1%, 
26.1%, and 34.9%, respectively). In contrast, the proportion of participants with recent 
musculoskeletal pain became decreasingly prevalent as age-at-HRJL increased (35.9%, 
31.1%, and 28.9%, respectively). See Table 60, below.  
Table 60: Frequency of musculoskeletal disorder variables, among case participants, by 
age at HRJL 
Variable HRJL <50 years old 
(%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ years old 
(%) 
Chronic MSD 9 (14.1) 69 (26.1) 58 (34.9) 
Recent MSD pain 23 (35.9) 82 (31.1) 48 (28.9) 
 
5.3.1.30 Mental Health Problems  
Among case participants, there was a trend for MHPs to be more prevalent among those 
who left work at an earlier age, for example, the prevalence of primary care-level MHPs 
(31.3%, 31.1%, and 16.3, respectively), sleep disorders (9.4%, 6.8% and 7.8%, respectively) 
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and history of severe MHP (10.9%, 9.1%, 3.6%, respectively), was higher in the younger age-
bands. See Table 61, below.   
Table 61: Frequency of mental health problem variables, among case participants, by age 
at HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ 
years old (%) 
Primary care-level MHPs 20 (31.3) 82 (31.1) 27 (16.3) 
Sleep disorders 6 (9.4) 18 (6.8) 13 (7.8) 
Psychiatric care-level MHPs 1 (1.6) 6 (2.3) 1 (0.6) 
Severe MHP 7 (10.9) 24 (9.1) 6 (3.6) 
 
5.3.1.31 Cardiovascular disease 
Cardiovascular disorders tended to occur with greater frequency among case participants 
who left work at an older age. Specifically, ischaemic heart disease (1.6%, 5.3% and 9.0%, 
respectively), severe ischaemic heart disease (1.6%, 1.1% and 4.8%, respectively), heart 
failure (1.6%, 4.9% and 18.1%, respectively), structural heart disease (0.0%, 1.1% and 2.4%, 
respectively), and hypertension (14.1%, 26.5% and 32.5%, respectively) occurred with 
greater frequency at older age-bands. No obvious patterns were clear for cardiac 
arrythmias, venous thromboembolic disease, and peripheral atherosclerosis, for which total 
prevalence was very low. See Table 62, below. 
Table 62: Frequency of cardiovascular problem variables, among case participants, by age 
at HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ 
years old (%) 
Ischaemic heart disease 1 (1.6) 14 (5.3) 15 (9.0) 
Severe ischaemic heart disease 1 (1.6) 3 (1.1) 8 (4.8) 
Heart failure 1 (1.6) 13 (4.9) 30 (18.1) 
Structural heart disease 0 (0.0) 3 (1.1) 4 (2.4) 
Hypertension 9 (14.1) 70 (26.5) 54 (32.5) 
Cardiac arrythmias 0 (0.0) 5 (1.9) 2 (1.2) 
Venous thromboembolic disease 0 (0.0) 1 (0.4) 0 (0.0) 
Peripheral atherosclerosis 1 (1.6) 7 (2.7) 3 (1.8) 
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5.3.1.32 Respiratory disorders 
Among case participants, asthma occurred with greatest prevalence among those who fell 
out of work aged 50 to <60 years (11.4%) although there were no clear patterns by age-
band. COPD occurred more commonly among case participants who left work at an older 
age (0.0%, 2.7%, and 4.8%, respectively). See Table 63, below. 
Table 63: Frequency of respiratory disorder variables, among case participants, by age at 
HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ years 
old (%) 
Asthma 4 (6.3) 30 (11.4) 13 (7.8) 
Severe asthma  0 (0.0) 3 (1.1) 0 (0.0) 
COPD 0 (0.0) 7 (2.7) 8 (4.8) 
 
5.3.1.33 Neurological disorders 
Cerebrovascular accident occurred with increasing prevalence among case participants who 
left work at older ages (0.0%, 2.7%, and 4.8%, respectively). Epilepsy was rare and no clear 
patterns emerged by age at HRJL. See Table 64, below. 
Table 64: Frequency of neurological disorder variables, among case participants, by age 
at HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ years 
old (%) 
CVA 0 (0.0) 10 (3.8) 7 (4.2) 
Epilepsy 2 (3.1) 4 (1.5) 1 (0.6) 
 
5.3.1.34 Diabetes 
Among case participants, the prevalence of diabetes increased by age at HRJL (7.8%, 11.7%, 
and 14.5%, respectively). However, the prevalence of poorly controlled diabetes was 
highest in the 50 to <60 years age-band (9.1%). See Table 65, below.  
Table 65: Frequency of diabetes variables, among case participants, by age at HRJL 
Variable HRJL <50 
years old (%) 
HRJL 50 to <60 
years (%) 
HRJL 60+ 
years old (%) 
Diabetes 5 (7.8) 31 (11.7) 24 (14.5) 
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Diabetes with poor control 4 (6.3) 24 (9.1) 9 (5.4) 
 
5.3.4 Describing cases by “type” of HRJL 
5.3.1.35 Demographic factors 
Among case participants, 220 (46.6%) stated that job loss was mainly due to a health 
problem, and 274 (53.4%) reported job loss was partly due to a health problem. Compared 
to “partly” cases, “mainly” cases were more often male (50.9% vs 39.0%) and a younger age 
when their HRJL occurred (median 55.19 years, IQR 50.50 to 59.73 vs median 59.57 years, 
IQR 56.03 to 61.32). “Mainly” cases also less frequently had a university-level education 
(14.4% vs 24.6%) and more frequently left school with no qualifications (26.5% vs 18.2%). 
“Mainly” cases were less frequently married (64.5% vs 69.6%) and more frequently 
widowed (21.1% vs 15.6%). Otherwise, these sub-groups were similar for ethnicity. See 
Table 66, below.  
Table 66: Distribution of demographic factors among case participants, by type of HRJL. 




Gender (male) 117 (50.9) 103 (39.0) 
Age at HRJL 55.19 (50.50 – 
59.73) 
59.57 (56.03 – 
61.32) 
Ethnicity (non-white) 4 (1.7) 5 (1.9) 
Ethnicity (white) 226 (98.3) 259 (98.1) 
University degree 33 (14.4) 65 (24.6) 
Vocational 91 (39.6) 105 (39.8) 
High school qualifications 45 (19.6) 46 (17.4) 
No qualifications 61 (26.5) 48 (18.2) 
Married/Civil partnership 147 (64.5) 183 (69.6) 
Single 24 (10.5) 24 (9.1) 
Divorced 9 (4.0) 15 (5.7) 
Widowed 48 (21.1) 41 (15.6) 
 
5.3.1.36 Occupations  
Using the SOC-10 major occupational groups, the largest differences between “mainly” and 
“partly” cases were for having previously worked in elementary (16.5% vs 9.5%) and skilled 
trade occupations (13.5% vs 8.3%), which were more frequently worked among “mainly” 
cases. While administrative/secretarial occupations (11.3% vs 19.3%) and professional 
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occupations (15.2% vs 24.2%) were less frequently worked among “mainly” cases. See 
Table 67, below. Using the SOC-10 sub-major groupings, occupations mostly occurred with 
similar frequency across “mainly” and “partly” cases. However, more “mainly” cases were 
previously working in skilled construction and building trades (6.1% vs 0.4%) and 
elementary administration and service occupations (13.9% vs 8.0%); while more “partly” 
cases were previously working as teaching and educational professionals (14.0% vs 4.8%) or 
in administrative occupations (16.3% vs 9.6%). See Table 18, Appendix.  
Table 67: Strata of SOC-10 major occupational groups among case participants, by type of 
HRJL. 




Managers, directors and senior officials 16 (7.0) 17 (6.4) 
Professional occupations 35 (15.2) 64 (24.2) 
Associate professional and technical occupations 18 (7.8) 26 (9.9) 
Administrative and secretarial occupations 26 (11.3) 51 (19.3) 
Skilled trades occupations 31 (13.5) 22 (8.3) 
Caring, leisure, and other service occupations 23 (10.0) 24 (9.1) 
Sales and customer service occupations 18 (7.8) 17 (6.4) 
Process, plant and machine operatives 20 (8.7) 15 (5.7) 
Elementary occupations 38 (16.5) 25 (9.5) 
 
5.3.1.37 Socio-economic class  
Using the three-tier NS-SEC, 46.1% of “mainly” cases and 33.3% of “partly” cases were 
previously working routine and manual jobs, 24.8% and 28.4% of cases were previously 
working in intermediate class occupations, and 27.0% and 37.1% were working in higher 
managerial or professional class occupations, respectively. See Table 68, below.   
Table 68: Three-level strata of NS-SEC, among case participants, by type of HRJL. 




Higher managerial class 62 (27.0) 98 (37.1) 
Intermediate class 57 (24.8) 75 (28.4) 
Routine and manual class 106 (46.1) 88 (33.3) 
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5.3.1.38 Lifestyle  
Compared to “partly” cases, “mainly” cases were more frequently current smokers (22.2% 
vs 11.7%) and ex-smokers (36.5% vs 31.4%) at the time of HRJL. However, history of heavy 
drinking was similar between the two groups. See Table 69, below.  
Table 69: Distribution of lifestyle factors among case participants, by type of HRJL 





Never smokers 95 (41.3) 150 (56.8) 
Ex-smokers 84 (36.5) 83 (31.4) 
Current smokers 51 (22.2) 31 (11.7) 
Drinking 
No history of heavy drinking 221 (96.1) 255 (96.6) 
History of heavy drinking 9 (3.9) 9 (3.4) 
 
5.3.1.39 Musculoskeletal disorders 
Chronic MSDs occurred with a similar frequency among “mainly” and “partly” cases. A 
slightly higher proportion of “mainly” cases were diagnosed with recent musculoskeletal 
pain (34.4% vs 28.0). See Table 70, below.  
Table 70: Frequency of musculoskeletal disorder variables, among case participants, by 
type of HRJL 




Chronic MSD 62 (27.0) 74 (28.0) 
Recent MSD pain 79 (34.4) 74 (28.0) 
 
5.3.1.40 Mental Health Problems  
Psychiatric-care-level MHPs were similarly uncommon in “mainly” and “partly” case 
participants. However, recent primary-care-level MHPs occurred more frequently in 
“mainly” cases (30.0% vs 22.7%). Similarly, sleep disorders (8.3% vs 6.8%) and history of 
severe MHP (8.7% vs 6.4%) was slightly more common among “mainly” cases. See Table 71, 
below.   
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Table 71: Frequency of mental health problem variables, among case participants, by type 
of HRJL 




Primary-care-level MHPs 69 (30.0) 60 (22.7) 
Sleep disorders 19 (8.3) 18 (6.8) 
Psychiatric-care-level MHPs 3 (1.3) 5 (1.9) 
Severe MHPS 20 (8.7) 17 (6.4) 
 
5.3.1.41 Cardiovascular disease 
Cardiovascular disorders occurred with a similar prevalence in “mainly” and “partly” cases, 
except for hypertension which occurred more frequently in “partly” cases (30.3% vs 23.0%), 
and arrythmias which mostly occurred among “mainly” cases (2.6% vs 0.4%). See Table 72, 
below. 
Table 72: Frequency of cardiovascular disorder variables, among case participants, by 
type of HRJL 




Ischaemic heart disease 14 (6.1) 16 (6.1) 
Severe ischaemic heart disease 5 (3.9) 7 (2.7) 
Heart failure 22 (9.6) 22 (8.3) 
Structural heart disease 4 (1.7) 3 (1.1) 
Hypertension 53 (23.0) 80 (30.3) 
Cardiac arrythmias 6 (2.6) 1 (0.4) 
Venous thromboembolic disease 1 (0.4) 0 (0.0) 
Peripheral atherosclerosis 4 (1.7) 7 (2.7) 
 
5.3.1.42 Respiratory disorders 
A similar proportion of “mainly” and “partly” cases were diagnosed with asthma (9.6% and 
9.5%, respectively) and indicators of severe asthma (0.9% and 0.4%, respectively). COPD 
occurred slightly more commonly among “mainly” cases (4.4% vs 1.9%). See Table 73, 
below. 
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Table 73: Frequency of respiratory disorder variables, among case participants, by type of 
HRJL 




Asthma 22 (9.6) 25 (9.5) 
Severe asthma  2 (0.9) 1 (0.4) 
COPD 10 (4.4) 5 (1.9) 
 
5.3.1.43 Neurological disorders 
Cerebrovascular accident was reported more commonly among “mainly” cases (5.2% vs 
1.9%). Epilepsy was similarly uncommon among “mainly” and “partly” cases. See Table 74, 
below. 
Table 74: Frequency of neurological disorder variables, among case participants, by type 
of HRJL 




CVA 12 (5.2) 5 (1.9) 
Epilepsy 4 (1.7) 3 (1.1) 
 
5.3.1.44 Diabetes 
Diabetes occurred with a similar prevalence between “mainly” and “partly” cases, although 
the proportion of participants with indicators of poor diabetic control was slightly higher 
among “mainly” cases (9.1% vs 6.1%). See Table 75, below.  
Table 75: Frequency of diabetes variables, among case participants, by type of HRJL 




Diabetes 26 (11.3) 34 (12.9) 
Diabetes with poor control 21 (9.1) 16 (6.1) 
 
5.4 Discussion 
This chapter has described a contemporary cohort of older-workers with HRJL (cases) for 
their demographic, occupational, lifestyle, and health-related factors. Results were 
stratified by gender, age at time of HRJL, and whether a health problem was reported to be 
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mainly or partly the cause of the job loss. Important differences between these strata were 
considered in order to decide whether sub-group analysis might be appropriate in future 
chapters (see discussions below). However, no statistical analysis of the differences 
between these strata was performed as the current cohort was highly selected to answer 
only the research questions outlined in the objectives (Chapter 2). Therefore, statistical 
analysis would not have been meaningful.  
Case participants were most frequently white, married, and qualified at a vocational level 
(more advanced than high-school but lower than university level). Prior to job loss, cases 
had commonly worked as teachers, in administration, and in elementary service 
occupations, which together comprised approximately one third of the jobs lost. Regarding 
socioeconomic class, there was a relatively equal split between higher managerial, 
intermediate, and routine/manual class participants with most cases last working routine-
level jobs (39.9%). However, it should be noted that this classification was based on job title 
alone and did not consider size of company or whether the participant was self-employed. 
For lifestyle factors, a slim majority of case participants were ever smokers, with 16.6% 
current smokers, 33.8% ex-smokers, and just less than half never smokers (49.6%). 
Next, cases were considered for their CPRD-defined health disorders. The most prevalent 
conditions included musculoskeletal disorders, primary-care level mental health problems, 
hypertension, ischaemic heart disease, heart failure, asthma, and diabetes. Chronic 
musculoskeletal disorders were mostly comprised of participants with osteoarthritis, while 
participants with recent musculoskeletal pain most commonly had low back pain and knee 
pain. Recent primary care-level mental health problems were the most common mental 
health problem group and were mostly comprised of people with mood disorders, 
depressive disorders, or anxiety. The most common cardio-metabolic problems among 
cases were hypertension, ischaemic heart disease, heart failure, and diabetes. A 
participant’s self-reported cause of job loss did not always correspond to their CPRD-
defined health disorder, for example, 66.7% of those with COPD ascribed their job loss to a 
health problem of the heart or lungs, while only 28.6% of those with epilepsy indicated that 
“another type of health condition” had contributed to their job loss. The perceived severity 
of the underlying health disorder could account for this difference, as well as a participant’s 
own recall bias (since job loss had occurred some time ago, in many cases). Additionally, 
some confusion about the questionnaire categories may be apparent, for example, is 
hypertension a condition of the “heart and lungs”? Finally, respondents may be thinking 
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about the totality of factors contributing to their decision to leave work, for example, their 
finances, job quality and support, not only the symptomatic impact of the health condition.  
Considerably more male than female cases were single and previously worked manual 
careers such as protective services, agricultural work, metal, electrical and electronic 
trades, construction and building trades, process, plant and machine operating, and driving 
and machine operating. Meanwhile, female cases were more likely to have been working as 
health professionals, in administrative and secretarial occupations, in caring services, and in 
sales occupations. If this difference reflects a true difference in the work context of men 
and women, this could be important as some health conditions may be more incompatible 
with certain types of work. For example, musculoskeletal disorders are known to be caused 
by, and predictors of, work disability in occupations requiring heavy physical lifting.(392–
394) More male than female cases were ever smokers, mostly due to the greater 
proportion of ex-smokers. Male cases were also more frequently diagnosed with cardio-
metabolic disorders such as hypertension, heart failure, ischaemic heart disease, and 
diabetes. Also, the greater prevalence of ever-smokers among men may have been 
responsible for the higher prevalence of COPD. Conversely, women with HRJL more 
frequently experienced recent primary-care level mental health problems, the majority of 
which were mood or anxiety disorders. These differences likely reflect the underlying 
distributions of such disorders in the general population, in which, the greater prevalence 
of cardio-metabolic disorders among men(395) and mental health disorders among women 
is already known.(235) In this sample, the observed differences between male and female 
cases, both for their common work environments and health exposures, provides evidence 
to support the use of sub-group evaluation by gender in future chapters. 
Most case participants lost their jobs in the 50 – 60 year-old age band (53.4%). Vocational 
or professional level qualifications were most prevalent among those over 60 at HRJL, 
university-level education was most prevalent among those aged 50 – 60 at HRJL, and 
participants with no qualifications or high school level education were most prevalent 
among those with HRJL earlier than age 50. Correspondingly, intermediate socioeconomic 
class was most common among cases who left work in the oldest age band, professional 
and managerial class was most common in the 50 – 60 age band, and routine and manual 
class was most common among those with HRJL earlier than age 50. All these participants 
were experiencing poor health, however, those with more advanced education may be 
better equipped to survive later in the workforce, even with poor health (e.g. because of 
the greater availability of non-manual work options). For those who earn enough, there 
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may also be the financial option to leave work at an earlier age with less necessity to 
“struggle on”- which could explain the U-shaped distribution of university level 
qualifications across the age bands. Finally, for people working routine and manual 
occupations, with poor health, few qualifications, and often more physical work, the 
options may be fewer and exit from work may occur earlier, on average.  
The prevalence of certain health problems also varied depending on age of HRJL. Among 
cases, chronic musculoskeletal problems became significantly more common as age of HRJL 
increased; this is likely to represent the growing prevalence of osteoarthritis at older 
ages.(396) Similarly, age-related cardio-metabolic diseases (such as heart failure, 
hypertension, atherosclerotic disease, and diabetes) were also more prevalent among 
those who lost work at an older age.(397) Interestingly, the prevalence of primary-care-
level MHDs appeared to be considerably lower among those aged over 60 with HRJL. This 
has been outlined in the literature already, with most mental health problems dipping in 
prevalence as they approach age 65.(398) Older patients may be more reluctant to present 
with a mental health problem at an older age, or additionally mental health problems may 
be missed more frequently in the older patient due to the coexistence of other health 
problems. Alternatively, mental health problems may simply be more strongly linked to 
premature exit from work at earlier ages.(398) The differences between these populations 
once again supports the use of sub-group analysis by age of HRJL, going forwards.  
Cases who answered that job loss was mainly due to a health problem were different from 
cases who answered that job loss was partly due to a health problem e.g. they were more 
often male. A participant’s perception that their health problem was the main cause of job 
loss also appeared to be related to the severity of their underlying health disorder(s). 
“Mainly” cases had a greater prevalence of more disabling conditions, such as CVA, COPD, 
and diabetes with indicators of poor control. “Mainly” cases were also younger on average 
when their job loss occurred. Finally, there was a slightly higher prevalence of recent 
musculoskeletal pain, primary-care level mental health problems, and current smoking, 
among “mainly” cases. These indicators of worse overall health also coincided with 
indicators of lower socioeconomic class. For example, “mainly” cases were less often 
university educated, and more often left school with no qualifications, compared to 
“partly” cases. Correspondingly, fewer “mainly” cases were working in professional and 
managerial jobs, while more were working routine and manual jobs. This accords with the 
socioeconomic gradient in health described in the literature, whereby being of a lower 
socioeconomic class is associated with a greater disease burden.(399) While these groups 
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will still be analysed together going forwards, sensitivity analysis will also be used to unpick 
any important differences between “mainly” and “partly” cases for the impact of health 
upon work.  
This chapter has some limitations. Strong inferences about the cause of HRJL can’t be made 
since cases have been described without reference to a control group. In addition, while 
the HEAF study population was found to be broadly representative of the general UK 
population, this study sample did not include all HEAF participants who had left work 
because of a health problem (there were 907 such participants in total). Excluded 
participants either did not have sufficient coverage for their CPRD data (extending back to 
at least a year prior to their job loss) or had refused consent for its linkage in the first place. 
Furthermore, all participants who agreed to take part in the HEAF study were well enough 
to fill in a lengthy questionnaire: this survivor bias means that people with particularly poor 
health, or those who had died, would not have been represented in the study. Some data 
was also potentially subject to recall bias, including the reported date of job loss, whether 
the loss was mainly or partly due to a health problem, and the health factors that a 
participant felt had contributed to their leaving work.  
While the entirety of participant’s CPRD health records were not requested, it was a 
strength of this study that the selected health problems for which information was 
available were those recognised as being responsible for two-thirds of sickness absence and 
long-term incapacity in the UK: mental health problems, musculoskeletal disorders, and 
cardio-respiratory conditions.(48) The use of objective data here was also a strength, with 
CPRD records representing a validated source of health information that did not rely on the 
memory of study participants. The size of the study sample from which these cases were 
drawn, provided the opportunity to select working controls from the same study 
population who could be matched on multiple important confounding factors. An 
examination of the association between CPRD-defined health disorders and HRJL, including 
important subgroup analysis, is detailed in the next chapter.   
5.5 Summary 
• Case participants commonly lost work as teachers, in administration, and in 
elementary service occupations. Overall, cases had most frequently worked 
routine-level jobs. 
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• Musculoskeletal disorders, mental health problems, and cardio-metabolic 
disorders were common among cases. 
• Male cases more commonly fell out of work in routine and manual-type jobs, and 
were more commonly diagnosed with cardiovascular diseases, COPD, and diabetes, 
while female cases were more commonly diagnosed with primary-care level 
mental health disorders.  
• Cases who experienced HRJL at an earlier age were broadly less well educated and 
were of lower socioeconomic class. However, cases with university level education 
commonly exited work aged 50 – 60 years old.  
• Cases who experienced HRJL at an earlier age were less likely to have chronic 
musculoskeletal disorders and cardiovascular disorders, but more likely to have 
mental health problems.  
• Cases who stated that a health problem was the main cause of their job loss, 
compared to part of the cause, were more commonly male, less well educated, 
and more likely to be working in routine and manual occupations. Disabling 
conditions such as CVA, COPD, and poorly controlled diabetes were more common 
in this group.  
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Chapter 6- the associations between 
CPRD-defined health disorders and 
health-related job loss 
6.1 Introduction 
In order to address the third research objective of this thesis (see Chapter 2), this chapter 
explores the association of demographic factors, lifestyle factors, and CPRD-defined health 
disorders with health-related job loss (HRJL). In the last chapter, participants with HRJL, the 
“cases”, were described and important subgroups were established. In this chapter, a 
nested-case control analysis is performed: cases are compared to matched control 
participants (see Figure 34) who were similar for key confounding factors and were working 
at the time of the case participant’s job loss. Given the important differences described 
between: male and female cases; cases who left work at different ages; and cases who 
described a health problem as being “mainly” or “partly” the cause of their job loss (see 
Chapter 5); stratified analysis is performed according to these subgroups.  
Figure 34: the cohort studied in this chapter, as indicated by the red square 
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6.2 Methods 
As outlined previously, cases were participants of the HEAF study who were unemployed at 
baseline and reported that a health problem was “part of the reason” or “the main reason” 
reason for their dropping out of work. Cases were included in the current study if they had 
CPRD coverage for a minimum of a year prior to their job loss. Control participants were 
participants of HEAF who did not report HRJL at baseline. Controls were working at the time 
their matched case participant experienced HRJL. All control participants were within 1 year 
of age of their matched cases, were of the same sex, and from the same GP practice. 
Control participants were included if they had CPRD coverage for a minimum of a year prior 
to the date of health-related job loss of their matched case. 
Cases and controls were compared using simple descriptive statistics. Conditional logistic 
regression was used to assess the association between the occurrence of HRJL and 
individual demographic, lifestyle, and CPRD-defined health disorder exposures.  Available 
CPRD information included date-stamped Read codes for the following disorders: 
musculoskeletal disorders, mental health problems, cardiovascular disorders, asthma, 
COPD, CVA, epilepsy, and diabetes. Using these data, CPRD-derived health disorder 
variables were defined according to the classification criteria, outlined in Chapter 3. 
Conditional logistic regression takes case and control matched pairs into account, meaning 
all associations found were independent of age, gender, and GP practice, since cases and 
controls were matched on these factors. Other factors may confound the observed 
relationship between HRJL and health exposures of interest, such as: ethnicity; education; 
socioeconomic class; factors representing familial support, such as marital status; and 
lifestyle-related variables such as heavy alcohol intake and smoking. The number of 
available control participants was not sufficient to match for all these factors; therefore, 
where appropriate, important confounding factors were adjusted for statistically in 
multivariable conditional logistic regression models.  
Demographic and lifestyle variables were considered in turn to elicit their possible roles as 
confounders. As discussed earlier in this thesis (Section 3.6.5), to adjust for confounders 
appropriately in multivariable analysis (i.e. to avoid unnecessary adjustment or over-
adjustment) there needed to be strong reason to believe a factor was associated both with 
the health exposure of interest and outcome of interest, without being an intermediate 
variable on the causal pathway between the exposure of interest and the outcome of 
interest.(319) Some factors measured in this study, such as lower education 
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attainment,(400) single relationship status,(401) and lifestyle factors such as 
smoking(402,403) and heavy alcohol intake(404) are already known to be associated with 
greater morbidity in the literature. In this chapter, the relationship between HRJL and these 
demographic and lifestyle variables was also assessed using matched logistic regression 
analysis. Factors that were significantly associated with HRJL were considered confounders 
and were included in adjusted multivariable models, going forwards.  
CPRD-defined health exposures were initially assessed for their relationship to HRJL in 
univariable analysis, then with statistical adjustment for confounding lifestyle and 
demographic variables in multivariable conditional logistic regression models. Statistical 
analysis was performed using Stata-13. 
Analysis was then stratified for important sub-groups, which included gender (stratified for 
men and women), age (stratified for <50 years of age, between 50 – <60 years of age, and 
greater than age 60), and type of HRJL (stratified by whether a health problem was 
reported “mainly” or “partly” the cause of job loss). Stratifications were considered for how 
they modulated the association between HRJL and CPRD-defined health exposures.  
Throughout this chapter, qualitative descriptors were used to distinguish strength of 
association using Cohen’s classification scheme and Rosenthal’s later extension for odds 
ratios(405) which is as follows: about 1.5 to 1 is a small effect, about 2.5 to 1 is a moderate 
effect, about 4 to 1 is a strong effect, and about 10 to 1 is a very strong effect. Although 
these are arbitrary parameters, they help to facilitate consistent data interpretation and 
communication.  
Where effect estimates suggested an important relationship, but analysis was 
underpowered to show a statistically significant result, it was important not to interpret 
this as evidence of no association. Therefore, post-hoc power calculations were also 
performed to aid interpretation. To calculate statistical power, a method for matched case-
control studies using 1:1 matching was applied (Schlesselman 1982).(327,328) Statistical 
power was affected by: the number of case participants available (maximum 498 for this 
thesis, with fewer available for subgroup analyses); the number of controls per case (1:1 for 
all analyses); the alpha significance level (set by convention at 5%); and the prevalence of 
the exposure of interest among control participants. I considered the minimum (most 
subtle) strength of association that could be detected at a statistical power of 80% and an 
alpha significance level of 5%, for common, moderately prevalent, and rare exposures of 
interest.  




6.3.1 Statistical power calculations 
Across the total sample (n=988), in most cases, sample size and prevalence of exposures 
meant that analyses were well powered. For example, for health exposures that were 
common, it was possible to detect a weak strength of association with HRJL at a sufficient 
statistical power e.g. for musculoskeletal pain disorders (prevalence 29.4% in this sample) it 
was possible to detect a minimum odds ratio of 1.55 at 80% power and 5% alpha 
significance level. For moderately common health exposures it was also possible to detect a 
weak strength association with HRJL at sufficient statistical power. For example, for 
diabetes (prevalence 9.2% in this sample) it was possible to detect a minimum odds ratio of 
1.90 at 80% power. However, for rarer conditions, it must be noted that was only possible 
to detect a strong association with HRJL at sufficient statistical power. For example, for 
COPD (prevalence 2.0% in this sample) odds ratios of 3.6 and upwards were detectable at 
80% power. Some analyses became particularly underpowered after stratification for 
gender, age, and “type” of HRJL. Using the male only subgroup as an example (n=440), for 
common health exposures, it was still possible to detect a weak strength association with 
HRJL e.g. for musculoskeletal pain (prevalence 24.6% among men) it was possible to detect 
a minimum odds ratio of 1.87 at 80% power. For moderately common health exposures it 
was only possible to detect a moderate strength association HRJL at sufficient statistical 
power. For example, for diabetes (prevalence 13.4% among men) it was possible to detect a 
minimum odds ratio of 2.20 at 80% power. However, for rarer conditions such as COPD 
(prevalence 2.7% among men), at sufficient statistical power, it was only possible to detect 
very strong associations at odds ratios of 5.87 and upwards. 
6.3.2 Assessment of confounding factors, with stratification by gender 
In the following section, lifestyle, demographic, and occupational class variables are 
assessed for their relationship to HRJL and considered for their possible role as confounding 
factors. Results are also stratified by gender.   
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6.3.2.1 Demographic factors 
Ethnicity 
The difference between cases and controls for ethnicity was minor since both groups were 
vast-majority white (98.2% vs. 98.0%, respectively), this reflected the characteristics of the 
whole HEAF study population; of which participants were also mostly white Caucasian. In 
conditional logistic regression, no significant association was found between white ethnicity 
and the likelihood of being out of work for health reasons, see Table 76. Point estimates 
were in the direction of white ethnicity being predictive of HRJL, however, confidence 
intervals were wide (OR 1.11 95%CI 0.45 to 2.73). Similarly, confidence intervals were too 
wide to draw reasonable conclusions after considering men and women separately. Given 
its apparent weak association with the main outcome of interest, ethnicity was not 
adjusted for as a confounder in multivariable analysis, going forwards.  
Table 76: Association between ethnicity and health-related job loss, across total study 
population and by gender 
Variable Prevalence 
among 
controls, n (%) 
Prevalence 
among cases, n 
(%) 
Association with HRJL, 
unadjusted.  
OR (95% CI) 
Total study sample 
Ethnicity (non-white) 10 (2.0) 9 (1.8) 1.00 
Ethnicity (white) 484 (98.0) 485 (98.2) 1.11 (0.45 to 2.73) 
Men 
Ethnicity (non-white) 3 (1.4) 4 (1.8) 1.00 
Ethnicity (white) 217 (98.6) 216 (98.2) 0.75 (0.17 to 3.35) 
Women 
Ethnicity (non-white) 7 (2.6) 5 (1.8) 1.00 
Ethnicity (white) 267 (97.5) 269 (98.2) 1.40 (0.44 to 4.41) 
 
Educational attainment 
There were a slightly higher proportion of cases with no qualifications (22.1% vs 17.2%) and 
a slightly lower proportion of cases with university degrees (19.8% vs 25.3%) compared to 
controls. Proportions were otherwise similar for school level and vocational or professional 
level degrees between groups. Using university-level qualifications as the reference group, 
high school-level qualifications, and vocational or higher-professional qualifications trended 
towards association with HRJL, although this did not reach statistical significance (OR 1.23 
95%CI 0.84 to 1.81; and OR 1.30 95%CI 0.94 to 1.79, respectively). Having no qualifications 
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was significantly associated with HRJL compared to university-level qualifications (OR 1.66 
95%CI 1.12 to 2.48), see Table 77. Overall, a lower level of educational attainment had a 
statistically significant association with HRJL (OR 1.15 95%CI 1.02 to 1.30). Therefore, this 
variable was adjusted for in multivariable analysis, going forwards.   
Lower level of educational attainment was similarly predictive of HRJL amongst men and 
women, however, was only statistically significant among men (OR 1.21 95%CI 1.00 to 1.46; 
and OR 1.11 95%CI 0.94 to 1.30, respectively). Similarly, having no qualifications was 
significantly associated with HRJL among men but not women, compared to having 
university-level qualifications (OR 2.01 95%CI 1.08 to 3.74; and OR 1.45 95%CI 0.86 to 2.44, 
respectively).  
Table 77: Association between level of education and health-related job loss, across total 
study population and by gender 
Variable Prevalence 
among 




Association with HRJL, 
unadjusted.  
OR (95% CI) 
Total study sample 
 University degree 125 (25.3) 98 (19.8) 1.00 
 Vocational/professional 191 (38.7) 196 (39.7) 1.30 (0.94 to 1.79) 
 High school qualifications 93 (18.8) 91 (18.4) 1.23 (0.84 to 1.81) 
 No qualifications 85 (17.2) 109 (22.1) 1.66 (1.12 to 2.48) 
Men 
 University degree 59 (26.8) 45 (20.5) 1.00 
 Vocational/professional 96 (43.6) 96 (43.6) 1.35 (0.84 to 2.17) 
 High school qualifications 32 (14.6) 31 (14.1) 1.26 (0.68 to 2.33) 
 No qualifications 33 (15.0) 48 (21.8) 2.01 (1.08 to 3.74) 
Women 
 University degree 66 (24.1) 53 (19.3) 1.00 
 Vocational/professional 95 (34.7) 100 (36.5) 1.28 (0.82 to 1.99) 
 High school qualifications 61 (22.3) 60 (21.9) 1.20 (0.73 to 1.98) 
 No qualifications 52 (19.0) 61 (22.3) 1.45 (0.86 to 2.44) 
 
Marital status 
Relatively few participants reported themselves as single among cases or controls (n= 76). 
However, single relationship status was significantly associated with HRJL (OR 1.82 95%CI 
1.11-3.01), compared to being married or in a civil partnership, see Table 78. In contrast, 
being widowed or divorced was not associated with HRJL (being widowed may even be 
protective) (OR 0.77 95%CI 0.43 to 1.35; and OR 1.07 95%CI 0.76 to 1.50, respectively). 
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After adjusting for educational attainment, singleness remained associated with HRJL (aOR 
1.79 95%CI 1.08 to 2.96). Therefore, single status appeared to be independently associated 
with HRJL and was adjusted for in multivariable analysis, going forwards.  
In both men and women, single relationship status was positively associated with HRJL, 
although this was not statistically significant among women (OR 2.01 95%CI 1.05 to 3.83; 
and OR 1.76 95%CI 0.78 to 3.97, respectively). Being divorced or widowed was associated 
with HRJL among men (OR: 1.55 95%CI 0.89 to 2.71; and OR 2.36 95%CI 0.70 to 7.97, 
respectively), but had a protective effect among women (OR: 0.84 95%CI 0.54 to 1.29; and 
OR 0.51 95%CI 0.26 to 1.01, respectively), compared to being married or in a civil 
partnership. However, these effects were not statistically significant.  
Table 78: Association between marital status and health-related job loss, across total 






cases, n (%)2 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level.  
aOR (95%CI)3 
Total study sample 
Married/Civil 
partnership 
334 (70.5) 330 (67.2) 1.00 1.00 
Single 28 (5.7) 48 (9.8) 1.82 (1.11 to 3.01) 1.79 (1.08 to 2.96) 
Divorced 86 (17.6) 89 (18.1) 1.07 (0.76 to 1.50) 1.07 (0.76 to 1.50) 




171 (77.7) 145 (66.2) 1.00 1.00 
Single 17 (7.7) 29 (13.2) 2.01 (1.05 to 3.83) 1.83 (0.95 to 3.52) 
Divorced 28 (12.7) 37 (16.9) 1.55 (0.89 to 2.71) 1.62 (0.92 to 2.84) 




173 (64.6) 185 (68.0) 1.00 1.00 
Single 11 (4.1) 19 (7.0) 1.76 (0.78 to 3.97) 1.89 (0.83 to 4.30) 
Divorced 58 (21.6) 52 (19.1) 0.84 (0.54 to 1.29) 0.82 (0.53 to 1.27) 
Widowed 26 (9.7) 16 (5.9) 0.51 (0.26 to 1.01) 0.51 (0.26 to 1.01) 
1. Data on relationship status was missing for three case participants 
2. Data on relationship status was missing for six control participants 
3. Missing data on relationship status meant that data from nine pairs (18 participants) were not included in adjusted analysis. 
Adjusted analysis included data from 970 participants.  
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6.3.2.2 Lifestyle prior to HRJL 
History of heavy alcohol intake 
CPRD-defined history of heavy alcohol intake was classified using Read codes referring to 
heavy alcohol intake that occurred any time prior to the point of analysis (for example, 
“chronic alcoholism” or “ex-heavy drinker”, see Table 6, Appendix). This was more 
prevalent amongst cases than controls (3.6% vs 1.2%) and had a strong association with 
HRJL (OR 3.00 95%CI 1.19 to 7.56), see Table 79. In multivariable analysis, after adjusting for 
educational attainment and single relationship status, history of heavy drinking remained 
associated with HRJL (aOR 2.84 95%CI 1.11 to 7.23). Only a small number of study 
participants had CPRD-defined history of heavy alcohol consumption (n=24) but it was 
clearly associated with HRJL, and therefore was adjusted for in multivariable analysis, going 
forwards. 
More men than women had a history of heavy alcohol intake (3.6% vs 1.5%), which was 
similarly associated with HRJL in men and women. However, analysis was underpowered to 
show statistical significance. 
Table 79: Association between heavy alcohol intake and health-related job loss, across 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education and 
single status.  
aOR (95% CI) 
Total study sample 
No heavy drinking 488 (98.8) 476 (96.4) 1.00 1.00 
Heavy alcohol intake 6 (1.2) 18 (3.6) 3.00 (1.19 to 7.56) 2.84 (1.11 to 7.23) 
Men 
No heavy drinking 216 (98.2) 208 (94.6) 1.00 1.00 
Heavy alcohol intake 4 (1.8) 12 (5.5) 3.00 (0.97 to 9.30) 3.01 (0.95 to 9.51) 
Women 
No heavy drinking 272 (99.3) 268 (97.8) 1.00 1.00 
Heavy alcohol intake 2 (0.7) 6 (2.2) 3.00 (0.61 to 14.86) 2.61 (0.52 to 13.22) 
Smoking 
Ex-smokers were more prevalent among cases than controls (33.8% vs 29.6%) although the 
proportion of current smokers was similar (16.6% vs 17.4%). In matched analysis, ex-
smoking and current smoking were not associated with HRJL (OR 1.24 95%CI 0.92 to 1.66; 
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and OR 1.03 95%CI 0.72 to 1.47, respectively), see Table 80. Smoking status remained 
unassociated after adjusting for low educational attainment, single status, and history of 
heavy alcohol consumption (aOR 1.02 95%CI 0.82 to 1.22). Given its apparent weak 
association with the main outcome of interest, smoking was not adjusted for as a 
confounder in multivariable analysis, going forwards. 
Table 80: Association between smoking and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Total study sample 
Non-smoker 262 (53.0) 245 (49.6) 1.00 1.00 
Ex-smoker 146 (29.6) 167 (33.8) 1.24 (0.92 to 1.66) 1.23 (0.91 to 1.65) 
Current smoker 86 (17.4) 82 (16.6) 1.03 (0.72 to 1.47) 0.96 (0.67 to 1.39) 
Men 
Non-smoker 106 (48.2) 96 (43.6) 1.00 1.00 
Ex-smoker 70 (31.8) 89 (40.5) 1.41 (0.93 to 2.16) 1.42 (0.92 to 2.19) 
Current smoker 44 (20.0) 35 (15.9) 0.89 (0.53 to 1.48) 0.84 (0.50 to 1.42) 
Women 
Non-smoker 156 (56.9) 149 (54.4) 1.00 1.00 
Ex-smoker 76 (27.7) 78 (28.5) 1.09 (0.72 to 1.64) 1.06 (0.70 to 1.62) 
Current smoker 42 (15.3) 47 (17.2) 1.21 (0.72 to 2.02) 1.09 (0.64 to 1.86) 
 
6.3.2.3 Socioeconomic status 
Participant’s occupations were grouped using the Standard Occupational Classification 
(SOC-10) based on reported job title and industry alone. These occupational groups were 
then arranged by socioeconomic status using the National Statistics Socioeconomic 
Classification, NS-SEC. Refer to Chapter 3, Section 3.4.6 for a full discussion of these 
classification systems. 
Case participants were mostly similar to controls for SOC-10 major occupational categories 
(see Tables 19 and 20, Appendix). However, more cases were working in elementary 
occupations (12.8% vs 8.5%) and as teaching or educational professionals (9.7% vs 6.5%), 
see Figure 35, below. Using SOC-10 occupational categories, participants were organised 
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into the three-tier NS-SEC categories: higher managerial class, intermediate class, and 
routine and manual class.(205) 
More case participants were in the routine and manual class (39.9% vs 33.5%) and more 
controls were in the higher managerial class (38.6% vs 32.9%), with almost identical 
proportions in the intermediate class (27.9% vs 27.2%). Compared to being in the higher 
managerial and professional class, routine and manual class was associated with HRJL (OR 
1.43 95%CI 1.05 to 1.94). However, this effect was non-significant after adjusting for 
education level, single status, and history of heavy alcohol intake (aOR 1.28 95%CI 0.91 to 
1.80), see Table 81. 
Educational attainment is known as a key indicator of socioeconomic status, along with 
income, and occupational status.(406) NS-SEC has also been validated by its ability to 
measure and predict education.(407) Therefore, in the adjusted model, it is likely that 
educational attainment is acting as a mediator between NS-SEC socioeconomic class and 
HRJL, resulting in a non-significant finding. The inclusion of both NS-SEC and education in 
multivariable analysis amounts to statistical over-adjustment so, given the established use 
of education as an indicator of socioeconomic status, and the fact that NS-SEC was 
calculated on the basis of job title alone (an 88% accuracy compared to the gold-standard 
full method of deriving NS-SEC from SOC-10), multivariable models were adjusted for 
education, not NS-SEC, going forwards.  
By gender, there was a statistically significant overall association between NS-SEC 
socioeconomic class and HRJL, among men (OR 1.33 95%CI 1.05 to 1.68) but not women 
(OR 1.10 95%CI 0.90 to 1.35). As above, no statistically significant effect was observed 
among men or women after adjustment for education, single status, and history of heavy 
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Table 81: Association between social class and health-related job loss, across total study 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI)3 
Total study sample 
Higher managerial 
and professional 
188 (38.6) 160 (32.9) 1.00 1.00 
Intermediate  136 (27.9) 132 (27.2) 1.19 (0.86 to 1.63) 1.09 (0.78 to 1.53) 
Routine and 
manual 




88 (40.6) 59 (27.1) 1.00 1.00 
Intermediate  50 (23.0) 64 (29.4) 1.81 (1.11 to 2.96) 1.82 (1.08 to 3.05) 
Routine and 
manual 




100 (37.0) 101 (37.7) 1.00 1.00 
Intermediate  86 (31.9) 68 (25.4) 0.85 (0.55 to 1.30) 0.73 (0.47 to 1.16) 
Routine and 
manual 
84 (31.1) 99 (36.9) 1.21 (0.81 to 1.81) 1.07 (0.68 to 1.68) 
1. Data on SOC-10/NS-SEC was missing for eight case participants 
2. Data on SOC-10/NS-SEC was missing for seven control participants 
3. Missing data on SOC-10/NS-SEC meant that data from 15 pairs (30 participants) were not included in adjusted analysis. 
Adjusted analysis included data from 958 participants.  
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Figure 35: SOC-10 sub-major occupational categories among cases and controls 
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6.3.3 Assessment of CPRD-defined health disorders, with stratification by gender 
In the following sections, cases and controls are compared for the presence of CPRD-
defined health disorders, and I present the association of these health exposures with HRJL. 
Health disorders for which CPRD-information was available included chronic MSDs, recent 
MSD pain, primary care-level MHPs, sleep disorders, psychiatric care-level MHPs, history of 
severe MHPs, hypertension, heart failure, ischaemic heart disease, PAD, venous 
thromboembolism, cardiac arrythmias, structural heart disease, asthma, COPD, CVA, 
epilepsy, and diabetes. A full discussion of these CPRD-defined disorders and their 
classifications is presented in Chapter 3, Section 3.5.8 and Section 3.7. Most study 
participants had at least one of these health problems (n=653, 66.1%), including 77.7% of 
cases and 54.5% of controls. 
6.3.3.1 Musculoskeletal disorders 
Almost half of all case participants (46.8%) were diagnosed with an MSD (chronic MSD or 
recent MSD pain) and prevalence was lower among control participants (30.8%). The 
presence of an MSD was moderately associated with HRJL (OR: 2.10 95%CI 1.58 to 2.78). 
After adjustment for known confounders, MSDs remained associated with HRJL (aOR 2.08 
95%CI 1.55 to 2.78). Gender did not appear to be an important modifier of this effect, as 
effect estimates remained similar strength among men and women, and after adjustment. 
Chronic musculoskeletal disorders 
Chronic MSDs included participants with diagnostic codes for osteoarthritis, inflammatory 
rheumatic disease, connective tissue disease, or who had arthroplasty of the hip or knee 
prior to the point of analysis. In total, 218 participants fulfilled classification criteria for 
having “chronic MSDs.” These were more common among cases (27.5% vs 16.6%). A 
significant association was observed between chronic MSDs and HRJL (OR 1.9 95%CI 1.38 to 
2.60), which remained significant after adjustment for known confounders, see Table 82. 
Among men, the strength of association was slightly higher (aOR 2.30 95%CI 1.36 to 3.89) 
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Table 82: Association between chronic MSD and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No chronic MSD 412 (83.4) 358 (72.5) 1.00 1.00 
Chronic MSD 82 (16.6) 136 (27.5) 1.90 (1.39 to 2.60) 1.89 (1.36 to 2.57) 
Men 
No chronic MSD 191 (86.8) 165 (75.0) 1.00 1.00 
Chronic MSD 29 (13.2) 55 (25.0) 2.30 (1.36 to 3.89) 2.19 (1.29 to 3.74) 
Women 
No chronic MSD 221 (80.7) 193 (70.4) 1.00 1.00 
Chronic MSD 53 (19.3) 81 (29.6) 1.70 (1.15 to 2.51) 1.72 (1.15 to 2.56) 
Recent musculoskeletal pain 
Recent MSD pain included participants who were diagnosed with any musculoskeletal pain, 
widespread pain, discogenic or nerve root pain, or musculoskeletal injury in the year prior 
to the point of analysis. There were 241 participants who met the criteria for recent MSD 
pain. There were more cases than controls with these symptoms (31.0% vs 17.8%), which 
occurred in nearly a third of all people with HRJL. Recent MSD pain was moderately-
strongly associated with HRJL (OR 2.23 95%CI 1.65 to 3.00) and this remained a significant 
and similar strength association in adjusted analysis, see Table 83.  
Table 83: Association between musculoskeletal pain and health-related job loss, across 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No MSD pain  406 (82.2) 341 (69.0) 1.00 1.00 
MSD pain 88 (17.8) 153 (31.0) 2.23 (1.61 to 3.08) 2.17 (1.56 to 3.03) 
Men 
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No MSD pain  178 (80.9) 154 (70.0) 1.00 1.00 
MSD pain 42 (19.1) 66 (30.0) 1.83 (1.16 to 2.87) 1.79 (1.12 to 2.85) 
Women 
No MSD pain  228 (83.2) 187 (68.3) 1.00 1.00 
MSD pain 46 (16.8) 87 (31.8) 2.71 (1.70 to 4.33) 2.69 (1.66 to 4.38) 
  
6.3.3.2 Mental Health Problems 
Mental health problems were sub-classified as primary care-level MHPs (such as 
depression, anxiety and other mood disorders), sleep disorders, or psychiatric care-level 
MHPs (including schizophrenia, bipolar disorders). I also considered participants who had a 
history of severe MHPs (such as those requiring crisis admission or involving self-harm). 
Overall, MHPs had a moderate-strong association with HRJL (OR 3.36 95%CI 2.32 to 4.88) 
and remained similarly associated after adjustment for known confounders. The association 
was strong among men, and moderate among women (OR 4.08 95%CI 2.17 to 7.68; and OR 
3.00 95%CI 1.89 to 4.76, respectively). 
Primary-care-level mental health problems 
Recent primary-care-level MHPs included participants with evidence of mood disorders, 
anxiety disorders, somatoform disorders, or adjustment disorders in the year prior to the 
point of analysis. These were the most prevalent mental health problems (n=177) affecting 
approximately a quarter of cases and one in 10 controls (26.1% vs 9.7%). Primary care-level 
MHPs were significantly and strongly associated with HRJL (OR 3.53 95%CI 2.38 to 5.23), 
see Table 84. 
Around a fifth of men with HRJL, and a third of women with HRJL, had a recent primary-
care-level MHP, which was strongly associated with HRJL in both subgroups (OR: 4.20 
95%CI 2.11 to 8.37 and 3.23 95%CI 2.00 to 5.21, respectively). After adjustment for known 
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Table 84: Association between primary-care-level mental health problems and health-







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No primary care-
level MHPS 
446 (90.3) 365 (73.9) 1.00 1.00 
Primary care-
level MHPs 




206 (93.6) 174 (79.1) 1.00 1.00 
Primary care-
level MHPs 




240 (87.6) 191 (69.7) 1.00 1.00 
Primary care-
level MHPs 
34 (12.4) 83 (30.3) 3.23 (2.00 to 5.21) 3.23 (2.00 to 5.21) 
Recent sleep disorders 
Recent sleep disorders included participants who had evidence of sleep problems such as 
insomnia or somnolence in the year prior. Fifty-one participants met the criteria for having 
a recent sleep disorder. This was more prevalent among cases than controls (7.5% vs 2.8%). 
Recent sleep disorders were significantly and moderately associated with HRJL (OR: 2.92 
95%CI 1.51 to 5.62). The strength of association was similar for male and female sub-groups 
(OR: 3.00 95%CI 0.97 to 9.30 and 2.87 95%CI 1.29 to 6.43, respectively). After adjustment 
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Table 85: Association between sleep disturbance and health-related job loss, across total 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No sleep disorder 480 (97.2) 457 (92.5) 1.00 1.00 
Sleep disorder 14 (2.8) 37 (7.5) 2.92 (1.51 to 5.62) 2.74 (1.40 to 5.38) 
Men 
No sleep disorder 216 (98.2) 208 (94.6) 1.00 1.00 
Sleep disorder 4 (1.8) 12 (5.5) 3.00 (0.97 to 9.30) 3.40 (1.04 to 11.08) 
Women 
No sleep disorder 264 (96.4) 249 (90.9) 1.00 1.00 
Sleep disorder 10 (3.7) 25 (9.1) 2.87 (1.29 to 6.43) 2.58 (1.12 to 5.90) 
Psychiatric-care-level mental health problems 
Psychiatric-care-level MHPs included participants with schizophrenia, psychotic disorders, 
bipolar disorders or sexual and gender identity disorders. In total, there were only 15 
participants who met the criteria for psychiatric care-level MHPs. However, these mental 
health problems were more common among cases (1.6% vs 0.4%). There was an estimated 
strong association between psychiatric care-level MHPs and HRJL but this was not 
statistically significant (OR 4.00 95%CI 0.85 to 18.84), nor after adjustment for known 
confounders (see Table 86). Analysis was also underpowered to confidently assess for 
differences between male and female subgroups. 
Table 86: Association between psychiatric-level mental health problems and health-







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No psychiatric-
level MHPs 
492 (99.6) 486 (98.4) 1.00 1.00 
Psychiatric-
level MHPs 
2 (0.4) 8 (1.6) 4.00 (0.85 to 18.84) 3.77 (0.77 to 18.46) 
Men 




218 (99.1) 216 (98.2) 1.00 1.00 
Psychiatric-
level MHPs 




274 (100.0) 270 (98.5) 1.00 1.00 
Psychiatric-
level MHPs 
0 (0.0) 4 (1.5) NE NE 
History of severe mental health problems 
Participants with CPRD codes relating to self-harm or suicidal ideation, who were under 
psychiatric care, had been on a severe mental health register, or had experienced crisis 
admission or section any time prior to HRJL, were classified as having a history of severe 
mental health problems. There were 47 such participants, who were more common among 
cases (7.5% vs 2.0%). History of severe mental-health disorders was significantly and 
strongly associated with HRJL (OR 4.38 95%CI 2.03 to 9.43), see Table 87. This association 
appeared to be stronger among women compared to men, however confidence intervals 
were wide (OR 6.00 95%CI 1.77 to 20.37 and OR 3.40 95%CI 1.25 to 9.22, respectively). 
Estimated strength of association remained similar after adjusting for known confounders 
(aOR 4.36 95%CI 1.91 to 9.98), while the difference between women and men widened 
(aOR 3.22 95%CI 1.16 to 8.95 and aOR 8.53 95%CI 1.82 to 40.00, respectively). However, 
confidence intervals were very wide.  
Table 87: Association between severe mental health disorders and health-related job loss, 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No severe MHPs 484 (98.0) 457 (92.5) 1.00 1.00 
Severe MHPs 10 (2.0) 37 (7.5) 4.38 (2.03 to 9.43) 4.36 (1.91 to 9.98) 
Men 
No severe MHPs 214 (97.3) 202 (91.8) 1.00 1.00 
Severe MHPs 6 (2.7) 18 (8.2) 3.40 (1.25 to 9.22) 3.22 (1.16 to 8.95) 
Women 
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No severe MHPs 270 (98.5) 255 (93.1) 1.00 1.00 
Severe MHPs 4 (1.5) 19 (6.9) 6.00 (1.77 to 20.37) 8.53 (1.82 to 40.00) 
 
6.3.3.3 Cardiovascular disease 
Cardiovascular disorders were sub-classified as: hypertension, heart failure, ischaemic heart 
disease, peripheral atherosclerotic disease, venous thromboembolic disease, cardiac 
arrythmia, and structural heart disease. Hypertension is a key risk factor for many of these 
conditions and therefore is considered separately. Excluding hypertension, a higher 
proportion of cases had cardiovascular disorders than controls (14.4% vs 5.7%). Having a 
cardiovascular disorder had a significant moderate-strong association with HRJL (OR 3.05 
95%CI 1.86 to 4.99). This association appeared stronger, and was statistically significant, 
among men, in whom cardiovascular disorders were also more common compared to 
women (OR 3.54 95%CI 1.91 to 6.55 and OR 2.25 95%CI 0.98 to 5.17, respectively). Strength 
of association remained broadly similar after adjusting for confounding factors. 
Hypertension 
Participants with codes relating to hypertension (e.g. “high blood pressure”, “essential 
hypertension”) prior to the time of analysis were classified as having hypertension. In total, 
217 participants had CPRD-defined hypertension. Hypertension was more common among 
cases compared to controls (26.9% vs 17.0%) and was weakly, but significantly, associated 
with HRJL (OR 1.89 95%CI 1.36 to 2.62), see Table 88. Hypertension appeared to have a 
stronger association with HRJL among women, in whom there was a moderate-strength 
association (OR 2.90 95%CI 1.74 to 4.82), than among men, in whom there was no 
significant association (OR 1.31 95%CI 0.85 to 2.04). After adjustment for known 
confounders, associations remained similar strength. 
Table 88: Association between hypertension and health-related job loss, across total 







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No hypertension 410 (83.0) 361 (73.1) 1.00 1.00 
Hypertension 84 (17.0) 133 (26.9) 1.89 (1.36 to 2.62) 1.79 (1.28 to 2.50) 
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Men 
No hypertension 162 (73.6) 151 (68.6) 1.00 1.00 
Hypertension 58 (26.4) 69 (31.4) 1.31 (0.85 to 2.04) 1.27 (0.81 to 2.00) 
Women 
No hypertension 248 (90.5) 210 (76.6) 1.00 1.00 
Hypertension 26 (9.5) 64 (23.4) 2.90 (1.74 to 4.82) 2.74 (1.63 to 4.61) 
Heart failure 
Heart failure was defined as having codes relating to heart failure, or a heart transplant, any 
time prior to the point of analysis. In total, 61 participants were classified as having heart 
failure which was more common among cases (8.9% vs 2.8%). There was a strong 
association between heart failure and HRJL (OR 3.73 95%CI 1.92 to 7.25), see Table 89. 
Heart failure was strongly associated regardless of sex (OR 3.37 95%CI 1.53 to 7.43 in men, 
and OR 4.67 95%CI 1.34 to 16.24 in women), although there were fewer female participants 
with heart failure. After adjustment for known confounders, associations remained a 
similar strength. 
The last known occupations of the fourteen participants who managed to remain in work 
despite heart failure were varied and included non-manual occupations such as managing, 
shop assistant, salesman, supervisor, computer operator, customer advisor, and journalist, 
and manual occupations such as, courier, machine operator, van driver, production 
engineer, engineer, sub assembler, and cleaner/gardener.   
Table 89: Association between heart failure and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No heart failure 480 (97.2) 450 (91.1) 1.00 1.00 
Heart failure 14 (2.8) 44 (8.9) 3.73 (1.92 to 7.25) 3.56 (1.80 to 7.03) 
Men 
No heart failure 210 (95.5) 191 (86.8) 1.00 1.00 
Heart failure 10 (4.6) 29 (13.2) 3.37 (1.53 to 7.43) 3.35 (1.49 to 7.54) 
Women 
No heart failure 270 (98.5) 259 (94.5) 1.00 1.00 
Heart failure 4 (1.5) 15 (5.5) 4.67 (1.34 to 16.24) 4.14 (1.17 to 14.66) 
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Ischaemic heart disease 
Ischaemic heart disease included all participants with diagnostic codes relating to angina, 
myocardial infarction or ischaemia, or who had a coronary angioplasty, bypass, or stent. In 
total, 51 participants had CPRD-defined ischaemic heart disease, which was more common 
among cases (6.1% vs 4.3%). The presence of ischaemic heart disease was not significantly 
associated with HRJL (OR 1.45 95%CI 0.82 to 2.56), see Table 90. This was also true for more 
severe indicators of ischaemic heart disease (n=19) which, despite a larger (but still weak) 
estimate of effect, remained non-significantly associated with HRJL (OR 1.74 95%CI 0.68 to 
4.42). Strength of associations remained similar after adjustment for known confounders.  
Table 90: Association between ischaemic heart disease (IHD) and health-related job loss, 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
   No IHD 473 (95.8) 464 (93.9) 1.00 1.00 
   Non-severe IHD 14 (2.8) 18 (3.6) 1.31 (0.65 to 2.63) 1.32 (0.65 to 2.70) 
   Severe IHD 7 (1.4) 12 (2.4) 1.74 (0.68 to 4.42) 1.33 (0.51 to 3.45) 
Men 
   No IHD 205 (93.2) 197 (89.6) 1.00 1.00 
   Non-severe IHD 9 (4.1) 15 (6.8) 1.69 (0.74 to 3.87) 1.73 (0.74 to 4.09) 
   Severe IHD 6 (2.7) 8 (3.6) 1.39 (0.48 to 4.01) 1.03 (0.34 to 3.11) 
Women 
   No IHD 268 (97.8) 267 (97.5) 1.00 1.00 
   Non-severe IHD 5 (1.8) 3 (1.1) 0.60 (0.14 to 2.51) 0.59 (0.14 to 2.47) 
   Severe IHD 1 (0.4) 4 (1.5) 4.00 (0.45 to 35.79) 3.47 (0.38 to 31.41) 
Peripheral atherosclerotic disease 
PAD was classified as having CPRD diagnostic codes relating specifically to PAD, or evidence 
of non-coronary vascular atherosclerotic events, occlusions, or surgery any time prior to the 
point of analysis. Few participants met the criteria for PAD (n=12) but prevalence was 
greater among cases (2.2% vs 0.2%). PAD was significantly and very strongly associated with 
HRJL (OR 11.00 95%CI 1.42 to 85.2), although confidence intervals were wide. Prevalence of 
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PAD was too low to consider men and women separately. The association between PAD 
and HRJL remained significant and very strong after adjustment for confounding factors. 
Table 91: Association between peripheral atherosclerotic disease and health-related job 
loss, across total study population and by gender 
Variable Prevalence 
among 
controls, n (%) 
Prevalence 
among 
cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No PAD 493 (99.8) 483 (97.8) 1.00 1.00 
PAD 1 (0.2) 11 (2.2) 11.00 (1.42 to 85.20) 8.19 (1.04 to 64.65) 
Men 
No PAD 219 (99.6) 211 (95.9) 1.00 1.00 
PAD  1 (0.5) 9 (4.1) 9.00 (1.14 to 71.04) 6.48 (0.80 to 52.69) 
Women 
No PAD 274 (100.0) 272 (99.3) 1.00 1.00 
PAD 0 (0.0) 2 (0.7) NE NE 
Venous thromboembolism, cardiac arrhythmias, and structural heart disease 
Venous thromboembolism included participants with CPRD-evidence of pulmonary 
embolism or DVT, in the year prior. Cardiac arrhythmias included participants with CPRD-
evidence of atrial fibrillation, supraventricular tachycardia, other arrhythmias, or treatment 
for cardiac arrhythmias, in the year prior. Structural heart disease included participants 
with CPRD-evidence of cardiomyopathies or diseases of the endocardium or valves, any 
time prior to the point of analysis.  
There were few participants with CPRD-evidence of venous thromboembolism (n=1), 
cardiac arrhythmias (n= 8), and structural heart disease (n=7). With only a single 
participant, venous thromboembolism was dropped from further individual analysis. A 
greater proportion of cases were classified as having structural heart disease or recent 
cardiac arrhythmias, compared to controls (1.4% vs 0.2% and 0.0% vs 7.0%, respectively) 
however the number of exposed participants was too small to determine statistical 
association, see Table 21, and Table 22, Appendix.  
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6.3.3.4 Respiratory disorders 
The association between obstructive lung disease and HRJL was assessed by combining 
COPD and asthma categories (n=86). Obstructive lung disease was significantly, but weakly, 
associated with HRJL in matched analysis (OR 1.92 95%CI 1.20 to 3.09). The association 
appeared to be slightly stronger in women compared to men (OR 2.25 95%CI 1.14 to 4.44 
and 1.64 95%CI 0.85 to 3.19, respectively). All effect estimates remained similar after 
adjustment for known confounders.  
Asthma 
Asthma was defined as having CPRD-evidence of asthma, or severe asthma, that was still 
being treated, any time prior to the point of analysis. In total, 109 participants met the 
criteria for asthma, which was more prevalent among cases (13.0% vs 9.1%). Amongst 
these, only three people fulfilled the case definition for severe asthma and all three of 
these reported having HRJL. Asthma was weakly associated with HRJL (OR 1.66 95%CI 1.04 
to 2.65) and appeared to be more strongly associated with HRJL in women than men, in 
whom there was no significant association (OR 2.00 95%CI 1.00 to 4.00; and OR 1.29 95%CI 
0.64 to 2.59, respectively). Strength of association remained similar after adjustment for 
known confounders, see Table 92.  
Table 92: Association between asthma and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of 
heavy alcohol use.  
OR (95% CI) 
Total study sample 
No asthma 463 (93.7) 447 (90.5) 1.00 1.00 
Asthma 45 (9.1) 64 (13.0) 1.66 (1.04 to 2.65) 1.77 (1.10 to 2.87) 
Men 
No asthma 206 (93.6) 202 (91.8) 1.00 1.00 
Asthma 14 (6.4) 18 (8.2) 1.33 (0.68 to 2.61) 1.43 (0.72 to 2.84) 
Women 
No asthma 257 (93.8) 245 (89.4) 1.00 1.00 
Asthma 17 (6.2) 29 (10.6) 2.03 (1.05 to 3.94) 2.16 (1.09 to 4.28) 
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Chronic Obstructive Pulmonary Disease 
COPD was defined as having CPRD-evidence of COPD, emphysema, or chronic bronchitis 
any time prior to the point of analysis. In total, 20 participants were classified as having 
COPD, although this condition was more common among cases (3.0% vs 1.0%) and had a 
significant strong association with HRJL in matched analysis (OR 3.00 95%CI 1.09 to 8.25), 
see Table 93. While the association appeared to be much stronger among men than women 
(OR 5.00 95%CI 1.10 to 22.82 vs OR 1.67 95%CI 0.40 to 6.97), confidence intervals were 
wide. Associations with HRJL remained similar after adjustment for known confounders. 
Five control participants, classified as having COPD, were apparently still working. These 
participants had quite varied occupations including archivist, benefit fraud investigator, 
club stewardess, head teacher, and computer aided design operator. Notably, none of 
these roles seem to require physically demanding activities.   
Table 93: Association between COPD and health-related job loss, across total study 







cases, n (%) 
Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No COPD 489 (99.0) 479 (97.0) 1.00 1.00 
COPD 5 (1.0) 15 (3.0) 3.00 (1.09 to 8.25) 3.76 (1.22 to 11.60) 
Men 
No COPD 218 (99.1) 210 (95.5) 1.00 1.00 
COPD 2 (0.9) 10 (4.6) 5.00 (1.10 to 22.82) 5.50 (1.15 to 26.20) 
Women 
No COPD 271 (98.9) 269 (98.2) 1.00 1.00 
COPD 3 (1.1) 5 (1.8) 1.67 (0.40 to 6.97) 2.25 (0.42 to 11.91) 
 
6.3.3.5 Neurological disorders 
Cerebrovascular accident  
CVA was defined as having evidence of TIA, in the year prior, or stroke any time prior to the 
point of analysis. In total, 21 participants were classified as having CVA which was more 
common among cases (3.4% vs 0.8%). A strong significant association was observed 
between CVA and HRJL (OR 4.25 95%CI 1.43 to 12.63), see Table 94. Strength of association 
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remained similar after adjustment for known confounders, although the number of 
participants with CVA was too low to confidently compare men and women. 
The four participants that remained in work despite CVA had likely had strokes and their 
last known occupations included payroll administrator, chief technician, HGV driver, and 
carer. As well as the fact that, by law, HGV drivers would have been out of work for a year 
following CVA,(408) it is also likely that these participants must have made significant 
recovery following stroke/TIA to allow them to continue working. Additionally, TIA/stroke 
misdiagnosis is also possible, as this is a common error in CPRD, as described in Chapter 3. 
Table 94: Association between cerebrovascular accident and health-related job loss, 








Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No CVA 490 (99.2) 477 (96.6) 1.00 1.00 
CVA 4 (0.8) 17 (3.4) 4.25 (1.43 to 12.63) 4.82 (1.57 to 14.76) 
Men 
No CVA 217 (98.6) 210 (95.5) 1.00 1.00 
CVA 3 (1.4) 10 (4.6) 3.33 (0.92 to 12.11) 3.84 (1.01 to 14.59) 
Women 
No CVA 273 (99.6) 267 (97.5) 1.00 1.00 
CVA 1 (0.4) 7 (2.6) 7.00 (0.86 to 56.89) 7.54 (0.90 to 63.43) 
Epilepsy 
CPRD-defined epilepsy included participants diagnosed with epilepsy specific codes (e.g. 
“epileptic seizures”, “epilepsy medication review”) or participants with evidence of fits or 
seizures who were later diagnosed with epilepsy. Few participants were classed as having 
epilepsy (n=10) and these were more common among cases (1.4% vs 0.6%). Epilepsy was 
not significantly associated with HRJL, however, confidence intervals were wide (OR 3.00 
95%CI 0.81 to 11.08), see Table 95. Although analysis was underpowered, point estimates 
suggested a moderate-strong association between epilepsy and HRJL, as well as after 
adjustment for known confounders. The number of participants with epilepsy was also too 
low for conclusive findings among men and women.  
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Table 95: Association between epilepsy and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No epilepsy 491 (99.4) 487 (98.6) 1.00 1.00 
Epilepsy 3 (0.6) 7 (1.4) 3.00 (0.61 to 14.86) 3.74 (0.73 to 19.20) 
Men 
No epilepsy 219 (99.6) 216 (98.2) 1.00 1.00 
Epilepsy 1 (0.5) 4 (1.8) 4.00 (0.45 to 35.79) 6.11 (0.65 to 57.75) 
Women 
No epilepsy 272 (99.3) 271 (98.9) 1.00 1.00 
Epilepsy 2 (0.7) 3 (1.1) 2.00 (0.18 to 22.06) 1.73 (0.15 to 19.80) 
 
6.3.3.6 Diabetes 
Diabetes included participants with CPRD diagnostic codes for diabetes mellitus (e.g. “type 
2 diabetes mellitus”, “follow-up diabetic assessment”) prior to the point of analysis. Poorly 
controlled diabetes included participants with additional codes suggesting more “severe” 
diabetes (e.g. “diabetic neuropathy”, “unstable diabetes”). In total, there were 91 
participants with CPRD-defined diabetes and 55 with signs of poorly controlled diabetes. 
Both diabetes without complications and poorly controlled diabetes were more common 
amongst cases (4.7% vs 2.6% and 7.5% vs 3.6%, respectively).  Diabetes was moderately 
associated with HRJL (OR 2.32 95%CI 1.41 to 3.82); the association was only slightly 
stronger among those with indicators of poor diabetic control (OR 2.38 95%CI 1.31 to 4.35), 
see Table 96. Effect estimates were similar after adjustment for known confounders.  
In male participants, poorly controlled diabetes had a stronger association with HRJL (OR 
3.14 95%CI 1.40 to 7.05 vs OR 1.57 95%CI 0.65 to 3.82). Notably, this seemed to reverse in 
women, among whom diabetes without indicators of poor control was more strongly 
associated with HRJL (aOR 4.97 95%CI 1.05 to 23.45 vs aOR 1.62 95%CI 0.63 to 4.17). 
However, there were fewer female participants coded as having diabetes and confidence 
intervals were wide. 
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Table 96: Association between diabetes and health-related job loss, across total study 







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Total study sample 
No diabetes 463 (93.7) 434 (87.9) 1.00 1.00 
Diabetes no 
complications 
13 (2.6) 23 (4.7) 2.21 (1.05 to 4.67) 2.09 (0.98 to 4.47) 
Diabetes poorly 
controlled 
18 (3.6) 37 (7.5) 2.38 (1.31 to 4.35) 1.98 (1.07 to 3.67) 
Men 
No diabetes 200 (90.9) 181 (82.3) 1.00 1.00 
Diabetes no 
complications 
10 (4.6) 13 (5.9) 1.57 (0.65 to 3.82) 1.51 (0.60 to 3.76) 
Diabetes poorly 
controlled 
10 (4.6) 26 (11.8) 3.14 (1.40 to 7.05) 2.74 (1.20 to 6.28) 
Women 
No diabetes 263 (96.0) 253 (92.3) 1.00 1.00 
Diabetes no 
complications 
3 (1.1) 10 (3.7) 4.97 (1.05 to 23.45) 4.49 (0.94 to 21.39) 
Diabetes poorly 
controlled 
8 (2.9) 11 (4.0) 1.62 (0.63 to 4.17) 1.31 (0.49 to 3.47) 
 
6.3.4 Summary of the associations between CPRD-defined health disorders and 
HRJL 
For ease of reference, the information presented above was assimilated into a summary 
table showing the association between CPRD-defined health disorders and HRJL, across the 
total study sample, and split by gender, see Table 97. Relative effect sizes were adjusted for 
educational attainment, single relationship status, and history of heavy alcohol use, and can 
be visualised in Figure 36. 
Table 97: Summary table –adjusted association between CPRD-defined health disorders 
and HRJL, with stratification by gender 
CPRD-defined 
health disorder 
Total study sample 
(n=988) 
aOR* (95% CI) 
Male participants 
(n=440) 
aOR* (95% CI) 
Female Participants 
(n=548) 
aOR* (95% CI) 
Chronic MSD 1.89 (1.36 to 2.57) 2.19 (1.29 to 3.74) 1.72 (1.15 to 2.56) 
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Recent MSD pain 2.17 (1.56 to 3.03) 1.79 (1.12 to 2.85) 2.69 (1.66 to 4.38) 
Recent primary 
care-level MHP 
3.53 (2.38 to 5.23) 4.20 (2.11 to 8.37) 3.23 (2.00 to 5.21) 
Recent sleep 
disorder 
2.74 (1.40 to 5.38) 3.40 (1.04 to 11.08) 2.58 (1.12 to 5.90) 
Psychiatric care-
level MHP 
3.77 (0.77 to 18.46) 2.23 (0.39 to 12.68) NE 
History of severe 
MHP 
4.36 (1.91 to 9.98) 3.22 (1.16 to 8.95) 8.53 (1.82 to 40.00) 
Hypertension 1.79 (1.28 to 2.50) 1.27 (0.81 to 2.00) 2.74 (1.63 to 4.61) 
Heart failure 3.56 (1.80 to 7.03) 3.35 (1.49 to 7.54) 4.14 (1.17 to 14.66) 
Ischaemic heart 
disease 
1.32 (0.74 to 2.36) 1.44 (0.72 to 2.86) 1.09 (0.36 to 3.26) 
PAD 8.19 (1.04 to 64.65) 6.48 (0.80 to 52.69) NE 
Asthma 1.77 (1.10 to 2.87) 1.43 (0.72 to 2.84) 2.16 (1.09 to 4.28) 
COPD 3.76 (1.22 to 11.60) 5.50 (1.15 to 26.20) 2.25 (0.42 to 11.91) 
CVA 4.82 (1.57 to 14.76) 3.84 (1.01 to 14.59) 7.54 (0.90 to 63.43) 
Epilepsy 3.74 (0.73 to 19.20) 6.11 (0.65 to 57.75) 1.73 (0.15 to 19.80) 
Diabetes 2.02 (1.21 to 3.37) 2.13 (1.12 to 4.04) 1.91 (0.81 to 4.48) 
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Figure 36: Forest plot showing association between CPRD-defined health disorders and 
HRJL  
 
6.3.5 Subgroup analysis by age at time of analysis 
Subgroup analysis was performed comparing the association between CPRD-defined health 
disorders and HRJL, stratified by the age at which the case had experienced HRJL. Control 
participants were working at the time their matched cases had fallen out of work, and a 
control’s CPRD-defined health information was taken from this point in time.  Participants 
were grouped in the following age bands accordingly: aged <50 years old; aged 50 to <60 
years old; age 60 and older.   
The prevalence of musculoskeletal disorders together (chronic and recent pain conditions), 
was 29.7% in the age <50 subgroup, 38.3% in the age 50 - <60 subgroup, and 43.1% in the 
age >60 subgroup. Musculoskeletal disorders were strongly associated with HRJL in the age 
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subgroup (OR 1.90 95%CI 1.31 to 2.77), and moderately associated with HRJL in the age >60 
subgroup (OR 2.09 95%CI 1.27 to 3.43). Effect estimates were similar after adjustment for 
known confounders.  
The prevalence of MHPs together (primary care-level, psychiatric care-level, and sleep 
disorders) was 22.7% of the age <50 subgroup, 23.1% in the age 50 - <60 subgroup, and 
13.3% in the age >60 subgroup. MHPs were very strongly associated with HRJL in the age 
<50 subgroup (OR 18.00 95%CI 2.40 to 134.83), although confidence intervals were very 
wide. MHPs were also strongly associated with HRJL in the age 50 – 60 subgroup (OR 3.36 
95%CI 2.09 to 5.41), and moderately associated with HRJL in the age >60 subgroup (OR 2.23 
95%CI 1.16 to 4.29). Effect estimates were similar after adjustment for known confounders, 
except in the age <50 subgroup, in which association remained significant but confidence 
intervals became extremely wide (aOR 85.40 95%CI 5.85 to 1246.83), suggesting a very 
uncertain effect estimate in this group.  
Excluding hypertension, cardiovascular disease were present in 2.3% of the age <50 
subgroup, 8.3% of the age 50 - <60 subgroup, and 15.7% of the age >60 subgroup. 
Association with HRJL was non estimable in the <50 subgroup, however cardiovascular 
disease had a significant moderate association with HRJL in the age 50 – 60 subgroup (OR 
2.23 95%CI 1.16 to 4.29) and a significant strong association in the age >60 subgroup (OR 
4.00 95%CI 1.84 to 8.68). Estimates of effect remained similar after adjusting for known 
confounders. 
Obstructive lung disease (asthma and COPD, together) was present in 6.3% of the age <50 
subgroup, 10.0% of the age 50 - <60 subgroup, and 7.5% of the age >60 subgroup. 
Obstructive lung disease had a non-significant association with HRJL in the <50 group (OR: 
1.00 95%CI 0.25 to 4.00), a weak significant association in the 50 – 60 age group (OR: 1.87 
95%CI 1.00 to 3.49) and a moderate significant association in the >60 age group (OR 2.57 
95%CI 1.07 to 6.16). Estimates of association became slightly stronger after adjustment for 
known confounding factors (aOR: 1.12 95%CI 0.24 to 5.17; 2.09 95%CI 1.08 to 4.05; and 
3.19 95%CI 1.27 to 8.04, respectively). 
Psychiatric care-level MHPs, PAD, cardiac arrhythmias, structural heart disease, and 
epilepsy were present in 1.6%, 0.8%, 0.0%, 0.0%, and 1.6% of the age <50 subgroup, 
respectively; 1.3%, 1.5%, 1.0%, 0.6%, and 1.3% of the age 50 - <60 subgroup, respectively; 
and 0.3%, 0.9%, 0.9%, 1.2%, and 0.3% of the age >60 subgroup, respectively. The total 
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number of participants with these conditions was too small to meaningfully assess 
association with HRJL across different age subgroups, which was either non-significant with 
wide confidence intervals, or not estimable, see Tables 23 – 27, Appendix.  
For the remaining CPRD-defined health disorders, the associations between CPRD-defined 
health disorders and HRJL, split by age sub-group, are presented below (Table 98). Relative 
effect sizes are adjusted for educational attainment, single relationship status, and history 
of heavy alcohol use. For a full presentation of these data, including unadjusted effect sizes 
and the prevalence of CPRD-defined health disorders within each sub-group, see Tables 28 
– 39, Appendix.  
Table 98: Summary table –adjusted association between CPRD-defined health disorders 
and HRJL, with stratification by age at point of analysis 
CPRD-defined 
health disorder 
Age <50  
(n=128) 
aOR* (95% CI) 
Age 50 - <60 years old 
(n=528) 
aOR* (95% CI) 
Age >60 
(n=332) 
aOR* (95% CI) 
Chronic MSD 2.55 (0.63 to 10.33) 1.58 (1.04 to 2.41) 2.25 (1.31 to 3.88) 
Recent MSD pain 4.40 (1.48 to 13.08) 2.33 (1.46 to 3.71) 1.51 (0.85 to 2.67) 
Recent primary 
care-level MHP 
29.70 (2.78 to 317.56) 3.61 (2.14 to 6.09) 2.04 (0.98 to 4.25) 
Recent sleep 
disorder 
2.71 (0.46 to 16.05) 2.45 (0.94 to 6.42) 4.34 (1.18 to 15.97) 
History of severe 
MHP 
NE 4.00 (1.49 to 10.76) 3.09 (0.57 to 16.80) 
Hypertension 3.52 (0.77 to 16.01) 1.90 (1.19 to 3.04) 1.64 (0.97 to 2.76) 
Heart failure NE 1.83 (0.71 to 4.72) 7.63 (2.52 to 23.11) 
Ischaemic heart 
disease 
NE 1.25 (0.55 to 2.88) 1.23 (0.52 to 2.93) 
Asthma 1.12 (0.24 to 5.17) 1.94 (0.99 to 3.81) 2.19 (0.84 to 5.72) 
COPD NE 2.67 (0.54 to 13.30) 6.12 (1.14 to 32.74) 
CVA NE 5.76 (1.19 to 27.79) 3.33 (0.67 to 16.48) 
Diabetes NE 2.07 (1.03 to 4.19) 1.77 (0.81 to 3.87) 
*Adjusted odds ratio (aOR): adjusted for educational attainment, single relationship status, and history of heavy alcohol 
intake 
6.3.6 Sub-group analysis by “type” of HRJL 
In the HEAF study, cases indicated whether they had left work mainly because of a health 
problem or partly because of a health problem. Sub-group analysis was performed 
comparing the association between CPRD-defined health disorders and HRJL, stratified by 
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“mainly” or “partly” HRJL. The modifying influence of “type” of HRJL on the association 
between CPRD-defined health disorders and HRJL was considered.  
Musculoskeletal disorders (chronic and recent pain conditions together), were present in 
37.4% of the “mainly” subgroup and 40.0% of the “partly” subgroup. Musculoskeletal 
disorders were moderately associated with HRJL in the “mainly” subgroup (OR: 2.56 95%CI 
1.70 to 3.86) and weakly associated with HRJL in the “partly” subgroup (OR: 1.73 95%CI 
1.17 to 2.55). Effect estimates were similar after adjustment for known confounders.  
The prevalence of any MHP (primary care-level, psychiatric care-level, and sleep disorders) 
was 20.9% in the “mainly” subgroup and 18.8% in the “partly” subgroup. MHPs were 
strongly associated with HRJL in the “mainly” subgroup (OR 6.09 95%CI 3.22 to 11.52) and 
moderately associated with HRJL in the “partly” subgroup (OR 2.16 95%CI 1.34 to 3.47). 
Effect estimates were similar after adjustment for known confounders.  
Excluding hypertension, cardiovascular disease was present in 10.4% of the “mainly” 
subgroup and 9.7% of the “partly” subgroup. Cardiovascular disease had a significant strong 
association with HRJL in the “mainly” group (OR 4.00 95%CI 1.84 to 8.68), and a significant 
moderate strength association in the “partly” group (OR 2.46 95%CI 1.29 to 4.69). Effect 
estimates remained similar after adjustment for known confounding factors. 
Obstructive lung disease (asthma and COPD) was present in 8.5% of the “mainly” subgroup 
and 8.9% of the “partly” subgroup. Obstructive pulmonary disease had a significant 
moderate-strength association with HRJL in the “mainly” group (OR 2.50 95%CI 1.20 to 
5.21) and a non-significant weak association in the “partly” group (OR 1.56 95%CI 0.83 to 
2.93). Estimates of association remained similar after adjustment for known confounding 
factors. 
Psychiatric-care-level MHPs, PAD, cardiac arrhythmias, structural heart disease, COPD, and 
epilepsy were present in 1.1%, 1.1%, 1.3%, 0.9%, 2.2%, and 1.1% of the “mainly” sub-group, 
respectively; and 1.0%, 1.3%, 0.4%, 0.6%, 1.9% and 1.0% of the “partly” sub-group, 
respectively. The total number of participants with these conditions was too small to assess 
for differences in strength of association between these sub-groups. Estimates were either 
non-significant with wide confidence intervals, or not estimable, see Tables 40 – 45, 
Appendix. 
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For the remaining CPRD-defined health disorders, the associations between CPRD-defined 
health disorders and HRJL, split by “type” of HRJL, are presented below (Table 99). Relative 
effect sizes are adjusted for educational attainment, single relationship status, and history 
of heavy alcohol use. For a full presentation of these data, including unadjusted effect sizes, 
and the prevalence of these health disorders within “mainly” and “partly” sub-groups, see 
Tables 46 – 56, Appendix.  
Table 99: Summary table –adjusted association between CPRD-defined health disorders 





aOR* (95% CI) 
“Partly” HRJL 
(n=528) 
aOR* (95% CI) 
Chronic MSD 2.71 (1.60 to 4.57) 1.47 (0.98 to 2.22) 
Recent MSD pain 2.01 (1.30 to 3.12) 2.42 (1.44 to 4.07) 
Recent primary care-level 
MHP 
6.93 (3.37 to 14.25) 2.08 (1.24 to 3.46) 
Recent sleep disorder 3.57 (1.27 to 10.04) 2.18 (0.89 to 5.33) 
History of severe MHP 4.29 (1.42 to 12.92) 4.46 (1.27 to 15.72) 
Hypertension 1.34 (0.80 to 2.22) 2.26 (1.44 to 3.55) 
Heart failure 4.34 (1.46 to 12.95) 3.42 (1.38 to 8.44) 
Ischaemic heart disease 1.32 (0.56 to 3.12) 1.34 (0.61 to 2.97) 
Asthma 2.18 (1.05 to 4.55) 1.51 (0.79 to 2.87) 
CVA 13.49 (1.71 to 106.34) 2.09 (0.46 to 9.60) 
Diabetes 2.48 (1.08 to 5.70) 1.79 (0.93 to 3.44) 
*Adjusted odds ratio (aOR): adjusted for educational attainment, single relationship status, and history of heavy alcohol 
intake 
6.4 Discussion  
In this chapter, I conducted an analysis of the relationship between CPRD-defined health 
disorders and health-related job loss. Case and control participants, selected from the HEAF 
study, were compared in a nested, matched, case-control design. Lower level of 
educational qualification, single relationship status, and CPRD-defined history of heavy 
alcohol intake were found to be significantly associated with HRJL, and these confounding 
factors were adjusted for in multivariable analysis. Of the health disorders explored in this 
study, it was found that chronic MSDs, recent MSD pain, primary-care-level MHPs, sleep 
disorders, history of severe MHPs, hypertension, heart failure, PAD, asthma, COPD, CVA, 
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and diabetes are significantly associated with HRJL. Although underpowered to show 
statistical significance, effect estimates suggest that psychiatric-level MHPs, cardiac 
arrhythmias, structural heart disease, and epilepsy may also impact an older worker’s 
ability to stay in work.  
Demographic factors were initially assessed for their role in HRJL. Low qualification level 
and NS-SEC occupational class reflect facets of a participant’s socioeconomic status, which 
is well described for its associated gradient in health,(399) and is also an important 
predictor of sickness absence and work disability.(21–23,32,40,222,225–230) As a result, 
the weak strength of association found between these factors and HRJL in this analysis was 
surprising, but may be accounted for by the fact that cases and controls had already been 
matched for GP practice, which adjusts for regional levels of deprivation. Single relationship 
status was significantly associated with HRJL. One meta-review of modifiable and non-
modifiable risk factors for work outcomes found that, in general, marriage was a consistent 
protective factor for work disability.(21) Being married or in a committed relationship has 
also been associated with current employment and increased return to work across 
multiple conditions.(23,24) Interestingly, in this study, being divorced or widowed appeared 
of less importance as a predictor of HRJL than self-reported singleness; being divorced may 
even be protective of work loss in women. I am not aware that the sex-stratified impact of 
divorce and widowhood on work outcomes has been reported in the literature previously, 
and this may be worth follow up in future research, with better statistical power to detect 
an effect.   
Lifestyle factors were considered next. In the literature, smoking is an established risk 
factor for innumerable adverse health outcomes, leading to increased mortality, cancer, 
and chronic disease (particularly respiratory and cardiovascular disorders).(409) it has also 
been linked to work disability and long-term sickness absence in certain studies,(410) 
although found to be of little significance to work in others.(411,412) While no important 
association between smoking and HRJL was observed in this study, smoking status was self-
reported and a smoker’s status as a current or ex-smoker was based on their self-reported 
dates of quitting smoking. These may be strongly subject to recall bias. To derive 
information about a participant’s drinking habits, it was necessary to rely on CPRD coding. 
However, in CPRD, alcohol intake was not recorded for the majority of study participants. 
Instead, I considered evidence of heavy alcohol intake, or alcohol abuse, which is more 
likely to be consistently identified and recorded by a general practitioner. The evidence for 
heavy alcohol intake as an explanatory factor for poor work outcomes is understudied and 
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inconsistent,(413,414) however, in this study, a moderate-strong association between 
history of heavy alcohol intake and HRJL was observed. 
Chronic MSDs and recent MSD pain were both associated with HRJL. The mild-moderate 
strength associations observed and the very large prevalence of these disorders across the 
total study sample establishes these conditions as having a very important role in work 
disability, at the population level.  Similar effect sizes have previously been reported for 
MSDs and risk of disability pension (RR 2.23 95%CI 1.93 to 2.59).(115) Recent MSD pain 
disorders and chronic MSDs appeared to define different sets of diseases (e.g. mostly 
osteoarthritis in chronic MSDs and largely back pain in recent MSD pain, see Chapter 3 and 
5). However, there was considerable overlap between these conditions. Of participants 
with a chronic MSD, 34.9% had presented to their GP with MSD pain in the prior year. This 
suggests that some of the musculoskeletal pain may have stemmed from an underlying 
chronic MSD condition. 
Mental health problems were also highly prevalent in the study sample, and a strong 
relationship with HRJL was observed. Specifically, primary-care-level MHPs and having a 
history of severe MHPs, were strongly associated with HRJL; sleep disorders were 
moderately associated with HRJL; and point estimates suggest that psychiatric disorders 
may also be strongly associated, although this did not reach statistical significance. These 
findings correspond with those reported previously: a systematic review and meta-analysis 
using data from 282,459 patients found mental health problems (together) were associated 
with an increased risk of disability pension (RR 1.80 95%CI 1.41 to 2.31).(115) Specifically, 
mood disorders have been linked to work disability and long-term sickness absence in 
several studies(415–417) including a Finnish epidemiological study of over 3000 
participants, aged 30 – 58 years old, which found depression (OR 2.67 95%CI 1.58 to 4.52) 
and anxiety (OR: 3.34 95%CI 1.65 to 6.77) were significantly associated with disability 
pension.(413) Psychotic disorders, such as schizophrenia, are less well reported but in a 
Finnish twin study were strongly associated with disability pension (OR: 6.3 95%CI 2.0 to 
20.1 across all twins, 8.7 95%CI 2.1 to 36.8 among dizygotic twins, and 2.5 95%CI 0.2 to 30.8 
among monozygotic twins). In this study, as with the twin study, confidence intervals were 
wide and results were limited by the number of participants with psychiatric care-level 
MHPs, however point estimates suggested a strong positive relationship with HRJL among 
older workers. 
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As a whole, cardiovascular disorders were moderately associated with HRJL (OR: 2.72 95%CI 
1.65 to 4.49) and moderately-strongly if hypertension was excluded (OR: 3.05 95%CI 1.86 to 
4.99). Individually, heart failure and peripheral atherosclerotic disease were particularly 
strongly associated with HRJL. Seven participants had structural heart disease, and eight 
had cardiac arrhythmias; all but one of these participants had HRJL. Ischaemic heart disease 
is likely to be weakly associated with HRJL, however this study was underpowered to find 
statistical significance (OR 1.45 95%CI 0.82 to 2.56). Even after restricting to those 
participants who had a history of myocardial infarction or unstable angina (severe 
ischaemic heart disease) impact was non-significant (OR 1.45 95%CI 0.82 to 2.56). Coronary 
heart disease has previously been associated with higher rate of labour market withdrawal 
(HR 1.32 95%CI 1.11 to 1.57)(418) and higher rate of absenteeism (IRR 1.17 95%CI 1.03 to 
1.32).(419) However, comparisons with the literature are difficult since, despite the 
prevalence of cardiovascular disorders in the workforce, the evidence for their impact on 
work disability is scarce.(420) While findings may suggest a relatively encouraging outlook 
for remaining in work after acute coronary event, a survivor bias may impact findings here 
since people with fatal myocardial infarction (and possibly near-fatal myocardial infarction) 
would not have been captured in the HEAF study sample. Nonetheless, the findings of this 
study provide much needed evidence for the importance of cardiovascular disorders on 
ability to stay in work in the older working-age population. 
Hypertension was also statistically associated with work disability, but only weakly. In 
prospective studies, hypertension has been linked to increased risk of disability pension (RR 
1.50 95%CI 1.31-1.72)(421) as well as longer sickness absence duration.(422) The 
association between hypertension and HRJL is curious since it is usually symptomless, but 
this may reflect its role as a risk factor for other unmeasured adverse health problems. For 
example, hypertension is associated with obesity(423) and with microvascular 
complications in diabetes, such as nephropathy.(424) The high prevalence of hypertension 
in this older-age population also allows for the identification of small effect sizes. Finally, a 
bias (conceptually similar to Berkson’s bias) may arise, since people with more severe kinds 
of disease, or requesting sickness absence from work, may be seen more frequently in GP 
clinic and therefore have a greater opportunity to have their blood pressure measured and 
hypertension diagnosed. Interestingly, the association between hypertension and HRJL did 
become non-significant after adjusting for the number of GP consultations in the prior year 
(aOR 1.17 95%CI 0.80 to 1.70).  
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Diabetes had a moderate-strength association with HRJL in this study. Previous studies have 
also identified a relationship between diabetes and absenteeism (OR: 2.29 95%CI 1.17 to 
4.47),(425) and work disability (HR 1.7 95%CI 1.0 to 2.9).(420,426) Surprisingly, effect sizes 
were similar for participants with general diabetes codes and those with indicators of worse 
diabetic control. Codes indicating more severe diabetes may have been inconsistently 
recorded in CPRD, and as a result, these groups may be more similar than is apparent. 
Additionally, the fact that 60.44% of those with diabetes were defined as “diabetes with 
poor control” suggests that the Read codes used to define diabetic control were overly 
inclusive. Therefore, going forwards, diabetes was analysed without stratification for 
severity. 
A mild significant relationship between asthma and HRJL was observed in this older 
working-age population, and a moderate-strong association between COPD and HRJL. 
Similarly, in the literature, COPD and, to a lesser extent, asthma have been associated with 
a substantially shortened working life.(427) The evidence for the impact of asthma on 
health-related job loss is scarce, although asthma was associated with all-cause long-term 
work disability in one study (HR 1.8 95%CI 1.62 to 2.09).(428) Likewise, COPD is rarely 
reported for occupational outcomes but has been associated with absenteeism (IRR 1.57 
95%CI 1.33 to 1.86)(419,420) and prolonged labour force non-participation (OR: 2.92 95%CI 
1.35 to 6.29).(429)  
CPRD diagnostic information was available for two neurological conditions: epilepsy and 
cerebrovascular accident. Cerebrovascular accident was strongly associated with HRJL and 
epilepsy may have a moderate-strong association with HRJL, although this analysis was 
underpowered to show a significant effect. Evidence linking stroke to health-related work 
loss is scarce, however, several studies outlined the low rates of return to work a year or 
more following stroke which ranged from 21% – 75%.(420) Very few papers were found 
that considered the association between epilepsy and work status. In an old study (1991) in 
an area of high unemployment, people with epilepsy were found to have 59% 
unemployment, with 79% unemployment in those with associated neurological or 
psychiatric disability.(430) A dedicated study, with sufficient statistical power, is needed to 
assess the rate and predictors of adverse work outcomes in epilepsy. 
Generally, adjustment for confounders did not impact the estimates of association between 
these CPRD-defined health disorders and HRJL. This is unsurprising since qualification level 
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and single relationship status was only weakly associated with the main outcome (HRJL), 
and history of heavy alcohol intake was not common in the study sample.  
A unique strength of this study was the stratification of results by gender. The rationale for 
doing so was clear since, as described in Chapter 5, occupational environment differed in a 
gender-dependent manner and, surprisingly, gender differences have not yet been 
sufficiently explored in the literature. However, analysis was underpowered, and 
confidence intervals too wide, to confidently assess gender differences for psychiatric-level 
MHPs, history of severe MHPs, heart failure, ischaemic heart disease, peripheral 
atherosclerotic disease, cardiac arrhythmias, structural heart disease, COPD, CVA, and 
epilepsy. For chronic MSDs, sleep disorders, and asthma there was no strong evidence of 
effect-modification by gender. Recent MSD pain appeared to have a slightly stronger 
association with HRJL among women than men (OR: 2.71 vs 1.83), differences may result 
from the different kinds of pain conditions experienced by men and women in this sample, 
for example, there were 17 female participants with widespread pain and only three male. 
Hypertension was also more significantly associated with HRJL among women, compared to 
men (OR: 2.90 vs 1.31). There is some evidence to suggest post-menopausal women 
present with more advanced cardiovascular disease than men, and that hypertension acts 
as a stronger risk factor for heart disease among women.(431) Unfortunately, this study 
was underpowered to explore these differences for other cardiovascular disorders. Primary 
care-level MHPs may be more strongly associated with HRJL among men than women (OR: 
4.20 vs 3.23). Although these conditions are more prevalent among women, men appear 
broadly more reluctant to present with MHPs (432) and are less often detected as having 
MHPs by their general practitioners.(433) The men presenting with mental health problems 
in this study may therefore have had more severe MHPs (that are more easily detectable) 
resulting in the observed stronger impact on work. Overall, it should be noted that these 
differences were small, and indeed may not exist, since confidence intervals were 
overlapping.  
After stratification by age at HRJL, chronic MSDs, recent MSD pain, primary-care-level MHP, 
sleep disorders, history of severe MHPs, hypertension, CVA, and diabetes remained 
significantly associated with HRJL in the age 50 to <60 subgroup. As described in Chapter 5, 
the 50 – 60 year old age band are of particular economic interest in the UK, since they are 
the most common group to drop out of work while still being some distance from state 
pension retirement age.(46) For certain, progressive age-related conditions, such as chronic 
MSDs, heart failure, and COPD, strength of association increased towards the older age 
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groups, in whom the disease is more prevalent and likely more severe. Interestingly, 
primary-care-level MHPs and recent musculoskeletal pain, seemed more strongly 
associated with HRJL in the younger age groups. However, in all cases, confidence intervals 
were wide and overlapping between subgroups and observed differences in size of 
association may not be meaningful.  
Finally, I stratified analysis by whether a case had stated that a health problem was the 
main reason or part of the reason for their leaving employment. Since this response 
indicates the extent that a person recalled poor health had affected their job loss, it is also 
likely to be related to the overall health burden among cases. Unsurprisingly then, for the 
majority of CPRD-defined health disorders (apart from recent musculoskeletal pain and 
hypertension) the estimated strength of association with HRJL was greater when analysis 
was restricted to “mainly” cases. However, recent MSD pain, primary care-level MHPs, 
sleep disorders, history of severe MHPs, hypertension, and diabetes also remained 
significantly associated with HRJL among “partly” cases. Both “mainly” and “partly” HRJL 
appeared to be related to CPRD-indicators of poor health and, for the purposes of this 
thesis, I was interested in either of these outcomes. So for the remainder of the thesis, 
cases were recombined to assess relative odds of HRJL.  
The main weaknesses of this study have already been highlighted, particularly the fact that 
in several cases analysis was underpowered to detect a statistically significant effect. In the 
total sample (n=988), as described in Section 6.3.1, for certain rarer health exposures, 
analysis would not have been powered to detect a weak or even moderate-strength 
association. This was true for psychiatric care-level mental health problems, epilepsy, 
venous thromboembolic disease, cardiac arrhythmias, and structural heart disease, for 
which non-statistically significant associations were observed but an important relationship 
with HRJL could not be ruled out. For other rarer exposures such as peripheral arterial 
disease, COPD, and CVA the large strength of association observed meant that analysis was 
sufficiently powered (power ≥ 80%) to detect a statistically significant effect. However, for all 
other health exposures, analysis was sufficiently powered to detect weak, moderate, or 
strong associations with HRJL.  
Statistical power dropped further after stratification for gender, age, and “type” of HRJL. 
For example, analysis in the male subgroup (n=440), as well as being underpowered to 
assess the rare exposures described above, was only sufficiently powered to detect 
moderate or strong associations with HRJL for chronic MSDs, heart failure, ischaemic heart 
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disease, and asthma, and strong associations only for sleep disorders and history of severe 
mental health problems. Nonetheless, due to the large strength of association observed 
with HRJL, analyses were sufficiently powered (power ≥ 80%) to detect a statistically 
significant relationship for chronic MSDs, heart failure, and history of severe mental health 
problems even after stratification by male participants. In addition, analysis remained 
sufficiently powered to detect a weak, moderate, or strong association with HRJL for 
musculoskeletal pain, primary care-level mental health problems, and hypertension.  
In addition, while this work describes multiple health disorders that have not yet been 
studied for their association with work disability in the literature, there were many health 
problems for which no CPRD information was available, for example, cancers and 
gastrointestinal disorders.  Other weaknesses mentioned in the previous chapter remain a 
problem, including the fact that case definitions were subject to recall bias. Extent of 
measurement error is also likely to vary between CPRD-defined health disorders, which 
makes comparing the effects of these conditions difficult. This study is overly reliant on face 
validity to define health exposures; the CPRD-defined health disorders used here ideally 
require their own validation study, however, time resources were limited to accomplish 
this. Finally, there were weaknesses related to unmeasured confounders. It is particularly 
difficult to adequately adjust for a complicated concept such as socioeconomic status. For 
example, in this study, no information was available for a participant’s income at the point 
of HRJL. Instead, qualification level was used to define educational attainment, which is 
frequently used as an indicator of socioeconomic status in the literature.(19–
24,28,32,36,132,221–224) Certain factors related to the workplace have also been found to 
be associated with the risk of work disability. For example, heavy manual 
work,(19,21,24,25,136,222,232) absence of workplace accommodations,(25) high job 
strain,(231,232) and poor colleague support.(25,232) Available data limited the ability to 
adjust for all of these factors. However, case and control participants were found to be 
broadly similar for SOC-10 categories of occupation, with some exceptions (for example, 
teaching and elementary administrative jobs were more common among cases, business 
professionals and managers were more common among control participants, see Figure 
35). 
Otherwise, the adjusted analysis is a strength of this study. The major (non-health) 
predictors of work disability reported in the literature were accounted for. These included: 
age (19–41); female gender (19,21–24,28,30,31,33,39,132); socioeconomic status (21–
23,32,40,222,225–230); education (19–24,28,32,36,132,221–224); geography or regional 
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differences (21,23,221,223,233,434,435); ethnicity (20,21,23,30,32); maritial status 
(21,23,24); and the beliefs and practices of treating healthcare professionals.(436,437) In 
matched analysis, age, gender, and GP practice were accounted for. By matching for GP 
practice, it was also possible to adjust for regional differences in work, the ethos and 
practices of any particular general practice and, to some extent, local levels of deprivation. I 
also adjusted statistically for educational attainment and marital status and adjustment for 
ethnicity was not necessary in this majority-white study population. The use of stratification 
in this chapter provides some preliminary data to show how the impact of health disorders 
upon ability to stay in work is modified across important age-bands and gender. Other 
strengths of this study have been touched on previously. In brief, CPRD records provided an 
objective source of health information that did not rely on the memory of study 
participants. Selected health problems for which information was available covered those 
recognised as being responsible for two-thirds of sickness absence and long-term incapacity 
in the UK.(48) Finally, working controls were drawn from the same study population as the 
case participants.  
6.5 Summary 
• Chronic musculoskeletal disorders, recent musculoskeletal pain, primary-care-level 
mental health problems, sleep disorders, hypertension, heart failure, peripheral 
arterial disease, COPD, cerebrovascular accident, and diabetes were significantly 
associated with the development of HRJL, after statistical adjustment for other 
known confounders.  
• The effect estimates for psychiatric-level mental health disorders, ischaemic heart 
disease, cardiac arrythmias, and epilepsy suggested that they may also be 
associated with HRJL, however analysis was underpowered to show a statistically 
significant effect. Structural heart disease is also likely to be important at the 
individual level since all seven participants with this condition were cases, however 
for this reason it was also not possible to estimate strength of association. 
• Studied health disorders appeared to have a broadly consistent association with 
HRJL after stratification by gender.  
• Generally, studied health disorders appeared to have a stronger association with 
HRJL in the sub-group of cases for whom a health problem was the main reason, 
rather than partly the reason for job loss. However, many health disorders 
appeared to have a positive association with both classifications of HRJL. 
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• For certain progressive age-related conditions, such as chronic MSDs, heart failure, 
and COPD, the strength of association was greater in the sub-group of cases with 
HRJL at older ages, in whom these diseases were more prevalent and possibly more 
severe. Conversely, the association between primary-care-level MHPs or recent 
musculoskeletal pain and HRJL seemed more marked in the younger age groups. 
However, in all cases following stratification, confidence intervals were wide.  
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Chapter 7- the patterns of CPRD-
defined multimorbidity  
7.1 Introduction 
In the previous chapter, the association between individual health disorders and health-
related job loss (HRJL) was explored. However, these disorders often do not occur in 
isolation, a large proportion of the older working-age population, particularly, have to 
manage multiple health problems (multimorbidity).(438) The co-presentation of health 
disorders may inhibit a person’s ability to stay in work for reasons that go beyond the 
physical manifestations of these conditions and includes aspects of treatment burden and 
the necessity of attending multiple healthcare appointments.(190) In this chapter, 
participants under study are described for the presence and patterns of CPRD-defined 
multimorbidity. All participants are analysed together (unmatched) rather than by their 
case/control status, see Figure 37. 
Figure 37: the cohort described in this chapter, as indicated by the red square 
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7.2 Methods  
7.2.1 Description of multimorbidity and common disease pairs 
Study participants were described for the presence of multimorbidity, which was defined as 
two or more co-occurring CPRD-defined health problems. As outlined previously, CPRD-
defined health disorders included: chronic or recent musculoskeletal disorders, structural 
heart disease, hypertension, heart failure, ischaemic heart disease, venous 
thromboembolism, peripheral atherosclerotic disease, arrhythmias, primary-care-level 
mental health problems, psychiatric-care-level mental health problems, sleep disorders, 
COPD, asthma, cerebrovascular accident, epilepsy, and diabetes. With each health problem 
weighted equally as 1, participants were described for “number of morbidities” (in this 
case, participants were not scored twice for having both a chronic MSD and recent MSD 
pain). All CPRD-defined health disorders were also cross-tabulated and the most frequently 
co-occurring comorbidity pairs were described. Proportional statistics (i.e. percentages) 
were used to describe these categorical outcomes.  
Additionally, participants were described for the total number of drug prescriptions they 
had been issued in the prior year, and the number of GP consultations they had attended. 
While these metrics are not true measures of multimorbidity, they are related to the overall 
health burden experienced. These continuous outcomes had a skewed distribution, 
therefore medians and inter-quartile ranges were used to report central tendency and 
spread.  
7.2.2 Cluster analysis 
Cluster analysis is a set of techniques used to separate participants into groups or “clusters” 
based on specific characteristics. Cluster analysis uses geometric distance (if plotted 
graphically) to find participants who are similar for a set of predefined variables, and is 
distinct from factor analysis, which defines a construct or “factor” which is a condensed 
statement of the relationships between a set of variables, and is based on 
correlations.(439) In the literature, cluster analysis has been used in many different clinical 
areas, including for finding groups of genes that have similar functions,(440) and in 
taxonomy, for example, when trying to characterise the clinical features of a certain subset 
of people with a disease.(441) 
In this chapter, cluster analysis was used to describe common groups, or patterns, of 
multimorbidity. Many different methods are available for performing cluster analysis; the 
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rationales behind selecting the methods used in this chapter are outlined in Chapter 3, 
Section 3.8.3. The specific methods used in this chapter are outlined again, in brief, below.  
In the first stage, the variables on which to perform cluster analysis were selected. 
Participants were clustered based on the presence or absence of disease codes alone, 
which included the list of CPRD-defined health disorders described above.  
Cluster analysis grouped individuals based on their mathematical “similarity” for these 
selected variables. To mathematically describe the degree of similarity, the Jaccard 
coefficient was used.(321) This coefficient defines similarity between two individuals using 
a count-based algorithm which considers the proportion of binary variables that are 
present in two individuals over those that are present in both or only in one person, J = M11 
/ M01 + M10 + M11, see Figure 38.  
















    
Cluster analyses can take hierarchical or non-hierarchical approaches. In order to take an 
explorative approach to cluster analysis and to visualise how groups merged at different 
levels of similarity, I undertook a hierarchical cluster analysis, making use of the generated 
dendrograms to visualise the clustering solution. For the current chapter, analysis was 
performed in STATA v13, which uses agglomerative, rather than divisive, hierarchical cluster 
analysis.(322) 
Similarity measures, such as the Jaccard coefficient, may be employed in different 
clustering algorithms. These choose which groups of individuals (clusters) should be 
grouped together at each step in the clustering solution. In this chapter, an average-linkage 
algorithm was used which considered the average dissimilarity between participants of two 
clusters, and combines groups accordingly. Average-linkage algorithms are commonly used, 
reasonably robust, and produce more stable dendrograms.(324,325) 
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During hierarchical cluster analysis, the researcher must consider at what point clusters are 
most meaningful i.e. when individuals within each cluster are similar enough for their 
selected characteristics but the total number of clusters is also small enough to allow for 
intelligible comparison. This process is facilitated by the production of a tree-like 
dendrogram which allows the researcher to observe the overall similarity measure (the 
average within-cluster distance) at each point in the stepwise process. As part of this 
process, I observed points at which there were large leaps in the within-cluster dissimilarity 
between cluster steps, reflecting the algorithm’s “reluctance” to join two clusters together, 
as occurs when there appear to be substantial inter-cluster differences. This was visualised 
by longer drawn out vertical lines on the dendrogram. When such leaps were visible, the 
process was stopped, and the comparative disease and demographic profiles of the 
generated clusters were examined.  To compliment this process, the variance ratio 
criterion, or pseudo F-statistic, was calculated to suggest the optimum number of 
clusters.(326) When the F-statistic was similar at different stop points, the dendrogram was 
observed to make a final decision regarding number of clusters.  
As part of this process, outlying clusters were identified and described. Such clusters are 
usually composed of few or single individuals with marked differences to the majority (e.g. 
rarer disorders). Outlying clusters were defined as those composed of less than 10 
participants and were discarded from further analysis.  
I have previously described how the relative prevalence of CPRD-defined health disorders 
varied between men and women in the study population (see Chapter 5). As a result, I was 
interested in whether the major patterns of multimorbidity also varied by gender. Cluster 
analysis was performed with stratification for men and women, accordingly.  
Participants with chronic MSDs and participants with recent MSD pain tended to cluster 
together since approximately one third (34.9%) of participants with chronic MSDs also had 
recent MSD pain. As I could not rule out that recent MSD pain was a direct result of the 
underlying chronic MSD, and in order to avoid the formation of a meaningless 
musculoskeletal cluster, cluster analysis was run twice for each section of this chapter: first 
using chronic MSDs, then recent MSD pain. The generated clusters were compared.  




Including all cases and controls, there were 988 participants, half of whom had experienced 
HRJL and half who were matched controls. The median age was 58.21 years (IQR 53.36 to 
60.89 years), at the point of analysis. Of these, 44.5% were men, 98.1% were white, 68.9% 
were married, and 7.8% were single. A university-level qualification had been attained by 
22.6% and 19.6% reported having no qualifications. Finally, 35.8% were working in higher 
managerial or professional class occupations, 27.5% in intermediate occupations, and 
36.7% in routine or manual occupations.  
In total, 33.2% had multimorbidity, according to the definition of two or more co-occurring 
CPRD-defined health disorders (or morbidities); this was 38.0% among men and 29.4% 
among women. In total, there were 335 participants with no known health disorders 
(33.9%), 325 participants with one health problem (32.9%), 179 participants with two 
morbidities (18.1%), 103 participants with three morbidities (10.4%), 31 participants with 
four morbidities (3.1%), 12 participants with five morbidities (1.2%), two participants with 
six morbidities (0.2%), and one participant with seven morbidities (0.1%).  
Figure 39: Prevalence of multimorbidity among participants with specific health disorders 
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The proportion of participants with multimorbidity by the number with specific health 
disorders was assessed (see Figure 39). Multimorbidity was present in 58.5% of participants 
with musculoskeletal disorders, 75.1% of participants with hypertension, 72.3% of 
participants with primary-care-level mental health problems, 79.1% of participants with 
diabetes, 73.1% of participants with asthma, 91.4% of participants with heart failure, 88.2% 
of participants with sleep disorders, 76.2% of participants with cerebrovascular accident, all 
participants with COPD, all participants with peripheral atherosclerotic disease, 90.0% of 
participants with psychiatric-level mental health disorders, 60.0% of participants with 
epilepsy, and all participants with arrhythmias, structural heart disease, or venous 
thromboembolism.   
CPRD-defined health disorders were then cross tabulated to find the proportion of 
participants with specific comorbidity pairs (see Appendix, Table 57 and 58). In order of 
frequency, the most common comorbid disease pairs were: musculoskeletal disorders with 
hypertension (n=111, 11.2%); musculoskeletal disorders with primary-care-level mental 
health problems (n=89, 9.0%); diabetes with hypertension (n=46, 4.7%); musculoskeletal 
disorders with diabetes (n=39, 4.0%); primary-care-level mental health problems with sleep 
disorders (n=37, 3.7%); musculoskeletal disorders with asthma (n=34, 3.4%); primary-care-
level mental health problems with hypertension (n=34, 3.4%); musculoskeletal disorders 
with sleep disorders (n=31, 3.1%); hypertension with ischaemic heart disease (n=27, 2.7%); 
musculoskeletal disorders with heart failure (n=24, 2.4%); heart failure with ischaemic heart 
disease (n=26, 2.6%); hypertension with heart failure (n=23, n=2.3%); musculoskeletal 
disorders with ischaemic heart disease (n=22, 2.2%); and hypertension with asthma (n=21, 
2.1%).  
CPRD data on the number of GP consultations attended by all study participants in the year 
prior to the point of analysis was considered. The median number of GP consultations in 
the prior year was four (IQR 1 to 9) ranging from 0 to 35 consultations. Information on the 
number of drug prescriptions issued in the prior year was also available (it is important to 
note that this is not the same as the total number of drugs taken by a patient in the prior 
year and would include repeat prescriptions). Across the total sample, the median number 
of prescriptions issued in the prior year was five (IQR 0 to 18) ranging from 0 to 86 
prescriptions.  
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7.3.2 Cluster analysis of health problems across the total sample 
Performing a cluster analysis of the total population (n=988) resulted in clusters that were 
primarily characterised by the presence of one condition, in addition to one large cluster of 
people with no known health disorders, see Appendix, Tables 59 and 60. This result was 
unsurprising since a sizable proportion of participants had only one known health disorder 
(n=325). However, these generated clusters were uninformative for characterising patterns 
of multimorbidity (overlapping health problems). Multimorbidity, as defined by the 
presence of two or more CPRD-defined health disorders, was common in the study 
population, but it was still unclear what combinations of diseases most frequently 
contributed to this condition. I therefore excluded participants with one or fewer known 
health problems from analysis and performed cluster analysis again, restricted to 
participants with multimorbidity. 
7.3.3 Cluster analysis of health problems among people with multimorbidity 
7.3.3.1 Using chronic MSDs as a measure of musculoskeletal disorders 
An agglomerative hierarchical cluster analysis was performed using average-linkage 
methods and including participants with multimorbidity only.  
Figure 40: Dendrogram of the clustering solution, for participants with multimorbidity 
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Figure 40 shows the resultant dendrogram. On the dendrogram, each vertical line 
represents a cluster at any point in the analysis, each horizontal line represents the merging 
of two clusters to become one. The graph has been simplified by hiding any clustering that 
occurred prior to around 0.5 Jaccard similarity. By observing which clusters are 
geometrically near to one another it was possible to consider which clusters would have 
merged had the clustering solution been permitted to continue for more steps.  
Following the cluster solution, the pseudo F-statistics for each stop point were examined 
(see Table 100). For this analysis, the pseudo F-statistic suggested three possible stop 
points at a similar optimum stop-level with no clear peak. After reviewing the dendrogram, 
the analysis was stopped at six clusters (see orange dashed line, Figure 40). These clusters 
were characterised for their health disorder composition below. 
Table 100: pseudo-F statistic across different stop points in the cluster solution for 



















Two small outlier groups were observed in the cluster solution. These included one cluster 
comprising four people with epilepsy (66.7% of the total number with epilepsy) and 
another made up of five participants with arrythmias (62.5% of the total number with 
arrhythmias). Excluding these, there were four main clusters which are summarised below, 
see Table 101 and Table 102. For a full description of these clusters for their demographics 
and CPRD-defined health disorders, see Tables 63 and 64, Appendix. 
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Cluster A was moderately large (n=88, 32.2% of multimorbid participants). All participants 
in this group had mental health problems, 96.6% of which were primary-care-level MHPs, 
with a 39.8% prevalence of sleep disorders. Additionally, this group contained five 
participants with psychiatric-care-level MHPs, 55.6% of the total number with these 
disorders. 50.0% also had chronic musculoskeletal disorders and 23.9% had hypertension. 
This group was characterised as the MHP-chronic MSD group. The majority in this group 
were case participants (77.3%). 
Cluster B was smaller (n=35, 12.8%). Participants in this cluster all had cardiovascular 
disease, with a 94.3% prevalence of ischaemic heart disease, 74.3% prevalence of heart 
failure, and 62.9% prevalence of hypertension. In addition, 31.4% of participants had 
diabetes (accounting for 15.9% of the total number of multimorbid participants with 
diabetes). This group was characterised as the cardio-metabolic cluster. Most were cases 
(60.0%).  
Cluster C was large (n=109, 39.9%). This cluster was comprised of a majority with chronic 
musculoskeletal disorders (73.4%) and hypertension (77.1%). The prevalence of participants 
with diabetes was also high in this group at 43.12% (68.1% of the total number of 
participants with diabetes). This group was characterised as the chronic MSD-hypertension 
cluster. Most in this cluster were cases (71.6%). 
Lastly, Cluster D was small (n=32, 11.7%). The contributors to this cluster all had respiratory 
disorders. The majority had asthma (93.8%) and 40.6% had COPD, which represents 56.6% 
and 68.4% of the total multimorbid participants with asthma and COPD, respectively. 
Within this cluster, 40.6% had hypertension and 37.5% had primary-care-level mental 
health problems. This group was characterised as the respiratory cluster. Once again, the 
majority were cases (71.9%).  
Table 101: major disease constituents of clusters among people with multimorbidity, 












88 (32.2) 2 (2 – 3) Primary care MHPs (96.6%) 
Chronic musculoskeletal 
disorders (50.0%) 
Sleep disorders (39.8%) 





35 (12.8) 3 (2 – 4) Ischaemic heart disease (94.3%) 
Hypertension (62.9%) 












32 (11.7) 2 (2 – 3) Asthma (93.8%) 
COPD (40.6%) 
Hypertension (40.6%) 
Primary care MHPs (37.5%) 
 
Table 102: major demographics in clusters among people with multimorbidity, using 



















88 (32.2) 57.30 
(54.12 to 
60.17) 
29 (33.0) 68 (77.3) University: 18 (20.5) 
Vocational: 29 (33.0) 
High school: 21 (23.9) 





35 (12.8) 61.13 
(58.50 to 
62.44) 
29 (82.9) 21 (60.0) University: 5 (14.3) 
Vocational: 13 (37.1) 
High school: 5 (14.3) 





109 (39.9) 59.63 
(56.42 to 
61.27) 
61 (56.0) 78 (71.6) University: 17 (15.6) 
Vocational: 44 (40.4) 
High school: 19 (17.4) 





32 (11.7) 57.43 
(53.96 to 
61.37) 
14 (43.8) 23 (71.9) University: 6 (18.8) 
Vocational: 13 (40.6) 
High school: 5 (15.6) 
No qualifications: 8 
(25.0) 
 
7.3.3.2 Using recent MSD pain as a measure of musculoskeletal disorders 
Cluster analysis was run again for participants with multimorbidity, this time using recent 
MSD pain but not chronic MSDs in the analysis, any differences in the results were 
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considered. Excluding outliers, there were five main clusters, which are briefly summarised 
below, see Table 103 and Table 104. For a full description of these clusters for their 
demographics and CPRD-defined health disorders, see Table 65 and 66, Appendix.  
Cluster E was large (n=95, 32.5% of multimorbid participants) and corresponded to Cluster 
C, above, as it was largely composed of participants with hypertension (76.8%) and recent 
MSD pain (77.9%). However, the proportion of participants with diabetes was not as high 
(16.8%) as an extra cluster (Cluster F) formed, which was comprised of diabetes and 
hypertension without recent MSD pain, see below. These two clusters merged in the next 
step of the clustering solution.  
Cluster F was smaller (n=36, 12.3%). This cluster was comprised of participants with 
diabetes, the majority of whom had hypertension (72.2%). In addition, 30.6% of these 
participants had been diagnosed with a recent primary-care level MHP. 
Cluster G was also small (n=35, 12.0%) and corresponded to Cluster B, above. This cluster 
was comprised of participants with majority cardiometabolic disorders, such as ischaemic 
heart disease (97.1%), heart failure (68.6%), hypertension (57.1%), and diabetes (34.3%).  
Cluster H was large (n=110, 37.7%) and corresponded to Cluster A, above. The majority of 
participants in this cluster had primary-care-level MHPs (93.6%) and recent MSD pain 
(53.6%). A large proportion of this cluster also had recent sleep disorders (39.1%).   
Lastly, Cluster I was small (n=12, 4.1%) and corresponded to Cluster D, above. Like Cluster 
D, the majority had asthma (83.3%) and COPD (97.7%). However, unlike Cluster D, Cluster I 
did not have a high prevalence of any other CPRD-defined health disorders.  
Table 103: major disease constituents of clusters among people with multimorbidity, 





Median number of 











36 (12.3) 2 (2 – 3) Diabetes (100.0%) 
Hypertension (72.2%) 
Primary care mental 
health problems (30.6%) 




35 (12.0) 3 (2 – 3) Ischaemic heart disease 
(97.1%) 





110 (37.7) 2 (2 – 3) Primary care mental 
health problems (93.6%) 
Musculoskeletal pain 
(53.6%) 
Sleep disorders (39.1%) 
Cluster I (OPD) 12 (4.1) 2 (2 – 2.5) COPD (97.7%) 
Asthma (83.3%) 
 
Table 104: major demographics in clusters among people with multimorbidity, using 




















95 (32.5) 59.10 
(55.37 – 
61.72) 
56 (59.0) 64 (67.4) University: 12 (12.6) 
Vocational: 44 (46.3) 
High school: 20 (21.1) 





36 (12.3) 59.18 
(54.88 – 
61.01) 
23 (63.9) 26 (72.2) University: 4 (11.1) 
Vocational: 12 (33.3) 
High school: 9 (25.0) 





35 (12.0) 60.09 
(58.39 – 
62.36) 
30 (85.7) 24 (68.6) University: 6 (17.1) 
Vocational: 14 (40.0) 
High school: 5 (14.3) 





110 (37.7) 56.04 
(51.99 – 
60.00) 
35 (85.7) 90 (81.8) University: 27 (24.6) 
Vocational: 34 (30.9) 
High school: 25 (22.7) 




12 (4.1) 61.23 
(58.21 – 
63.99) 
75 (68.2) 6 (50.0) University: 2 (16.7) 
Vocational: 5 (41.7) 
High school: 3 (25.0) 
No qualifications: 2 
(16.7) 
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7.3.4 Cluster analysis of health disorders among multimorbid men 
7.3.4.1 Using chronic MSDs as a measure of musculoskeletal disorders 
To determine whether multimorbidity patterns manifest in the same way among men and 
women, analysis was stratified by sex and cluster analysis was repeated, starting with 
multimorbid men.  
Figure 41: Dendrogram of the clustering solution, for male participants with 
multimorbidity 
 
Following the cluster solution, the pseudo F-statistic suggested five possible optimal cut 
points, but with a clearer peak around 7 (see Table 105). After consideration of the 
dendrogram the analysis was stopped at seven clusters (see orange dashed line, Figure 41). 
These clusters were characterised for their health disorder composition.  






















There were three outlying clusters. These included: a cluster of seven participants with 
chronic MSDs, of whom four also had heart failure; a “cluster” comprised of one participant 
with heart failure and a recent sleep disorder; and a cluster of two participants with 
psychiatric-care level MHPs. Excluding these, there were four main clusters which are 
summarised below, see Table 106 and Table 107. For a full description of these clusters for 
their demographics and CPRD-defined health disorders, see Table 67 and 68, Appendix. 
Cluster J among multimorbid men (n=21, 15.1%) was composed of participants with mental 
health disorders, including primary-care-level MHPs (90.5%) and sleep disorders (52.4%). 
Most also had chronic MSDs (66.7%). The large majority of participants in this group were 
cases (85.7%).  
Cluster K (n=54, 38.9%) contained participants with a high prevalence of hypertension 
(96.30%), chronic MSDs (48.2%), and diabetes (44.4%). Most were cases (72.2%).  
Cluster L (n=37, 26.6%) represented participants with cardio-metabolic conditions including 
83.8% with ischaemic heart disease, 70.3% with heart failure, 62.2% with hypertension, and 
35.1% with diabetes. The majority were cases (62.2%).  
Finally, Cluster M contained people with respiratory disorders and was the smallest cluster 
(n=17, 12.2%). Most participants in this group had asthma (94.1%) however a large 
proportion also had COPD (41.2%), chronic MSDs (41.2%), and hypertension (41.2%). The 
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Table 106: major disease constituents of clusters among multimorbid men, using chronic 









Major disease constituents 
(prevalence >30%) 
Cluster J  
(MHP-cMSD) 




Sleep disorders (52.4%) 
Cluster K  
(HTN-cMSD-diab) 




Cluster L  
(Cardio-metabolic) 
37 (26.6) 3 (2 – 3) Ischaemic heart disease (83.8%) 
Heart failure (70.3%) 
Hypertension (62.2%) 
Diabetes (35.1%) 
Cluster M  
(OPD-HTN-cMSD) 






Table 107: major demographics of clusters among multimorbid men, using chronic MSDs 











Qualification level, n (%) 
Cluster J  
(MHP-cMSD) 
21 (15.1) 56.07 (51.71 
to 62.03) 
18 (85.7) University: 4 (19.1) 
Vocational: 7 (33.3) 
High school: 4 (19.1) 
No qualifications: 4 (19.1) 
Cluster K  
(HTN-cMSD-diab) 
54 (38.9) 58.84 (56.05 
to 60.72) 
39 (72.2) University: 11 (20.4) 
Vocational: 22 (40.7) 
High school: 8 (14.8) 
No qualifications: 11 (20.4) 
Cluster L  
(Cardio-metabolic) 
37 (26.6) 61.13 (58.67 
to 63.47) 
23 (62.2) University: 11 (29.7) 
Vocational: 13 (35.1) 
High school: 6 (16.2) 
No qualifications: 11 (29.7) 
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Cluster M  
(OPD-HTN-cMSD) 
17 (12.2) 59.10 (55.82 
to 63.47) 
12 (70.6) University: 4 (23.5) 
Vocational: 12 (70.6) 
High school: 0 (0.0) 
No qualifications: 4 (23.5) 
 
7.3.4.2 Using recent MSD pain as a measure of musculoskeletal disorders 
Cluster analysis was run again for male participants with multimorbidity, this time using 
recent MSD pain but not chronic MSDs in the analysis, any differences in the results were 
considered.  Excluding outliers, this also resulted in four main clusters, which are briefly 
described below, see Table 108 and Table 109. For a full description of these clusters for 
their demographics and CPRD-defined health disorders, see Table 69 and 70, Appendix.  
Cluster N was moderate sized (n=64, 41.6% of male multimorbid participants) and 
corresponded to Cluster K, above, as it was largely composed of participants with 
hypertension (73.4%) and recent MSD pain (62.5%), with a high prevalence of diabetes 
(43.8%).  
Cluster O was smaller (n=31, 20.1%). This cluster corresponded to Cluster L, above, and was 
comprised of participants with cardio-metabolic conditions. These included ischemic heart 
disease (96.8%), heart failure (67.7%), hypertension (54.8%), diabetes (35.5%), and 
structural heart disease (12.9%). 
Cluster P was also small (n=36, 12.0%) and corresponded to Cluster J, above. This cluster 
contained a high proportion of participants with primary care-level MHPs, many of whom 
also had musculoskeletal pain (44.4%), and sleep disorders (25.0%). However, unlike Cluster 
J, Cluster P also had a high prevalence of hypertension (38.9%). 
Cluster Q was small (n=19, 12.3%) and corresponded well to Cluster M, above. Like Cluster 
M, the majority of participants in this cluster had asthma (94.7%) or COPD (36.8%), with a 
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Table 108: major disease constituents of clusters among multimorbid men, using recent 









Major disease constituents 
(prevalence >30%) 
Cluster N  
(MSpain-HTN-Diab) 
64 (41.6) 2 (2 – 3) Musculoskeletal pain (62.5%) 
Hypertension (73.4%) 
Diabetes (43.8%) 
Cluster O  
(Cardio-metabolic) 
31 (20.1) 3 (2 – 4) Ischaemic heart disease (96.8%) 
Heart failure (67.7%) 
Hypertension (54.8%) 
Diabetes (35.5%) 
Cluster P  
(pcMHP-MSpain-HTN) 
36 (23.4) 2 (2 – 3) Primary care mental health 
problems (100.0%) 
Musculoskeletal pain (44.4%) 
Hypertension (38.9%) 
Cluster Q  
(OPD-MSpain-HTN) 
19 (12.3) 2 (2 – 3) Asthma (94.7%) 




Table 109: major demographics of clusters among multimorbid men, using recent MSD 








HRJL, n (%) 




64 (41.6) 59.29 (55.98 
– 61.29) 
44 (68.8) University: 11 (17.2) 
Vocational: 28 (43.8) 
High school: 15 (23.4) 








University: 6 (19.4) 
Vocational: 12 (38.7) 
High school: 5 (16.1) 




36 (23.4) 55.90 (50.44 
– 60.05) 
29 (80.6) University: 9 (25.0) 
Vocational: 11 (30.6) 
High school: 7 (19.4) 




19 (12.3) 59.45 (54.19 
– 63.70) 
12 (63.2) University: 2 (10.5) 
Vocational: 13 (68.4) 
High school: 1 (5.3) 
No qualifications: 3 (15.8) 
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7.3.5 Cluster analysis of health disorders among multimorbid women 
7.3.5.1 Using chronic MSDs as a measure of musculoskeletal disorders 
As with the multimorbid men, cluster analysis was restricted to multimorbid women and 
run again to assess common patterns of co-occurring health disorders among women.  
Figure 42: Dendrogram of the clustering solution, for female participants with 
multimorbidity 
 
The cluster solution for multimorbid women produced the dendrogram seen in Figure 42. 
Following this analysis, the pseudo F-statistic clearly suggested that three clusters was the 
optimal cut point (see Table 110). These clusters are characterised below. Given the small 
overall number of clusters I also looked for any important sub-clusters, using the 
dendrogram as guide.  























There was one outlying group which did not merge with other groups until late in the 
clustering solution. This group comprised four participants with COPD, three of whom had 
asthma and two who had heart failure. Since it was difficult to derive useful information 
from this small cluster it was excluded from further analysis. This left two main clusters 
which are summarised below, see Table 111 and Table 112. For a full description of these 
clusters for their demographics and CPRD-defined health disorders, see Table 71 and 72, 
Appendix. 
Cluster R (n=71, 53.0%) could be characterised by its high prevalence of hypertension 
(77.5%) and chronic MSDs (64.8%). A significant proportion also had diabetes (32.4%), 
primary care-level MHPs (25.4%), and asthma (23.9%). Four major sub-clusters were 
observed, three of which were small and comprised of four, nine, and two participants, 
respectively. The first sub-cluster was the largest and composed of participants who mostly 
had hypertension (n=91.1%) and chronic musculoskeletal disease (67.9%). This group also 
contained a significant proportion of participants with asthma (26.8%), diabetes (21.4%), 
and primary care level MHPs (25.0%). As a consequence of its size, it was the major driver 
of the characteristics of the larger cluster it contributed to. The second sub-cluster 
comprised four participants, all with hypertension, three with heart failure, two with 
cerebrovascular accident, and two with diabetes. The next sub-cluster was composed of 
nine participants with diabetes, six of whom also had a chronic MSD, and four with a 
primary-care-level MHPs. The last sub-cluster had two participants with chronic MSDs, one 
with comorbid cerebrovascular accident and another with comorbid epilepsy. Most 
participants in Cluster R were cases (71.8%).  
Cluster S (n=59, 44.0%) was characterised by a high prevalence of mental health disorders 
(94.9%) including primary-care-level MHPs (94.9%) and sleep disorders (47.5%), primarily. 
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Once again, the prevalence of chronic MSDs was relatively high (42.4%). Three sub-clusters, 
contributing to this broad cluster group, were observable. The larger sub-cluster (n=51) was 
similar to the broad group; all members had mental health disorders, including 98.0% with 
primary care-level MHPs, and 51.0% with sleep disorders, also 45.1% in this sub-cluster had 
chronic MSDs. The second sub-cluster was small (n=5) and contained participants with 
ischaemic heart disease and heart failure, three participants in this sub-cluster had mental 
health disorders and two had chronic MSDs. Lastly, the third sub-cluster contained three 
participants with epilepsy (75% of all multimorbid women with epilepsy). Once again, the 
majority in Cluster S were cases (74.6%).  
Table 111: Major disease constituents of clusters among multimorbid women, using 









Major disease constituents 
(prevalence >30%) 
Cluster R  
(HTN-cMSD-diab) 




Cluster S  
(MHP-cMSD) 
59 (44.0) 2 (2 – 3) Primary care mental health 
problems (93.2%) 




Table 112: Major demographics of clusters among multimorbid women, using chronic 









with HRJL, n 
(%) 




71 (53.0) 59.86 (56.42 
– 61.48) 
51 (71.8) University: 11 (15.5) 
Vocational: 27 (38.0) 
High school: 13 (18.3) 
No qualifications: 20 (28.2) 
Cluster S 
(MHP-cMSD) 
59 (44.0) 56.80 (52.65 
– 60.00) 
44 (74.6) University: 7 (11.9) 
Vocational: 19 (32.2) 
High school: 15 (25.4) 
No qualifications: 18 (30.5) 
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7.3.5.2 Using recent MSD pain as a measure of musculoskeletal disorders 
Cluster analysis was run again for female participants with multimorbidity, this time using 
recent MSD pain but not chronic MSDs in the analysis.  Excluding outliers, this also resulted 
in two main clusters, which are briefly described below, see Table 113 and Table 114. For a 
full description of these clusters for their demographics and CPRD-defined health disorders, 
see Table 73 and 74, Appendix.  
Cluster T was moderate sized (n=67, 48.6% of female multimorbid participants) and 
corresponded to Cluster R, above. It was largely composed of participants with 
hypertension (80.6%) and recent MSD pain (56.7%), with a high prevalence of diabetes 
(28.4%), primary care level MHPs (29.9%), and asthma (29.9%).  
Cluster U was also moderate sized (n=62, 44.9%) and corresponded to Cluster S, above. The 
majority of participants in this cluster had primary care-level MHPs (98.4%) and recent MSD 
pain (54.8%). The prevalence of recent sleep disorders was also high (45.2%).  
Table 113: Major disease constituents of clusters among multimorbid women, using 









Major disease constituents 
(prevalence >30%) 
Cluster T  
(HTN-MSpain) 
67 (48.6) 2 (2 – 3) Hypertension (80.6%) 
Musculoskeletal pain (56.7%) 
Cluster U  
(MHP-MSpain) 
62 (44.9) 2 (2 – 3) Primary care mental health 
problems (98.4%) 
Musculoskeletal pain (54.8%) 
Sleep disorders (45.2%) 
Table 114: Major demographics of clusters among multimorbid women, using recent MSD 











Qualification level, n (%) 
Cluster T 
(HTN-MSpain) 
67 (48.6) 59.06 (55.24 
– 61.21) 
49 (73.1) University: 6 (9.0) 
Vocational: 25 (37.3) 
High school: 16 (23.9) 




62 (44.9) 56.28 (52.35 
– 60.00) 
50 (80.7) University: 15 (24.2) 
Vocational: 19 (30.7) 
High school: 16 (25.8) 
No qualifications: 12 (19.4) 
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7.3.6 Cluster analysis of health disorders among people with musculoskeletal 
disorders (recent pain or chronic) 
Because of sample size limitations, and since the observed clustering behaviours of chronic 
MSDs and recent MSD pain were similar, I combined chronic MSD and recent MSD pain 
groups to look for multimorbidity (or comorbidity) patterns among participants with 
musculoskeletal disorders. Cluster analysis was restricted to people with chronic MSDs or 
recent MSD pain and run again.   
Figure 43: Dendrogram of the clustering solution, for participants with musculoskeletal 
disorders 
 
The cluster solution for participants with musculoskeletal disorders produced the 
dendrogram seen above (Figure 43). Following this analysis, the pseudo F-statistic 
promoted the stopping point of 2 clusters (Table 115), however, stopping analysis here 
would have resulted in two groups: people with musculoskeletal disorders with 
comorbidities and without comorbidities. A stopping point of 13 or 14 was also suggested, 
however, as observed in Section 7.3.2, this would have resulted in many smaller clusters 
characterised by the presence of one other health problem, a result that could be achieved 
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with the use of simple cross tabulations and would have been uninformative for 
deciphering common patterns of comorbidity. I therefore stopped the analysis at a smaller 
number of clusters to look for common groups of co-occurring disorders. The pseudo F-
statistic suggested eight clusters as offering the next best variance ratio criteria, therefore, I 
chose this as the stop point (see orange dashed line, Figure 43). The generated clusters are 
characterised below.  
Table 115: Pseudo-F statistic across different stop points in the cluster solution for people 



















Three small outlier groups were observed in the cluster solution. One cluster contained 
three participants with COPD, another “cluster” contained one person with a cardiac 
arrythmia, and another was comprised of three participants with cerebrovascular accident. 
Excluding these, there were five main clusters which are summarised below, see Table 116 
and Table 117. For a full description of these clusters for their demographics and CPRD-
defined health disorders, see Table 75 and 76, Appendix. 
Cluster V was the cluster on the far right-hand side on the dendrogram (Figure 43). This 
cluster comprised participants with musculoskeletal disorders, and no other known 
comorbid health problems (n=159, 41.5%). 56.6% of these participants had a chronic MSD 
and 61.6% had recent MSD pain. Since all participants in this group were identical from the 
perspective of known health disorders, this group was resistant to merge with the other 
clusters and merged last. Most participants in this cluster (56.6%) did not report HRJL (were 
controls). 
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Cluster W was large (n=96, 25.1%) and contained participants with a high prevalence of 
comorbid hypertension (87.5%). 61.5% of these participants had a chronic MSD and 60.4% 
had recent MSD pain. The prevalence of other cardiometabolic conditions was also high in 
this group. For example, 33.3% had comorbid diabetes, 10.4% had comorbid heart failure, 
12.5% had comorbid ischaemic heart disease, and 4.2% had comorbid peripheral 
atherosclerotic disease. Most participants in Cluster W were cases (62.5%). 
Cluster X was small (n=25, 6.5%) and the majority had comorbid asthma (96.0%). Chronic 
MSDs were present in 64.0% and recent MSD pain in 56.0%. In addition, 36.0% of this group 
had comorbid hypertension and 12.0% had comorbid ischaemic heart disease. Most 
participants were cases (68.0%). 
Cluster Y was large (n=86, 22.5%) and most of these participants had comorbid primary 
care-level MHPs (91.9%). Recent MSD pain was present in 69.8% and chronic MSDs in 
50.0%. A large proportion of this cluster also had comorbid sleep disorders (34.9%) and 
comorbid hypertension (19.8%). The large majority were cases (83.7%). 
Cluster Z was very small (n=10, 2.6%) and contained nine participants with comorbid heart 
failure, and five participants with comorbid ischemic heart disease, although no participants 
with hypertension. Five of these participants had a chronic MSD and seven had recent MSD 
pain. Seven participants in this group were cases. 










Major disease constituents 
(prevalence >30%) 
Cluster V (MSD alone) 159 (41.5) 1 (1 – 1) Musculoskeletal disorders 
alone (100.0%) 
Cluster W (HTN-Diab) 96 (25.1) 2 (2 – 3) Hypertension (87.5%) 
Diabetes (33.3%) 
Cluster X (Asthma-HTN) 25 (6.5) 3 (2 – 3) Asthma (96.0%) 
Hypertension (36.0%) 
Cluster Y (MHP) 86 (22.5) 3 (2 – 3) Primary care-level MHP 
(91.9%) 
Sleep disorders (34.9%) 
Cluster Z (Cardio-
metabolic) 
10 (2.6) 3 (2 – 4) Heart failure (90.0%) 
Ischaemic heart disease 
(50.0%) 
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Median age, y 
(IQR) 
Proportion 
with HRJL, n 
(%) 
Qualification level, n (%) 
Cluster V 
(MSD alone) 
159 (41.5) 58.10 (53.36 – 
60.99) 
69 (43.4) University: 35 (22.0) 
Vocational: 70 (44.0) 
High school: 23 (14.5) 
No qualifications: 31 (19.5) 
Cluster W 
(HTN-Diab) 
96 (25.1) 59.72 (55.98 – 
61.39) 
60 (62.5) University: 14 (14.6) 
Vocational: 42 (43.8) 
High school: 18 (18.8) 




25 (6.5) 59.45 (56.07 – 
61.85) 
17 (68.0) University: 4 (16.0) 
Vocational: 12 (48.0) 
High school: 3 (12.0) 
No qualifications: 6 (24.0) 
Cluster Y 
(MHP) 
86 (22.5) 55.99 (52.36 – 
60.07) 
72 (83.7) University: 17 (19.8) 
Vocational: 29 (33.7) 
High school: 21 (24.4) 




10 (2.6) 60.59 (57.26 – 
62.13) 
7 (70.0) University: 0 (0.0) 
Vocational: 4 (40.0) 
High school: 3 (30.0) 
No qualifications: 3 (30.0) 
 
7.4 Summary of results 
• Among participants with multimorbidity, there were four main clusters, including: a 
large cluster of participants with mental health disorders and MSDs, primarily; a 
small cluster of participants with ischaemic heart disease, heart failure, and 
hypertension primarily; a large cluster of participants with hypertension and MSDs, 
primarily; and a small cluster of participants with asthma and COPD, primarily. 
Formed clusters were similar regardless of whether chronic MSDs or recent MSD 
pain was used in analysis.  
• Among male multimorbid participants, there were four main clusters, including: a 
cluster of participants with mental health disorders and MSDs, primarily; a cluster 
of participants with hypertension, diabetes, and MSDs, primarily; a cluster of 
participants with cardio-metabolic disorders, primarily; and a cluster of participants 
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with asthma, COPD, MSDs, and hypertension, primarily. Formed clusters were 
similar regardless of whether chronic MSDs or recent MSD pain was used in 
analysis. 
• Among female multimorbid participants, there were two main clusters, including: a 
cluster of participants with hypertension and MSDs, primarily; and a cluster of 
participants with mental health disorders and chronic MSDs, primarily.  Formed 
clusters were similar regardless of whether chronic MSDs or recent MSD pain was 
used in analysis. 
• Among participants with musculoskeletal disorders (chronic or recent pain), there 
were five main clusters of comorbid disorders, the largest of which was formed by 
participants with musculoskeletal disorders without known comorbidities. 
Otherwise, the following clusters were identified: a large cluster of participants 
with comorbid hypertension, primarily; a small cluster of participants with 
comorbid asthma, primarily; a large cluster of participants with comorbid mental 
health problems, primarily; and a very small cluster of participants with other 
comorbid cardiometabolic disorders, primarily.  
7.5 Discussion  
The most frequently occurring pairs of health disorders in the study sample were 
musculoskeletal disorders (chronic or pain) with hypertension, followed by musculoskeletal 
disorders (chronic or pain) with primary-care level MHPs, then diabetes with hypertension. 
In cluster analysis, among participants with two or more health problems, the most 
commonly occurring disease clusters were hypertension-musculoskeletal and mental health 
disorder-musculoskeletal groups, which together included over two thirds of all 
multimorbid participants. The musculoskeletal-mental health cluster was more prominent 
among women than men, while among men a cardio-metabolic cluster was also apparent, 
reflecting the relative prevalence of these conditions in these sub-populations.   
A quick description of participants by number of health conditions revealed that 
approximately a third had no known health disorders, and of those with known health 
disorders, approximately half had only one. This was reflected in the cluster analysis of the 
total sample in which prominent clusters tended to form around the presence or absence 
of single conditions. Multimorbidity, by the definition used in this chapter, was present in 
approximately a third of all participants (33.2%). It is difficult to compare this prevalence 
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figure to those reported in the literature, which are often based on very different 
classifications of multimorbidity (using different constituent diseases, for instance), and 
therefore have highly variable estimates (12.9% to 95.1%).(164)  
In cluster analysis of participants with multimorbidity, prominent groups formed more 
clearly into “body systems.” For example, sleep disorders and primary-care level MHPs 
tended to cluster together, as did cardio-metabolic disorders, and respiratory disorders 
(asthma and COPD). Chronic musculoskeletal disorders, and recent musculoskeletal pain, 
were found to commonly cluster with mental health disorders and also with hypertension. 
These clusters were only generated among people with two or more conditions; there was 
also a significant proportion of participants with chronic musculoskeletal disorders, 
hypertension, and primary-care-level mental health problems who did not have other 
known health disorders.  
Comparisons between these findings and those of existing population-based research, 
examining common patterns of multimorbidity, are hampered by the considerable 
heterogeneity in the literature. Studies differ for number, demographics, and selectivity of 
recruited participants; the data sources and classifications used to define health disorders; 
the number of health disorders considered; and the statistical techniques used (cluster and 
factor analysis are common approaches used). Nevertheless, a well-cited systematic review 
of 14 such studies (Prados-Torres, 2014) found three broad patterns, or clusters, of diseases 
were commonly reported: 1) cardiovascular and metabolic disease clusters 2) disorders 
related to mental health and 3) disorders related to musculoskeletal problems.(442) 
Importantly, little of the reviewed work was age- or sex-stratified, and no studies had a 
focus on the older-working-age population.  
The results reported in this chapter show some similarities. For instance, mental health 
disorders were observed to naturally cluster together, as did cardiovascular-metabolic 
disorders. By design, the formation of a musculoskeletal disease cluster was prohibited 
since only one MSD variable was entered into cluster analysis at a time (see Section 7.2.2). 
However, this made it possible to observe how musculoskeletal disorders (the focus of this 
thesis) commonly overlap with other prominent disease clusters. Results showed that when 
musculoskeletal disorders form clusters with non-musculoskeletal conditions, they form 
them commonly with mental health disorders and with cardio-metabolic disorders, 
particularly hypertension.  
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Another systematic review, including primary care populations only, considered other 
aspects of multimorbidity including its overall prevalence and the frequency of specific 
comorbidity pairs.(164)  This review found that osteoarthritis with hypertension constituted 
the most common comorbidity in primary care, a relationship largely driven by the high 
individual prevalence of these two conditions. The common clustering of pain conditions 
(such as chronic musculoskeletal disorders) with mental health disorders was also 
highlighted in some studies.(443–445) In this chapter, hypertension with musculoskeletal 
disorders (many of whom had osteoarthritis - see Chapter 5) was also the most frequently 
occurring comorbidity pair, followed by musculoskeletal disorders with primary-care-level 
mental health disorders. In cluster analysis of multimorbid participants, the hypertension-
musculoskeletal clusters and mental health-musculoskeletal clusters were also the largest 
clusters.  
In cluster analysis, large clusters formed by common health disorders may obscure the 
existence of smaller naturally occurring clusters. However, two smaller clusters were 
observed among multimorbid participants, including an asthma-COPD cluster and a cluster 
composed of cardio-metabolic disorders alone. The cardio-metabolic cluster was driven 
primarily by ischaemic heart disease, heart failure, and hypertension. This likely reflects the 
particularly strong pathogenetic relationship shared by these conditions, since 
hypertension is a major risk factor for coronary heart disease(446) and ischaemic heart 
disease is the most common underlying cause of heart failure.(447) The relationship 
between asthma and COPD is more surprising, since these are etiologically distinct 
conditions, but could be explained by misdiagnosis, common among older patients,(448) or 
the so called “overlap syndrome” between the two disorders.(449)  
Sub-group analysis of multimorbid participants by sex found mental health disorder-
musculoskeletal clusters, and hypertension-musculoskeletal clusters in both men and 
women, as in the broader sample. However, a cluster of cardio-metabolic disorders was 
observed among men, but not women. Additionally, the proportion of women in the 
mental health disorder-musculoskeletal clusters was also considerably larger than the 
corresponding clusters among men. These differences are likely driven by the significantly 
greater prevalence of structural cardiovascular disorders among men in this age 
group,(236) and the greater prevalence of diagnosed anxiety and depression among 
women across most age groups.(235)  
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Surprisingly few differences were observed between chronic MSDs or recent MSD pain in 
cluster analysis. Generated clusters were similar in size and composition regardless of 
which musculoskeletal variable was used, both in cluster analysis of multimorbid 
participants and after stratification by gender. It was reasonable, therefore, to combine 
these groups and look for clusters of comorbidities that commonly occur in the MSD 
population as a whole. The generated clusters mirrored those which occurred in the wider 
study sample: There was a large cluster of participants with comorbid hypertension, 
primarily; a small cluster of participants with comorbid asthma, primarily; a large cluster of 
participants with comorbid mental health problems, primarily; and a very small cluster of 
participants with other comorbid cardiometabolic disorders, primarily. 
It was beyond the scope of this piece of work to study why certain conditions co-occur; 
rather the purpose of this chapter was to show how health disorders group together in the 
older working-age population, and which specific disorders are most commonly observed 
together. The use of cluster analysis, to achieve this, has strengths. These techniques use 
mathematical relationships that are data driven, rather than reliant upon biological or 
clinical assumptions, to provide new insight into relationships which are not fully 
understood. They also allow the exploration of complex data in a new way. For example, 
the prevalence of specific disease pairs in a population could be described using simple 
cross-tabulations; however, this task becomes precipitously more complex the more 
overlapping diseases are considered. Statistical techniques such as cluster analysis and 
factor analysis can help cut through this complexity to identify common comorbidity groups 
of varying size and composition.  
However, a weakness of both cluster analysis and factor analysis is that the selection of 
defining variables, or clustering analysis options (e.g. similarity measures and clustering 
algorithms), can strongly influence the resultant clusters or factors. Additionally, a cluster 
analysis will always create clusters, even regardless of the existence of any actual patterns 
in the data. Therefore, there is an inherent assumption in the interpretation of such 
clusters that the observed patterns are based on some underlying structure. Strong 
conceptual support and validation is required to evidence the existence of such patterns. I 
performed a manner of internal validity of the cluster analysis by running Calinski-Harabasz 
criterion to suggest the most distinct clusters possible.(326) In addition, there was strong 
conceptual support, and some external validity, since the groups identified in this chapter 
had similarities to those found in existing systematic reviews.(164,442) Finally, generated 
clusters remained stable regardless of whether a recent musculoskeletal pain or chronic 
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MSD classification of MSDs was used. It would have also been desirable to re-run results in 
a randomly split or comparable dataset,(325) however, sample-size constraints meant such 
cross-validation methods were unfeasible. 
In conclusion, the descriptive analyses outlined in this chapter reveals a high degree of 
multimorbidity in this older working age sample. Results suggest that the studied health 
disorders should not be viewed in isolation when assessing their role as catalysts of adverse 
work outcomes in older workers. Specifically, researchers and policymakers considering 
work outcomes and musculoskeletal disorders should be aware that these conditions 
frequently overlap with mental health problems and hypertensive disorders. An increased 
focus on multimorbidity will promote holistic work solutions for older working-age patients 
in a system that too often targets single illnesses alone. The findings of this chapter also 
lend themselves to a study of the relationship between common multimorbidity clusters 
and health-related job loss.   
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Chapter 8 - the impact of 
multimorbidity upon HRJL 
8.1 Introduction 
In the previous chapter, participants were described for patterns of multimorbidity. The 
work of this chapter moves beyond the study of individual diseases and their association 
with HRJL (as studied in Chapter 6) and focusses on the relationship between 
multimorbidity and HRJL. This topic is especially important in the older working-age 
population, in whom up to a half have been found to be multimorbid.(153) However, the 
relationship between multimorbidity and premature exit from work for health reasons 
remains understudied. In this chapter, cases and controls will be compared for four specific 
indicators of multimorbidity, including: the number of known CPRD-defined health 
disorders, the number of drug prescriptions in the prior year, the number of GP 
consultations attended in the prior year, and lastly the presence of disease clusters, as 
defined in the prior chapter. The role of gender as a mediator of this relationship is 
considered. Additionally, the impact of comorbidity on the relationship between MSDs and 
HRJL is also explored. This work will address Research Objectives 5 and 6 of this thesis (see 
Chapter 2). 
Figure 44: the cohort studied in this chapter, as indicated by the red square 
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8.2 Methods  
Descriptive analysis 
To begin, the total study population were described for their demographic, lifestyle and 
occupational factors and for the overall prevalence of CPRD-defined health disorders. In 
addition, participants with MSDs (chronic or pain) specifically were described, since they 
form a focus of this chapter. I used proportions to describe categorical data and medians 
and inter-quartile ranges to describe continuous data with non-Gaussian distributions.   
Cases and controls were then compared for the proportion with multimorbidity. 
Multimorbidity was defined as the presence of two or more of the following CPRD-defined 
health disorders: structural heart disease, hypertension, heart failure, ischaemic heart 
disease, venous thromboembolism peripheral atherosclerosis, cardiac arrhythmias, primary 
care mental health problem, psychiatric mental health problem, sleep disorder, COPD, 
asthma, CVA, epilepsy, diabetes, or a musculoskeletal disorder (chronic or pain). 
Additionally, with each health disorder weighted equally as 1, cases and controls were 
described and analysed for “number of health disorders.” Participants with MSDs were 
described for the number of known comorbid health problems. These included the non-
musculoskeletal CPRD-defined health disorders, as listed above. Each of these was 
weighted equally as 1, and case and control participants with MSDs were described for 
“number of comorbidities.”  
The number of GP consultations in the prior year and number of drug prescriptions in the 
prior year were described using medians and interquartile ranges (IQR). These were then 
categorised by quartiles and cases and controls were compared for their exposure to these 
variables. It was unknown for what reason a participant had attended their GP practice, or 
the specific indication of the drug prescribed, however, these measures gave some 
indication of overall disease burden: number of GP consultations is a crude measure of 
disease burden as it relates to the attendance of multiple appointments to manage health; 
and number of drugs prescribed in the prior year also reflects treatment burden and is 
related to polypharmacy. Available drug prescription information was limited to health 
disorders of interest. For example, drug prescriptions relating to musculoskeletal and pain 
disorders, cardiovascular disorders, mental health disorders, diabetes, asthma, COPD, and 
epilepsy were known but there was no information relating to prescriptions for 
gastrointestinal problems, cancer or other health disorders for which there was no CPRD-
information available in the current study.  
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Lastly, cases and controls were described for their disease cluster categories, as defined in 
the previous chapter. This included clusters that were generated from all participants with 
multimorbidity; from men with multimorbidity; from women with multimorbidity; and from 
participants with musculoskeletal disorders. 
Conditional logistic regression 
I used conditional logistic regression analyses to assess the association between 
multimorbidity and the occurrence of HRJL. The analysis took case and control matched 
pairs into account; all associations found were therefore independent of age, gender, and 
GP practice (see Chapter 3).  
Exposures of interest were first assessed in univariable analysis, then with statistical 
adjustment for important confounders. Known demographic and lifestyle factors which 
might confound the relationship between multimorbidity and HRJL included educational 
attainment, single relationship status, and history of heavy alcohol intake (see Chapter 6). 
Therefore, these factors were adjusted for in multivariable analysis. As previously, sub-
group analysis was undertaken for men and women to assess whether the impact of 
multimorbidity on HRJL was modified by gender.  
For conditional logistic regression of disease clusters, dummy variables were generated for 
each cluster and for participants with no known health disorders. Each generated cluster 
was then assessed for its relationship to HRJL, with no known health disorders as the 
reference group. Disease clusters generated among multimorbid men and multimorbid 
women were also assessed for their relationship to HRJL. In this case, the reference 
populations were men with no known health disorders and women with no known health 
disorders, respectively.   
Analysis of musculoskeletal disorders, comorbidity, and HRJL 
Conditional logistic regression was used to assess the association between musculoskeletal 
disorders and HRJL, stratified by number of comorbidities. Participants with no known 
health disorders were the reference group. Subgroup analysis using participants with 
chronic musculoskeletal disorders and recent musculoskeletal pain was also performed 
here. 
Finally, I considered the prominent comorbidity clusters generated among participants with 
musculoskeletal disorders (see Chapter 7, Section 7.3.6.). Conditional logistic regression 
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was used to assess the association between musculoskeletal disorders and HRJL, stratified 
by these comorbidity clusters. Once again, participants with no known health disorders 
were the reference group.  
Throughout , qualitative descriptors were used to distinguish the strength of association 
using Cohen’s classification scheme and Rosenthal’s later extension for odds ratios(405) as 
follows: about 1.5 to 1 defined as a small effect, about 2.5 to 1 as a moderate effect, about 
4 to 1 as a strong effect, and about 10 to 1 as a very strong effect.  
8.3 Results 
8.3.1 Describing total study participants, and participants with MSDs 
8.3.1.1 Demographics 
The 988 study participants have been described previously. In brief, half were cases with 
HRJL and half were matched controls. The median age was 58.21 years (IQR 53.36 to 60.89 
years), at the point of analysis. 44.5% were men, 98.1% were white, 68.9% were married, 
and 7.8% were single. 22.6% had a university-level qualification and 19.6% had no 
qualifications. Finally, 35.8% were working in higher managerial or professional class 
occupations, 27.5% in intermediate occupations, and 36.7% in routine or manual 
occupations.  
Of these, 383 (38.8%) had CPRD-defined musculoskeletal disorders. These participants had 
a median age of 58.53 years (IQR 54.08 to 61.08) at the point of HRJL and were majority 
female (55.3%). Most were married (69.5%), 17.6% divorced, 6.1% widowed, and only 6.8% 
single. Most had vocational/higher professional qualifications (42.6%), while 21.2% had no 
qualifications, 18.5% had a university level degree, and 17.8% had high-school level 
qualifications. These participants most commonly worked, or had worked, routine 
occupations (41.7%), with 32.2% in managerial roles, and 26.1% in intermediate 
occupations.  
Chronic musculoskeletal disorders and recent musculoskeletal pain sub-groups were 
broadly similar for demographic factors, although there were a slightly greater proportion 
of women and widowed among participants with chronic MSDs. People with chronic MSDs 
were also slightly older, on average, than those with recent MSD pain, see Table 118, 
below. Participants with chronic MSDs and recent MSD pain were also similar for 
occupational SOC-10 sub-major categories, although due to the limited number of 
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participants, clear differences were hard to observe. There appeared to be a slightly greater 
proportion of people in sales occupations (11.5% vs 7.9%) among participants with chronic 
MSDs, which could be as a result of the slightly higher proportion of women in this group. A 
full description of participants with MSDs for SOC-10 sub-major occupational categories, 
stratified by type of MSD, can be found in Table 77, Appendix.  
Table 118: Demographic factors of study participants and participants with MSDs 
(stratified by type of MSD) 


















with MSD pain, 
n (%) 
Total 998 (100.0) 383 (38.8) 218 (22.1) 241 (24.4) 








57.83 (52.65 to 
61.03) 
Sex (m) 440 (44.5) 158 (41.3) 84 (38.5) 108 (44.8) 
Ethnicity (white) 969 (98.1) 375 (97.9) 215 (98.6) 234 (97.1) 
Married/Civil 
partnership 
674 (68.9) 264 (69.5) 153 (70.2) 169 (71.0) 
Single 76 (7.8) 26 (6.8) 9 (4.1) 19 (8.0) 
Divorced 54 (5.5) 67 (17.6) 38 (17.4) 42 (17.7) 
Widowed 175 (17.9) 23 (6.1) 18 (8.3) 8 (3.4) 
University degree 223 (22.6) 71 (18.5) 40 (18.4) 43 (17.8) 
Vocational/higher 
professional 
387 (39.2) 163 (42.6) 93 (42.7) 103 (42.7) 
High school 
qualifications 
184 (18.6) 68 (17.8) 34 (15.6) 45 (18.7) 
No qualifications 194 (19.6) 81 (21.2) 51 (23.4) 50 (20.8) 
Managerial Occupation 348 (35.8) 122 (32.2) 69 (31.9) 77 (32.2) 
Intermediate 
Occupation 
268 (27.5) 99 (26.1) 54 (25.0) 65 (27.2) 
Routine Occupation 257 (36.7) 158 (41.7) 93 (43.1) 97 (40.6) 
 
8.3.1.2 The prevalence of health disorders and comorbidities  
The prevalence of CPRD-defined health disorders in the total study sample has been 
described previously. In brief, 22.1% had chronic MSDs, 24.4% had recent MSD pain, 17.9% 
had primary care level MHPs, 1.0% had psychiatric care level MHPs, 5.2% had recent sleep 
disorders, 22.0% had hypertension, 5.2% had ischaemic heart disease, 5.9% had heart 
failure, 0.7% had structural heart disease, 1.2% had peripheral atherosclerotic disease, 0.1% 
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had venous thromboembolic disease, 0.8% had cardiac arrhythmias, 7.9% had asthma, 2.0% 
had COPD, 2.1% had cerebrovascular accident, 1.0% had epilepsy, and 9.2% had diabetes. 
The prevalence of multimorbidity (two or more CPRD-defined health disorders) was 33.2%.  
In general, participants with MSDs had a high prevalence of comorbidity (defined as the 
presence of another CPRD-defined health disorder) which was 58.7% among people with 
chronic MSDs and 59.3% among people with recent MSD pain. Among participants with 
chronic MSDs, 41.3% had no comorbidities, 26.2% had one comorbidity, 24.3% had two 
comorbidities, and 8.3% had three or more comorbidities. Among people with recent MSD 
pain, 40.7% had no comorbidities, 31.5% had one comorbidity, 17.0% had two 
comorbidities, and 10.8% had three or more comorbidities. Musculoskeletal disorders 
commonly presented among participants with an existing CPRD-defined health disorder 
(45.3%) and in the majority of those with multimorbidity (68.3%). See Figure 45.  
Figure 45: proportional Venn diagram showing the proportion of participants with MSDs, 
the proportion with two or more conditions (multimorbidity) and the proportion with 
MSDs and multimorbidity, in the total sample. Area on the chart corresponds to 
proportion of participants.        
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Among people with musculoskeletal disorders, hypertension was the most prevalent 
comorbidity (29.0%), followed by primary-care-level mental health problems (23.2%), 
diabetes (10.2%), asthma (8.9%), sleep disorders (8.1%), heart failure (6.3%), and ischaemic 
heart disease (5.7%). Comparing participants with chronic musculoskeletal disorders and 
those with recent musculoskeletal pain, the prevalence of specific comorbidities was 
similar, although there appeared to be a slightly higher prevalence of participants with 
diabetes among the chronic musculoskeletal disease group (12.4% vs 8.3%). See Table 119, 
below. 
Table 119: A description of the prevalence of CPRD-define health disorders (other than 




















pain, n (%) 
Primary care level MHPs 117 (17.9) 89 (23.2) 48 (22.0) 59 (24.5) 
Psychiatric care level 
MHPs 
10 (1.0) 6 (1.6) 4 (1.8) 5 (2.1) 
Sleep disorders 51 (5.2) 31 (8.1) 21 (9.6) 17 (7.1) 
Hypertension 217 (22.0) 111 (29.0) 63 (28.9) 72 (29.9) 
Ischaemic heart disease 51 (5.2) 22 (5.7) 11 (5.1) 16 (6.6) 
Heart failure 58 (5.9) 24 (6.3) 12 (5.5) 17 (7.1) 
Structural heart disease 7 (0.7) 2 (0.5) 1 (0.5) 1 (0.4) 
Peripheral 
atherosclerotic disease 
12 (1.2) 7 (1.8) 5 (2.3) 3 (1.2) 
Venous 
thromboembolism 
1 (0.1) 1 (0.3) 0 (0.0) 1 (0.4) 
Arrhythmias 8 (0.8) 3 (0.8) 2 (0.9) 2 (0.8) 
Asthma 78 (7.9) 34 (8.9) 19 (8.7) 21 (8.7) 
COPD 20 (2.0) 8 (2.1) 5 (2.3) 5 (2.1) 
CVA 21 (2.1) 8 (2.1) 3 (1.4) 7 (2.9) 
Epilepsy 10 (1.0) 4 (1.0) 2 (0.9) 3 (1.2) 
Diabetes 91 (9.2) 39 (10.2) 27 (12.4) 20 (8.3) 
 
8.3.2 Number of health problems 
In total, 328 participants (33.2% of the total sample) were classified as having 
multimorbidity (two or more CPRD-defined health disorders). Participants with 
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multimorbidity had a median age of 58.68 years (IQR 54.58 – 61.22). 50.9% were male, 
10.5% were single, 22.9% had no qualifications and 18.3% had attained university-degree 
level qualifications. Most participants with multimorbidity had health-related job loss 
(71.3%). 29.9% were working in higher managerial or professional class occupations, 29.9% 
in intermediate occupations, and 40.2% in routine or manual occupations. 
Participants with “severe” multimorbidity (four or more health disorders) were also 
majority cases (78.3%) and had a median age of 59.03 years at the point of analysis (IQR 
55.82 – 61.22). 56.5% were male, 6.5% were single, 32.6% had no qualifications and 8.7% 
had university-degree level qualifications. 23.9% were working in higher managerial or 
professional class occupations, 32.6% in intermediate occupations, and 43.5% in routine or 
manual occupations. Of the 10 control participants who managed to remain in work despite 
such morbidity burden, job titles included: Salesman, Supervisor, Personal Assistant, Club 
Stewardess, Advisor, Journalist, Payroll Manager, Van Driver, Printing Business Proprietor, 
and Engineer.   
Multimorbidity was more prevalent amongst cases than controls (47.4% vs 19.0%) and was 
associated with 5.95-fold increased odds of HRJL (95%CI 1.32 to 2.58) compared to 
participants with no known health disorders. Given the small number of participants with 
four CPRD-defined health disorders (n=31), five health disorders (n=12), six health disorders 
(n=2), or seven health disorders (n=1) these groups were merged into a category of four or 
more health disorders. In matched analysis, as number of health disorders increased, 
association with HRJL increased (one morbidity: OR 1.86 95%CI 1.33 to 2.59; two 
morbidities: OR 5.02 95%CI 3.23 to 7.79; three morbidities: OR 6.71 95%CI 3.87 to 11.64; 
four or more morbidities: OR 10.89 95%CI 4.67 to 25.39). The strength of association 
remained similar after adjustment for educational attainment, single status, and history of 
heavy alcohol intake, see Table 120 and Figure 46. In sub-group analysis, multimorbidity 
was similarly associated with HRJL among men and women (OR 5.86 95%CI 3.27 to 10.49 in 
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cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
aOR (95% CI) 
No health 
disorders 
225 (45.6) 110 (22.3) 1.00 1.00 
One health 
disorder 
175 (35.4) 150 (30.4) 1.86 (1.33 to 2.59) 1.91 (1.35 to 2.68) 
Two health 
disorders 
58 (11.7) 121 (24.5) 5.02 (3.23 to 7.79) 5.02 (3.21 to 7.84) 
Three health 
disorder 
26 (5.3) 77 (15.6) 6.71 (3.87 to 11.64) 6.04 (3.43 to 10.62) 
Four or more 
health disorders 
10 (2.0) 36 (7.3) 10.89 (4.67 to 25.39) 11.04 (4.60 to 26.47) 
Any 
multimorbidity 
(two or more 
health disorders) 




90 (40.9) 42 (19.1) 1.00 1.00 
One health 
disorder 
79 (35.9) 62 (28.2) 1.83 (1.08 to 3.08) 1.76 (1.03 to 2.99) 
Two health 
disorder 
33 (15.0) 54 (24.6) 4.28 (2.23 to 8.22) 4.32 (2.22 to 8.40) 
Three health 
disorder 
12 (5.5) 42 (19.1) 8.25 (3.63 to 18.72) 7.27 (3.15 to 16.77) 
Four or more 
health disorders 
6 (2.7) 20 (9.1) 11.48 (3.72 to 35.45) 12.03 (3.73 to 38.83) 
Any 
multimorbidity 
(two or more 
health disorders) 




135 (49.3) 68 (24.8) 1.00 1.00 
One health 
disorder 
96 (35.0) 88 (32.1) 1.85 (1.20 to 2.85) 2.03 (1.29 to 3.19) 
Two health 
disorder 
25 (9.1) 67 (24.5) 5.83 (3.17 to 10.74) 5.84 (3.15 to 10.85) 




14 (5.1) 35 (12.8) 5.47 (2.57 to 11.64) 5.35 (2.42 to 11.81) 
Four or more 
health disorders 
4 (1.5) 16 (5.8) 9.68 (2.59 to 36.19) 9.10 (2.38 to 34.76) 
Any 
multimorbidity 
(two or more 
health disorders) 
43 (15.7) 118 (43.1) 6.04 (3.57 to 10.21)  5.96 (3.46 to 10.26)  
 
Figure 46: Forest plot showing association between number of CPRD-defined health 
disorders and HRJL 
 
8.3.3 Number of GP consultations in the prior year 
The relationship between number of GP consultations in the prior year and HRJL was 
considered; number of consultations was divided into quartiles for analysis. Quartile 1 was 
the reference group, containing the lowest 25% centile of numbers of consultations and 
included participants who had attended their GP practice once, or less than once, in the 
prior year (n=256, 25.9%). Quartile two, three, and four contained participants who had 
attended the GP two to four times (n=273, 27.6%), five to nine times (n=231, 23.4%), and 






















adjusted odds ratio (95% CI), logarithmic scale 




Association between number of health disorders and HRJL 
(aOR)
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Participants in the highest quartile of GP attendance were most commonly cases (72.8%) 
and had a median age of 59.12 years at the point of analysis (IQR 55.31 – 61.54). 54.0% 
were male, 9.7% were single, 26.8% had no qualifications, and 16.2% had attained 
university-degree level qualifications. 31.1% were working in higher managerial or 
professional class occupations, 28.4% in intermediate occupations, and 40.4% in routine or 
manual occupations. 
The median number of GP consultations was higher among cases than controls (median: 6 
IQR 3 to 12 and median 2.5 IQR 0 to 6, respectively). In matched analysis, the overall 
number of consultations attended in the prior year was significantly associated with HRJL 
(OR 1.12 95%CI 1.09 to 1.15). Compared to the lowest quartile of GP attendance, the 
second quartile had a 2.01-fold increased odds of HRJL (95%CI 1.37 to 2.94), the third 
quartile had a 4.00-fold increased odds of HRJL (95%CI 2.60 to 6.17), and the fourth quartile 
had a 9.33-fold increased odds of HRJL (95%CI 5.72 to 15.21). The strength of these 
relationships remained similar after adjusting for possible confounders, see Table 121.  
The overall number of GP consultations in the prior year was similarly associated with HRJL 
among men and women (OR 1.09 95%CI 1.05 to 1.13 vs OR 1.15 95%CI 1.10 to 1.20). 
Women in the third quartile for number of consultations appeared to have a stronger 
relationship with HRJL than men in the third quartile (OR 4.93 95%CI 2.77 to 8.79 vs OR 3.21 
95%CI 1.67 to 6.17, respectively) and in the fourth quartile (OR 9.27 95%CI 4.85 to 17.74 vs 
OR 6.88 95%CI 3.39 to 13.98, respectively), however confidence intervals were wide and 
overlapping.  







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
aOR (95% CI) 
Number of GP 
consultations  
NA NA 1.12 (1.09 to 1.15) 1.11 (1.08 to 1.14) 
0 - 1 GP consultations 
(1st quartile) 
179 (36.2) 77 (15.6) 1.00 1.00 
2 - 4 GP consultations 
(2nd quartile) 
154 (31.2) 119 (24.1) 2.01 (1.37 to 2.94) 1.98 (1.35 to 2.91) 
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5 - 9 GP consultations 
(3rd quartile) 
99 (20.0) 132 (26.7) 4.00 (2.60 to 6.17) 3.86 (2.47 to 6.02) 
10 - 52 GP 
consultations (4th 
quartile) 
62 (12.6) 166 (33.6) 9.33 (5.72 to 15.21) 8.74 (5.32 to 
14.38) 
Men 
Number of GP 
consultations  
NA NA 1.09 (1.05 to 1.13) 1.09 (1.05 to 1.13) 
0 - 1 GP consultations 
(1st quartile) 
75 (34.1) 36 (16.4) 1.00 1.00 
2 - 5 GP consultations 
(2nd quartile) 
67 (30.5) 58 (26.4) 2.17 (1.22 to 3.83) 2.20 (1.23 to 3.94) 
6 - 11 GP consultations 
(3rd quartile) 
49 (22.3) 58 (26.4) 3.21 (1.67 to 6.17) 3.08 (1.58 to 5.99) 
12 - 40 GP 
consultations (4th 
quartile) 
29 (13.12) 68 (30.9) 6.88 (3.39 to 13.98) 6.41 (3.11 to 
13.18) 
Women 
Number of GP 
consultations  
NA NA 1.15 (1.10 to 1.20) 1.15 (1.10 to 1.20) 
0 - 1 GP consultations 
(1st quartile) 
104 (38.0) 41 (15.0) 1.00 1.00 
2 - 3 GP consultations 
(2nd quartile) 
80 (29.2) 53 (19.3) 1.75 (1.05 to 2.92) 1.84 (1.09 to 3.11) 
4 - 8 GP consultations 
(3rd quartile) 
56 (20.4) 88 (32.1) 4.93 (2.77 to 8.79) 4.75 (2.60 to 8.66) 
9 - 52 GP consultations 
(4th quartile) 
34 (12.4) 92 (33.6) 9.27 (4.85 to 17.74) 10.11 (5.09 to 
20.08) 
 
8.3.4 Number of drugs prescribed in the prior year 
The relationship between number of drug prescriptions in the prior year and HRJL was 
considered and number of prescriptions was divided into quartiles for analysis. Quartile 1 
contained participants who had no known drug prescriptions in the prior year (n=321, 
32.5%) and was the main comparison group. Quartile two, three, and four contained 
participants who had two to five prescriptions (n=187, 18.9%), six to 18 prescriptions 
(n=238, 24.1%), and 19 to 131 prescriptions (n=242, 24.5%) in the prior year, respectively.  
Participants in the highest quartile of drug prescriptions were most commonly cases 
(68.6%) and had a median age of 58.95 years at the point of analysis (IQR 54.98 to 61.22). 
56.2% were male, 10.5% were single, 26.0% had no qualifications, and 17.8% had attained 
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university-degree level qualifications. 35.6% were working in higher managerial or 
professional class occupations, 24.7% in intermediate occupations, and 39.8% in routine or 
manual occupations. 
The median number of drug prescriptions was much higher among cases, compared to 
controls (median 10 IQR 1 to 25 vs median 1 IQR 0 to 12, respectively). In matched analysis, 
the number of drugs prescribed in the prior year was significantly associated with 
development of HRJL (OR: 1.03 95%CI 1.02 to 1.04). Compared to the lowest quartile of 
drug prescription, the second quartile had 3.93-fold increased odds of HRJL (95%CI 2.55 to 
6.07), the third quartile had a 4.33-fold increased odds of HRJL (95%CI 2.55 to 6.07), and 
the fourth quartile had a 7.61-fold increased odds of HRJL (95%CI 4.86 to 11.91). The 
strength of these relationships remained similar after adjusting for possible confounders, 
see Table 122.   
The number of drug prescriptions in the prior year was similarly associated with HRJL 
among men and women (OR 1.03 95%CI 1.02 to 1.04 vs OR 1.04 95%CI 1.02 to 1.05). Once 
again, the strength of association appeared to be stronger among women in the third 
quartile compared to men in the third quartile (OR 5.94 95%CI 3.33 to 10.59 vs OR 3.92 
95%CI 2.04 to 7.54, respectively) and in the fourth quartile (OR 8.43 95%CI 4.52 to 15.71 vs 
OR 5.94 95%CI 3.33 to 10.59, respectively). However, confidence intervals were wide and 
overlapping. 







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
aOR (95% CI) 
Number of drug 
prescriptions  
NA NA 1.03 (1.02 to 1.04) 1.03 (1.02 to 1.04) 
0 prescriptions  
(1st quartile) 
233 (47.2) 88 (17.8) 1.00 1.00 
1 - 5 prescriptions  
(2nd quartile) 
81 (16.4) 106 (21.5) 3.93 (2.55 to 6.07) 4.19 (2.68 to 6.57) 
6 - 18 prescriptions 
(3rd quartile) 
104 (21.1) 134 (27.1) 4.33 (2.55 to 6.07) 4.60 (2.97 to 7.14) 
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19 - 131 prescriptions 
(4th quartile) 
76 (15.4) 166 (33.6) 7.61 (4.86 to 11.91) 7.52 (4.72 to 11.98) 
Men 
Number of drug 
prescriptions  
NA NA 1.03 (1.02 to 1.04) 1.03 (1.02 to 1.05) 
0 prescriptions  
(1st quartile) 
92 (41.8) 36 (16.4) 1.00 1.00 
1 - 5 prescriptions  
(2nd quartile) 
42 (19.1) 53 (24.1) 3.13 (1.71 to 5.72) 3.35 (1.79 to 6.25) 
6 - 18 prescriptions 
(3rd quartile) 
50 (22.7) 58 (26.4) 3.92 (2.04 to 7.54) 3.99 (2.02 to 7.85) 
19 - 131 prescriptions 
(4th quartile) 
36 (16.4) 73 (33.2) 5.78 (3.07 to 10.90) 5.97 (3.07 to 11.60) 
Women 
Number of drug 
prescriptions  
NA NA 1.04 (1.02 to 1.05) 1.04 (1.02 to 1.05) 
0 prescriptions  
(1st quartile) 
141 (51.5) 52 (19.0) 1.00 1.00 
1 - 5 prescriptions  
(2nd quartile) 
45 (16.4) 42 (15.3) 3.62 (1.95 to 6.73) 4.08 (2.13 to 7.81) 
6 - 18 prescriptions 
(3rd quartile) 
50 (18.3) 90 (32.9) 5.94 (3.33 to 10.59) 6.67 (3.63 to 12.26) 
19 - 131 prescriptions 
(4th quartile) 
38 (13.9) 90 (32.9) 8.43 (4.52 to 15.71) 8.74 (4.51 to 16.96) 
 
8.3.5 Cluster analysis 
8.3.5.1 Association of major multimorbidity clusters with HRJL  
As described in Chapter 7, participants with multimorbidity were clustered for the following 
CPRD-defined health disorders: structural heart disease, hypertension, heart failure, 
ischaemic heart disease, venous thromboembolism, peripheral atherosclerosis, cardiac 
arrhythmias, primary care mental health problem, psychiatric mental health problem, sleep 
disorder, COPD, asthma, CVA, epilepsy, diabetes, and musculoskeletal disorders (chronic or 
pain, separately) using agglomerative hierarchical cluster analysis. A full description of the 
participants within each of these clusters can be found in Chapter 7, however the major 
disease constituents are summarised in Table 123 and 125, below. I explored the 
relationships between these multimorbidity clusters and HRJL. Results are reported 
separately according to whether chronic MSDs or recent MSD pain was used to define 
musculoskeletal disorders in the clustering solution. For these analyses, outlying clusters 
were not considered i.e. a cluster with fewer than 10 participants. 
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Chronic musculoskeletal disorders used to define MSDs 
Participants without known CPRD-defined health disorders were the reference group in all 
analyses. For ease of reference, Cluster A was referred to as the MHP-cMSD cluster, Cluster 
B was the cardio-metabolic cluster, Cluster C was the HTN-cMSD-diab cluster, and Cluster D 
was the OPD-HTN-MHP cluster.  
Compared with participants with no known health disorders, having one known health 
disorder was associated with HRJL (OR 2.20 95%CI 1.59 to 3.05) the MHP-cMSD cluster was 
strongly associated with HRJL (OR 7.56 95%CI 4.17 to 13.71), the cardio-metabolic cluster 
was moderately associated with HRJL (OR 2.82 95%CI 1.29 to 6.17), the HTN-cMSD-diab 
cluster was strongly associated with HRJL (OR 5.52 95%CI 3.27 to 9.30), and the OPD-HTN-
MHP cluster was very strongly associated with HRJL (OR 8.25 95%CI 3.01 to 22.61), 
although confidence intervals were wide. After adjustment for educational attainment, 
single status, and history of heavy alcohol intake, effect estimates remained similar 
strength, see Table 124 and Figure 47. 
Table 123: Major disease constituents of clusters among people with multimorbidity, 





Major disease constituents 
(prevalence >30%) 
Cluster A  
(MHP-cMSD) 
88 (32.2) Primary care MHP (96.6%) 
Chronic MSD (50.0%) 
Sleep disorders (39.8%) 
Cluster B  
(Cardio-metabolic) 
35 (12.8) Ischaemic heart disease (94.3%) 
Hypertension (62.9%) 
Heart failure (74.3%) 
Diabetes (31.4%) 
Cluster C  
(HTN-cMSD-diab) 
109 (39.9) Hypertension (77.1%) 
Chronic MSD (73.4%) 
Diabetes (43.1%) 
Cluster D  
(OPD-HTN-MHP) 
32 (11.7) Asthma (93.8%) 
COPD (40.6%) 
Hypertension (40.6%) 
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OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
aOR (95% CI) 
Participants with 
no known health 
disorders 
270 (54.7) 134 (27.1) 1.00 1.00 
One known health 
disorder 
148 (30.0) 163 (33.0) 2.20 (1.59 to 3.05) 2.27 (1.62 to 3.18) 
Cluster A  
(MHP-cMSD) 
20 (4.1) 68 (13.8) 7.56 (4.17 to 13.71) 6.81 (3.71 to 12.52) 
Cluster B  
(cardio-metabolic) 
14 (2.8) 21 (4.3) 2.82 (1.29 to 6.17) 2.69 (1.20 to 6.00) 
Cluster C 
(HTN-cMSD-diab) 
31 (6.3) 78 (15.8) 5.52 (3.27 to 9.30) 5.28 (3.12 to 8.95) 
Cluster D  
(OPD-HTN-MHP) 
9 (1.8) 23 (4.7) 8.25 (3.01 to 22.61) 10.08 (3.33 to 30.48) 
 
Figure 47: Association between multimorbidity clusters and HRJL (using chronic MSDs to 




















Association between multimorbidity clusters and HRJL (aOR)
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Recent musculoskeletal pain used to define MSDs 
For ease of reference, Cluster E was referred to as the MSpain-HTN cluster, Cluster F was 
the Diab-HTN-pcMHP cluster, Cluster G was the cardio-metabolic cluster, Cluster H was the 
MHP-MSpain cluster, and Cluster I was the OPD cluster. Participants without known CPRD-
defined health disorders were the reference group. 
Compared with participants with no known health disorders, having one known health 
disorder was moderately associated with HRJL (OR 2.14 95%CI 1.52 to 2.99) the MSpain- 
HTN cluster was strongly associated with HRJL (OR 5.33 95%CI 3.03 to 9.39), the Diab-HTN-
pcMHP cluster was strongly associated with HRJL (OR 5.57 95%CI 2.41 to 12.87), the cardio-
metabolic cluster was strongly associated with HRJL (OR 5.41 95%CI 2.37 to 12.32), the 
MHP-MSpain cluster was very strongly associated with HRJL (OR 10.68 95%CI 5.82 to 
19.57), and the OPD cluster was moderately associated with HRJL (OR 2.26 95%CI 0.63 to 
8.08), although this didn’t reach statistical significance. After adjustment for possible 
confounders, effect estimates remained at a similar strength, see Table 126 and Figure 48. 
Table 125: major disease constituents of clusters among people with multimorbidity, 
using recent MSD pain to measure musculoskeletal disorders 




Major disease constituents 
(prevalence >30%) 
Cluster E  
(MSpain- HTN) 
95 (32.5) MSD pain (77.9%) 
Hypertension (76.8%) 
Cluster F  
(Diab-HTN-pcMHP) 
36 (12.3) Diabetes (100.0%) 
Hypertension (72.2%) 
Primary care MHP (30.6%) 
Cluster G  
(Cardio-metabolic) 
35 (12.0) Ischaemic heart disease (97.1%) 
Heart failure (68.6%) 
Hypertension (57.1%) 
Diabetes (34.3%) 
Cluster H  
(MHP-MSpain) 
110 (38.0) Primary care MHP (93.6%) 
MSD pain (53.6%) 
Sleep disorders (39.1%) 
Cluster I  
(OPD) 
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OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol 
use.  
aOR (95% CI) 
Participants with no 
known health 
disorders 
262 (53.0) 134 (27.1) 1.00 1.00 
Participants with one 
known health 
disorder 
153 (31.0) 147 (29.8) 2.14 (1.52 to 2.99) 2.20 (1.56 to 3.11) 
Cluster E  
(MSpain- HTN) 
31 (6.3) 64 (13.0) 5.33 (3.03 to 9.39) 5.18 (2.93 to 9.14) 
Cluster F  
(Diab-HTN-pcMHP) 
10 (2.0) 26 (5.3) 5.57 (2.41 to 12.87) 5.25 (2.24 to 12.33) 
Cluster G  
(Cardio-metabolic) 
11 (2.2) 24 (4.9) 5.41 (2.37 to 12.32) 5.04 (2.19 to 11.61) 
Cluster H  
(MHP-MSpain) 
20 (4.0) 90 (18.2) 10.68 (5.82 to 19.57) 9.92 (5.37 to 18.32) 
Cluster I (OPD) 6 (1.2) 6 (1.2) 2.26 (0.63 to 8.08) 2.25 (0.58 to 8.73) 
 
Figure 48: Association between multimorbidity clusters and HRJL (using recent MSD pain 

















Cluster E (MSpain- HTN)
One health disorder
Association between multimorbidity clusters and HRJL (aOR)
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8.3.5.2 Association of major multimorbidity clusters with HRJL among men 
As described in Chapter 7, male participants with multimorbidity were clustered for CPRD-
defined health disorders. Clusters of less than ten participants were excluded as outliers. 
The relationship between these multimorbidity clusters and HRJL was explored in analysis 
restricted to male participants.  
A full description of participants within each of these clusters can be found in Chapter 7 and 
the major disease constituents of each cluster are summarised in Tables 127 and 129, 
below.  
Chronic musculoskeletal disorders used to define MSDs  
Male participants with no known health disorders were the comparison group. For ease of 
reference, Cluster J was referred to as the MHP-cMSD cluster, Cluster K was the HTN-cMSD-
diab cluster, Cluster L was the cardio-metabolic cluster, and Cluster M was the OPD-HTN-
cMSD cluster.  
Compared to male participants with no known health disorders, having one known health 
disorder was weakly associated with HRJL among men (OR 1.82 95%CI 1.11 to 2.98), the 
MHP-cMSD cluster was very strongly associated with HRJL, although confidence intervals 
were wide (OR 15.00 95%CI 3.28 to 68.62), the HTN-cMSD-diab cluster was strongly 
associated with HRJL (OR 6.03 95%CI 2.72 to 13.39), the cardio-metabolic cluster was 
moderately associated with HRJL (OR 3.40 95%CI 1.50 to 7.70), and the OPD-cMSD-HTN 
cluster was strongly associated with HRJL (OR 4.65 95%CI 1.46 to 14.84). After adjustment 
for educational attainment, single status, and history of heavy alcohol intake, a similar 
strength of relationship was observed, see Table 128. 
Table 127: Major disease constituents of clusters among multimorbid men, using chronic 





Major disease constituents 
(prevalence >30%) 
Cluster J  
(MHP-cMSD) 
21 (15.1) Primary care MHP (90.5%) 
Chronic MSD (66.7%) 
Sleep disorders (52.4%) 
Cluster K  
(HTN-cMSD-diab) 
54 (38.9) Hypertension (96.3%) 
Chronic MSD (48.2%) 
Diabetes (44.4%) 
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Cluster L  
(Cardio-metabolic) 
37 (26.6) Ischaemic heart disease (83.8%) 
Heart failure (70.3%) 
Hypertension (62.2%) 
Diabetes (35.1%) 
Cluster M  
(OPD-HTN-cMSD) 
17 (12.2) Asthma (94.1%) 
COPD (41.2%) 
Chronic MSD (41.2%) 
Hypertension (41.2%) 
 
Table 128: Multimorbidity clusters among men and HRJL, using chronic MSDs to measure 
musculoskeletal disorders 










OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
aOR (95% CI) 
Male participants 
with no known 
health conditions 
108 (49.1) 53 (24.1) 1.00 1.00 
Male participants 
with one known 
health disorder 
73 (33.2) 67 (30.5) 1.82 (1.11 to 2.98) 1.84 (1.11 to 3.04) 
Cluster J  
(MHP-cMSD) 
3 (1.4) 18 (8.2) 15.00 (3.28 to 68.62) 14.24 (3.05 to 66.45) 
Cluster K  
(HTN-cMSD-diab) 
15 (6.8) 39 (17.7) 6.03 (2.72 to 13.39) 5.83 (2.58 to 13.14) 
Cluster L  
(cardio-metabolic) 
14 (6.4) 23 (10.5) 3.40 (1.50 to 7.70) 3.13 (1.35 to 7.27) 
Cluster M  
(OPD-HTN-cMSD)  
5 (2.3) 12 (5.5) 4.65 (1.46 to 14.84) 5.56 (1.60 to 19.34) 
 
Recent musculoskeletal pain used to define MSDs 
As above, male participants with no known health disorders were the comparison group. 
For ease of reference, Cluster N was referred to as the MSpain-HTN-diab cluster, Cluster O 
was the cardio-metabolic cluster, Cluster P was the pcMHP-MSpain-HTN cluster, and 
Cluster Q was the OPD-MSpain-HTN cluster.  
Compared to male participants with no known health disorders, having one known health 
disorder was weakly associated with HRJL among men (OR 1.89 95%CI 1.13 to 3.14), the 
MSpain-HTN-diab cluster was strongly associated with HRJL (OR 5.60 95%CI 2.75 to 11.44), 
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the cardio-metabolic cluster was strongly associated with HRJL (OR 5.41 95%CI 2.14 to 
13.67), the pcMHP-MSpain-HTN cluster was very strongly associated with HRJL, although 
confidence intervals were wide (OR 10.90 95%CI 4.02 to 29.55) and the OPD-MSpain-HTN 
cluster was strongly associated with HRJL (OR 3.85 95%CI 1.33 to 11.15). After adjustment 
for possible confounders, a similar strength relationship was observed across all clusters, 
see Table 130. 
Table 129: Major disease constituents of clusters among multimorbid men, using recent 
MSD pain to measure musculoskeletal disorders 
 Cluster name (abbreviation) Number of 
participants (%) 
Major disease constituents 
(prevalence >30%) 
Cluster N  
(MSpain-HTN-diab) 
64 (41.6) MSD pain (62.5%) 
Hypertension (73.4%) 
Diabetes (43.8%) 
Cluster O  
(Cardio-metabolic) 
31 (20.1) Ischaemic heart disease (96.8%) 
Heart failure (67.7%) 
Hypertension (54.8%) 
Diabetes (35.5%) 
Cluster P  
(pcMHP-MSpain-HTN) 
36 (23.4) Primary care MHP (100.0%) 
Musculoskeletal pain (44.4%) 
Hypertension (38.9%) 
Cluster Q  
(OPD-MSpain-HTN) 
19 (12.3) Asthma (94.7%) 




Table 130: Multimorbidity clusters among men and HRJL, using recent MSD pain to 







cases, n (%) 
Association with 
HRJL, unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
aOR (95% CI) 
Male participants 
with no known health 
conditions 
100 (45.5) 49 (22.3) 1.00 1.00 
Male participants 
with one known 
health condition 
75 (34.1) 62 (28.2) 1.89 (1.13 to 3.14) 1.87 (1.11 to 3.15) 
Cluster N  
(MSpain-HTN-diab) 
20 (9.1) 44 (20.0) 5.60 (2.75 to 11.44) 5.33 (2.59 to 10.95) 
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Cluster O  
(Cardio-metabolic) 
10 (4.6) 21 (9.6) 5.41 (2.14 to 13.67) 4.87 (1.91 to 12.40) 
Cluster P  
(pcMHP-MSpain-HTN)  
7 (3.2) 29 (13.2) 10.90 (4.02 to 29.55) 10.52 (3.79 to 29.22) 
Cluster Q  
(OPD-MSpain-HTN) 
7 (3.2) 12 (5.5) 3.85 (1.33 to 11.15) 4.07 (1.34 to 12.29) 
 
8.3.5.3 Association of major multimorbidity clusters with HRJL among women 
As described in Chapter 7, female participants with multimorbidity were clustered for the 
CPRD-defined health disorders listed above and clusters of less than ten participants were 
excluded as outliers. The relationship between these multimorbidity clusters and HRJL was 
explored in analysis restricted to female participants. 
A full description of the participants within each of these clusters can be found in Chapter 7 
however the major disease constituents of each cluster are summarised in Table 131 and 
133, below.  
Chronic disorders used to define MSDs 
Women without known health disorders were the comparison group. For ease of reference, 
Cluster R was referred to as the HTN-cMSD-diab cluster, and Cluster S was the MHP-cMSD 
cluster.  
Compared with female participants with no known health disorders, the HTN-cMSD-diab 
cluster was strongly associated with HRJL (OR 5.52 95%CI 2.84 to 10.74), and the MHP-
cMSD cluster was strongly associated with HRJL (OR 6.62 95%CI 3.05 to 14.37). After 
adjustment for educational attainment, single status, and history of heavy alcohol intake, 
the strength of association remained similar, see Table 132. 
Table 131: Major disease constituents of clusters among multimorbid women, using 





Major disease constituents 
(prevalence >30%) 
Cluster R  
(HTN-cMSD-diab) 
71 (53.0) Hypertension (77.5%) 
Chronic MSD (64.8%) 
Diabetes (32.4%) 
Cluster S  
(MHP-cMSD) 
59 (44.0) Primary care MHP (93.2%) 
Sleep disorders (47.5%) 
Chronic MSD (42.4%) 
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Table 132: Multimorbidity clusters among women and HRJL, using chronic MSDs to 
measure musculoskeletal disorders 






cases, n (%) 
Association with HRJL 
in matched analysis, 
unadjusted. 
OR (95% CI) 
Association with 
HRJL, adjusted for 
education, single 
status, and history 
of heavy alcohol 
intake 
aOR (95% CI) 
Female participants 
with no known 
health conditions 
162 (59.1) 81 (29.6) 1.00 1.00 
Female participants 
with one known 
health disorder  
75 (27.4) 96 (35.0) 2.46 (1.59 to 3.81) 2.63 (1.67 to 4.16) 
Cluster R  
(HTN-cMSD-diab) 
20 (7.3) 51 (18.6) 5.52 (2.84 to 10.74) 5.33 (2.71 to 10.48) 
Cluster S  
(MHP-cMSD) 
15 (5.5) 44 (16.1) 6.62 (3.05 to 14.37) 6.34 (2.85 to 14.12) 
 
Recent musculoskeletal pain used to define MSDs 
Women without known health disorders were the comparison group. For ease of reference, 
Cluster T was referred to as the HTN-MSpain cluster, and Cluster U was the MHP-MSpain 
cluster.  
Compared to female participants with no known health disorders, the HTN-MSpain cluster 
was strongly associated with HRJL (OR 6.15 95%CI 3.05 to 12.41), and the MHP-MSpain 
cluster was very strongly associated with HRJL, although confidence intervals were wide 
(OR 9.07 95%CI 4.17 to 19.75). After adjustment for possible confounders the strength of 
these relationships remained similar, see Table 134.  
Table 133: Major disease constituents of clusters among multimorbid women, using 





Major disease constituents 
(prevalence >30%) 
Cluster T  
(HTN-MSpain) 
67 (48.6) Hypertension (80.6%) 
Musculoskeletal pain (56.7%) 
Cluster U  
(MHP-MSpain) 
62 (44.9) Primary care mental health 
problems (98.4%) 
Musculoskeletal pain (54.8%) 
Sleep disorders (45.2%) 
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Table 134: Multimorbidity clusters among women and HRJL, using recent MSD pain to 











OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
aOR (95% CI) 
Female participants 
with no known 
health conditions 
162 (59.1) 85 (31.0) 1.00 1.00 
Female participants 
with one known 
disorder 
78 (28.5) 85 (31.0) 2.32 (1.48 to 3.64) 2.57 (1.60 to 4.12) 
Cluster T  
(HTN-MSpain) 
18 (6.6) 49 (17.9) 6.15 (3.05 to 12.41) 6.07 (2.96 to 12.45) 
Cluster U  
(MHP-MSpain) 
12 (4.4) 50 (18.3) 9.07 (4.17 to 19.75) 8.82 (3.96 to 19.66) 
 
8.3.6 The impact of comorbidity on HRJL, among people with musculoskeletal 
disorders 
Musculoskeletal disorders, number of comorbidities, and HRJL 
Compared to participants with no known health disorders, having any MSD was increasingly 
associated with HRJL as number of comorbid conditions increased (aOR 2.07 95%CI 1.68 to 
2.56). Participants with MSDs but no known comorbidities had 2.13-fold increased odds of 
HRJL (95%CI 1.31 to 3.46). However, association with HRJL increased as number of 
comorbidities increased (OR: one comorbidity 5.32 95%CI 2.88 to 9.83; two comorbidities 
7.93 95%CI 3.61 to 17.45; three or more comorbidities 19.49 95%CI 5.42 to 70.10). The size 
of these effect estimates remained similar after adjustment for confounding factors, see 
Table 135. 
This pattern was replicated among participants with chronic MSDs and recent MSD pain, 
specifically. Having chronic MSDs or recent MSD pain, without comorbid health disorders 
remained moderately associated with HRJL, compared to those with no known health 
disorders (OR 2.09 95%CI 1.16 to 3.77; and OR 2.22 95%CI 1.17 to 4.20, respectively). For 
both these conditions, strength of association increased considerably as number of 
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comorbidities increased. Effect estimates remained similar after adjustment for 
confounding factors, see Table 135. 
Table 135: Impact of musculoskeletal disorders on HRJL, stratified by number of 













OR (95% CI) 
Association with 
HRJL, adjusted for 
education, history of 
heavy alcohol 
intake, and single 
status. 
aOR (95% CI) 
All musculoskeletal disorders1 
No known health 
disorders  
225 (45.6) 110 (22.3) 1.00 1.00 
MSD alone 90 (18.2) 69 (14.0) 2.13 (1.31 to 3.46) 2.18 (1.33 to 3.59) 
MSD and one 
comorbidity 
39 (7.9) 73 (14.8) 5.32 (2.88 to 9.83) 5.38 (2.88 to 10.05) 
MSD and two 
comorbidities 
19 (3.9) 57 (11.5) 7.93 (3.61 to 17.45) 7.37 (3.28 to 16.58) 
MSD and three or 
more comorbidities 
4 (0.8) 32 (6.5) 19.49 (5.42 to 70.10) 17.74 (4.84 to 65.06) 
Chronic musculoskeletal disorders2 
No known health 
disorders  
270 (76.7) 134 (49.6) 1.00 1.00 
MSD alone 45 (12.8) 45 (16.7) 2.09 (1.16 to 3.77) 2.10 (1.15 to 3.83) 
MSD and one 
comorbidity 
21 (6.0) 36 (13.3) 5.08 (2.19 to 11.79)  5.24 (2.24 to 12.27) 
MSD and two or 
more comorbidities 
16 (4.6) 55 (20.4) 6.35 (2.82 to 14.32) 5.96 (2.57 to 13.80) 
Recent musculoskeletal pain3 
No known health 
disorders  
262 (74.9) 134 (46.7) 1.00 1.00 
MSD alone 53 (15.1) 45 (15.7) 2.22 (1.17 to 4.20) 2.25 (1.15 to 4.37) 
MSD and one 
comorbidity 
24 (6.9) 52 (18.1) 7.17 (3.14 to 16.33) 7.40 (3.20 to 17.07) 
MSD and two or 
more comorbidities 
11 (3.1) 56 (19.5) 11.70 (4.23 to 32.32) 11.45 (3.99 to 32.89) 
1. 536 and 524 participants contributed to the unadjusted and adjusted logistic models, respectively 
2. 400 and 394 participants contributed to the unadjusted and adjusted logistic models, respectively 
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Musculoskeletal disorders, comorbidity clusters, and HRJL  
The association between patterns of comorbidity among MSDs and HRJL was considered. 
Once again, participants without known CPRD-defined health disorders were the 
comparison group. For reference, Cluster V contained participants with MSDs and no 
comorbidities and was the MSD-alone cluster, Cluster W was the HTN-diab comorbidity 
cluster, Cluster X was the Asthma-HTN comorbidity cluster, Cluster Y was the MHP 
comorbidity cluster, and Cluster Z was the cardio-metabolic comorbidity cluster. A 
summary of the constituents of these clusters can be found in Table 136 below.  
Compared with participants with no known health disorders, having an MSD with no known 
comorbidity was moderately associated with HRJL (OR 2.20 95%CI 1.35 to 3.60). The HTN-
Diab cluster was strongly associated with HRJL (OR 4.25 95%CI 2.27 to 7.95), the Asthma-
HTN cluster was strongly associated with HRJL (OR 7.42 95%CI 2.12 to 25.92), the MHP 
cluster was very strongly associated with HRJL (OR 16.18 95%CI 6.51 to 40.25), and the 
cardio-metabolic cluster was strongly associated with HRJL (OR 5.79 95%CI 1.23 to 27.17), 
although confidence intervals were wide for all comorbidity clusters. After adjustment for 
educational attainment, single status, and history of heavy alcohol intake, effect estimates 
remained similar strength, see Table 137. 






Major disease constituents 
(prevalence >30%) 
Cluster V  
(MSD-alone) 
159 (41.5) Musculoskeletal disorders alone 
(100.0%) 
Cluster W  
(HTN-Diab) 
96 (25.1) Hypertension (87.5%) 
Diabetes (33.3%) 
Cluster X  
(Asthma-HTN) 
25 (6.5) Asthma (96.0%) 
Hypertension (36.0%) 
Cluster Y  
(MHP) 
86 (22.5) Primary care-level MHP (91.9%) 
Sleep disorders (34.9%) 
Cluster Z  
(Cardio-metabolic) 
10 (2.6) Heart failure (90.0%) 
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OR (95% CI)1 
Association with HRJL, 
adjusted for 
education, history of 
heavy alcohol intake, 
and single status.2 
aOR (95% CI) 
No known health 
disorders 
225 (59.7) 110 (32.3) 1.00 1.00 
Cluster V  
(MSD alone) 
90 (23.9) 69 (20.2) 2.20 (1.35 to 3.60) 2.26 (1.36 to 3.74) 
Cluster W  
(HTN-Diab) 
36 (9.6) 60 (17.6) 4.25 (2.27 to 7.95) 4.09 (2.15 to 7.77) 
Cluster X 
(Asthma-HTN) 
8 (2.1) 17 (5.0) 7.42 (2.12 to 25.92) 7.34 (2.09 to 25.77) 
Cluster Y 
(MHP) 
14 (3.7) 72 (21.1) 16.18 (6.51 to 40.25) 15.04 (5.99 to 37.77) 
Cluster Z (Cardio-
metabolic) 
3 (0.8) 7 (2.1) 5.79 (1.23 to 27.17) 5.80 (1.20 to 28.08) 
1. 536 participants contributed to the conditional logistic model 
2. 524 participants contributed to the adjusted conditional logistic model 
8.4 Summary 
• Multiple indicators of multimorbidity were significantly associated with health-
related job loss, including number of known health disorders, number of drug 
prescriptions in the prior year, and number of GP consultations in the prior year.  
• Among those with multimorbidity, compared to participants with no known health 
disorders, clusters formed by majority hypertension-musculoskeletal disorders and 
mental health problem-musculoskeletal clusters were common and strongly 
associated with health-related job loss. Particularly, clusters formed by mental 
health problem-musculoskeletal disorders were most strongly associated with HRJL. 
In addition, a small OPD-HTN-MHP cluster formed and was very strongly associated 
with health-related job loss, although confidence intervals were wide.  
• Clusters formed primarily by hypertension-musculoskeletal disorders and mental 
health problems-musculoskeletal disorders remained strongly associated with HRJL 
in both multimorbid men and multimorbid women. Once again, clusters primarily 
formed by musculoskeletal disorders-mental health problems were mostly strongly 
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associated with health-related job loss in all cases, and these were more prevalent 
among multimorbid women.  
• Clusters of cardio-metabolic disorders, and of obstructive pulmonary disease-
hypertension-musculoskeletal disorders, which formed prominently among 
multimorbid men but not women, were found to be strongly associated with HRJL, 
compared to participants with no known health disorders.  
• The strength of association between musculoskeletal disorders and HRJL increased 
as number of known comorbidities increased. Considering patterns of comorbidity 
among participants with musculoskeletal disorders, the HTN-Diab, Asthma-HTN, 
and cardio-metabolic comorbidity clusters were strongly associated with HRJL. The 
MHP comorbidity cluster had the strongest association with HRJL.  
8.5 Discussion  
In this chapter, in order to study the impact of multimorbidity upon HRJL, several indicators 
of multimorbidity and their association with HRJL were explored. Cases and controls were 
compared for the number of known health disorders, number of GP consultations in the 
prior year, number of drugs prescribed in the prior year, and cluster-analysis-defined 
multimorbidity groups in a nested matched case-control study. Adjusted analyses have 
been presented. It was observed that as the number of health disorders, number of GP 
consultations in the prior year, and number of drug prescriptions in the prior year 
increased, association with HRJL significantly increased. Compared to having no known 
health disorders, being in any multimorbidity cluster was also significantly, and usually 
strongly, associated with HRJL. In general, clusters dominated by mental health problems 
and musculoskeletal disorders (chronic or pain) were both common and very strongly 
associated with HRJL.  
Multimorbid participants (two or more known health disorders) were prevalent in the study 
sample (33.2%) and multimorbidity was strongly associated with HRJL. The strength of this 
association also increased as number of known disorders increased. Although this is the 
first study of the impact of multimorbidity upon health-related job loss in the literature, the 
direction of effect broadly correlates with other reported work outcomes. Several other 
cross-sectional studies among western (non-UK) working populations observed that 
number of health disorders was correlated with sickness absence,(450,451) increased work 
impairment scores,(199) or presenteeism.(450) In one study among the wider population, 
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number of health disorders was also associated with self-reported unemployment, work 
disability, and receipt of living allowance.(200) The impact of multimorbidity on these work 
outcomes was also shown to substantially worsen with each additional condition.(200)  
Number of GP consultations in the prior year was associated with HRJL. Compared to the 
lowest quartile of GP consultations, being in the third or fourth quartile for consultations 
was strongly associated with HRJL. Frequent GP attendance is a biopsychosocial 
phenomenon(452–454) that has been shown to carry a strong relationship with 
multimorbidity.(455) It shares many risk factors with premature work loss, including 
increasing age,(454) low socioeconomic status,(456) low educational attainment,(457) 
severity of existing health disorders,(453) and particularly, the presence of chronic 
disease,(454) arthritis,(458) back pain,(459) and mental health disorders.(454,459,460) In 
one study, 41% of frequent GP attendance was attributable to chronic physical illness and 
30.9% to mental health disorders.(454) Evidence linking GP consultations to work outcomes 
is scarce and the findings of this chapter will help to establish the relationship between rate 
of GP consultation and premature exit from work. However, it remains unclear how much 
this relationship is independent of the effects of disease burden, since frequency of GP 
consultation also represents significant work-time cost that could be deleterious to 
maintaining employment. In one population-based cross sectional study, after adjustment 
for physical, psychological health, and tendency towards somatisation, frequent GP 
attendance remained associated with unemployment among men and women, and with 
disability pension among men.(457)  
Similarly, number of drugs prescribed in the prior year was found to be associated with 
HRJL. Compared to the lowest quartile of drug prescription, being in the third or fourth 
quartile for number of drugs prescribed was strongly associated with HRJL. However, only 
prescription data related to the selected CPRD conditions was available for this analysis. In 
addition, participants taking certain drugs that are prescribed more frequently throughout 
the year would have had an inflated prescription count. This is appropriate if the overall 
number of drugs taken was higher, however, it could also be for arbitrary reasons such as 
the GP supplying fewer drugs per prescription. As such, this measure can only be 
interpreted as a crude indicator of treatment burden and multimorbidity. The concurrent 
use of multiple medications is referred to as polypharmacy, which is itself strongly related 
to multimorbidity, although different conditions are associated with different degrees of 
polypharmacy.(461) Polypharmacy is associated with several factors related to a person’s 
likelihood of premature work loss, such as lower socioeconomic status,(462) increasing 
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age,(462,463) and chronic health disorders,(462) diabetes,(463–465) asthma,(464) and 
cardiovascular disease,(463–465) specifically. However, available evidence is mostly derived 
from elderly populations (>65 years old) and different definitions of polypharmacy 
exist,(466) the most common definition being five or more daily medications.(467) While 
preliminary, the relationship described between drug prescriptions and HRJL in this chapter 
is novel; no other literature exploring polypharmacy and work outcomes was identified.  
Next, I considered the association between generated clusters (see Chapter 7) and the 
development of HRJL. In all models, compared to participants with no known health 
disorders, having one known health disorder did not reach higher than 2.46-fold increased 
odds of HRJL (a moderate strength association). Whereas being part of any multimorbidity 
cluster had an estimated 2.26- to 15.00-fold increased odds of HRJL. Nineteen of 21 
generated multimorbidity clusters were at least strongly associated with HRJL (3.40- to 
15.00-fold increased odds of HRJL) and six were very strongly associated with HRJL (7.56- to 
15.00-fold increased odds of HRJL). For the individual, certain health problems may have an 
important impact on the ability to stay in work, regardless of the presence of comorbidity. 
However, these results suggest that those who are dealing with multiple health problems 
may represent the most common high-risk group among the older working age population.  
I considered the impact of specific clusters generated in the total multimorbid population. 
Compared to participants with no known health disorders, clusters formed primarily by 
MSDs and mental health problems (Cluster A [MHP-cMSD]/Cluster H [MHP-MSpain]) were 
very strongly associated with HRJL; and clusters formed primarily by MSDs and 
hypertension (Cluster C [HTN-cMSD-diab]/Cluster E [HTN-MSpain]) were strongly 
associated with HRJL. These clusters were also large and together contained over two-
thirds of those with multimorbidity (32.2%/37.7% and 39.9%/32.5%, respectively). At the 
population level, these findings represent supportive evidence that the co-occurrence of 
mental health disorders and musculoskeletal disorders, particularly, is of key importance to 
HRJL among older workers. Cluster F (Diab-HTN-pcMHP) and Cluster G (Cardio-metabolic) 
were also strongly associated with HRJL, although these groups accounted for a much 
smaller proportion of overall multimorbidity. Cluster D (OPD-HTN-MHP) was also small but 
very strongly associated with HRJL, although confidence intervals were especially wide. In 
this cluster, COPD and mental health disorders likely drove the strength of association since 
asthma was found to have only a weak association with HRJL in adjusted analysis (see 
Chapter 6). 
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Cluster B/Cluster G comprised cardio-metabolic clusters which were large majority male 
(82.9%/85.7%). Naturally, similar clusters formed again when analysis was restricted to 
male multimorbid participants: Cardio-metabolic clusters (Clusters L and O) accounted for 
26.6%/20.1% of multimorbid men and were strongly associated with HRJL (OR 3.40 95%CI 
1.50 to 7.70; and OR 5.41 95%CI 2.14 to 13.67, respectively), compared to male participants 
with no known health disorders. A cardio-metabolic cluster did not form prominently 
among women.  
Among women with multimorbidity, clusters formed primarily by MSDs and hypertension 
(Cluster R [HTN-cMSD]/Cluster T [HTN-MSpain]) and clusters formed primarily by MSDs and 
mental health problems (Cluster S [MHP-cMSD]/Cluster U [MHP-MSpain]) were strongly 
associated with HRJL, compared with female participants with no known health disorders. 
Together, these clusters contained almost all women with multimorbidity in the study 
sample (53.0%/48.6% and 44.0%/44.9%, respectively). Chronic musculoskeletal disorders 
featured prominently in both clusters, establishing these conditions as a key source of 
multimorbidity associated with HRJL in women. The MHP-cMSD cluster was more prevalent 
among multimorbid women (44.0%) than among multimorbid men (15.1%). However, 
among both men and women musculoskeletal-mental health disorder clusters showed the 
strongest association with HRJL. 
This chapter described the characteristics of the 383 HEAF participants with 
musculoskeletal disorders. Their known demographic, lifestyle, and occupational factors 
have been described. Musculoskeletal disorders are known to have a strong positive 
relationship with age, and occurred more frequently in older participants.(396) 
Proportionally fewer participants with any kind of musculoskeletal disorder appeared to be 
university educated and proportionally more had no qualifications. Routine occupations 
were the most common kind of work among participants with MSDs. Routine work is 
frequently worked by those of lower educational attainment and, more importantly, is 
often manual work, which has a known association with the development of 
musculoskeletal disorders.(392–394)  
It must be emphasised that the majority (58.5%) of older working-age participants with 
MSDs were dealing with multiple health problems. The manner in which these 
musculoskeletal disorders form clusters with other disease groups was described in Chapter 
7. As the number of comorbid conditions increased among people with musculoskeletal 
disorders, it was observed that the association with HRJL increased dramatically; this was 
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true for chronic MSD and recent MSD pain conditions. The literature broadly agrees that 
comorbidity is an important associate of work disability amongst different musculoskeletal 
populations,(9–13,339) although few studies have stratified exposure by number of 
comorbidities to show a dose-response relationship, as has been done here. Comorbidities 
may play a mediating role between MSDs and job loss; for example, chronic MSD pain may 
lead to mental health problems leading to subsequent difficulty maintaining work. 
Therefore, non-comorbid participants may represent those with generally less severe 
musculoskeletal problems, as severe MSDs are both more likely to lead to job loss (468,469) 
and have been associated with the co-development of mental health problems(470–472) 
and cardiovascular disease.(473–475) The lack of CPRD-information on underlying 
musculoskeletal disease severity meant I was unable to explore this, which was a limitation 
of this research. 
Finally, an assessment of the relationship between musculoskeletal disorders and HRJL was 
split by the observed patterns of comorbidity among participants with MSDs. Results 
corresponded to those observed for analysis of multimorbidity patterns in the total study 
sample. Of the generated MSD comorbidity clusters, the cluster with mental health 
problems was both common and most strongly associated with HRJL.  
As mentioned previously, some caution is required when interpreting these results since 
information used to comprise multimorbidity measures was only available for selected 
health disorders and did not include certain prevalent health disorders such as 
gastrointestinal problems. In addition, confidence intervals were frequently wide and 
overlapping, which makes it difficult to compare effect estimates across clusters. However, 
multiple indicators of multimorbidity were analysed, lending greater convergent validity to 
the observed results, which establish multimorbidity as an important exposure in HRJL that 
should not be overlooked in health and work research among the older working-age 
population. There is currently little published about the impact of multimorbidity on work 
outcomes and where present, this is often restricted to the study of two specific types of 
diseases in combination.(476,477) I was unable to find any other study that considered the 
impact of multimorbidity upon health-related job loss in the older working age population. 
In addition, this is the first study to consider common disease clusters among the 
multimorbid, and their relative occupational health impact.  
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Chapter 9 – The population 
attributable fraction of HRJL for CPRD-
defined health disorders  
9.1 Introduction 
As has been described, MSDs occur frequently among the older working-age population 
and are a common associate and cause of HRJL. It has also been observed that they 
commonly co-present alongside other health conditions, forming clusters at the population 
level, and that these clusters have a strong association with HRJL, when compared with 
participants with no known health disorders. This final results chapter considers the 
independent association between musculoskeletal disease exposures and HRJL, after 
adjusting for the presence of other CPRD-defined health disorders. Then I consider how 
these specific health disorders can modify the relationship between MSDs and HRJL, 
thereby addressing research objective 6 (see Chapter 2). Lastly, to conclude this work, I 
estimate the proportion of HRJL that can be attributed to MSDs (and other CPRD-defined 
health disorders) among the UK older working population, thereby addressing research 
objective 7 (see Chapter 2). Throughout the chapter, cases (with HRJL) are compared to 
matched working control participants to attain relative estimates of association (see Figure 
49). 
Figure 49: the cohort used in this chapter, as indicated by the red square 
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9.2 Methods 
9.2.1 Description  
In brief, the total study population were described again for their demographic, lifestyle 
and occupational factors and for the overall prevalence of CPRD-defined health disorders. I 
used proportions to describe categorical data and medians and inter-quartile ranges to 
describe continuous data with non-Gaussian distributions.   
9.2.2 Preliminary main-effects model  
To determine the independent association of musculoskeletal disorders with HRJL, I ran a 
multivariable conditional logistic regression analysis, adjusting for the presence of other 
known health disorders, as well as possible confounders (e.g. educational attainment, 
single relationship status, and history of heavy alcohol intake). Using this “independent” 
estimate of effect, it was possible to derive the Population Attributable Fraction (PAF) of 
HRJL for musculoskeletal disorders in the UK older working population (see below for a 
description of PAF).  
Therefore, a parsimonious model of all known explanatory and confounding variables was 
built using the “purposeful selection” process first described by Hosmer and 
Lemeshow.(478) Over several stages, a small set of important (predictive) variables were 
included in the model from a larger initial set of possible variables. This process is described 
below. From the final model I derived an estimate of the relative association of MSDs with 
HRJL, taking into account the presence of other important health conditions and 
confounders.  
Health and demographic factors were examined in turn for their association to HRJL at a 
univariable level. Chapter 6 has already outlined the resulting effect sizes. The Wald test 
output (z-value) from these logistic regression models, was used to select factors into a 
large multivariable model based on an arbitrary cut-off value (p=0.25).(479) A cut-off value 
of 0.20 – 0.25 is recommended since the traditional p-value of 0.05 has been found to miss 
important variables.(480,481) 
Next, an iterative backward selection process was applied, whereby non-significant 
variables were removed from the large model one by one. Covariables considered non-
significant at the 0.1 alpha-level, were removed from the model in order of least 
significance. Non-significant variables were permitted to remain in the model if they were 
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considered important confounding factors, defined by a 15 – 20% or more change in the 
effect estimate of any remaining parameter after removal of the confounder from the 
model.(479) After this stage, the remaining multivariable model consisted only of known 
important confounders and explanatory variables.  
Following this, variables found to be non-significant at the univariable level were entered 
into the multivariable model one at a time to assess their contribution after adjustment for 
other important covariables and confounders. In this phase, any introduced variables 
significant at the 0.15 level were entered into the model, followed by backward selection of 
these variables to iteratively reduce the model down to a “preliminary main effects” 
model.(478,479)  
In the total study sample, of those with chronic MSDs, 34.9% had recent MSD pain. Of 
those with recent MSD pain, 31.5% had a chronic MSD. The considerable overlap between 
these two groups and the possible role of recent MSD pain as a mediator between chronic 
MSDs and HRJL led to the decision to model these musculoskeletal groups separately. 
The assumptions of logistic regression are fewer than for linear regression models, 
however, for each preliminary main effects model an assessment of goodness-of-fit, 
specification errors, and multicollinearity was performed.(482) Goodness-of-fit was 
assessed using the pseudo-R2 value produced in the STATA output for each model. 
Specification error was assessed using the “linktest” command in STATA and by observing 
the linear predicted value and the squared linear predicted value for statistical significance. 
Finally, I assessed the degree of multicollinearity among independent variables using the 
Variance Inflation Factor (VIF). VIF is a measure of how much the variance of the estimated 
regression coefficient is “inflated” by the existence of correlation among included 
explanatory variables in the model.(483) 
9.2.3 Interaction analysis 
The presence of specific comorbidities may modify the influence of MSDs upon HRJL 
occurrence. For example, the presence of certain mental health problems may worsen pain 
perception and multiply the impact of musculoskeletal pain upon work, such that the effect 
of the diseases combined is more than their individual effects added together. If this is true, 
evidence of statistical interaction may be apparent. I looked for the statistical interaction 
between musculoskeletal disorders and other CPRD-defined health disorders in their 
association with HRJL, as below. 
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As is recommended in the literature, interaction effects were assessed on two “scales”: the 
additive scale or the multiplicative scale.(484) Calculating additive interaction is used to 
describe whether the association of two exposures together is greater than the sum of the 
effects of two exposures individually. If so, this is known as additive interaction. Where risk 
ratios can be calculated, additive interaction can be formulated as (RR11 – RR00) – ((RR10 – 
RR00) + (RR01 – RR00)) or RR11 – RR10 – RR01 + RR00 (see Figure 50).  





















Where the outcome is rare enough that OR approximates RR (as in this case), this formula 
can be rewritten as: OR11 – OR10 – OR01 + 1. This calculates the Relative Excess Risk due to 
Interaction (known as RERI) which approximates the additive interaction. If the result of 
applying the RERI formula is greater than 0 there is a positive or “super-additive” 
interaction, if the interaction is less than 0 the interaction is negative or “sub-
additive.”(484) 
Multiplicative interaction describes whether the effect of both exposures together exceeds 
the product of the effects of the two exposures considered separately. Interactions on the 
multiplicative scale can be calculated with the following formula: RR11/(RR10 x RR01) (see 
Figure 50). Once again, where the outcome is rare, ORs approximate RR and the same 
formula can be applied for ORs to approximate multiplicative interaction: OR11/(OR10 x 
OR01). Multiplicative interactions can be calculated easily by adding an interaction term to 
the multivariable logistic model. The interaction term is calculated by multiplying two 
exposure variables together. In this case, if the resulting interaction is significantly greater 
than 1 there is a positive multiplicative interaction, and if less than 1 this is a negative 
multiplicative interaction.(484) 
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An interaction between two exposures may be additive or multiplicative and therefore 
more apparent on one scale or the other. This depends on the underlying natural 
mechanism. For example, smoking has been found to be strongly associated with lung 
cancer but not other diseases on the relative risk scale, but similarly associated with lung 
cancer and other diseases on the absolute risk scale. In this case, the specificity on the 
multiplicative scale helped to provide evidence of causality between smoking and lung 
cancer.(485) On which scale to appropriately report interaction effects has been the topic 
of debate for some time, however, it is broadly agreed that assessments of interaction 
should be reported on both scales.   
9.2.4 Population Attributable Fraction 
Until this point in the thesis, I have considered, separately, the prevalence of CPRD-defined 
health disorders in the study population and the association of these disorders with HRJL. 
However, from a public health perspective, neither of these measures provides a sufficient 
estimate of the total burden of HRJL that would be prevented by modification of a given 
health exposure. The population attributable fraction (PAF) is a useful metric that can 
inform efforts to reduce population HRJL, by identifying exposures that are responsible for 
the greatest proportion of this adverse work outcome i.e. higher risk/higher prevalence 
exposures. The units of PAF are percentages, which express the estimated proportion of an 
outcome (in this case, HRJL) that is attributable to an exposure, and indeed estimates the 
proportion that would disappear if that exposure were removed from the population 
(assuming causality).  
For the use and interpretation of PAF, the examples provided by Mary Northridge are 
instructive.(486) One of the first uses of PAF was by Levin et al, who showed that smoking 
was associated with a high risk of lung cancer, and was also highly prevalent among men. 
He found a PAF of between 56 – 92%, meaning that the elimination of smoking could 
possibly reduce population lung cancer levels by more than 90% among men.(487) Another 
example involves the link between the BRCA1 gene and breast cancer; the risk of breast 
cancer is high among individuals with this allele although the prevalence in the general 
population is only 0.0007. Despite the low prevalence, the high individual risk associated 
with BRCA1 means PAF can be as high as 8.2%, depending on age.(486) Finally, certain 
exposures have a low associated risk but are highly prevalent in the population, and 
therefore warrant continued public health attention. This includes ultraviolet light 
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exposure, which affects virtually everyone, but has a relatively low individual risk. In this 
case, the PAF remains considerable (13 – 33%) due to the large population prevalence.(486) 
I considered the results of the preliminary main effects model(s), and used the independent 
effect estimates to calculate PAF of HRJL for CPRD-defined health disorders. PAF can be 
calculated from effect estimates observed in matched case-control studies, so long as a 
reliable estimate of the population prevalence can also be derived.(488) I used the 
prevalence of these CPRD-defined health disorders in the total HEAF baseline study sample 
(n=8109): a representative UK-based sample of the older working-age (aged 50 – 65 
years).(6) The formula for calculation of PAF is displayed in Figure 51, below.  
Figure 51: mathematical expression for the population attributable fraction 
𝑃𝐴𝐹 % = 100 ∗
𝑝 (𝑅𝑅 − 1)
𝑝(𝑅𝑅 − 1) + 1
 
Once again, where the outcome is rare enough that OR approximates RR (as in this case), 
this formula can be rewritten as: PAF = 100*p(OR – 1)/p(OR – 1) +1. 
9.3 Results 
9.3.1 Describing total study participants 
The 988 study participants have been described previously. In brief, half were cases with 
HRJL and half were matched controls. The median age was 58.21 years (IQR 53.36 to 60.89 
years), at the point of analysis. 44.5% were men, 98.1% were white, 68.9% were married, 
and 7.8% were single. 22.6% had a university-level qualification and 19.6% had no 
qualifications. Finally, 35.8% were working in higher managerial or professional class 
occupations, 27.5% in intermediate occupations, and 36.7% in routine or manual 
occupations.  
Of these participants, 22.1% had chronic MSDs, 24.4% had recent MSD pain, 17.9% had 
primary-care-level MHPs, 1.0% had psychiatric-care-level MHPs, 5.2% had recent sleep 
disorders, 22.0% had hypertension, 5.2% had ischaemic heart disease, 5.9% had heart 
failure, 0.7% had structural heart disease, 1.2% had peripheral atherosclerotic disease, 0.1% 
had venous thromboembolic disease, 0.8% had cardiac arrhythmias, 7.9% had asthma, 2.0% 
had COPD, 2.1% had cerebrovascular accident, 1.0% had epilepsy, and 9.2% had diabetes. 
The prevalence of multimorbidity (two or more CPRD-defined health disorders) was 33.2%.  
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9.3.2 The independent association of MSDs with HRJL, adjusting for other specific 
health disorders 
Using purposeful selection methods and known demographic, occupational, lifestyle, and 
health variables, a model was built for the prediction of HRJL.  
At the univariable level (using a p=0.25 threshold) the following factors were found to be 
associated with HRJL: level of education, single relationship status, history of heavy alcohol 
intake, chronic musculoskeletal disorders, recent musculoskeletal pain, primary care level 
mental health problems, sleep disturbances, psychiatric mental health problems, 
hypertension, heart failure, ischaemic heart disease, peripheral arterial disease, arrythmias, 
asthma, COPD, CVA, epilepsy, and diabetes. Ethnicity and smoking did not meet the 
threshold and were not initially entered into statistical models. As in previous chapters, 
participants with any musculoskeletal disorders were modelled together, as well as chronic 
musculoskeletal disorders and recent musculoskeletal pain disorders in separate models. 
In the first model, I considered participants with any MSD (chronic MSD or recent MSD 
pain). After iterative backward selection, the following variables were removed: 
educational attainment, sleep disorders, psychiatric-care-level MHPs, and COPD. Variables 
not initially included in the model (smoking and white ethnicity) were tested however no 
further important variables were found. Results from the final model are displayed in Table 
138, below. 
The following health disorders remained significantly associated with HRJL in this 
preliminary main effects model: any musculoskeletal disorder (aOR 1.86 95%CI 1.35 to 
2.56), primary-care-level MHP (aOR 3.49 95%CI 2.26 to 5.40), hypertension (aOR 1.58 
95%CI 1.07 to 2.32), heart failure (aOR 5.02 95%CI 2.14 to 11.77), asthma (aOR 2.18 95%CI 
1.24 to 3.82), cerebrovascular accident (aOR 3.88 95%CI 1.17 to 12.94), epilepsy (aOR 5.74 
95%CI 1.02 to 32.45), and diabetes (aOR 1.93 95%CI 1.06 to 3.52). 
From this model, I could also calculate the estimated combined effects of having both a 
musculoskeletal disorder and primary-care-level mental health disorder (aOR 6.49), MSD 
and hypertension (aOR 2.94), MSD and heart failure (aOR 9.34), MSD and asthma (aOR 
4.05), MSD and CVA (aOR 7.22), MSD and epilepsy (aOR 10.68), and MSD and diabetes (aOR 
3.59).  
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Table 138: Multivariable model of important health disorders and their association with 
HRJL, including any MSD to define musculoskeletal disorders 
Explanatory variable Association with HRJL, aOR 
(95%CI) 
Single relationship status 1.78 (0.99 to 3.19) 
History of heavy alcohol intake 2.72 (0.87 to 8.51) 
Musculoskeletal disorder 1.86 (1.35 to 2.56) 
Primary-care mental health problem 3.49 (2.26 to 5.40) 
Hypertension 1.58 (1.07 to 2.32) 
Heart failure 5.02 (2.14 to 11.77) 
Ischaemic heart disease 0.45 (0.20 to 1.01) 
Peripheral arterial disease 8.46 (0.93 to 77.22) 
Arrhythmias 6.90 (0.71 to 67.09) 
Asthma 2.18 (1.24 to 3.82) 
Cerebrovascular accident 3.88 (1.17 to 12.94) 
Epilepsy 5.74 (1.02 to 32.45) 
Diabetes 1.93 (1.06 to 3.52) 
 
In the second model, I considered participants with chronic MSDs. After iterative backward 
selection, the following variables were removed: level of education, sleep disturbance, 
psychiatric-level mental health problems, and arrhythmias. Variables not initially included 
in the model (smoking and white ethnicity) were tested however no further important 
variables were found. Results from the final model are displayed in Table 139, below. 
The following health disorders remained significantly associated with HRJL in the 
preliminary main effects model: chronic musculoskeletal disorders (aOR 1.69 95%CI 1.19 to 
2.41), primary-care-level mental health disorders (aOR 3.25 95%CI 1.10 to 5.54), 
hypertension (aOR 1.66 95%CI 1.13 to 2.42), heart failure (aOR 4.50 95%CI 1.94 to 10.45), 
asthma (aOR 1.80 95%CI 1.02 to 3.20), cerebrovascular accident (aOR: 4.12 95%CI 1.23 to 
13.77), and diabetes (aOR 2.10 95%CI 1.10 to 3.67). 
From this model, I could also calculate the estimated combined effects of having both a 
chronic musculoskeletal disorder and primary-care-level MHP (aOR 6.05), chronic MSD and 
hypertension (aOR 2.81), chronic MSD and heart failure (aOR 7.61), chronic MSD and 
asthma (aOR 3.04), chronic MSD and CVA (aOR 6.96), and a chronic MSD and diabetes (aOR 
3.40).    
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Table 139: Multivariable model of important health disorders and their association with 
HRJL, using chronic MSDs to define musculoskeletal disorders 
Explanatory variable Association with HRJL, aOR 
(95%CI) 
Single relationship status         1.80 (1.01 to 3.22) 
History of heavy alcohol intake 3.25 (1.10 to 9.63) 
Chronic MSD 1.69 (1.19 to 2.41) 
Primary-care-level MHP 3.58 (2.32 to 5.54) 
Hypertension 1.66 (1.13 to 2.42) 
Heart failure 4.50 (1.94 to 10.45) 
Ischaemic heart disease 0.48 (0.22 to 1.04) 
Peripheral arterial disease 7.78 (0.89 to 68.12) 
Asthma 1.80 (1.02 to 3.20) 
COPD 3.58 (0.86 to 14.92) 
Cerebrovascular accident 4.12 (1.23 to 13.77) 
Epilepsy 5.59 (0.98 to 31.76) 
Diabetes 2.01 (1.10 to 3.67) 
 
In the third model, participants with recent MSD pain were considered. After iterative 
backward selection, the following variables were removed: psychiatric-level mental health 
problems, level of education, sleep disorders, single relationship status, ischaemic heart 
disease and cardiac arrhythmias. Once again, variables not initially included in the model 
(smoking and white ethnicity) were tested however no further important variables were 
found. Results from the final model are displayed in Table 140, below. 
The following health disorders remained significantly associated with HRJL in the 
preliminary main effects model: recent musculoskeletal pain (aOR 2.14 95%CI 1.48 to 3.09), 
primary-care-level MHPs (aOR 3.41 95%CI 2.24 to 5.20), hypertension (aOR 1.56 95%CI 1.07 
to 2.28), heart failure (aOR 3.82 95%CI 1.78 to 8.10), cerebrovascular accident (aOR 3.93 
95%CI 1.13 to 13.63), epilepsy (aOR 5.92 95%CI 1.06 to 33.17), and diabetes (aOR 2.04 
95%CI 1.14 to 3.63). 
From this model, I could also calculate the estimated combined effects of having both 
recent musculoskeletal pain and a primary-care-level MHP (aOR 7.30), recent MSD pain and 
hypertension (aOR 3.34), recent MSD pain and heart failure (aOR 8.17), recent MSD pain 
and CVA (aOR 8.41), recent MSD pain and epilepsy (aOR 12.67), and recent MSD pain and 
diabetes (aOR 4.37).    
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Table 140: Multivariable model of important health disorders and their association with 
HRJL, using recent MSD pain to define musculoskeletal disorders 
Explanatory variable Association with HRJL, aOR 
(95%CI) 
History of heavy alcohol intake 3.30 (1.07 to 10.14) 
Musculoskeletal pain 2.14 (1.48 to 3.09) 
Primary-care-level MHP 3.41 (2.24 to 5.20) 
Hypertension 1.56 (1.07 to 2.28) 
Heart failure 3.82 (1.78 to 8.10) 
Peripheral arterial disease 7.47 (0.90 to 62.04) 
Asthma 1.73 (0.97 to 3.06) 
COPD 3.34 (0.89 to 12.56) 
Cerebrovascular accident 3.93 (1.13 to 13.63) 
Epilepsy 5.92 (1.06 to 33.17) 
Diabetes 2.04 (1.14 to 3.63) 
 
9.3.3 The statistical interaction between musculoskeletal disorders and other 
CPRD-defined health disorders associated with HRJL 
I examined the first, second, and third preliminary effects models above for the presence of 
statistical interactions between musculoskeletal health disorders and other CPRD-defined 
health disorders that were significantly associated with HRJL. Interactions on the additive 
and multiplicative scale were considered, as recommended by VanderWeele et al.(484) See 
Tables 78, 79, and 80, Appendix, for a full examination of preliminary main effects model 
interactions. 
In the second model, a significant interaction was observed between chronic MSDs and 
diabetes on the multiplicative scale (aOR 0.24 95%CI 0.07 to 0.82) but not the additive scale 
(RERI -2.53 95%CI -5.13 to 0.07). On the multiplicative scale, this appeared to show a 
slightly protective interaction, i.e. the combined effect of having both diabetes and a 
chronic MSD appeared to have a smaller association with HRJL than the product of the 
effects of the two disorders individually.  
No interaction between musculoskeletal disorders and any other health problem was 
observed across all three models.  
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9.3.4 The Population Attributable Fraction 
The population attributable fraction (PAF) of HRJL was calculated for each of the CPRD-
defined health disorders that were significantly associated with HRJL in the preliminary 
main-effects model(s) outlined above. As described in the methods, PAF was calculated 
using two metrics 1) an estimate of the association between a CPRD-defined health 
disorder and HRJL and 2) an estimate of the prevalence of this CPRD-defined health 
disorder in the population of interest (UK older-age workers).  
Prevalence estimates were calculated using the baseline HEAF study population (n=8109), a 
UK-representative population.(201) Effect estimates for musculoskeletal disorders (chronic 
or pain), primary-care-level MHPs, hypertension, heart failure, asthma, cerebrovascular 
accident, epilepsy, or diabetes was derived from the first main-effects model. The effect 
estimate for chronic MSDs was derived from the second main-effects model; and the effect 
estimate for recent MSD pain was derived from the third main-effects model. Finally, the 
effect estimate for multimorbidity was derived from a separate model of the association 
between multimorbidity (two or more CPRD-defined health disorders) and HRJL, compared 
to not having multimorbidity, adjusted for single status, qualification level, and history of 
heavy alcohol intake.  
Of the individual health disorders, primary care-level MHPs had the largest PAF (25.0%). 
Recent musculoskeletal pain was found to have a PAF of 18.2% and chronic MSDs had a PAF 
of 13.0%, although, together, musculoskeletal disorders had the second largest PAF of 
22.5%. Heart failure had the next largest PAF at 17.7% as it was strongly associated with 
HRJL and its prevalence was 5.4% in the HEAF baseline population. This was followed by 
hypertension (10.5%), asthma (9.0%), diabetes (7.3%), epilepsy (4.4%), and cerebrovascular 
accident (3.7%). However, multimorbidity was observed to have a greater PAF than any 
individual condition, which was estimated to be 55.6% for the UK older-working age 
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Table 141: Population Attributable Fraction of HRJL for CPRD-defined health disorders 











Any MSD 33.7% 1.86 (1.35 to 2.56) 22.5% 
Chronic MSD 21.6% 1.69 (1.18 to 2.42) 13.0% 
Recent MSD pain 19.6% 2.14 (1.48 to 3.09) 18.2% 
Primary care MHP 13.4% 3.49 (2.26 to 5.40) 25.0% 
Hypertension 20.2% 1.58 (1.07 to 2.32) 10.5% 
Heart failure 5.4% 5.02 (2.14 to 11.77) 17.7% 
Asthma 8.4% 2.18 (1.24 to 3.82) 9.0% 
CVA 1.3% 3.88 (1.17 to 12.94) 3.7% 
Epilepsy 1.0% 5.74 (1.02 to 32.45) 4.4% 
Diabetes 8.5% 1.93 (1.06 to 3.52) 7.3% 
Multimorbidity 41.4% 4.02 (2.87 to 5.64) 55.6% 
 
Figure 52: the estimated population attributable fraction of CPRD-defined health 
disorders and multimorbidity for HRJL in the older working age population 
 
9.4 Summary 
• Musculoskeletal disorders, including chronic MSDs and recent MSD pain, remained 
independently associated with HRJL after adjustment for other important CPRD-








Population Attributable Fraction of HRJL (%)
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• Primary care-level MHPs, hypertension, heart failure, cerebrovascular accident, and 
diabetes were also observed to be independently and significantly associated with 
HRJL, in all analyses. 
• Musculoskeletal disorders comorbid with primary-care-level MHPs, heart failure, 
cerebrovascular accident, or epilepsy were estimated to have a particularly strong 
association with HRJL. 
• Of the individual health disorders, primary-care-level MHPs and musculoskeletal 
disorders (chronic or pain) had the largest estimated population attributable 
fraction of HRJL in the UK older working-age population (PAF 25.0% and 22.5%, 
respectively). However, multimorbidity was estimated to account for over half of all 
HRJL in the UK older working-age population (PAF 55.6%). 
9.5 Discussion 
In the previous chapter, participants with MSDs were found to have a high degree of 
comorbidity (58.7%) compared to the level of multimorbidity in the general study 
population (33.2%). This chapter contributed important data helping establish the 
independent effect of musculoskeletal disorders (chronic and/or pain) on HRJL, after 
adjusting for the presence of other common health disorders. The independent effect 
estimates generated in multivariable modelling were then used to estimate the proportion 
of HRJL that could be attributed to these CPRD-defined health disorders in the UK older 
working-age population. Findings confirm that musculoskeletal disorders and mental health 
problems are the two greatest contributors to HRJL, however results also suggested that 
considerably more HRJL could be attributed to multimorbidity than any individual health 
disorder. These findings should encourage a greater interest in research focussed on 
multimorbidity, both for its role as a predictor of adverse work outcomes and to develop 
interventions to support people with multimorbidity to remain at work.  
Across all three preliminary main effects models, chronic MSDs (aOR 1.69 95%CI 1.19 to 
2.41), recent MSD pain (aOR 2.14 95%CI 1.48 to 3.09), primary care-level MHPs (aOR 3.49 
95%CI 2.26 to 5.40), hypertension (aOR 1.58 95%CI 1.07 to 2.32), heart failure (aOR 5.02 
95%CI 2.14 to 11.77), cerebrovascular accident (aOR 3.88 95%CI 1.17 to 12.94), and 
diabetes (aOR 1.93 95%CI 1.06 to 3.52) remained independently and significantly 
associated with HRJL after adjustment for other CPRD-defined health problems. Asthma 
may also have a weak-moderate independent association with HRJL (aOR 1.73 to 2.18), 
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epilepsy may have a strong independent association (aOR 5.59 to 5.92), COPD may have a 
strong independent association (aOR 3.34 to 3.58), and peripheral atherosclerotic disease 
may have a very strong association (aOR 7.47 to 8.46), although this effect was not 
statistically significant across all models. Cardiac arrhythmias were included in only the first 
model and may also have a strong association with HRJL, although effect estimates were 
very uncertain (aOR 6.90 95%CI 0.71 to 67.09).  
In Chapter 6, CPRD-defined ischaemic heart disease was found to have a mild, but non-
significant, association with HRJL, after adjustment for educational attainment, single 
relationship status, and history of heavy alcohol intake (aOR 1.32 95%CI 0.74 to 2.37). In 
this chapter, ischaemic heart disease was included in two preliminary main effects models 
but tended towards a more protective effect (aOR 0.45 and 0.48). Although running a 
statistical test of multicollinearity (VIF) in these models did not suggest substantial 
intercorrelation between ischaemic heart disease and other covariables, it was found that 
when other indicators of cardiometabolic disease (hypertension, heart failure, peripheral 
arterial disease, cardiac arrhythmias, and diabetes) were adjusted for, the estimated 
direction of effect for ischaemic heart disease reversed. Therefore, it is possible that other 
indicators of the “cardiometabolic syndrome” were acting as the primary mediators of the 
relationship between ischaemic heart disease and HRJL. Participants with particularly 
severe forms of ischaemic heart disease (i.e. myocardial infarction) may not have taken part 
in the HEAF study to begin with, or, where occurring, may have been better captured by 
other CPRD-defined disorders relating to severe cardiovascular disorders e.g. heart failure 
and peripheral arterial disease.   
In Chapter 6, sleep disorders were also moderately associated with HRJL after adjustment 
for educational attainment, single relationship status, and history of heavy alcohol intake 
(aOR 2.74 95%CI 1.40 to 5.38). These also occurred commonly alongside primary-care-level 
MHPs in cluster analysis (see Chapter 7). However, sleep disorders were non-significantly 
associated with HRJL after adjustment for the presence of primary care-level MHPs (aOR 
1.43 95%CI 0.70 to 2.93) and, as a result, did not achieve inclusion in any of the preliminary 
main effects models in this chapter. Since 72.6% of participants with sleep disorders also 
had a recent primary-care-level MHP, it seems likely that MHPs are the primary mediator of 
the previously observed relationship between sleep disorders and HRJL. 
In Chapter 8, among participants with musculoskeletal disorders, the mental health 
problem comorbidity cluster was found to have the strongest association with HRJL. From 
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the preliminary main effect models, it was possible to estimate the combined effects of 
having both a musculoskeletal disorder and a primary care-level MHP specifically, which 
was associated with a 6.05- to 7.30-fold increased odds of HRJL. Previous studies have 
considered musculoskeletal-mental health comorbidity and its relationship to adverse work 
outcomes. I’ve commented on the heterogeneity of such studies in the systematic review 
chapter of this thesis (Chapter 4, Section 4.3.2), which makes direct comparisons difficult. 
However, among studies using the general population as the reference group, the 
relationship between musculoskeletal-mental health comorbidity and sickness absence or 
“work-loss” days,(335,364,489) work cut-back days,(335) reduced physical work 
ability,(385) thoughts of early retirement,(385) and disability retirement,(490) has been 
reported. In all cases, these studies found that the combination of musculoskeletal 
disorders with mental health problems resulted in considerably worse work outcomes than 
for participants with purely musculoskeletal or mental health morbidity. For example, Kaila-
Kangas et al. presented a longitudinal analysis of disability retirement in 3943 working 
Finns, aged 30 to 63 years old. Over follow up, participants with MSDs (including low back 
pain and osteoarthritis) had a hazard ratio of 2.2 (95%CI 1.8 to 2.7), participants with 
common mental health problems (including mostly primary care-level MHPs) had a hazard 
ratio of 2.4 (95%CI 1.7 to 2.7), and participants with both conditions had a hazard ratio of 
4.1 (95%CI 2.9 to 5.7) for the receipt of disability pension. 
Identified studies also considered the possibility of an interaction between comorbid 
musculoskeletal and mental health problems for adverse work outcomes. Kaila-Kangas et 
al., the most comparable study, found no such interaction for receipt of disability pension 
on the additive or multiplicative scale.(490) In contrast, synergistic behaviour has been 
observed between musculoskeletal pain and depression for self-reported thoughts of early 
retirement;(385) and between chronic back pain and mental health disorders for work loss 
days in the past 12 months.(364) In this chapter, no such interactions were observed on the 
additive or multiplicative scale for HRJL, meaning I found no evidence that the impact of 
these conditions together was more than the combination of their individual effects. 
However, analysis may have been underpowered to detect this effect.  
Interaction effects were also used to explore any modification of the relationship between 
MSDs and HRJL by other co-occurring health conditions. A negative multiplicative 
interaction between chronic musculoskeletal disorders and diabetes was observed. In other 
words, the combined impact was less than the product of their individual effects. One 
possible reason for this could involve increased monitoring and contact with healthcare 
334 | P a g e  
 
professionals leading to overall improved care and outcomes for both musculoskeletal and 
diabetic health problems. However, no such interaction was observed on the additive scale, 
and it is possible that statistical significance occurred by chance (as may occur periodically 
with multiple testing). No other significant interactions were observed between 
musculoskeletal disorders and other health disorders, however the sample size may have 
been underpowered to confidently assess interactions between MSDs and cerebrovascular 
accident or epilepsy.  
Finally, results from the preliminary main effects models were used to calculate the 
population attributable fraction of HRJL for each CPRD-defined health disorder. In order to 
avoid extremely skewed estimates of PAF, I focussed on conditions that had a statistically 
significant association with HRJL in the final adjusted models of this chapter. In order of 
importance, the following health disorders were estimated to account for the greatest 
proportion of HRJL among the UK older working-age population: Primary-care-level MHP 
(25.0%), any MSD (22.5%), recent MSD pain (18.2%), heart failure (17.7%), chronic MSD 
(13.0%), hypertension (10.5%), asthma (9.0%), diabetes (7.3%), epilepsy (4.4%), and CVA 
(3.7%). As mentioned previously, it is known that common mental health disorders, 
musculoskeletal disorders, and cardio-respiratory disorders are, together, responsible for 
the majority of work disability.(48) This is reflected in the results of this chapter. However, 
the quantity of health-related work loss that can be attributed to multimorbidity has been 
previously unexplored. In this study, an estimated 55.6% of HRJL could be attributed to the 
presence of two or more CPRD-defined health disorders, a fraction that was at least double 
that of any individual condition. In Chapter 8, it was shown how the odds of HRJL increases 
precipitously with number of comorbid health conditions. In this chapter, the large PAF 
observed for multimorbidity also suggests that a significant proportion of premature work 
loss in the population could be avoided by preventing multimorbidity. It has already been 
shown that a large proportion of this multimorbidity is due to musculoskeletal-mental 
health comorbidity, which has a particularly strong association with HRJL. Therefore, the 
avoidance of mental health comorbidity in musculoskeletal disorders (and vice versa) 
should be considered a priority area for preventive interventions to support the older 
working-age population to remain in work. In addition, populations with musculoskeletal-
mental health comorbidity should be examined to manage additional risks to their physical, 
mental, and occupational health that occur as a direct result of their comorbidity. This will 
encourage person-centred, rather than disease-centred, solutions that go beyond the 
management of isolated clinical health disorders.   
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An assessment of population attributable fractions resulted in some surprising results. 
Particularly, the large PAF observed for heart failure, which is discussed below, as well as 
the considerable PAF observed for hypertension and asthma. As previously discussed, 
despite being a generally symptomless condition, hypertension is likely associated with 
other health disorders that were unmeasured in this thesis, for example, obesity.(423) The 
1.56 to 1.66-fold increased odds of HRJL observed in the multivariable models for 
hypertension was in line with its previously reported risk of disability pension (RR 1.50 
95%CI 1.31-1.72).(421) However, it is certainly the high prevalence of hypertension that 
drives its importance among the older working age population (PAF 10.5%). 
Asthma too, was associated with a considerable PAF (9.0%). This condition may be more 
complicated among older adults, as a result of age-related deterioration of lung function, 
degenerative changes in respiratory musculature, and immunological and inflammatory 
changes. At older ages, asthma also associates with several comorbidities, some of which 
were unmeasured in this thesis, such as obesity, gastro-intestinal reflux disease, cataracts, 
and osteoporosis.(491) In addition, as alluded to in earlier chapters, an overlap syndrome 
exists between asthma and COPD at older ages. The extent of such a syndrome is not 
insignificant, such that after the age of 65 years, most people with obstructive airway 
disease have both asthma and COPD diagnoses.(492,493) It should also be noted that a 
stricter classification of asthma was employed in this study, requiring that participants were 
continuing to receive treatments for asthma in the year prior. This may have ruled out very 
mild presentations of asthma.  
The population attributable fraction observed for heart failure was very large (PAF 17.7%) 
which was a similar level to that observed for recent musculoskeletal pain (PAF 18.2%) and 
a greater level than that observed for chronic MSDs (13.0%). I had previously thought the 
high prevalence of heart failure observed in this study (5.9%) was due to the number of 
study participants with health-related job loss (and therefore worse health than the general 
population). However, the prevalence of this CPRD-defined disorder was also high in the 
HEAF baseline population (5.4%). As a result, I reviewed the Read codes that had been used 
to classify heart failure in this study (see Appendix Table 4). Unfortunately, despite the 
Read codes having been proofed by two personnel (myself and Professor Keith Palmer), 
one diagnostic code “seen in cardiac clinic” had been sorted into the heart failure category. 
Although all other Read codes in this category were heart failure specific, it cannot be ruled 
out that this code was particularly noisy, and it must be assumed, was the cause of the 
large prevalence and, by extension, PAF for HRJL. CPRD-defined heart failure was strongly 
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associated with HRJL throughout this thesis, however, this measurement error must now be 
taken into account in the interpretation of this finding. In the UK, cardiac clinic is where 
diagnostic cardiac investigations (such as echocardiography, tilt testing, and ECG) occur, as 
well as Rapid Access Chest Pain Clinic, cardiac monitoring, cardiac rehabilitation, and 
services related to the management of heart failure and atrial fibrillation. As such, this 
variable is unlikely to be heart failure specific, and more likely represents a cross-section of 
the study sample with more severe kinds of cardiovascular disease, including heart failure. 
It should also be noted, that to be classified as having heart failure participants were 
required to have received a prescription for treatments used in heart failure. This improves 
specificity of CPRD-defined heart failure, although such drugs may have multiple 
indications.  
Other than the limitations already outlined above and in other chapters of the thesis, one 
of the major limitations of this study was the sample size which, in many cases, was 
underpowered to assess the impact of having two specific concomitant disorders on HRJL. 
Instead, I estimated the combined effects of exposure to musculoskeletal disorders and 
other health disorders from the preliminary main effects models constructed in this 
chapter. It is also possible that analysis was underpowered for the detection of statistical 
interactions between health exposures in these models. This was particularly true for rarer 
diseases.  
In recognition of the fact that health disorders do not occur in isolation, the strengths of 
this chapter included its adjusted analyses of the impact of health disorders on HRJL. These 
analyses accounted for the presence of several other prevalent and important health 
disorders and included an examination of how these health disorders interact with one 
another in their association with HRJL. While it is commonplace in the literature to adjust 
for the presence of comorbidity, or number of comorbidities, when considering the 
association between a specific health problem and work status, few studies examined 
several conditions concurrently. In addition, the reporting of population attributable 
fractions will help the reader to judge the public health impact of these exposures among 
the older working-age population. I found only one other similar study, looking at the 
relationship between several chronic conditions and being out of the labour force for 
health reasons.(494) This paper used self-report data from the representative Canadian 
Community Health Survey to classify health-related worklessness and the presence of seven 
physical chronic conditions: arthritis, hypertension, back problems, migraine, diabetes, 
heart disease, and thyroid disorders. However, PAF was calculated using prevalence figures 
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derived from participants with health-related worklessness, and included participants as 
young as 25 years old, therefore results are not comparable. Unlike the work in this 
chapter, this study also did not consider mental health problems which have been shown to 
be a key health exposure in worklessness. 
In conclusion, musculoskeletal disorders (chronic and/or recent pain) remained 
independently associated with health-related job loss after adjustment for the presence of 
other common health conditions. Primary-care-level MHPs, hypertension, heart failure, 
cerebrovascular accident, diabetes, asthma, epilepsy, COPD, and peripheral atherosclerotic 
disease also remained independently and significantly associated with HRJL in multivariable 
modelling. At the population level, a large proportion of HRJL was estimated to be 
attributable to musculoskeletal disorders and mental health disorders, individually. These 
conditions, in previous chapters, have also been shown to commonly co-occur in clusters 
with very strong association to HRJL. Overall, far more HRJL could be attributed to 
multimorbidity than to any individual condition, which suggests a stronger public health 
focus on co-occurring health problems is required for the prevention of premature exit 
from work.   
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Chapter 10 - discussion and 
conclusions 
10.1 Introduction  
In this chapter, I summarise the major research findings across the entire thesis and discuss 
their significance both for the individual and the UK population as a whole. In relation to 
the wider scientific literature, I discuss how the work of this thesis has added to previous 
findings, the strengths and limitations, and I highlight important research gaps to prioritise 
areas for future research. Next, I examine relevant policy at a national and local level and 
consider where the findings of this thesis buttress current recommendations or suggest the 
need for change. Lastly, I discuss interventions and strategies that could be used to help 
support high-risk groups identified in this thesis to remain in work.   
10.2 Summary of findings in the context of previous research 
The thesis began with a narrative review chapter introducing musculoskeletal disorders, 
multimorbidity, and the work and health context. From this review work, research 
questions were generated. Using a systematic review, I explored what is currently known 
about the impact of comorbidity upon work outcomes among people with musculoskeletal 
disorders. Then, using linked data from the English population-based Health and 
Employment After Fifty (HEAF) study and the Clinical Practice Research Datalink (CPRD) 
among the older working-age population (aged 50 – 65 years old) 1) I described a 
representative sample of participants with HRJL 2) I explored factors associated with the 
development and persistence of HRJL 3) I found patterns of multimorbidity that feature 
commonly within this population, and 4) I considered the importance of these 
multimorbidity patterns in relation to HRJL. Finally, 5) I considered the population 
attributable fraction of HRJL for each of the studied health disorders, and of multimorbidity 
itself. 
Chapter 4: systematic review 
In the first results chapter, a systematic review was performed to answer the question, 
“how does comorbidity impact work outcomes in musculoskeletal disease?” Compared to 
having a musculoskeletal disorder alone, comorbidity, and specifically comorbid mental 
health problems, were consistently associated with a range of adverse work outcomes 
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across different MSD populations. While a statistically significant impact was observed in 
most studies, reported effect sizes varied considerably, reflecting differences in underlying 
study populations, classification of work outcomes, and criteria for comorbidity. However, 
overall, the direction of effect was very consistent (see Figures 26 and 27). The detrimental 
impact of comorbidity on work was an important finding in this key disease group for work 
disability in the UK (see Figure 53).(118) MSDs are highly prevalent among the working-age 
population, and interventions that help support people to remain in work can be expensive 
and time-consuming. Therefore, the identification of high-risk groups within MSD 
populations can help to focus efforts towards the patients who are most likely to struggle 
to remain in work.  
Figure 53: Health and Work infographic: spotlight on musculoskeletal disorders. Contains 
public sector information licensed under the Open Government Licence v3.0. (118) 
 
One of the primary findings of the systematic review concerned the limitations of the 
evidence base. Weaknesses included inconsistencies in the classification of the study 
population, the exposure of interest, and the work outcome of interest.  
Few included papers studied participants with osteoarthritis (the most common chronic 
musculoskeletal disorder) or low back pain (the most common type of musculoskeletal pain 
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condition) which meant indirectness was an issue when applying results to the entire MSD 
population.  
Comorbidity was poorly and inconsistently defined. While some studies used validated 
comorbidity checklists, these were validated against criteria unrelated to work ability, such 
as mortality or healthcare utilisation.(9,13,334,341,343,361–363) In analysis, comorbidity 
exposure was also often reduced to a simplified yes/no criteria with no exploration of a 
gradient in effect, or the common patterns of 
comorbidity.(10,11,199,342,348,349,353,357,359,366) 
Reported work outcomes were also inconsistently defined, to the extent that grouping 
them together for the purposes of review was challenging. For example, classifications of 
work disability, sickness absence, and health-related productivity loss may be so broadly 
defined that definitions overlap.(12,199,338,353,365) For these and other work outcomes, 
particularly return to work following disability,(345–348,351,355,356,364,366) the 
timeframe over which the outcome was assessed differed by months or years between 
studies. 
Studies reporting the impact of specific comorbidities upon work in MSD populations, 
mostly focussed on comorbid mental health problems (frequently depression), which were 
generally associated with worse work outcomes. Additionally, some studies observed a 
multiplicative interaction, whereby musculoskeletal disorders and mental health problems 
worked synergistically in association with sickness absence and impaired work 
ability.(335,357,364,385) Other comorbid disorders were under-reported, which was 
surprising particularly for health problems such as diabetes and cardiovascular disorders, 
which commonly co-occur with musculoskeletal disorders in the general 
population.(388,389) Importantly, few studies compared the effect of multiple specific 
comorbidities in the same musculoskeletal population, which made it difficult to determine 
which comorbid health disorders were likely to be the most impactful. 
Overall, this review found strong and consistent evidence that comorbidity, and comorbid 
mental health problems, are important risk factors for the development of a range of poor 
work outcomes across various musculoskeletal populations. The scope of this review was 
considerably broader than previous work in this area: only two previous systematic reviews 
had looked at comorbidities and occupational outcomes in MSD populations. One of these 
studies (Baumeister et al.) found a mixture of supportive and inconclusive evidence 
regarding the detrimental impact of comorbid mental health problems on return to work 
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and sickness absence in a low back pain population; the other (Lloyd et al.), found 
depression was linked to worsened return-to-work rates when comorbid with 
MSDs.(330,331) Both of these studies were old (published 2008 – 2012), were limited in 
their focus on comorbid mental health problems alone, and only considered selected work 
outcomes. To my knowledge, no previous review has been completed looking at the impact 
of any comorbidity on work-related outcomes in MSDs, covering all major employment 
outcomes including work disability, unemployment, job loss, return-to-work time, and 
productivity. To consider all of these outcomes was important in order to get a sense of the 
continuum of work-health interactions which may begin in the workplace with 
presenteeism, leading to absenteeism, job loss, and finally permanent work 
disability.(495,496) By showing that comorbidity impacts work at each of these stages, my 
review suggests a rationale for addressing comorbidity (and mental health problems) at an 
early stage in people with musculoskeletal disorders, while it is still possible to maintain 
their work situation. The Department of Work and Pensions have found less than 50% of 
people with 6 months sickness absence ever return to work and few people return to any 
form of work after 1-2 years absence, irrespective of further treatment.(47) Therefore early 
identification of high risk groups needing support is key, something that this review can 
help to inform.  
Finally, this review chapter highlighted the little that is known about non-psychiatric 
disorders and their impact upon work in MSDs. The convincing evidence showing that 
higher comorbidity scores (all of which included non-psychiatric disorders in their 
classifications) were associated with poorer work outcomes, suggests that non-psychiatric 
health problems may also have an important role to play in the work ability of people with 
MSDs. Study of the impact of these disorders on work in MSDs is an important omission 
from the evidence base identified by this review. As described below, this has implications 
for the direction of future research. 
Chapter 5: describing a cohort of older workers with HRJL 
Participants of HEAF with HRJL, for whom CPRD data was available around the time of their 
job loss, were described for known demographic, lifestyle, and health-factors. These 
participants commonly had been working in occupations such as teaching, administration, 
and service industries. Certain health problems were particularly prevalent in this cohort 
such as musculoskeletal disorders (recent MSD pain and chronic MSDs), primary care-level 
mental health problems, hypertension, ischaemic heart disease, heart failure, asthma, and 
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diabetes. These findings provided important descriptive evidence showing the types of 
health problems commonly affecting those with health-related exit from work in the UK, 
and the kinds of employment they were unable to maintain.  
It was observed that participants in whom HRJL occurred at an earlier age were broadly less 
well educated, less likely to have chronic musculoskeletal disorders and cardiovascular 
disorders, but more likely to have mental health problems. Whereas those who 
experienced HRJL at older ages were more likely to be diagnosed with age-associated 
conditions such as MSDs and cardiovascular disorders. This finding helped to delineate two 
distinct groups within the study sample, those with long-term HRJL from a younger age, and 
those with HRJL that occurred between 50 – 65 years of age (the focus of this thesis). The 
differences between these subgroups, only hinted at in this chapter, may encourage further 
research to consider whether different approaches are required to support employment for 
those with HRJL at younger ages.   
An interesting distinction was also observed between men and women with HRJL for the 
types of jobs previously worked. For example, men were predominantly in careers such as 
construction and trade, agriculture, electronics, and transport while participants in 
healthcare, management, administration, caring, service, and sales occupations were 
mostly women. Men with HRJL were also more likely to have lost work from routine and 
manual-type jobs compared to women with HRJL. Aside from the much-debated drivers of 
these gender differences,(497) this was an important observation which showed that the 
work environments of older working-age men and women were, on average, quite distinct. 
In addition, men and women (with HRJL) had broadly different disease profiles: 
cardiovascular problems were more prevalent in men and primary-care level mental health 
disorders were more prevalent among women. Similar findings have been well observed in 
the literature.(235,395) However, for the purposes of this thesis, the observed differences 
in occupational environment and disease burden between men and women prompted the 
use of stratified analysis by gender. By extension, this finding also provides support for 
exploration of gender-influences upon health-related work outcomes in future research. In 
the reviewed literature, stratification of results by gender was uncommon, even in recent 
publications,(200,340) although most studies adjusted for gender statistically.  
Primarily, the strength of this chapter lies in its description of a contemporary and 
representative UK-based population who have fallen out of work for health reasons. Few 
UK-based studies of health-related job loss amongst the older working-age have been 
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conducted. Yet this is an important research gap since those aged over 50 are highest risk 
for leaving the work force.(46) As such, understanding the profile and health status of this 
unique cohort is key to understanding the interplay of factors leading to their poor work 
outcomes, and to inform the design of policy and workplace interventions to support 
employment.  
Chapter 6: case-control study of CPRD-defined health disorders and HRJL 
In Chapter 6, participants with HRJL were matched to controls for important confounders 
including age, gender, and GP practice, and a case-control analysis was performed. 
Differences were assessed between participants with HRJL (the cases) and matched 
participants who remained working at the point of time that cases lost their jobs (the 
controls). Using conditional logistic regression, several CPRD-defined health disorders were 
significantly associated with the development of HRJL, after statistical adjustment for other 
known confounders. These included: chronic musculoskeletal disorders, recent 
musculoskeletal pain, primary care-level mental health problems, sleep disorders, 
hypertension, heart failure, peripheral arterial disease, COPD, cerebrovascular accident, 
and diabetes (see Figure 36, Chapter 6). The effect estimates of other CPRD-defined health 
disorders suggested that they may also be associated with HRJL, however analysis was 
underpowered to show a statistically significant effect, these included: psychiatric-level 
mental health disorders, cardiac arrythmias, and epilepsy. Structural heart disease is also 
likely to be important at the individual level since all seven participants with this condition 
were cases. However, for this reason, I was also unable to generate an effect estimate for 
this variable in conditional logistic regression. 
Studied health disorders appeared to have a broadly consistent association with HRJL after 
stratification by gender. For certain progressive age-related conditions, such as chronic 
MSDs, heart failure, and COPD, the strength of association was larger among those with 
HRJL at older ages, in whom these diseases were more prevalent and possibly more severe. 
The association between primary care-level MHPs or recent musculoskeletal pain and HRJL 
seemed more marked in the younger age groups. However, in all cases following 
stratification, confidence intervals were wide.  
 A considerable amount of research has already outlined the relationship between mental 
health problems and musculoskeletal disorders for disability pension, although these 
studies largely included broader age groups and non-UK nationalities (and used 
heterogeneous classifications for exposures and outcomes). For example, a systematic 
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review and meta-analysis by van Rijn et al. (2014) pooled estimates of effect from 17 
studies of mental health problems and 12 studies of musculoskeletal disorders, and found 
these conditions were significantly associated with disability pension (RR 1.80 95%CI 1.41 to 
2.31 and RR 2.23 (1.93 to 2.56, respectively),(115) these estimates of association were 
comparable to those observed for HRJL in this thesis. However, the work of this chapter 
contributes to these findings by confirming the importance of these conditions in a 
contemporary and narrowly-defined population of pivotal importance to UK 
policymakers.(46)  
For conditions unrelated to musculoskeletal disorders or mental health problems, the 
available research for comparison was scarce. This represents a considerable research gap 
which the work of this chapter can help to fill: cardiovascular disorders, diabetes, and some 
respiratory conditions, such as asthma and COPD, occur frequently among older 
workers,(329) yet their impact upon health-related work loss is not yet sufficiently 
accounted for. The systematic review by van Rijn et al. found only four studies considering 
the association between other health disorders and disability pension (including two 
studies of “chronic bronchitis”, and two studies considering low resolution categories of 
health problems such as “circulatory disease” and “respiratory disease”) for which point 
estimates suggested an important relationship.(115) In addition, one recent prospective 
study from the Netherlands, among older workers, also suggested cardiovascular and 
respiratory disorders have an important impact upon work disability (SHR 2.13 95%CI 1.44 
to 3.16 and 2.11 95%CI 1.45 to 3.07, respectively)(498) – these findings, and those of this 
thesis, suggest cardiovascular disorders and respiratory disorders deserve closer attention 
in future research. In this chapter, however, cardiovascular disorders (hypertension, heart 
failure, ischaemic heart disease, peripheral arterial disease) and respiratory disorders 
(asthma, COPD) were considered at a greater resolution, allowing for differences between 
distinct clinical conditions to be considered.  
This chapter also found the presence of diabetes to be detrimental for maintaining work to 
older ages, a finding that is both supported(420,426) and contradicted(498) in existing 
research. The lack of association between diabetes and disability benefits observed in the 
Netherlands cohort study may have been due to the adjustment of analysis for 
cardiovascular disorders (which may have adjusted for participants with more severe 
diabetic disorders), however, diabetes remained importantly associated with HRJL in this 
thesis, even after adjustment for other cardiovascular disorders (see Chapter 9). More work 
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is needed to study the contribution of this condition to work outcomes, particularly 
addressing common clinical sequelae within diabetic populations.  
Finally, this chapter considered specific health disorders that, to my knowledge, have not 
yet been studied for their association with HRJL in the older working age population: these 
included epilepsy, cerebrovascular accident, peripheral arterial disease, COPD, cardiac 
arrythmias, structural heart disease, and asthma. The direction of effect observed 
suggested that these conditions, also, have an important role to play in HRJL among older 
workers. Future research, with greater statistical power is needed to confirm the 
relationship between these conditions and premature exit from work. 
Chapter 7: describing patterns of multimorbidity 
Using the 16 health disorder variables, for which CPRD-data was available, I explored 
common patterns of co-occurrence across the total study sample (cases and controls). The 
most common comorbid pairs were comprised of highly prevalent conditions in the 
population; for example, musculoskeletal disorders with hypertension, musculoskeletal 
disorders with primary-care level mental health problems, and diabetes with hypertension.  
Recognising the overlap between chronic MSDs and recent MSD pain (34.9% of participants 
with chronic MSDs had recent MSD pain. 31.5% of participants with recent MSD pain had a 
chronic MSD disorder), cluster analysis to study patterns of multimorbidity were run 
separately for these two musculoskeletal groups. The generated multimorbidity clusters 
were similar regardless of whether chronic MSDs or recent MSD pain groups were included. 
The following multimorbidity clusters appeared consistent: large clusters of participants 
with mental health disorders and musculoskeletal disorders, primarily; small clusters of 
participants with ischaemic heart disease, heart failure, and hypertension, primarily; large 
clusters of participants with hypertension and musculoskeletal disorders (and a high 
prevalence of diabetes), primarily; and small clusters of participants with asthma and COPD, 
primarily.  
Among multimorbid men the clusters that formed were similar to those that had occurred 
among all participants with multimorbidity, these included: a cluster of participants with 
mental health disorders and musculoskeletal disorders, primarily; a cluster of participants 
with hypertension, musculoskeletal disorders, and diabetes, primarily; a cluster of 
participants with other cardio-metabolic disorders, primarily; and a cluster of participants 
with asthma and COPD, primarily. Among women, two main clusters formed consistently, 
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including: a cluster of participants with hypertension and musculoskeletal disorders, 
primarily; and a cluster of participants with mental health disorders and musculoskeletal 
disorders, primarily. 
Lastly, a cluster analysis of comorbid health disorders was performed among participants 
with musculoskeletal disorders (chronic or pain). A cluster of participants with 
musculoskeletal disorders and no other known health disorders formed. Other prominent 
clusters included participants with comorbid hypertension, primarily (and a high prevalence 
of comorbid diabetes); participants with comorbid cardiovascular disorders, primarily 
(ischaemic heart disease and heart failure); participants with comorbid asthma, primarily; 
and participants with comorbid mental health problems. Among people with 
musculoskeletal disorders, the two most prominent comorbidity clusters were those 
formed by comorbid hypertension and by comorbid mental health problems.  
The descriptive analyses outlined in this chapter revealed a high degree of multimorbidity 
in this older working age sample. Multimorbidity, classified as two or more CPRD-defined 
health disorders, was present in approximately a third of all participants (33.2%). It is 
difficult to compare this prevalence to figures reported in the literature, which are often 
based on very different classifications of multimorbidity (using different constituent 
diseases). However, findings supported the high degree of multimorbidity observed for the 
older working-age group in other UK population-based studies, most notably, the Scottish 
epidemiological study of multimorbidity produced by Barnett et al.(438) Also, among those 
with a known health problem, approximately half (47.9%) had multimorbidity. Importantly, 
this result suggests that the health disorders studied here should not be viewed in isolation 
when assessing their role as catalysts of adverse work outcomes in older workers. An 
increased focus on multimorbidity by researchers and policymakers will promote holistic 
work solutions for older working-age people in a system that too often targets single 
illnesses alone. For example, researchers and policymakers considering employment 
outcomes and musculoskeletal disorders should be aware that these conditions frequently 
overlap with mental health problems and hypertensive disorders. 
Similarly, it was difficult to compare the multimorbidity patterns observed in this chapter to 
those of existing research describing patterns of multimorbidity. Identified studies differed 
for number, demographics, and selectivity of recruited participants; the data sources and 
classifications used to define health disorders; the number of health disorders considered; 
and the statistical techniques used (cluster and factor analysis were common approaches). 
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Nevertheless, a well-cited systematic review of 14 such studies (Prados-Torres, 2014) found 
three broad patterns, or clusters, of diseases were commonly reported: 1) cardiovascular 
and metabolic disorders 2) disorders related to mental health and 3) disorders related to 
musculoskeletal problems.(442) The results reported in this chapter show some similarities. 
For instance, mental health disorders were observed to naturally cluster together, as did 
cardiovascular-metabolic disorders. By design, the formation of a musculoskeletal disease 
cluster was prohibited since only one MSD variable was entered into cluster analysis at a 
time (see Section 7.2.2). However, this was advantageous as it made it possible to observe 
how musculoskeletal disorders (the focus of this thesis) commonly overlap with other 
prominent disease clusters. Importantly, little of the work reviewed by Prados-Torres et al. 
was age- or sex-stratified, and no studies had a focus on the older-working-age population, 
or participants with MSDs. The work of this chapter can contribute to existing knowledge by 
outlining how multimorbidity patterns differ within older working-age men and women, 
and within those with MSDs. Therefore, these results can guide the design of tailored 
interventions to support employment among the multimorbid, within these important 
subgroups. 
Chapter 8: the impact of multimorbidity upon HRJL  
Crude indicators of multimorbidity burden were examined. Having two or more known 
health disorders was strongly associated with HRJL compared to participants with no known 
health disorders and the strength of association increased as the number of disorders 
increased (see Figure 46, Chapter 8). Likewise, the number of GP consultations in the year 
prior and the number of drug prescriptions were significantly associated with the 
development of HRJL. 
Next, I explored the association between generated multimorbidity clusters and HRJL. 
Compared to participants with no known health disorders, being part of any multimorbidity 
cluster appeared to be important and generally had a strong statistically significant 
increased odds of HRJL (range OR 2.26 to 10.68). The clusters that formed between 
musculoskeletal disorders and cardiovascular disorders, or musculoskeletal disorders and 
mental health problems, were the largest clusters. Multimorbidity clusters formed by 
musculoskeletal disorders and mental health problems appeared to be very strongly 
associated with HRJL (range OR 7.56 to 10.68), although confidence intervals were wide 
(see Figures 47 and 48, Chapter 8). 
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After stratification by gender, number of health disorders, number of GP consultations, and 
number of drug prescriptions in the prior year remained significantly associated with HRJL. 
Compared to participants with no known health disorders, being part of any multimorbidity 
cluster was observed to have a strong association with HRJL among men or women (range 
OR 3.40 to 15.00). Once again, comorbidity clusters formed by musculoskeletal disorders 
and mental health problems were common (especially among women) and consistently had 
the strongest association with HRJL (range OR 6.62 to 15.00), although confidence intervals 
were wide.  
Finally, the analysis was restricted to participants with musculoskeletal disorders. 
Compared to participants with CPRD-defined musculoskeletal disorders but no known 
comorbidities, number of comorbid health disorders was significantly associated with HRJL. 
Being part of any comorbidity cluster had a strong association with HRJL (range OR 4.25 to 
16.18). Once again, a large cluster formed by participants with comorbid mental health 
problems was observed to have the strongest association with HRJL (OR: 16.18 95%CI 6.52 
to 40.25), although confidence intervals were wide.  
There is currently little published about the impact of multimorbidity on work outcomes 
and where present, this is often restricted to the study of two specific types of diseases in 
combination.(476,477) To my knowledge, this was the first study of the impact of 
multimorbidity upon health-related job loss in the literature, although the direction of 
effect broadly correlated with other previously reported work outcomes: Several other 
cross-sectional studies among western (non-UK) working populations observed that 
number of health disorders was correlated with sickness absence,(450,451) increased work 
impairment scores,(199) and presenteeism.(450) This chapter contributed further unique 
analyses by exploring the relationship between frequency of GP consultation and HRJL, and 
number of drug prescriptions (as a proxy for polypharmacy) and HRJL. These factors may 
prove to be additional “red flags” that can be used to identify those at imminent risk of job 
loss due to poor health. With approximately, one third of sample participants experiencing 
multimorbidity, the results of this chapter suggested that those who are dealing with 
multiple health problems may represent one of the most common high-risk groups for 
premature work exit among the older working-age population. 
In addition, to my knowledge, this was the first study to consider common disease clusters 
among multimorbid older workers, and to consider the relative occupational health impact 
of these clusters. Given the large proportion of participants with multimorbidity, it was 
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desirable to characterise this group further by considering the specific groups of diseases 
with the strongest association to HRJL. At the population level, findings represented 
supportive evidence that the co-occurrence of mental health disorders and musculoskeletal 
disorders, particularly, is of key importance to HRJL in this cohort. This was true also when 
considering comorbidity clusters among those with musculoskeletal disorders. Previous 
studies have considered musculoskeletal-mental health comorbidity and its relationship to 
adverse work outcomes. Using the general population as the reference group, the 
relationship between musculoskeletal-mental health comorbidity and sickness absence or 
“work-loss” days,(335,364,489) work cut-back days,(335) reduced physical work 
ability,(385) thoughts of early retirement,(385) and disability retirement,(490) has been 
reported. In all cases, these studies found that the combination of musculoskeletal 
disorders with mental health problems resulted in considerably worse work outcomes than 
for participants with purely musculoskeletal or mental health morbidity. However, the work 
of this chapter represents an important next step, showing not only that musculoskeletal-
mental health comorbidity is detrimental to employment longevity, but also that it is 
important relative to other common multimorbidity clusters in the older working age 
population.  
Chapter 9: the population attributable fraction of HRJL for CPRD-defined health disorders 
In the final chapter, multivariable conditional logistic models were constructed using 
purposeful selection. These models were informative in numerous ways. Firstly, they could 
be used to estimate the independent impact of CPRD-defined health disorders on HRJL, 
after adjustment for other known health disorders. Secondly, models could be used to 
estimate the impact of having a combination of musculoskeletal disorders and other CPRD-
defined health problems. Thirdly, models were used to assess multiplicative or additive 
interactions between musculoskeletal disorders and other health problems. Finally, effect 
sizes from these adjusted models were used to estimate the HRJL population attributable 
fraction (PAF) in the broader population from which these participants were drawn (the 
English older-working-age population). 
After purposeful selection, chronic MSDs (aOR 1.69 95%CI 1.19 to 2.41), recent MSD pain 
(aOR 2.14 95%CI 1.48 to 3.09), primary-care-level MHPs (aOR 3.49 95%CI 2.26 to 5.40), 
hypertension (aOR 1.58 95%CI 1.07 to 2.32), heart failure (aOR 5.02 95%CI 2.14 to 11.77), 
cerebrovascular accident (aOR 3.88 95%CI 1.17 to 12.94), and diabetes (aOR 1.93 95%CI 
1.06 to 3.52) remained independently and significantly associated with HRJL after 
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adjustment for other CPRD-defined health problems and confounding factors in the final 
preliminary effects model. A significant interaction was observed between chronic MSDs 
and diabetes on the multiplicative scale (aOR 0.24 95%CI 0.07 to 0.82) but not the additive 
scale (RERI -2.53 95%CI -5.13 to 0.07). However, no other significant positive multiplicative 
or additive interactions were identified between musculoskeletal disorders and other 
health disorders. From one model, the combination of musculoskeletal disorders with 
primary-care-level mental health problems (aOR 6.49), heart failure (aOR 9.34), epilepsy 
(aOR 10.68), or cerebrovascular accident (aOR 7.22) was estimated to be particularly 
strongly associated with inability to stay in work.  
Lastly, I estimated the PAF of HRJL associated with each of the CPRD-defined health 
disorders that remained significantly associated with HRJL after adjustment (see Figure 52, 
Chapter 9). Primary-care level MHPs accounted for the greatest PAF of any individual health 
disorder (25.0%). Recent MSD pain disorders had a considerable PAF (18.2%) which was 
greater than that for having ever been diagnosed with a chronic MSD (13.0%). However, 
combined, musculoskeletal disorders had an estimated PAF of 22.5%. This was followed by 
heart failure (PAF 17.7%), although the unusually large prevalence of this variable in the 
sample population may have been due to the erroneous inclusion of one broad cardiology 
Read code in its classification. In order of PAF, the remaining conditions were hypertension 
(10.5%), asthma (9.0%), diabetes (7.3%), epilepsy (4.4%), and CVA (3.7%). However, the 
prevalence of multimorbidity and the strength of its relationship with HRJL, meant that the 
PAF due to multimorbidity was more than double that of any individual condition (55.6%).  
In recognition of the finding that health problems commonly do not occur in isolation, the 
strengths of this chapter included its adjusted analyses of the impact of individual health 
disorders on HRJL. Multivariable analyses accounted for the presence of several other 
prevalent and important health disorders and included an examination of how these health 
disorders interact with one another in their association with HRJL. While it is commonplace 
in the literature to adjust for the presence of “comorbidity”, or “number of comorbidities”, 
when considering the association between a specific health problem and work status, few 
studies have examined several conditions concurrently. Participants with MSDs, for 
example, were found to have a high degree of comorbidity (58.7%) compared to the level 
of multimorbidity in the general study population (33.2%). This chapter contributed 
important data helping establish the independent effect of musculoskeletal disorders 
(chronic and/or pain) on HRJL, after adjusting for the presence of other common health 
disorders. 
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In addition, the reporting of population attributable fractions was an important aspect of 
this work that can help to judge the public health impact of these health disorders among 
the older working-age population. I found only one other similar study by Smith et al., 
looking at the relationship between several chronic conditions and being out of the labour 
force for health reasons.(494) This cross-sectional paper used self-report data from the 
representative Canadian Community Health Survey to classify health-related worklessness 
and the presence of seven physical chronic conditions: arthritis, hypertension, back 
problems, migraine, diabetes, heart disease, and thyroid disorders. Authors attributed the 
highest PAF to arthritis (29.0%) and back problems (23.8%). However, PAF was calculated 
using prevalence figures derived from a cohort with health-related worklessness, and 
included participants as young as 25 years old, therefore results are not comparable. Unlike 
the work in this chapter, the study also did not consider mental health problems which 
have been shown to be a key health exposure in worklessness.  
Among the health disorders studied in this chapter, findings confirmed that musculoskeletal 
disorders and mental health problems are the two greatest contributors to HRJL, however 
results also suggested that considerably more HRJL could be attributed to multimorbidity 
than to any individual health disorder. The dramatically large PAF observed for 
multimorbidity was a key finding of this chapter, suggesting that more than half of all 
health-related job loss among older workers could be avoided by preventing 
multimorbidity. These findings should encourage a greater interest in research focussed on 
multimorbidity, both for its role as a predictor of adverse work outcomes and to develop 
interventions to support people with multimorbidity to remain at work.   
As has already been discussed above, a large proportion of this multimorbidity is due to 
musculoskeletal-mental health comorbidity, which has a particularly strong association with 
HRJL. Therefore, these results also suggest that the avoidance of mental health comorbidity 
in musculoskeletal disorders (and vice versa) should be considered a priority area for 
preventive interventions to support the older working-age population to remain in work. In 
addition, populations with musculoskeletal-mental health comorbidity should be identified 
early to manage additional risks to their physical, mental, and occupational health as well 
as those that occur as a direct result of their comorbidity. This will encourage person-
centred, rather than disease-centred, solutions that go beyond the management of isolated 
clinical health disorders.   
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10.3 Limitations of this work  
After summarising the results of this thesis, and their significance, I reflect on some 
limitations, below. 
Sample population 
Included study participants were from the Health and Employment after Fifty (HEAF) study. 
As often occurs with questionnaire postal studies, the percentage of participants 
approached for the HEAF study who agreed to participate was low: 39,359 people were 
contacted and 8,134 returned a valid questionnaire (20.7%). While this study recruited 
participants that were broadly representative of the 50 – 65 years old English population, 
there were some notable differences. Participants were drawn from relatively less deprived 
catchment areas than the population of England as a whole. Additionally, responding 
participants were generally older, more often women, Caucasian, married, and home 
owners than in the general English population aged 50 – 65 years old.(6)  
Survival bias was also an issue: People who had experienced particularly severe diseases 
such as stroke or myocardial infarction were less likely to have been recruited into the HEAF 
study. Possibly because they had died prior to recruitment but also because a person with 
disabling disease, e.g. stroke, may find it more physically challenging to fill out a 
questionnaire.  
Another considerable limitation of this study was the sample size. As described in the 
methods section (Chapter 3), and Chapter 6, the available statistical power was sufficient to 
observe, at minimum, a small to moderate association with HRJL for most of the health 
exposures of interest. However, analyses were more often underpowered to assess the 
impact of these exposures in subpopulations of interest (e.g. analysis stratified by gender) 
due to the reduced number of case-control pairs available. Despite this, statistically 
significant associations were frequently observed at sufficient statistical power in subgroup 
analyses (see Tables 97 – 99, Chapter 6) often due to the strong associations observed. 
Statistical power was also limited to assess the impact of having two specific comorbid 
disorders on HRJL because of the low prevalence of these comorbidities. Instead, this thesis 
mainly considered multimorbidity at the level of the larger disease clusters that formed in 
cluster analysis. The combined effects of exposure to musculoskeletal disorders and other 
health disorders were also estimated using preliminary main effects models constructed in 
Chapter 9. While it was not possible to increase the number of case participants for this 
354 | P a g e  
 
thesis, one method of increasing statistical power is to increase the number of matched 
control participants from a 1:1 ratio to 1:2 or even 1:3 ratio as recommended in standard 
epidemiology textbooks (the benefit to cost of increasing the ratio of matched controls 
drops off above 1:3).(217) However, after matching for age, gender, and GP practice the 
number of available control participants was limited in the HEAF study. As a result, 
achieving a greater control-to-case ratio would have required broadening the matching 
criteria for age. Since age has a well-documented influence on both health and work 
outcomes, the judgement was made to remain at 1:1 matching in order to preserve the 
comparability of case and control participants for this important confounder. Instead, 
throughout the thesis, care was taken not to overinterpret non-significant results as 
evidential of lack of association where statistical power was low, i.e. less than 80%.   
Classification of case participants from HEAF questionnaire data 
Cases included participants who reported HRJL at HEAF baseline, however, a HEAF 
participant who had previously lost work for health reasons, and was later reemployed 
before HEAF baseline, would not be identified as a case. This means the classification of 
cases was influenced by duration of health-related job loss, and not only occurrence, and 
cases were more likely to reflect those who have had a longer duration of HRJL. Therefore, 
data would be more likely to show an association between a health disorder and job loss, if 
that health disorder puts people out of work for a longer time (i.e. is chronic or the cause of 
long-standing disability). Additionally, it is possible that some control participants had 
experienced HRJL in the past, but had later gained re-employment. Where this occurred, it 
would result in a bias effect towards the null.  
Secondly, with cross-sectional data, it is often unclear whether the health condition was 
first present before or after the event of interest. This is less of an issue for the current 
project since CPRD diagnostic codes were date-stamped and patients also reported the 
date of HRJL. Health exposures were therefore only “counted” if they were active prior, and 
in proximity, to the event of interest (job loss). However, errors in the self-reported date of 
job loss are possible and may have led to unreliable information regarding health status 
prior to work loss.  
Classifying exposures of interest using HEAF questionnaire data  
Similarly, some data used to classify exposures of interest were derived from the HEAF 
baseline questionnaire and were therefore susceptible to recall bias. Data on ethnicity, 
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qualifications, occupations, and marital status were self-reported but also unlikely to be 
strongly affected by recall bias. However, participants also reported when they started 
smoking, and when they stopped, this information was used to assess whether a study 
participant were currently smoking or were an ex-smoker at the time of HRJL. Since people 
are unlikely to know the precise date of their stopping smoking, if it were some time ago, 
this variable may have been more strongly affected by recall bias.  
Classifying exposures of interest using CPRD data  
The use of CPRD data was both a strength of this work, and a limitation. While use of CPRD 
carried some inherent advantages over self-reported data (see below), there were also 
some weaknesses. Detailed diagnostic information is not available in CPRD, which may not 
be a problem in conditions for which there is clear accepted national diagnostic criteria but 
can create uncertainty otherwise.(214) For example, one doctor’s diagnosis of anxiety 
disorder may be coded as an affective disorder by another doctor. Similarly, CPRD allows 
the coding of symptoms as well as diagnoses, so for example, a knee osteoarthritis 
diagnosis may be coded as “knee pain” depending on the practitioner’s level of confidence 
in the diagnosis. Additionally, conditions may have been initially misdiagnosed and later 
recoded.(499) Even if a participant received their true diagnosis at a later date, they could 
still have appeared to have the initial incorrect diagnosis in the studied dataset.  
I mitigated against these weaknesses using CPRD prescription codes to validate diagnostic 
data wherever possible, however, even when this was possible some uncertainty remained 
since drug prescriptions often have multiple indications other than for the disease code 
being validated. Additionally, drugs primarily prescribed in hospital settings or over-the-
counter, rather than in primary care, were less likely to be coded.(214) Where confidence in 
the diagnostic distinction between CPRD-defined health disorders was in doubt, such as for 
mood disorders, anxiety disorders, and affective disorders, groups were merged for 
analysis. Of course, this approach can also be problematic as important distinctions 
between clinical sub-groups may be concealed.  
Missing data was also a concern in CPRD: new diagnoses are manually recorded and may be 
missed from time to time. Available literature reporting validation outcomes for CPRD 
diagnostic data mostly reports positive predicative values, therefore, it is not clear how 
often clinical diagnoses are missed.(499) Secondly, the range of CPRD health disorders for 
which information was available was specified prior to this work and was not 
comprehensive for all diagnoses. Those included were: all musculoskeletal disorders; all 
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cardiovascular disorders; all mental health problems; and selected respiratory (asthma and 
COPD), endocrine (diabetes), and neurological conditions (CVA and epilepsy), but not other 
common and important conditions such as kidney disease or cancer, which have previously 
been included in published multimorbidity indices (see Figure 54). Since I classified 
multimorbidity according to these variables, it is probable that there were multimorbid 
participants who were not identified in this study. It is worth considering that the 
multivariable models constructed in Chapter 9 only achieved a Pseudo R2 of 0.20 which, 
while not unusual for statistical models in public health, suggests that there are other 
important unmeasured factors affecting the development of HRJL among older workers. 
However, musculoskeletal disorders, mental health problems, and cardio-respiratory 
conditions are reported to account for two-thirds of sickness absence and long-term 
incapacity in the UK,(47) therefore it is likely that the major health predictors of HRJL were 
captured by this dataset, although not exhaustively. To address the problem of unavailable 
CPRD diagnostic codes, plans have been made to use future follow-up work in the HEAF 
study to gather additional information about diagnosed health problems via a validated 
self-report questionniare (see Section 10.5). Doing so will have dual benefits: 1) being able 
to identify more participants with multimorbidity, and therefore to study work outcomes in 
multimorbidity using a more sensitive classification 2) to study the contribution of other 
common comorbid disorders to poor work outcomes in the older working-age population, 
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Figure 54: list of diseases which were considered across 39 different multimorbidity 
indices, from a Systematic review by Diederichs et al.(500,501) 
 
It is recognised that the results of this thesis were based on health exposure variables 
which were defined using a novel classification system. I grouped Read codes for 
classification with the input of experts in occupational and musculoskeletal medicine, 
however, face validity was ultimately relied upon to define these study variables. 
Therefore, the classifications used here ideally require their own validation study. 
Resources were limited to accomplish this within the timeframe of the PhD. Instead, plans 
have been made to produce formal validation of these CPRD-defined health exposures 
using future follow-up work in the HEAF study (see Section 10.5). It is possible that 
validation work may result in revisions to the coding criteria used in this study, however, 
this is unlikely to impact the key findings of this research, which have both confirmed and 
built upon prior research findings: for example, that musculoskeletal disorders and mental 
health problems have the most significant impact on work outcomes at the population 
level, and that this is compounded by their comorbidity. Some CPRD-defined variables may 
be more likely to undergo revision than others. For example, I found that the prevalence of 
heart failure in this study was notably higher than that reported elsewhere.(329) As 
described previously, this is likely due to a known misclassification error which was taken 
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into account when interpreting findings. However, the prevalence of other health 
exposures studied in this thesis were within the expected range when compared to those 
reported in other UK population-based studies such as the Age UK almanac of disease 
profiles in later life.(329) In addition, the study variables broadly behaved in expected ways, 
for example, rare but debilitating conditions such as stroke were found to have a low 
prevalence but a strong association with HRJL (OR 4.82 95%CI 1.57 to 14.76), while 
common and less debilitating conditions such as hypertension were found to have a high 
prevalence and weak association with HRJL (OR 1.79 95%CI 1.28 to 2.50). Results like these 
are encouraging and suggest that the conclusions drawn from this study can be trusted – 
something that future validation work will be able to confirm.   
Finally, the back-record of CPRD data was not equally available for all HEAF study 
participants and depended on 1) how long a GP practice had been contributing CPRD data 
2) whether that data was “up to standard” for the whole period and 3) how long the 
participant themselves had been attending the contributing GP practice. Cases or controls 
who did not have available health data at least a year prior to the date of HRJL were not 
included. Over a long period of time this is likely to have favoured entry into the study of 
case participants who had left work more recently, since CPRD data was unlikely to be 
available from several decades prior to HEAF baseline. However, this effect was favourable 
to this thesis as the focus of this work was primarily participants who had lost work at a 
later (more recent) age, between the ages of 50 – 65 years old, as this is the age group in 
which the majority of premature exit from work occurs.(46) 
10.4 Strengths of this work 
HEAF study population 
Despite acknowledgement of the limitations outlined above, the underlying population 
data had important strengths. The HEAF study, from which this study sample was drawn, 
was rigorously performed and reasonably representative over a broad geographic area 
within England. Data attained from the HEAF questionnaires underwent several stages of 
cleaning to identify inconsistencies in participant responses and errors in data entry.  
The HEAF study also focussed on English older working-age participants, the group of 
primary interest for the study of premature exit from work.(45) The fact that these 
participants were recently recruited is important. Health is not the only influential factor 
when it comes to job loss (most employees with chronic diseases continue to work).(63) 
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Socioeconomic, political, and cultural context can have pivotal effects on a person’s ability, 
expectations, and need to leave work. As a result, research into the causes of work 
disability can be time-specific and may date quickly; therefore contemporary study 
populations, like the HEAF study, are desirable.(63) UK-specific data was also necessary 
since occupational and social welfare systems vary considerably by country. 
Study Design  
A common limitation of matched case-control design is the susceptibility to bias inherent in 
the selection of cases and controls i.e. participants may have been favourably selected 
based on prior knowledge of their exposure status. However, this case-control study was 
nested within the broader HEAF prospective population-based cohort study and 
participants within HEAF were not selected directly by administrators with prior in-depth 
knowledge of the study or it’s variables of interest. Rather, GPs, who were unaware of the 
hypotheses being tested, were asked to mail requests to all participants who fit the 
inclusion criteria for HEAF. By design, this should rule out the possibility of a case being 
chosen based on prior exposure.  
In addition, the method of recruitment was the same for both cases and controls. Certain 
diseases may make a person less likely to be recruited to the whole study, for example, if 
the condition was disabling or associated with fatigue. Other conditions could increase the 
likelihood of recruitment e.g. because a participant is more motivated to contribute to 
research. However, it seems unlikely that such factors would unevenly affect recruitment 
between cases and controls given the HEAF methodology.  
Lastly, matching cases to working controls at HEAF study baseline would have led to control 
participants who are inherently healthier since they remain in work till older ages. This 
could cause a work survivor bias, whereby observed effect sizes are accentuated. To avoid 
this bias in the current study, cases were matched to controls who were working at the 
point of time that HRJL occurred and may or may not have continued working up until HEAF 
study baseline thereafter.   
Health-related job loss 
It was necessary that the main work outcome under study reflected aspects of both work 
and health. Health-related job loss was an ideal work outcome since it was health-specific 
(unlike unemployment and job loss, for instance) and captured a work event of primary 
importance to the patient and society, i.e. permanent loss of employment. Other work 
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outcomes which are health-specific often focus on factors impairing a participant who is 
still employed (e.g. sickness absence and presenteeism) although these may be predictors 
of permanent work disability.(502) Health-related job loss captures participants who 
prematurely exit work for health reasons and may or may not successfully attain disability 
benefits. Individuals who do not receive direct payments from the government for their ill 
health still represent a cost to society in terms of the lost opportunities to contribute 
economically. Additionally, there is a cost to the individual in terms of their role, income, 
and ability to support their families.(48,52) Therefore, it is a strength of HRJL that it 
captures all forms of employment loss with a contributing health problem. I am unaware of 
any other UK-based study of health-related job loss in the older working age population. 
Clinical Practice Research Datalink 
Despite the weaknesses of CPRD data outlined above, CPRD had numerous strengths. 
Firstly, it was an objective clinical data source that did not rely on the memory of study 
participants. At one time, CPRD covered 6.4% of the population of England and is 
considered broadly representative since almost all members of the population are 
registered with a GP.(214) CPRD has also been collecting health information for over 30 
years, which facilitated the retrospective aspect of this thesis. It’s date-stamped clinical 
records help to evaluate temporality and reduce the likelihood of making a “correlation 
proves causation” fallacy. To date, over 2000 peer-reviewed research papers have been 
published using this data source.(212)  
CPRD also undertakes internal data-quality assessments both at the patient and practice 
level.(213) “Acceptable” patients are identified after excluding those for whom there is 
non-contiguous follow up or poor data recording (e.g. missing vital information such as first 
registration date, or errors such as age >115 years).(213) Participating GP practices are 
required to record a minimum of 95% of prescribing events and patient-consultations and 
are routinely validated by internal checks and sent a validation report after data collection. 
These checks will look at completeness of prescribing, demographic, registration, referrals, 
and cause of death data. Practices not meeting CPRD standards are removed from the 
database.(214) Therefore, the clinical diagnostic data used in this study were robust and 
rigorously collected. Such is the validity of CPRD data, that it has been used to investigate 
important public health problems such as a possible link between the measles, mumps and 
rubella (MMR) vaccine and autism.(503)  
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One systematic review of validation studies for clinical diagnostic information in the CPRD 
found that the median proportion of cases with a confirmed diagnosis was 89% (range 24 – 
100%). For this study, validation methods included external methods such as requesting GP 
medical records or sending the GP a questionnaire, and internal methods such as the use of 
a diagnostic algorithm using other CPRD data.(499) Importantly, this review also undertook 
sub-group analysis by type of health disorder: for musculoskeletal and connective tissue 
disorders the median proportion of cases confirmed was 80% (range 33 – 97); for mental 
and behavioural disorders, 83% (range 52 – 100); for circulatory system disorders, 85% 
(range 48 – 100); for respiratory disorders, 88% (range 26 – 100); for endocrine, nutritional 
and metabolic disorders, 88% (53 – 100); and for nervous system disorders, 81% (range 39 
– 100).(499) While these positive predictive values do not account for health diagnoses that 
have been missed, the high median values suggest that the large majority of CPRD 
diagnosed cases were true cases and a high degree of confidence in these data is possible. 
This review also recommended the use of internal diagnostic algorithms (e.g. using 
prescription data) to boost diagnostic accuracy, methods that I used in this thesis wherever 
appropriate and possible. 
By design, this case-control study was not prospective, however, I had the advantage of 
using date-stamped CPRD information. Using this information I could ensure independent 
variables preceded HRJL and was thus able to show evidence of temporality - one of the key 
elements of the Bradford-Hill criteria for causation.(504) As described, participants supplied 
the date at which they had left work on the HEAF questionnaire and I considered CPRD-
defined health disorders that had occurred prior to the date of job loss. Certain health 
problems, such as osteoarthritis, are chronic and, once diagnosed, are permanent and 
degenerative. However, for other potentially short-term health problems, e.g. depression, I 
could define a parameter within which participants needed to have been diagnosed or 
treated for the condition e.g. a year prior to the job loss. This way, the measurement of 
health exposures was restricted only to those that could conceivably have had an impact 
upon work, improving the validity of study observations.  
Multiple health exposures and cluster analysis  
In this thesis, it was possible to study the relative importance of common and important 
health disorders, such as musculoskeletal disorders, mental health problems, and cardio-
respiratory conditions, for their association with HRJL. I found few existing studies that 
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evaluated the impact of multiple individual health problems upon work,(340,344,347,351–
353,365,494) with most focussing on single health exposures.  
Even fewer studies have considered the impact of multimorbidity upon work. However, 
multimorbidity research takes a more patient-centred approach that focusses less on 
individual diseases,(505) and thereby reflects the common experience of older-age 
patients, in whom diseases more often occur alongside other health problems than in 
isolation.(153) Another strength of this piece of work is the use of cluster analysis to 
characterise patterns of multimorbidity. While cluster analysis has been used before to 
describe how health disorders group together within a population,(164,442) this was the 
first study to then assess the relationship between these multimorbidity clusters and the 
development of adverse work outcomes. It is certainly the first piece of work of its kind 
among older-age workers. 
10.5 Future research in the HEAF study 
Work is currently underway to validate the preliminary findings of this nested case-control 
study, although prospective data will not be available for a couple of years. The HEAF study 
has a motivated cohort of participants who have good response rates at follow-up 
(exceeding 80%).(506) In the broader HEAF study, I contributed to the questionnaire design 
for the fourth annual follow up in order to improve on areas where the work of this thesis is 
lacking, and also to answer new questions specific to participants with musculoskeletal 
disorders.   
Figure 55: Cover designs for the HEAF study baseline questionnaire and four annual 
follow-up questionnaires.(507) 
 
Following HEAF baseline, many GP practices moved their clinical records system from CPRD 
over to Egton Medical Information Systems (EMIS).(508) Concurrently, CPRD could no 
longer supply prospective clinical data for the HEAF study. To continue to explore the 
relationship between clinical health disorders, multimorbidity, and work outcomes, a new 
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source of diagnostic health information was needed. Therefore, with agreement from the 
rest of the HEAF study team, I included a modified version of the Self-Administered 
Comorbidity Questionnaire (SACQ) (509) in the fourth annual follow-up questionnaire for 
the HEAF study. The SACQ contains both a self-reported checklist of common health 
problems and also indicators of disease severity, such as: whether a doctor was consulted 
for the problem; if there had been a hospital visit for the problem; if the participant was 
prescribed medicine for the problem; and whether the problem has limited a participant’s 
activity. Although self-reported, this data is more detailed than the information provided by 
CPRD which, as I have found, could not provide clear indicators of disease severity. Data 
from the SACQ can improve on the work of this thesis in three main ways: 1) allowing 
validation of the CPRD-defined health disorders used in this thesis, as has been 
recommended by Herrett et al.(499) 2) allowing an assessment of how the underlying 
severity of health exposures relates to HRJL, and to look for a dose-response relationship, 
or “biological-gradient.”(504) 3) Finally, facilitating a more comprehensive analysis of 
patterns of multimorbidity in the HEAF study population, as additional disorders for which 
CPRD information was not available are included in the SACQ, such as gastrointestinal 
disorders or ulcers, kidney disease, liver disease, anaemia and other blood diseases, cancer, 
and lung diseases (other than asthma and COPD).   
In this thesis, it was observed that participants with musculoskeletal disorders were more 
likely to have had HRJL as their number of comorbidities increased. However, participants 
with musculoskeletal disorders and comorbidity may also have had more severe underlying 
musculoskeletal disease e.g. more severe pain can lead to increased risk of 
depression.(470–472) Therefore, to explore this possibility, in the HEAF fourth annual 
follow-up questionnaire, validated indicators of musculoskeletal disease severity (disability, 
pain, and fatigue) were included. Disability was measured using the Disability Rating Index 
(DRI) which assesses many aspects of musculoskeletal function such as dressing, walking, 
and climbing stairs.(510) Musculoskeletal pain was measured using the Von Korff Chronic 
Pain Scale which measures chronic musculoskeletal pain, containing items about: current 
pain; average pain intensity; worst pain intensity over the previous 6 months; and chronic 
pain limiting work and activities.(511) Lastly, fatigue was measured using the Fatigue 
Assessment Scale, which contains several questions about how fatigued a participant 
usually feels.(512) Using the new questionnaire data it should be possible to explore the 
relationship between musculoskeletal disability, pain, and fatigue and poor work outcomes. 
In addition, the relationship between comorbidity and work outcomes in people with 
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musculoskeletal disorders can be assessed, with adjustment or stratification for underlying 
musculoskeletal disease severity. 
While the primary work outcome of focus for this thesis was HRJL, in the HEAF fourth 
annual follow-up questionnaire, additional work outcomes were collected. These included: 
job satisfaction, job security, optimism for being able to continue working, sickness absence 
in the prior year, and questions relating to the struggle to perform work due to health 
problems. Additionally, this questionnaire includes items from the validated and widely 
used Work Productivity and Activity Impairment questionnaire,(380) from which it will be 
possible to assess whether a person’s health problems, or multimorbidity, impacts 
productivity, leading to “presenteeism,” while at work. The additional work outcomes 
available in the new questionnaire will give new insights about the experience of older 
employed workers with multiple health disorders.  
10.6 Recommendations for research 
The disability employment gap (defined by the Office of National Statistics) represents the 
difference in the employment rate between people with and without disabilities. As 
described in the introductory chapter, reducing this figure is economically desirable for 
society while employment may also improve the material and psychosocial wellbeing of 
disabled individuals.(52) However, the UK disability employment gap has been consistently 
greater than 30% over the past decade (albeit with a 4.1% improvement overall, see Figure 
56).(513) This suggests that much work still remains to encourage and enable people with 
disabling health problems to remain in employment. Initially, more research is needed to 
understand the journey that a person takes to becoming permanently work disabled, and 
the key risk factors involved.  
The systematic review (Chapter 4) highlighted the need for higher quality, and more 
consistently reported, research exploring the impact of comorbidities upon work among 
people with musculoskeletal disorders. Some work has already been done to encourage a 
unified approach to absenteeism and productivity-loss outcomes used in rheumatology 
research.(383) Future studies can help aid consistency and interpretability by adopting 
these recommended outcome measures wherever possible. For research questions relating 
to adverse work outcomes as a result of poor health, health-specific work outcomes should 
also be used where possible (rather than e.g. unemployment or job loss which may occur 
for reasons unrelated to health). Chapter 4 also identified several common comorbidities 
that remain unexplored for their impact upon work outcomes among people with MSDs.  
365 | P a g e  
 
This thesis has also highlighted the importance of multimorbidity, and particularly 
musculoskeletal-mental health comorbidity, for health-related job loss in the older working 
age population; however, prospective data is needed to support these findings. As 
mentioned already, the Pseudo R2 achieved in the multivariable models constructed in 
Chapter 9, while not unusual, suggested that there were remaining important unmeasured 
factors affecting the development of HRJL among older workers. Future research can 
explore these unknown factors by using a more comprehensive measure of multimorbidity, 
that considers other common health disorders in the UK population e.g. cancer and 
gastrointestinal disorders. Given enough statistical power, this research could also be used 
to explore interactions between these comorbid conditions in their relationship to adverse 
work outcomes. If certain comorbid conditions are found to have a strong additive or 
multiplicative interaction with poor work outcomes, this may have implications for 
preventative or targeted occupational interventions.  
Figure 56: The UK Disability Employment Gap, from 2013 to 2018. Contains Parliamentary 
information licensed under the Open Parliament Licence v3.0. (513) 
 
This thesis has highlighted the importance of multimorbidity for work, however, at the time 
of writing, there is very little research discussing the effectiveness of interventions 
specifically for improving occupational outcomes in multimorbidity. Existing literature 
mostly focusses on specific health problems. For example: there is reasonably strong 
evidence for CBT-based therapies for low back pain; workplace-based interventions such as 
ergonomic interventions, flexible working environment, and workplace rehabilitation have 
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been tested for musculoskeletal disorders and low back pain conditions; psychological 
interventions have been used for depression, such as occupational therapy and 
mindfulness-based interventions; and supported employment (including, individual 
placement and support) have been explored in people with severe mental health 
problems.(514,515) Studies of occupational outcomes for workplace interventions among 
people with musculoskeletal disorders mostly focusses on low back pain, and evidence is of 
weak quality among people with mental health problems;(514,516,517) Research 
concerning the effectiveness of occupational interventions to help people with cardio-
respiratory disorders or other common conditions to remain in work is particularly 
scarce.(514) To summarise, important research gaps remain for supportive occupational 
interventions in many specific health disorders, but particularly for people with 
multimorbidity. Additionally, cost-effectiveness outcomes have rarely been explored, 
evidence about which is desperately needed if governments and employers are to be 
encouraged to adopt these interventions. 
Prior to developing occupational support strategies for people with multimorbidity, 
preliminary research may be advisable. In 2017, “Work Matters” a UK-wide survey 
conducted by the National Rheumatoid Arthritis Society, took a focussed look at the impact 
of rheumatoid arthritis and juvenile idiopathic arthritis upon work. Participants with these 
conditions were asked about their main barriers and facilitators to staying in work.(518) A 
similar piece of research, particularly using qualitative face-to-face interviews, would be 
useful to better understand the challenges of managing multiple health conditions while 
working. Such research should focus on: perceived support at work; the advantages and 
challenges to staying in work in employed participants with multimorbidity; and the 
experience of multimorbid people who are no longer employed because of their health 
problems. For the unemployed with multimorbidity, such a survey should include 
information about benefits claimed and barriers and facilitators to returning to work 
(including ability and willingness). Given the complex nature of multimorbidity discussed 
throughout this thesis, the classification of multimorbidity used should be carefully 
considered and results stratified by number of concurrent health problems, and the type of 
multimorbidity (e.g. purely physical or mental-physical?). Research should facilitate the 
development of interventions and policy changes specifically aimed to support people with 
multimorbidity who want to remain in work.  
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10.7 Summary: research recommendations 
• To validate the findings of this thesis: A comprehensive analysis of the relationship 
between multimorbidity and health-related job loss should be undertaken using 
prospective data and a validated measure of multimorbidity including all common 
and important disorders in the UK older working-age population.  
• To validate the findings of this thesis: Using a validated measure of multimorbidity, 
patterns of multimorbidity, and relationship of these patterns to health-related job 
loss, should be explored in the older working-age population. Other indicators of 
disease burden should be explored where possible, such as healthcare utilisation 
and polypharmacy.  
• To continue the work of this thesis and study the impact of comorbidity upon work 
outcomes among people with musculoskeletal disorders, future research should: 
be prospective and capture incident comorbidity; consider the comparative impact 
of several common comorbid disorders; be powered to assess important 
interactions; and should adjust for the severity of the underlying musculoskeletal 
disorders.   
 
• Work should be considered an important health outcome and its reporting 
encouraged in the literature. To facilitate consistency in how these outcomes are 
classified and analysed, a standardised set of core work outcomes for effectiveness 
studies should be agreed. Future research studies can aid consistency and 
interpretability by adopting recommended work outcome measures wherever 
possible.  
• More research is needed to study the impact of multimorbidity on currently 
employed workers, using validated measures of presenteeism, sickness absence, or 
time to return to work following long-term sickness absence. For return to work 
outcomes, length of follow up should be consistent with existing studies to aid 
comparison. 
• Qualitative research is needed that considers the experience of working-age people 
with multimorbidity. Such research should focus on: perceived support at work; the 
advantages and challenges to staying in work amongst the employed; and the 
experience of people who are no longer employed because of their multiple health 
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problems (including information about benefits claimed and barriers and facilitators 
to returning to work). 
• Study authors should take care to stratify their results by gender wherever possible, 
in consideration of the differences in occupational environment and disease burden 
observed in this thesis.  
• Evidence is needed to support the use of workplace interventions for improving 
occupational outcomes in multimorbidity (and numerous other specific health 
disorders). Particularly needed is an assessment of cost-effectiveness for these 
interventions, which considers: the effectiveness of the intervention; the cost of the 
intervention; the cost of work-time lost; and the cost of replacing a worker who has 
left employment for health reasons.  
10.8 Policy Recommendations 
The need for workplace support among people with multimorbidity in England 
The work of this thesis has highlighted the powerful influence of multimorbidity upon early 
exit from work among older workers. While, little is known about the experience of people 
with multimorbidity at work, some survey data is available. The Work Foundation wrote a 
report on the complexities and challenges of working with multiple health conditions, using 
data from the 2013 Health Survey for England (HSE).(519,520) This report found that the 
employment rate among responders decreased with the number of concurrent health 
disorders. An additional telephone questionnaire survey was then conducted among a 
subsample of participants reporting multimorbidity in the 2011 – 2014 HSE. Questions were 
asked about disclosure of health problems to the employer, perceived support from 
employers, adjustments made by the employer, and use of occupational health 
services.(520) I consider some findings from this work, how they relate to the people with 
multimorbidity studied in this thesis, and how they may influence changes in policy or 
targets for interventions, below.  
According to the report, 20% of participants with multimorbidity had not told their 
employer about any of their long-term health conditions, while 23% of multimorbid 
employees had only disclosed one condition. Participants commonly reported “not seeing 
the point” and it “does not affect my work” as the most common reasons for not disclosing 
their health conditions. Public health initiatives may therefore focus on education for 
employers and employees, to try and encourage people with multiple health problems to 
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disclose their health problems to their employers at a stage where some support may 
gradually be put in place to reduce presenteeism and prevent sickness absences and 
health-related job loss. Of course, multimorbid workers who did not disclose may have 
been reluctant to tell their employers of their health problems for fear of threat to work 
relationships or job security. Encouragingly, of those who did disclose their condition, 73% 
felt their employer had been supportive, only 14% did not.(520) These results may not be 
representative however, since the telephone questionnaire survey was conducted only 
among people who were still in employment and did not include participants who had 
already fallen out of work, such as the “case” participants in this thesis.  
Among the participants who had disclosed, 53% had not had any adjustments made at 
work, 34% said the employer had made some form of adjustment, and 13% reported they 
did not require adjustments. Physical comorbidity, number of health disorders, frequency 
of symptoms experienced, and pain/discomfort were significantly associated with whether 
the employer had made workplace adjustments. Throughout this thesis, mental health 
problems appeared to be more strongly associated with HRJL than musculoskeletal 
disorders (although both were important). The results from the Work Foundation report 
suggest one possible mechanism for this finding: workplaces may be more equipped and 
willing to provide support for people with health problems if their condition is physical or 
painful.  
In the work foundation report, of those who had received adjustment to their workplace, 
“changes to working hours, breaks, or shift patterns” was considered the “most helpful to 
stay in work.” Overall, 60% of participants had access to an occupational health service, and 
of those who used it, 66% agreed that the occupational health service was “helpful in 
managing all of my health conditions at work,” only 13% did not.(520) This suggests that 
the role of occupational health services may be important in maintaining employment for 
people with multiple health problems. However, currently less than 50% of employees in 
the UK may have access to these services.(521) Interestingly, the fact that changes to 
working hours, breaks, or shift patterns were considered the most helpful is encouraging, 
since, depending on the work, these changes may be relatively inexpensive for employers 
but impactful for the employee with health problems.  
Recommendations for management of multimorbidity in the workplace 
The clinical management of multimorbidity is complex, as reflected in the National Institute 
for Health and Care Excellence (NICE) Guideline “Multimorbidity: clinical assessment and 
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management” published in 2016. This guideline recommends several aspects of good 
clinical management for people with two or more long-term health conditions. Healthcare 
professionals are recommended to provide a tailored approach to care that takes into 
account: difficulty managing treatments or daily activities; the need to receive care from 
multiple healthcare services; the possible presence of a combination of both physical and 
mental health conditions, or frailty; the possibility of a frequent need to seek unplanned or 
emergency care; the possibility of requiring multiple regular medications.(192) 
Management for people with multimorbidity should follow a person-centred, 
biopsychosocial approach incorporating the six desirable elements of care identified by 
people with long-term conditions (see Figure 57).(522) These elements can be enabled 
through systems to support self-management and shared decision-making, and the 
implementation of care and support planning. Models of managing people with health 
problems in the workplace can take inspiration from these systems by encouraging 
communication and shared decision making between the employer and employee, and by 
tailored forward planning that takes into account the possibility of needing to attend 
multiple healthcare appointments, or unplanned fluctuations in symptoms.  
Figure 57: A narrative for person-centred coordinated care.(522) 
 
Although evidence is lacking for the management of multimorbidity in the workplace, 
employers should be aware of health issues that could affect the ability of employees to 
cope with their workload and are required by law to provide “reasonable adjustments” 
wherever possible to help support people with disabling multimorbidity to remain 
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working.(523) Employers could help to support people with multimorbidity through the use 
of workplace interventions targeted at health disorders which are common contributors to 
multimorbidity. For example, as outlined in this thesis, musculoskeletal disorders were 
found to commonly exist alongside other health conditions.(181) There is some evidence 
that these conditions may be managed at work with CBT-based therapies for low back pain; 
and ergonomic interventions, flexible working arrangements, and workplace rehabilitation 
for general musculoskeletal disorders.(514) 
One intervention which may prove a useful approach for supporting people with 
multimorbidity in the workplace is “case management”, which involves person-centred co-
ordination between employers and healthcare and rehabilitation professionals, with an 
identifiable and accountable case manager.(514,524) Specific aspects of this intervention 
include motivation, goal setting, and return to work planning. This is an intervention with 
some evidence of benefits for people with long-term health conditions generally and 
therefore may be a useful approach for participants with multimorbidity.(514) 
Some management strategies can be time and resource intensive because of the 
complexity of care needed, and resources are increasingly stretched because of the 
growing number of individuals who need such services. For example, UK health and social 
care costs average nearly £8,000 per year to care for a person living with three or more 
long-term conditions as compared with an estimated £3,000 for a person living with only 
one long-term condition.(162) Therefore, such interventions may only be cost-effective 
among people at highest risk for work disability, or for whom there is strong evidence of 
benefit. However, the work cited above by the Work Foundation suggests that there may 
be inexpensive options that can be attempted before using more costly interventions, for 
example, employing a flexible approach to working hours, breaks, or shift patterns. 
The work of this thesis has contributed important evidence to suggest the highest risk of 
health-related job loss is among older workers with concurrent musculoskeletal and mental 
health problems. This suggests that a person developing mental health problems with pre-
existing musculoskeletal disorders (and vice versa) should be given priority occupational 
support to preserve their employment. For such a person, occupational support could 
include mindfulness-based interventions which have shown some benefit for anxiety, 
depression, and burnout in the workplace.(515) Supportive interventions should be 
employed promptly before periods of long sickness absence, based on evidence that 
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suggests that the longer a person remains out of work due to sickness, the greater the 
likelihood that they will never return to paid work.(47) 
10.9 Policy recommendations: summary  
• Public health initiatives should focus on education for employers and employees, to 
try and encourage people with multiple health problems to disclose their health 
problems to their employers at a stage where some support may be offered. 
Healthcare professionals can facilitate this in clinical appointments by asking about 
health struggles at work in people with multimorbidity.  
• Recommended clinical management for people with multimorbidity follows a 
person-centred, biopsychosocial approach. Likewise, systems that support 
multimorbid people at work should encourage communication and shared decision 
making between the employer and employee, as well as tailored forward planning 
that takes into account the possibility of needing to attend multiple healthcare 
appointments, or unplanned fluctuations in symptoms. 
• Employers should be aware that permitting flexibility in working hours, break times, 
or shift patterns is often inexpensive and may be particularly helpful to the 
employee to support remaining in work, especially for people with multimorbidity 
who may be managing multiple health appointments and fluctuations in disease 
symptom severity.  
• Odds of premature exit from work due to health problems appear to be 
considerably higher among people with multiple health problems. Employers 
should be aware that musculoskeletal disorders and mental health problems pose 
the greatest threat, particularly if occurring together. Certain workplace 
interventions such as CBT-based therapies, ergonomic interventions, flexible 
working arrangements, and workplace rehabilitation may be helpful for these 
conditions specifically, although there are few studies reporting cost-effectiveness. 
These interventions should be provided promptly in a person with concurrent 
musculoskeletal and mental health disorders in the workplace, in order to reduce 
the likelihood of long-term sickness absence and permanent loss of paid work.  
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10.10 Conclusions  
These results support the primary importance of common mental health problems and 
musculoskeletal disorders for health-related job loss in the older working-age UK 
population. In addition, the novel work conducted in this thesis was the first to study the 
relationship between multimorbidity and health-related job loss in this cohort. 
Multimorbidity (by the classification used in this thesis) was strongly associated with HRJL 
and accounted for a significantly greater proportion of HRJL than any individual health 
disorder. This stresses the importance of treating an individual holistically when managing 
their occupational health by considering the influence of comorbidity on their work 
situation. At a population level, the recognition of people with multimorbidity as a group at 
particularly high risk of premature job loss is crucial in order for policymakers to focus 
resources where they are needed. Another unique feature of this work was the use of 
cluster analysis to characterise multimorbidity among older workers. Musculoskeletal 
disorders were found to frequently co-occur with hypertension, and with mental health 
problems and these comprised the most common multimorbidity patterns. In men, a 
cluster of participants with cardio-metabolic disorders was also prominent. Most 
multimorbidity clusters identified were strongly associated with HRJL, however, clusters 
formed by musculoskeletal disorders and mental health problems appeared to have the 
greatest impact. Previous research has suggested the possibility of a synergistic relationship 
between musculoskeletal disorders and mental health problems for poor work outcomes. 
Therefore, policymakers and healthcare professionals who are concerned about supporting 
older working-age people in employment should be cautious to prevent, and treat, the 
occurrence of mental health disorders in persons with musculoskeletal disease (and vice 
versa) since the long term impact on employment may be dramatic. Future research will be 
undertaken to validate the findings of this thesis and to understand how a broader range of 
health problems interact to influence work outcomes among the older working age.  
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ABS - Australian Bureau of Statistics 
ACR - American College of Rheumatology 
aOR - adjusted Odds Ratio 
ARDS - Adult Respiratory Distress Syndrome 
AS - Ankylosing Spondylitis 
BNF - British National Formulary 
BSRBR - British Society for Rheumatology Biologics Registers 
CI - Confidence interval 
COPD - Chronic Obstructive Pulmonary Disease 
CPRD - Clinical Practice Research Datalink 
CVA - Cerebrovascular accident 
ERAS - Early Rheumatoid Arthritis Study 
GP- General Practice 
HEAF - Health and Employment After Fifty (study)  
HES – Hospital Episode Statistics  
HND - Higher National Diploma 
HR - Hazard ratio 
HTN - Hypertension 
ICD - International Classification of Disease 
IHD - Ischaemic Heart Disease 
IRD - Inflammatory Rheumatic Disorder 
IRR - Incidence Rate Ratio 
JL - Job loss 
LTC - Long Term Condition 
LTSA - Long Term Sickness Absence 
MHP - Mental Health Problem 
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MRC- Medical Research Council 
MSD - Musculoskeletal Disorder 
MSpain - musculoskeletal pain  
NA - Not Applicable 
NE – Not Estimable 
NOS - Newcastle-Ottawa Score  
NSLBP - Non-Specific Low Back Pain 
NS-SEC - National Statistics Socio-Economic Classification 
OA - Osteoarthritis 
OECD - Organisation for Economic Co-operation and Development 
OMERACT - Outcome Measures in Rheumatology 
ONS - Office of National Statistics 
OPD - Obstructive Pulmonary Disease 
OR - Odds Ratio 
PAD - Peripheral Arterial Disease 
Pres - Presenteeism 
PsA - Psoriatic Arthritis 
RA - Rheumatoid Arthritis 
RDCI - Rheumatic Disease Comorbidity Index 
RR - Risk Ratio 
RTW - Return to Work (time to return to work after work disability) 
SA - Sickness absence 
SHR – Standardised Hazard Ratio 
SLE - Systemic Lupus Erythematous  
SOC - Standard Occupational Classification 
SOC-10 - Standard Occupational Classification 2010 
SSRI - Selective Serotonin Reuptake Inhibitors  
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SpA - Spondyloarthritis 
TIA - Transient Ischemic Attack 
UE - Unemployment 
VTE - Venous Thromboembolism  
WAI - Work Ability Index 
WALS - Workplace Activity Limitations Scale 
WD - Work Disability 
WLQ PDmod - Work Limitations Questionnaire with modified physical demands scale 
WPAI - Work Productivity and Activity Impairment questionnaire 
WPS - Work Productivity Survey 
WT - Work Transition 
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Appendix  
Appendix to Chapter 3 
Appendix Table 1: Excluded Read codes by body system 
Body system Excluded Read codes 
Musculoskeletal 
disorders 
Acute rheumatic fever 
O/E - knee joint abnormal 
O/E - shoulder joint abnormal 
H/O: rheumatic fever 
O/E - finger joint abnormal 
O/E - wrist joint abnormal 
O/E - elbow joint abnormal 
O/E - joint abnormal 
O/E - neck joint abnormal 
O/E - toe joint abnormal 
O/E - hip joint abnormal 
O/E - hand joint abnormal 
Rheumatoid factor 
Back X-ray 
Adverse reaction to analgesics, antipyretics, antirheumatics 
[D]Head and neck symptoms 




Flashing lights seen 
O/E - irritable 
Tantrums 
O/E - disorientated 
Speech problem 
Nightmares 





H/O: psychiatric disorder 
Irritable - symptom 






Nightmares - symptom 
Speech problem - symptom 
[V]Other or unspecified general psychiatric examination 
Bruxism (teeth grinding) 
Post-concussion syndrome 
[D]Visual hallucinations 




Nervous system symptoms NOS 








[D]Strange and inexplicable behaviour 
[X]Mild mental/behav disorder assoc with the puerperium NEC 






Cardiovascular event risk 
Cardiac event recording 
[D]Functional heart murmur 
[D]Other abnormal heart sounds 
Primary pulmonary hypertension 
Ocular hypertension 
Portal hypertension 
Benign intracranial hypertension 
Chronic peripheral venous hypertension 
Sinus arrhythmia 
Transient neurological symptoms 
Pulmonary sarcoidosis 
Diffuse pulmonary fibrosis 
Pulmonary rehabilitation programme completed 
[SO]Pulmonary vein 
Pulmonary rehabilitation 
Referral to pulmonary rehabilitation 
Assessment for pulmonary rehabilitation completed 
Pulmonary rehabilitation declined 
Pulmonary rehabilitation offered 
Temporal artery biopsy 
Carotid artery doppler abnormal 
[SO]Common iliac artery 
Percutaneous embolisation of uterine artery 
[SO]Renal artery 
[SO]Ophthalmic artery 
Ligation of haemorrhoidal artery 
[SO]Basilar artery 
Atrial premature depolarization 
Atrial dilatation 
[SO]Valve of heart 
[SO]Aortic valve 
Respiratory Pulmonary tuberculosis 
Respiratory disease monitoring 
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Wheezing symptom 
Referred to chest physician 
Asthma screening 
Seen by respiratory physician 
Referral to chest physician 
At risk of chronic obstructive pulmonary disease 
Seen by chest physician 
Referral to respiratory physician 
Referral to thoracic physician 
Pulmonary aspergillus disease 
Inhaler technique - moderate 
Private referral to chest physician 
[V] Personal history of pulmonary tuberculosis 
Seen by respiratory physician 
Referral to respiratory nurse specialist 
CPAP - Continuous positive airways pressure 
Pulmonary eosinophilia 
Referral to respiratory rapid response team 
CPAP - Continuous positive airways pressure 
Seen by thoracic physician 
Pulmonary tuberculosis NOS 
Discharge by respiratory physician 
Continuous positive airways pressure 
Seen in respiratory clinic 
Referral to respiratory physician 
Pulmonary fibrosis 
Seen by respiratory nurse specialist 
Prescription of respiratory disease rescue medication 
Epilepsy Contraceptiv advice for patients with epilepsy not indicated 
Pre-conception advic fr patients with epilepsy not indicated 
Pregnancy advice for patients with epilepsy not indicated 
Epilepsy screen invite 3 
Diabetes Diabetic monitoring not required 
 
Appendix Table 2: Read codes used to compose musculoskeletal health disorder sub-
group categories 
Health disorder category 
and group number 
Clinical diagnostic codes (Read codes) used 
1. Rheumatoid arthritis  Rheumatoid arthritis 
Intramuscular gold therapy 
Rheumatoid factor positive 
Rheumatoid nodule 
H/O: rheumatoid arthritis 
Seronegative rheumatoid arthritis 
Flare of rheumatoid arthritis 
Seropositive errosive rheumatoid arthritis 
Rheumatoid lung 
Seropositive rheumatoid arthritis, unspecified 
Rheumatoid arthrit. monitoring 
Rheumatoid bursitis 
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Swan-neck finger deformity 
Rheumatoid arthritis and other inflammatory 
polyarthropathy 
Rheumatoid arthritis annual review 
Except rheumatoid arthritis qual indicator: informed dissent 
Exception reporting: rheumatoid arthritis quality indicators 
Except rheumatoid arthritis quality indicator: pt unsuitable 
Rheumatoid arthritis monitoring invitation 
Rheumatoid arthritis monitoring invitation first letter 
Rheumatoid arthritis monitoring invitation second letter 
Rheumatoid arthritis monitoring verbal invitation 
Rheumatoid arthritis monitoring invitation third letter 





Synovitis or tenosynovitis NOS 




Synovitis of hip 
Reactive arthropathy, unspecified 
Chronic post-rheumatic arthropathy 
Sero negative arthritis 
Arthropathy associated with infections 
Palindromic rheumatism 
Sero negative polyarthritis 
Acute arthritis 
Psoriatic arthropathy NOS 
Other synovitis and tenosynovitis 
Rheumat.dis.- joints affected 
Shoulder synovitis 
Behcet's syndrome 
Arthropathy associated with other viral diseases 
Arthropathy in Crohn's disease 
Inflammatory polyarthropathy 
Oligoarticular osteoarthritis, unspecified 
Reactive arthropathies 
Enthesopathy of the hip region 
Disease modifying antirheumatic drug monitoring 
Hip enthesopathy NOS 
Juvenile rheumatoid arthritis 
Inflammatory spondylopathies 
Sarcoid arthropathy 
Palindromic rheumatism NOS 
Adverse reaction to antirheumatics NOS 
Arthropathy associated with dermatological disorders 
Reactive arthropathy of knee 
Rheumat. drug side effect 
BASDAI - Bath ankylosing spondylitis disease activity index 
Suspected inflammatory arthritis 
Seen in GP DMARD monitoring clinic 
Psoriatic arthritis 
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Osteoarthritis and allied disorders 
Unspecified monoarthritis 






Localised, primary osteoarthritis of other specified site 
Primary generalized osteoarthrosis 
Osteoarthritis NOS 
Localised, primary osteoarthritis 
Osteoarthritis NOS, of unspecified site 
Erosive osteoarthrosis 
Unspecified monoarthritis of other specified site 
4. OA back  Lumbar disc degeneration 
Lumbar spondylosis 
Degeneration of lumbar spine 
Narrowing intervertebral disc space 
Plain X-ray lumbar spine abnormal 
Thoracic disc degeneration 
Thoracic spondylosis 
Lumbosacral instability 
Lumbar spinal stenosis 
Collapse of lumbar vertebra 
Lumbosacral spondylosis without myelopathy 
Spinal stenosis, excluding cervical region 
Dorsal spondylosis without myelopathy 
Thoracic spondylosis without myelopathy 
Other lumbar disc disorders 
Congenital lumbosacral spondylolysis 
Osteoarthritis of thoracic spine 
5. OA neck Cervical spondylosis 
Cervical spondylosis without myelopathy 
Plain X-ray cervical spine abnormal 
Cervical spinal stenosis 
Osteoarthritis cervical spine 
Cervical spine instability 
Degenerative cervical spinal stenosis 
Cervical spondylosis 
6. OA shoulder and 
elbow 
Osteoarthritis NOS, of acromioclavicular joint 
Osteoarthritis NOS, of shoulder region 
Joint ankylosis of the shoulder region 
Osteoarthritis NOS, of shoulder 
Shoulder arthritis NOS 
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Unspecified monoarthritis of the shoulder region 
Elbow arthritis NOS 
Localised, primary osteoarthritis of the shoulder region 
Localised, primary osteoarthritis of the upper arm 
7. OA hip Hip osteoarthitis NOS 
Hip osteoarthritis NOS 
Osteoarthritis NOS, of hip 
Hip arthritis NOS 
[X]Other primary coxarthrosis 
8. OA knee Knee osteoarthritis NOS 
Patellofemoral osteoarthritis 
Osteoarthritis NOS, of knee 
Knee arthritis NOS 
Arthritis associated with other disease, knee 
9. OA lower limb, not 
specified or other than 
hip or knee 
Foot osteoarthritis NOS 
Foot arthritis NOS 
Localised osteoarthritis, unspecified, of the ankle and foot 
Toe osteoarthritis NOS 
Osteoarthritis NOS, of 1st MTP joint 
Osteoarthritis NOS, of ankle 
Ankle arthritis NOS 
Osteoarthritis NOS, of the lower leg 
Osteoarthritis NOS, of ankle and foot 
Localised, primary osteoarthritis of the lower leg 
Localised, primary osteoarthritis of toe 
Ankle osteoarthritis NOS 
Arthritis associated with other disease, 1st MTP joint 
10. OA back or neck, not 
specified 
Degenerative disc disease NOS 
Osteoarthritis spine 
Spondylosis and allied disorders 
Arthritis of spine 
Spinal stenosis 
Spondylosis NOS 
Osteoarthritis of spine 
Osteoarthritis of spine 
Osteoarthritis of lumbar spine 
11. OA hand, wrist, digits Osteoarthritis NOS, of the hand 
Thumb osteoarthritis NOS 
Wrist arthritis NOS 
Heberdens' nodes 
Finger osteoarthritis NOS 
Osteoarthritis NOS, of MCP joint 
Hand arthritis NOS 
Osteoarthritis NOS, of wrist 
Osteoarthritis NOS, of DIP joint of finger 
Osteoarthritis NOS, of PIP joint of finger 
Wrist osteoarthritis NOS 
Periarthritis of wrist 
Localised, primary osteoarthritis of the hand 
Heberden's nodes with arthropathy 
Localised, primary osteoarthritis of the wrist 
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Generalised osteoarthritis of the hand 
Arthritis associated with other disease, PIP joint of finger 
12. OA pelvis Osteoarthritis NOS, pelvic region/thigh 
Localised, primary osteoarthritis of the pelvic region/thigh 
Sacroiliac ankylosis 





Gouty tophi of other sites 
Gouty arthropathy 
Gouty arthritis NOS 
Gout monitoring 
Gout NOS 
Gout treatment changed 
Gouty arthritis of the ankle and foot 





15. Non-specific disorder 
of joints 
Arthralgia of unspecified site 
Injection of therapeutic substance into joint 
Effusion of joint 
Injection into joint NEC 
O/E - joint swelling 
Arthralgia of multiple joints 
Arthropathy NOS 
Joint disorders NOS 
Arthropathies NOS 
Pain in joint - arthralgia 
O/E - joint effusion present 
Other and unspecified joint disorders 
O/E - reduced joint movement 
O/E - swelling - joint 
Swelling of joint - effusion 
Polyarthropathy NEC 
Transient arthropathy 
Arthropathies and related disorders 
Other specified joint disorders NOS 
Ankylosis of joint 
Swollen joint 
Arthropathy NOS, of the lower leg 
Unspecified polyarthropathy or polyarthritis 
Swollen joint count 
Other specified arthropathies 
Unspecified polyarthropathy or polyarthritis NOS 
O/E - joint movement painful 
Other and unspecified arthropathies 
Other joint symptoms NOS 
Unspecified polyarthropathy of unspecified site 
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16. Back pain  Backache 
Low back pain 
Backache, unspecified 
Pain in lumbar spine 
Sacroiliac strain 
Lumbago 
Therapeutic lumbar epidural injection 
Backache symptom 
Back pain without radiation NOS 
C/O - low back pain 
Spasm of back muscles 
Pain in thoracic spine 
Acute back pain - lumbar 
C/O - a back symptom 
C/O - lumbar pain 
Acute back pain - thoracic 
Acute back pain - unspecified 
Back stiffness 
C/O - upper back ache 
Backache symptom NOS 
Back disorders NOS 
H/O: back problem 
Back pain, unspecified 
Backache with radiation 
Referral to back pain clinic 
Lumbar traction 
Chronic low back pain 
Mechanical low back pain 
Lumbalgia 
Other back symptoms 
17. Discogenic nerve root 
pain 
Sciatica 
Intervertebral disc disorders 
Prolapsed lumbar intervertebral disc 
Slipped intervertebral disc 
Cervical disc degeneration 
Lumbar disc displacement 
Lumbosacral neuritis, unspecified 
Cervical disc displacement 
Acute back pain - disc 
Acute back pain with sciatica 
Cervical disc disorder with radiculopathy 
Intervertebral disc prolapse NOS 
Cervical disc displacement without myelopathy 
Cervical spondylosis with myelopathy 
Prolapsed lumbar intervertebral disc with sciatica 
Myelopathy due to spondylosis 
Cervical disc disorder with myelopathy 
Exploratory thoracic laminectomy 
Lumbosacral spondylosis with radiculopathy 
Cervical spondylosis with radiculopathy 
Disc prolapse with radiculopathy 
Lumbar disc prolapse with myelopathy 
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Prolapsed intervertebral disc without myelopathy 
Cervicobrachial syndrome 
Lumbago with sciatica 
Thoracic and lumbosacral neuritis 
Thoracic spondylosis with radiculopathy 
Cervical nerve root injury 
Disc prolapse with myelopathy 
Lumbar disc prolapse with radiculopathy 
Lumbosacral root lesions NEC 
Lumbar disc prolapse with cauda equina compression 
Thoracic disc displacement without myelopathy 
Thoracic and lumbosacral neuritis NOS 
Cervical disc prolapse with radiculopathy 
Disc disorder with myelopathy 
Prolapsed cervical intervertebral disc without myelopathy 
Lumbar nerve root injury 
Lumbar disc disorder with myelopathy 
Lumbosacral plexus injury 
Nerve root and plexus compressions in intervert disc disord 
Other cervical disc disorders 
18. Spinal surgery Primary laminectomy excision of lumbar intervertebral disc 
Primary laminectomy excision of cervical intervert disc 
Laminectomy approach to cervical spine 
Revisional lumbar microdiscectomy 
Exploratory cervical laminectomy 
Laminectomy approach to thoracic spine 
Primary posterior laminectomy decompression lumbar spine 
Laminectomy approach to lumbar spine 
Revision posterior laminectomy decompression lumbar 
spine 
Other specified operations on lumbar spine 
Decompression operations on unspecified spine 
Other specified primary foraminoplasty of spine 





Cervical and neck disorders NOS 
C/O - a neck symptom 
Stiff neck symptom 
Torticollis - symptom 
[V]Problems with neck 
Stiff neck NOS 
Torticollis NOS 
Wry neck/torticollis 
Neck sprain, unspecified 
Wry neck symptom 
Crick in neck 
Torticollis - traumatic 
Pain in cervical spine 
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Cervicalgia 
20. Hip pain Hip pain 
Hip joint pain 
Arthralgia of the pelvic region and thigh 
Arthralgia of hip 
21. Knee pain H/O: significant knee disorder 
Knee joint pain 
Arthralgia of knee 
Anterior knee pain 
Knee pain 
Anterior knee pain 
22. Lower limb pain 
unspecified or other than 
hip or knee 
Arthralgia of the ankle and foot 
23. Knee bursitis Prepatellar bursitis 






[X]Other bursitis of knee 
24. Knee joint swelling or 
effusion 
Knee joint effusion 
Swollen knee 
Rupture of Baker's cyst - knee 
Effusion of knee 
25. Widespread pain Fibromyalgia 
Myalgic encephalomyelitis 
Myalgia or myositis NOS 
Myalgic encephalomyelitis 
Chronic fatigue syndrome 
Fibromyalgia 
Fibrositis of neck 
CFS - Chronic fatigue syndrome 
Generalised pain [symptom] 
Myofascial pain syndrome 
[X]Chronic pain personality syndrome 
Myofascial pain syndrome 
Referral to chronic fatigue syndrome specialist team 
Chronic pain review 
26. Connective tissue 
disease 
Polymyalgia rheumatica 
Musculoskeletal and connective tissue diseases NOS 
Sicca (Sjogren's) syndrome 
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Myositis unspecified 
Lupus erythematosus NOS 
Systemic lupus erythematosus 
Cranial arteritis 
Giant cell arteritis 
Sjogren - Larsson syndrome 
Polymyositis 
Disseminated lupus erythematosus 
Lupus nephritis 
Subacute cutaneous lupus erythematosus 
Systemic sclerosis 
Lupus erythematosus profundus 
History of connective tissue disease 
27. Shoulder pain Shoulder pain 
Shoulder joint pain 
Shoulder stiff 
Shoulder pain 
Arthralgia of sternoclavicular joint 
Stiff joint NEC, of the shoulder region 
Other joint symptoms of the shoulder region 
Arthralgia of the shoulder region 
Arthralgia of the upper arm 
Arthralgia of shoulder 
Arthralgia of acromioclavicular joint 
Shoulder joint painful on movement 
28. Elbow pain Elbow joint pain 
Arthralgia of elbow 
Pain in elbow 
Elbow pain 
29. Wrist/hand or 
forearm pain 
Wrist joint pain 
Arthralgia of wrist 
Arthralgia of the hand 
Arthralgia of the forearm 
Arthralgia of DIP joint of finger 
Hand joint pain 
Arthralgia of PIP joint of finger 
Pain in wrist 
30. Specific disorders of 
the shoulder & shoulder 
girdle (not OA) 
Painful arc syndrome 
Bicepital tendonitis 
Supraspinatus tendonitis 
Adhesive capsulitis of the shoulder 
Frozen shoulder 
Scapulohumeral fibrositis 





Bursitis - shoulder 
O/E - painful arc 
Subacromial impingement 
427 | P a g e  
 






Rotator cuff syndrome, unspecified 
Rotator cuff syndrome NOS 
31. Specific disorders of 




Lateral epicondylitis of the elbow 
Medial epicondylitis of the elbow 
32. Specific disorders of 
the forearm, hand, wrist, 
or digits (not OA) 
De Quervain's disease 
Other tenosynovitis of the wrist 
Other tenosynovitis of hand or wrist 
33. Shoulder surgery & 
other procedures 
Injection of steroid into shoulder joint 
Shoulder joint operations 
Hemiarthroplasty of head of humerus 
Injection of hydrocortisone acetate into shoulder joint 
Plastic repair of rotator cuff of shoulder 
Bursitis of shoulder 
Pain due to shoulder joint prosthesis 
Prosthetic uncemented hemiarthroplasty of shoulder 
Shoulder joint operations NOS 
Other specified operations on shoulder joint 
Primary uncemented hemiarthroplasty of shoulder 
Total prosthetic replacement of shoulder joint using cement 
Resurfacing hemiarthroplasty of head of humerus NEC 
Arthroscopic subacromial decompression 
Plastic repair of rotator cuff of shoulder NEC 
Plastic repair of multiple tears of rotator cuff of shoulder 
Diagnostic arthroscopy of shoulder joint 
34. Elbow injections Injection of steroid into elbow joint 
35. Wrist 
injection/splinting 
None in study sample 
36. Other procedures 
upper limb (not 
shoulder) 
Injection of steroid into wrist joint 
Injection of steroid into carpometacarpal joint of thumb 
37. Upper limb pain not 
specified  
Pain in upper limb 
38. Non-specific 
sprain/injury group 
Sprains and strains of joints and adjacent muscles 
Ligament sprain NOS 
Joint sprain NOS 
Tendon sprain NOS 
Muscle sprain NOS 
Sprain - late effect 
Sprains and strains NOS 
Nontraumatic tendon rupture 
Other specified sprains and strains 
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Other and ill-defined sprains and strains 
Complex regional pain syndrome type I 
Complex regional pain syndrome 
39. Neck injury Whiplash injury 
Neck sprain 
Whiplash injury 
Dislocations, sprains and strains involving head with neck 
40. Back injury Back sprain NOS 
Sprain, lumbosacral ligament 
Lumbar sprain 
Pulled back muscle 
Sacroiliac ligament sprain 
Coccyx sprain 
Disloc,sprains + strains involv thorax wth lwr back + pelvis 
Thoracic sprain 
Lumbosacral strain 
Sprain & strain of oth & unsp parts of lumb spine & pelv 
41. Shoulder/upper limb 
injury 
Elbow sprain NOS 
Sprain wrist ligament 
Sprain finger 
Sprain thumb 
Rotator cuff sprain 
Sprain, acromio-clavicular ligament 
Hand and wrist extensor tendon rupture 
Shoulder strain 
Sprain tendon wrist or hand 
Sprain of shoulder and upper arm 
Complete tear, shoulder joint 
Sprain tendon of thumb 
Wrist sprain unspecified 
Hand and wrist flexor tendon rupture 
Hand sprain 
Biceps tendon rupture 
Sternoclavicular sprain 
Wrist and hand sprain NOS 
Sprain of elbow and forearm 
Sprain, supraspinatus tendon 
Forearm sprain 
Other shoulder sprain 
Sprain, biceps tendon 
Sprain, triceps tendon 
Rotator cuff complete rupture 
Sprain, infraspinatus tendon 
Sprain, subscapularis tendon 
Shoulder sprain NOS 
Sprain, elbow joint, medial collateral ligament 
Sprain, shoulder joint 
Sprain of wrist and hand 
Sprain tendon of finger 
Wrist sprain NOS 
Sprain & strain of oth & unspecif parts of should girdle 
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Finger sprain 
42. Hip injury  Hip sprain 
Sprain of hip and thigh 
43. Knee injury (including 
ligament tears) 
Knee sprain 
Complete tear, knee ligament 
Knee sprain NOS 
Acute meniscal tear, medial 
Sprain of cruciate ligament of knee 
Partial tear, knee, anterior cruciate ligament 
Complete tear, knee, posterior cruciate ligament 
Complete tear, knee, anterior cruciate ligament 
Sprain or partial tear, knee, lateral collateral ligament 
Sprain of medial collateral ligament of knee 
Partial tear, knee, medial collateral ligament 
Complete tear, knee, medial collateral ligament 
Adhesions of knee joint 





Quadriceps tendon rupture 
Hamstring sprain 
Sprain, tendocalcaneus (Achilles tendon) 
Toe sprain 
Leg sprain NOS 
Ankle sprain NOS 
Sprain gastrocnemius 
Leg sprain 
Sprain, patellar tendon 
Sprain, hamstring tendon 
Sprain of superior tibiofibular ligament 
Sprain, quadriceps tendon 
Sprain of knee and leg 
Sprain of ankle and foot 
Foot sprain NOS 
Sequelae of dislocation, sprain and strain of lower limb 
Sprain, inter-phalangeal joint, toe 
Complete tear, ankle or foot ligament 
45. Specific disorder that 
does not fit anywhere 
Tendonitis NOS 
Rib sprain 
Xiphoid cartilage sprain 
Intercostal myalgia 
Temporomandibular joint disorder NOS 
Sternum sprain 
Effusion of ankle 
46. Arthroplasty of the 
hip  
Total prosthetic replacement of hip joint NOS 
THR - Total prosthetic replacement hip joint without cement 
Hip joint operations 
Revision of total prosthetic replacement of hip joint NEC 
THR - Total prosthetic replacement of hip joint using cement 
THR - Other total prosthetic replacement of hip joint 
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Hip replacement planned 
Total prosthetic replacement of hip joint using cement 
Hemiarthroplasty of head of femur NEC 
Revision cemented total hip replacement 
Prosthetic hemiarthroplasty of head of femur using cement 
Other total prosthetic replacement of hip joint 
Other arthroplasty of hip joint 
Primary hybrid total replacement of hip joint NEC 
Primary cemented total hip replacement 
Pain due to hip joint prosthesis 
Hip joint operations NOS 
Total prosthetic replacement of hip joint not using cement 
Exeter total replacement of hip joint using cement 
Primary prosthetic hemiarthroplasty of hip NEC 
Primary total prosthetic replacement of hip joint NEC 
Total prosthetic replacement of hip joint using cement OS 
Closed reduction dislocated total prosthet replace hip joint 
Primary uncemented total hip replacement 
Primary hybrid total replacement of hip joint NEC 
Revision one component total prosthet replace hip joint NEC 
H/O hip replacement 
47. Other hip procedures Other specified operations on hip joint 
Injection of steroid into hip joint 
48. Arthroplasty of knee Other total prosthetic replacement of knee joint NOS 
Total prosthetic replacement of knee joint using cement 
TKR - Other total prosthetic replacement of knee joint 
TKR -Total prosthetic replacement of knee joint using 
cement 
Other total prosthetic replacement of knee joint 
TKR - Total prosthetic replacement knee joint without 
cement 
Other arthroplasty of knee joint 
Revision cemented total knee replacement 
Cemented unicompartmental knee replacement 
Revision of total knee replacement NEC 
Total prosthetic replacement of knee joint not using cement 
Primary cemented total knee replacement 
Primary total knee replacement NEC 
Primary cemented unicompartmental knee replacement 
Unicompartmental knee replacement NOS 
Prosthetic arthroplasty of the patellofemoral joint 
H/O knee replacement 
49. Other knee 
procedures  
Diagnostic arthroscopy of knee 
Open total meniscectomy of knee 
Knee joint operations 
Therapeutic arthroscopic operations on cavity of knee joint 
Therapeutic arthroscopy on knee joint 
Arthroscopic removal of loose body from knee joint 
Injection of steroid into knee joint 
Partial meniscectomy of knee 
Arthroscopic debridement of knee joint 
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Arthroscopic synovectomy knee joint 
Arthroscopic irrigation of knee joint 
Open meniscectomy of knee NEC 
Endoscopic washout of knee joint 
Diagnostic arthroscopy of knee NOS 
Lateral release of contracture of knee joint 
Knee joint operations NOS 
Therapeutic arthroscopic op on cavity of knee joint NOS 
Release of contracture of knee joint 
Endoscopic lavage of knee joint 
Other specified operations on knee joint 
Arthroscopic partial medial meniscectomy 
Arthroscopy of knee 
50. Referral/ seen by/ 








Refer to physiotherapist 
Referred to rheumatologist 
Refer to pain clinic 
Physiotherapy/remedial therapy 
Seen in physiotherapy dept 
Physiotherapy manipulation 
Under care of community-based physiotherapist 
Arthritis monitoring 
Refer to physiotherapist 
Refer to domiciliary physiotherapy 
Seen by orthopaedic surgeon 
Seen by rheumatologist 
Referral to physiotherapist 
Referral to rheumatologist 
Discharge by physiotherapist 
Refer to osteopath 
Referral to community-based physiotherapist 
Referral to rheumatology clinic 
Referral to hospital physiotherapist 
Private referral to orthopaedic surgeon 
Referral to hand surgeon 
Private referral to rheumatologist 
Private referral to physiotherapist 
Referral to community physiotherapist 
Referral to hand surgeon 
Rheumatism monitoring 
Physiotherapy 
Under care of rheumatologist 
Discharge from physiotherapy service 
Other physiotherapy 
Seen by physiotherapist 
Discharge by hospital-based physiotherapist 
Seen in physiotherapy department 
Refer to community physiotherapist 
Referral to musculoskeletal clinic 
Referral to hospital-based physiotherapist 
Rheumat. initial assessment 
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Rheumat. follow-up assessment 
Referral to orthopaedic physiotherapist practitioner 
Referral to musculoskeletal special interest GP 
Physiotherapy self-referral 
Referral to spinal surgeon 
Referral to orthopaedic surgeon 
Discharge from physiotherapy service 
Private referral to spinal surgeon 
Private referral to hand surgeon 









O/E - joint stiffness 
Joint stiffness NEC 
Rheumatic pain 
Morning stiffness - joint 
Musculoskeletal pain - joints 
Musculoskeletal and connective tissue diseases 
Menopausal arthritis 
Muscular rheumatism 
Rheumatol. disorder monitoring 
Hand rheumatism 
Arthralgia NOS 
[X]Other chronic pain 
Rheumatology drug monitoring 
Rheumatic disorder annual review invitation 
 
Appendix Table 3: Read codes used to compose mental health disorder sub-group 
categories.  
Health disorder category 
and group number 
Clinical diagnostic codes (Read codes) used 
1 Disorders usually first 
diagnosed in infancy, 
childhood, or adolescence 
Stammering or stuttering 
[X]Asperger's syndrome 
Childhood hyperkinetic syndrome 
Stuttering 
Tics 
Stammer - symptom 
[X]Autistic disorder 
Seen by child and adolescent psychiatrist 
Stutter - symptom 
Has a stammer/stutter 
2 Delirium, dementia, and 
amnestic and other 
cognitive disorders 
Confusion 
Acute confusional state 
[X] Unspecified dementia 
[D]Confusion 
Mild memory disturbance 
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[X]Acute / subacute confusional state, nonalcoholic 
[X]Dementia in other diseases classified elsewhere 
Senile and presenile organic psychotic conditions 
Dementia care plan 
Dementia care plan agreed 
Dementia medication review 
Cerebral atrophy 
3 Mental disorders due to 
a general medical 
condition not elsewhere 
classified 
Toxic confusional state 
Organic delusional syndrome 
[X]Organic emotionally labile [asthenic] disorder 
[X]Organic delusional [schizophrenia-like] disorder 
[X]Organic mood [affective] disorders 
Organic affective syndrome 
[X]Organic dissociative disorder 
4 Substance-related 
disorders 
[X]Alcohol withdrawal-induced seizure 



















Acute paranoid reaction 
[X]Schizophrenia, schizotypal and delusional disorders 
Delusion 
Psychosis, schizophrenia + bipolar affective disord resolved 
[X]Mania with psychotic symptoms 
[X]Acute and transient psychotic disorders 
[X]Brief reactive psychosis NOS 
Paranoid schizophrenia in remission 
Schizo-affective schizophrenia in remission 
Schizophrenia in remission 
Psychosis resolved 
[X]Nonorganic psychosis in remission 
6 Mood disorders or 
Depressive disorders 
Depressive disorder NEC 
[X]Depression NOS 
Endogenous depression 
Anxiety with depression 
Agitated depression 
Neurotic depression reactive type 
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Brief depressive reaction 





[X]Depressive episode, unspecified 
Postviral depression 
[X]Depressive disorder NOS 
[X]Recurrent depressive disorder 
Chronic depression 
[X]Depressive episode 
C/O - feeling depressed 
[X]Mood - affective disorders 
Agitated depression 
[X] Reactive depression NOS 
Recurrent depression 
Endogenous depression first episode 
[X]Other depressive episodes 
Endogenous depression - recurrent 
Endogenous depression first episode 
Single major depressive episode NOS 
[X]Single episode of reactive depression 
[X]Neurotic depression 
[X]Mild anxiety depression 
[X]Dysthymia 
[X]Depressive neurosis 
[X]SAD - Seasonal affective disorder 
[X]Recurrent episodes of depressive reaction 
[X]Recurrent episodes of reactive depression 
Low mood 
[X]Single episode of depressive reaction 
Masked depression 
[X]Moderate depressive episode 
[X]Severe depressive episode without psychotic symptoms 
Symptoms of depression 
Depressed mood 
Depressive symptoms 
Single major depressive episode 
[X]Mild depression 
Seasonal affective disorder 
[X]Endogenous depression without psychotic symptoms 
[X]Mild depressive episode 
[X]Mixed anxiety and depressive disorder 
[X]Severe depressive episode with psychotic symptoms 
Depression medication review 
Depression annual review 
[X]Postnatal depression NOS 
Recurrent major depressive episodes, moderate 
Recurrent major depressive episode 
[X]Persistant anxiety depression 
Single major depressive episode, mild 
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Prolonged depressive reaction 
Psychotic reactive depression 
Depression resolved 
[X]Single episode major depression w'out psychotic symptoms 
Recurrent major depressive episodes, severe, with psychosis 
Advice regarding symptoms on discontinuation of SSRI 
[X]Prolonged single episode of reactive depression 
Excepted from depression quality indicators: Patient unsuita 
[X]Recurrent depressive disorder, current episode moderate 
[X]Recurrent depressive disorder, current episode mild 
Depression interim review 
Patient given advice about management of depression 
[X]Recurr depress disorder cur epi severe without psyc sympt 
[X]Persistent mood affective disorders 
On depression register 
Excepted from depression quality indicators: Informed dissen 
[X]Recurrent depressive disorder, unspecified 
Removed from depression register 
[X]Recurrent depress disorder cur epi severe with psyc symp 
Exception reporting: depression quality indicators 
[X]Other single mood affective disorders 
Depression monitoring administration 
Depression monitoring first letter 
Depression monitoring second letter 
[X]Single major depr ep, severe with psych, psych in remiss 
7 Bipolar disorders [X]Manic-depressive illness 
[X]Hypomania 
Rebound mood swings 
[X]Mania NOS 
[X]Bipolar affective disorder 
Bipolar psychoses 
[X]Bipolar disorder, single manic episode 
H/O: manic depressive disorder 
[X]Manic episode 
[X]Mania without psychotic symptoms 
Unspecified bipolar affective disorder 
Manic-depressive - now manic 
[X]Cyclothymia 
Unspecified bipolar affective disorder, in full remission 
Single manic episode in full remission 
8 Anxiety disorders Panic attack 









General nervous symptoms 
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H/O: anxiety state 
'Nerves' 
[X]Panic state 
[X]Post - traumatic stress disorder 
Anxiety state NOS 
Recurrent anxiety 
Generalised anxiety disorder 
[X]Obsessive - compulsive disorder 
[X]Other anxiety disorders 
Compulsive neurosis 
[X]Panic attack 
Anxiety state unspecified 
[D]Restlessness and agitation 
Anxiety counselling 
[X]Panic disorder [episodic paroxysmal anxiety] 
Anxiety management training 
[X]Generalized anxiety disorder 
C/O - panic attack 
Neurotic disorder NOS 
Obsessive-compulsive disorder NOS 
[D]Nerves 
[X]Mixed obsessional thoughts and acts 
[X]Predominantly obsessional thoughts or ruminations 
[X]Obsessive-compulsive neurosis 
Compulsive behaviour 
[X]Anxiety disorder, unspecified 
[X]Anxiety NOS 
[X]Traumatic neurosis 
9 Somatoform disorders Hypochondriasis 
[D]Debility, unspecified 
Neurasthenia - nervous debility 
Writer's cramp neurosis 
Psychogenic dyspepsia 
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10 Factitious disorders No codes in study sample 
11 Dissociative disorders Depersonalisation syndrome 
[X]Depersonalization - derealization syndrome 
Other conversion disorder 
12 Sexual and gender 
identity disorders 
Psychosexual disorder NOS 
[X]Sex dysfunction not caused by organic disorder or disease 
Psychosexual dysfunction 
Psychogenic vaginismus 
[X]Excessive sexual drive 
13 Eating disorders [D]Anorexia 
Anorexia nervosa 
Bulimia (non-organic overeating) 
[X]Eating disorders 
Other and unspecified non-organic eating disorders 
H/O: anorexia nervosa 
[X]Bulimia nervosa 
Referral to eating disorders clinic 
[X]Anorexia nervosa 
14 Sleep disorders [D]Insomnia NOS 
Initial insomnia 
Insomnia NOS 
C/O - insomnia 
Late insomnia 
Non-organic sleep disorders 
C/O - somnolence 
[D]Insomnia - symptom 
Hypersomnia NOS 
Transient insomnia 
[X]Dream anxiety disorder 
Cannot sleep - insomnia 
[X]Nonorganic sleep disorders 
[D]Insomnia with sleep apnoea 
15 Impulse-Control 









Stress related problem 
Bereavement reaction 
[X]Reaction to severe stress, and adjustment disorders 
[X]Adjustment disorders 
[X]Grief reaction 
Adjustment reaction NOS 





Immature personality disorder 





Adolescent - emotional problem 
Emotionally unstable personality 
Inadequate personality disorder 
Hysterical personality disorders 
Paranoid personality disorder 
Aggressive personality 
[X]Emotionally unstable personality disorder 
[X]Anxious [avoidant] personality disorder 
Neurotic, personality and other nonpsychotic disorders 
Depressive personality disorder 
Cyclothymic personality disorder 
Personality disorder NOS 
Other personality disorder NOS 
Obsessional thoughts 
Borderline personality disorder 
Dependent personality 
Explosive personality disorder 
[X]Cyclothymic personality 
[X]Dependent personality disorder 
Introverted personality 
[X]Immature personality disorder 
Schizotypal personality 
18 Self-harm, suicidal 
actions or ideations 
[X]Deliberate drug overdose / other poisoning 
Suicidal ideation 
Suicide + selfinflicted poisoning by drug or medicine NOS 
Attempted suicide 




Cause of overdose - deliberate 
H/O: deliberate self harm 
[X]Para-suicide 
Suicidal - symptom 
Deliberate self-harm 
Self-harm 
Poisoning - self-inflicted 
[X]Self inflicted injury 
H/O: attempted suicide 
Self inflicted lacerations to wrist 




[X]Overdose - paracetamol 
At risk of DSH - deliberate self harm 
Cutting own wrists 
[X]Intent self poison/exposure to nonopioid analgesic 
Suicide + selfinflicted poisoning by other drugs/medicines 
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[X]Intentional self harm by sharp object 
Suicide + selfinflicted poisoning by solid/liquid substances 
[X]Intentional self harm by unspecified means 
19 Referral to a support 
service 
Psychotherapy 
Refer to psychologist 
Seen in psychology clinic 
Refer to CPN 
Psychological counselling 
Refer to community psych.nurse 
Counselling offered 
Referral to counsellor 
Counselling by other agency 
Psychiatric monitoring 
Stress counselling 
Mental health assessment 
Refer to counsellor 
Seen by psychologist 
Counselling requested 
Seen by nurse behavioural therapist 
Refer to counsellor 
Referral to psychotherapist 
Referral to mental health counsellor 
Mental health review 
Refer to psychologist 
Referral to psychologist 
Cognitive-behaviour therapy 
Seen by mental health counsellor 
Seen by psychotherapist 
Under care of counsellor 
Counselling 
Referral to psychotherapist 
Mental health medication review 
Referral to primary care mental health gateway worker 
Mental health personal health plan 
Referral to psychosexual clinic 
Referral to non NHS mental health community service 
Counselling carried out 
Under care of community psychiatric nurse 
Seen by psychologist 
Mental therapy follow-up 
Refer to mental health worker 
Seen by counsellor 
Counselled by a counsellor 
Mental health review follow-up 
Under care of mental health counsellor 
Mental health monitoring first letter 
Mental health monitoring second letter 
Mental health monitoring third letter 
Referral for mental health self-help literature 
Mental health monitoring verbal invitation 
Seen by primary care graduate mental health worker 
Seen by mental health triage nurse 
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Seen by primary care mental health gateway worker 
In-house counselling first appointment 
Referral for cognitive behavioural therapy 
Review of mental health care plan 
Agreeing on mental health care plan 
20 under the psychiatrist’s 
team 
Psychiatric referral 
Seen in psychiatry clinic 
Non-urgent psychiatric admisn. 
Referral to psychogeriatrician 
Seen by community psychiatric nurse 
Seen by CPN 
Seen by CPN 
Seen by psychiatrist 
Referral to psychiatric nurse 
Referral to psychiatrist 
Referral to community mental health team 
Under care of mental health team 
Under care of psychiatrist 
Referral to mental health team 
Psychiatry care plan 
Private referral to psychiatrist 
Under care of CPN 
Under care of psychiatrist 
Psychiatry D.V. done 
Seen by psychiatric nurse 
Discharge by psychiatrist 
Seen by community psychiatric nurse 
Seen by forensic psychiatrist 
Seen by liaison psychiatrist 
Seen by rehabilitation psychiatrist 
Referral to liaison psychiatrist 
Under care of hospital psychiatric team 
Psychiatry 
Referral to primary care mental health team 
Seen in mental health clinic 
Mental Health Care Programme Approach 
Electroconvulsive therapy 
21 Crisis admission, 
section, on a severe 
mental health register 
Mental Health Act examination 
Section 2 form - compulsory admission for assessment 
Admit psychiatric emergency 
Section 3 form - compulsory admission for treatment 
On severe mental illness register 
Referral to mental health crisis team 
Removed from severe mental illness register 
Mental health crisis plan 
[X]Crisis state 
Completion of mental health crisis plan 
22 Symptoms of 
psychological distress 





Stress at work 




Stress at home 
[V]Psychological problems 
Poor self esteem 
Work worries 
Worried 









Agitated - symptom 
[D]Lassitude 
Anxiousness - symptom 
Anger reaction 
[V]Stressful work schedule 
[D]Work stress 
Loss of confidence 
[D]Irritability and anger 
O/E - distressed 
C/O weepiness 




[X]Acute reaction to stress 
[D]Nervous tension 
Stress management 
[X]Acute stress reaction 
Anger management counselling 
O/E - angry 
O/E - anxious 
O/E - agitated 
[D]Demoralization and apathy 
Frightened 
H/O: low self-esteem 
Acknowledging anxiety 
[D]Unhappiness 
Acute stress reaction NOS 
[X]Reaction to severe stress, unspecified 
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Appendix Table 4: Read codes used to compose cardiovascular disorder sub-group 
categories.  
Health disorder category and 
group number 
Clinical diagnostic codes (Read codes) used 
1 Myocardial infarction/unstable 
angina 
Acute myocardial infarction 
MI - acute myocardial infarction 
Inferior myocardial infarction NOS 
Old myocardial infarction 
Other specified anterior myocardial infarction 
Acute non-ST segment elevation myocardial infarction 
Acute ST segment elevation myocardial infarction 
Acute myocardial infarction NOS 
Anterior myocardial infarction NOS 
H/O: myocardial infarct <60 
History of myocardial infarction 
Coronary thrombosis 




Post infarct angina 
Angina at rest 
Cardiac enzymes abnormal 
Heart attack 
Acute inferolateral infarction 
Acute non-Q wave infarction 
Acute anteroseptal infarction 
Acute Q-wave infarct 
2 Myocardial 
ischaemia/atherosclerosis/angina 
ECG: myocardial ischaemia 
Coronary artery disease 
Single coronary vessel disease 
Double coronary vessel disease 
Coronary atherosclerosis 
Acute coronary insufficiency 
Coronary heart disease medication review 
Angina on effort 
Angina pectoris 
H/O: angina pectoris 
Stable angina 
Angina control 
Angina control - improving 
Angina control - poor 
Worsening angina 
Angina control - good 
New onset angina 
Angina pectoris NOS 
Angina control - worsening 
Cardiac syndrome X 
Ischaemic heart disease 
Triple vessel disease of the heart 
Ischaemic heart disease NOS 
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IHD - Ischaemic heart disease 
Coronary heart disease review 
Asymptomatic coronary heart disease 
Arteriosclerotic heart disease 
Coronary heart disease monitoring 1st letter 
Suspected ischaemic heart disease 
Coronary heart disease monitoring 2nd letter 
Coronary heart disease monitoring 3rd letter 
Attends coronary heart disease monitoring 
Coronary heart disease monitoring verbal invitation 
Coronary heart disease monitoring check done 
Coronary heart disease monitoring telephone invite 
Atherosclerotic cardiovascular disease 
Other chronic ischaemic heart disease NOS 
Other specified ischaemic heart disease 
Other chronic ischaemic heart disease 
[X]Other forms of chronic ischaemic heart disease 
Coronary artery spasm 
Referred to acute chest pain clinic 
3 Cardiology/vascular 
investigations 
Myocardial perfusion scan 
Coronary arteriograph.abnormal 
Coronary arteriography 
Coronary arteriography NEC 
Diagnostic transluminal operations on coronary artery 
Cardiac catheterisation 
Cardiac computed tomography angiography 
Catheterisation of heart 
Catheterisation of heart NOS 




Vascular studies performed 
Cardiovascular stress test using Bruce protocol 
72 hour ambulatory electrocardiographic monitoring 
Arteriography of cerebral artery 
Arteriography of carotid artery 
Carotid artery angiography 
4 Coronary angioplasty/ bypass/ 
stent 
Transluminal balloon angioplasty of coronary artery NOS 
Coronary artery bypass graft operations 
[V]Presence of coronary artery bypass graft 
[V]Presence of coronary artery bypass graft - CABG 
Percutaneous balloon coronary angioplasty 
Open angioplasty of coronary artery 
Coronary artery operations 
Other autograft bypass of coronary artery 
Saphenous vein graft replacement of coronary artery OS 
Saphenous vein graft replacement of three coronary 
arteries 
Saphenous vein graft replacement of two coronary 
arteries 
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Coronary arteriogr.-general 
Saphenous vein graft replacement of one coronary 
artery 
Insertion of coronary artery stent 
Autograft replacement of three coronary arteries NEC 
Coronary artery operations NOS 
Saphenous vein graft replacement of four+ coronary 
arteries 
Coronary artery bypass graft occlusion 
Saphenous vein graft replacement of coronary artery 
Percut transluminal balloon angioplasty one coronary 
artery 
Rotary blade coronary angioplasty 
Percut translum balloon angioplasty mult coronary 
arteries 
Other bypass of coronary artery 
Transluminal balloon angioplasty of coronary artery OS 
Insertion of drug-eluting coronary artery stent 
Perc translumin balloon angioplasty stenting coronary 
artery 
Percutaneous coronary intervention 
Peroperative angioplasty 
Perc translum ball angio insert 1-2 drug elut stents cor 
art 




Percutaneous operations on heart 
Transluminal balloon angioplasty of coronary artery 
5 Cardiovascular problem non-
specific 
[D]Echocardiogram abnormal 
Cardiac treatment changed 
Cardiac dis.-treatment changed 
Patient advised about cardiovascular disorder 
Heart disease NOS 
Suspected heart disease 




H/O: cardiovascular disease 
Cardiovascular disease, unspecified 
[D]Cardiovascular system symptoms 
Cardiovascular procedures 
Occlusion of artery 
Operation on pulmonary vein 
Artery and vein operations NOS 
Other specified operations on artery or vein 
H/O: thrombosis 
Vein graft thrombectomy 
Thrombolytic therapy 
Prosthetic graft thrombectomy 
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Atherosclerosis 
ECG:left ventricle hypertrophy 
Admit cardiology emergency 
Circulatory system diseases 




H/O: pulmonary embolus 
[V] Personal history of pulmonary embolism 
Post operative pulmonary embolus 
Suspected pulmonary embolism 
7 Referrals/FU cardiac 
clinic/surgeon/GPSI and other 
follow up/monitoring 
Cardiac disease monitoring 
Follow-up cardiac assess. 
Cardiac rehabilitation 
Referral to cardiac rehabilitation nurse 
Cardiac rehabilitation class 
DNA - Did not attend cardiac clinic 
Seen by cardiac rehabilitation nurse 
Under care of cardiac rehabilitation nurse 
Cardiac rehabilitation declined 
Seen by cardiac surgeon 
Cardiac drug monitoring 
Referral to cardiac rehabilitation nurse 
Seen in cardiothoracic surgery clinic 
Heart disease monitoring 
Seen by vascular surgeon 
Seen in vascular clinic 
Cardiovascular clinic 
Referral to vascular surgeon 
Peripheral vascular disease monitoring 
Under care of vascular surgeon 
Private referral to vascular surgeon 
Discharge from vascular surgery service 
Stroke/transient ischaemic attack monitoring verbal 
invitati 
Cardiological referral 
Seen in cardiology clinic 
Seen by cardiologist 
Referral to cardiologist 
Referred to vascular surgeon 
Referral to rapid access chest pain clinic 
Private referral to cardiologist 
Referral to Cardiothoracic surgeon 
Attending cardiology clinic 
Discharge by cardiologist 
Referral for warfarin monitoring 
Referral to cardiology special interest general 
practitioner 
In-house cardiology first appointment 
Cardiology 
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Seen by private cardiologist 
Referral to community cardiology service 
8 Heart failure Seen in cardiac clinic 
Congestive cardiac failure 
Fast track HF referral for transthoracic 2D 
echocardiogram 
Congestive heart failure 
Heart failure 
Heart failure confirmed 
Seen in heart failure clinic 
New York Heart Association classification - class II 
New York Heart Association classification - class I 
New York Heart Association classification - class III 
Heart failure annual review 
Heart failure monitoring first letter 
Heart failure education 
Referral to rapid access heart failure clinic 
Pulmonary congestion 
Pulmonary oedema NOS 
Left ventricular failure 
9 Probable/possible heart failure Left ventricular hypertrophy 
Ventricular hypertrophy 
Impaired left ventricular function 
Impaired left ventricular function 
Left ventricular systolic dysfunction 
Echocardiogram shows left ventricular systolic 
dysfunction 
Left ventricular diastolic dysfunction 
Left ventricular cardiac dysfunction 
10 Diseases of the endocardium 
and valves 
Endocarditis, valve unspecified, NOS 
Subacute bacterial endocarditis - SBE 
Acute and subacute endocarditis 
Other diseases of endocardium 
Prosthetic replacement of valve of heart NEC 
H/O: artificial heart valve 
Mechanical complication of heart valve prosthesis 
Aortic stenosis, non-rheumatic 
Mitral stenosis 
Aortic stenosis alone, cause unspecified 
Rheumatic aortic stenosis 
Aortic stenosis 
Stenosis of unspecified heart valve 
Pulmonary stenosis, cause unspecified 
Pulmonary infundibular stenosis 
Pulmonary valve disorders 
Open pulmonary valvotomy 
Pulmonary incompetence, cause unspecified 
Percutaneous transluminal balloon angioplasty 
pulmonary vein 
Atrial septal defect NOS 
Ostium secundum atrial septal defect 
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Other specified atrial septal defect 
Ventricular septal defect 
Closure of defect of interventricular septum NOS 
Closure of defect of interventricular septum 
Mitral valve prolapse 
Replacement of aortic valve 
Mitral valve incompetence 
Bicuspid aortic valve 
Aortic valve disorders 
[SO]Mitral valve 
Plastic repair of mitral valve 
Mitral valve regurgitation 
Plastic repair of aortic valve 
Diseases of mitral and aortic valves 
Replacement of aortic valve NEC 
Tricuspid valve disease NEC 
Rheumatic mitral valve disease 
Open heart valvotomy 
Open mitral valvotomy 
Aortic valve disorders NOS 
Aortic valve sclerosis 
Aortic valvuloplasty 
Prosthetic replacement of aortic valve 
Mitral valvuloplasty 
Aortic valve calcification 
Patent ductus arteriosus 
Open correction of patent ductus arteriosus NOS 
11 Arrythmia other than AF or 
treated 
Paroxysmal tachycardia NOS 
Cardiac dysrhythmia NOS 
Cardiac arrhythmias 
Other cardiac dysrhythmias 
Heart beats irregular 
Heart block 
Fluttering of heart 
ECG: heart block 
[D] Other and unspecified abnormalities of heart beat 
Other heart block NOS 
Cardiac dysrhythmias 
Suspected arrhythmia 
Paroxysmal ventricular tachycardia 
Ventricular fibrillation 
ECG: ventricular tachycardia 
Ventricular tachycardia 
First degree atrioventricular block 
Anomalous atrioventricular excitation 
Mobitz type I (Wenckebach) atrioventricular block 
History of ventricular tachycardia 
12 Cardiomyopathies Cardiomegaly 
Cardiomyopathy 
Hypertrophic non-obstructive cardiomyopathy 
Primary dilated cardiomyopathy 
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Hypertrophic obstructive cardiomyopathy 




13 Pericardial diseases Acute pericarditis 
Viral pericarditis NOS 
Other and unspecified acute pericarditis 
Acute pericarditis - unspecified 
Pericardial effusion 
14 Possible/probable acute 
coronary syndrome 
No codes in study sample 
15 Vascular/ atherosclerotic/ 
peripheral arterial disease (non-
coronary) 
Peripheral arterial disease 
Claudication 
Peripheral vascular disease NOS 
Peripheral vascular disease NOS 
Arteriosclerotic vascular disease NOS 
Other specified peripheral vascular disease NOS 
Peripheral ischaemic vascular disease 
Other peripheral vascular disease 
Vascular calcification 
Small vessel cerebrovascular disease 
Intermittent claudication 
Carotid artery stenosis 
Claudication distance 
Extremity artery atheroma 
Therapeutic transluminal operation on other artery NOS 
Thrombosis - arterial 
16 Aneurysms (all body)- only one 
rupture code (n=1) 
Aortic aneurysm 
Abdominal aortic aneurysm without mention of rupture 
Dissecting aortic aneurysm 
Transluminal coil embolisation of aneurysm 
Cerebral aneurysm, nonruptured 
Percutaneous coil embolisation of cerebral artery 
aneurysm 
Aneurysm NOS 
Clipping of aneurysm of cerebral artery 
Other aneurysm NOS 
Aneurysm of common carotid art 
Operation on aneurysm of carotid artery 
17 Heart transplant Other transplantation of heart 
Other transplantation of heart NOS 
19 Hypertension Hypertensive disease 
High blood pressure 
Essential hypertension 
Benign essential hypertension 
H/O: hypertension 
On treatment for hypertension 
Hypertension NOS 
Seen in hypertension clinic 
Systolic hypertension 
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Referral to hypertension clinic 
Hypertensive retinopathy 
Hypertensive disease NOS 
BP - hypertensive disease 
Cardiomegaly - hypertensive 
Essential hypertension NOS 
Patient on maximal tolerated antihypertensive therapy 
Hypertension clinical management plan 
Hypertensive treatm.changed 
Malignant essential hypertension 
Hypertensive heart disease 
Good hypertension control 
Antihypertensive therapy 
Hypertension six month review 
Moderate hypertension control 
Hypertension annual review 
Hypertension treatm. started 
Suspected hypertension 
Poor hypertension control 
Seen in hypertension clinic 
Hypertens.monitor phone invite 
Hypertension:follow-up default 
Hypertens.monitor.1st letter 
Hypertens.monitor 2nd letter 
Hypertens.monitor 3rd letter 
Hypertens.monitoring admin.NOS 
DNA - Did not attend hypertension clinic 
Hypertension monitor.chck done 
Hypertens.monitor verbal inv. 
Attends hypertension monitor. 
Diastolic hypertension 
Hypertension 9 month review 
Stage 1 hypertension 
20 DVT Deep vein thrombosis 
Post operative deep vein thrombosis 
DVT - Deep vein thrombosis 
Deep vein phlebitis and thrombophlebitis of the leg 
H/O: Deep Vein Thrombosis 
Deep vein thrombosis, leg 
Deep vein thrombophlebitis of the leg unspecified 
Thrombophlebitis of the posterior tibial vein 
Suspected deep vein thrombosis 
Referral to deep vein thrombosis clinic 
Axillary vein thrombosis 
On deep vein thrombosis care pathway 
21 Stoke/CVA Stroke and cerebrovascular accident unspecified 
H/O: stroke 
Stroke monitoring 
Excepted from stroke quality indicators: Patient 
unsuitable 
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Excepted from stroke quality indicators: Informed 
dissent 
Stroke / transient ischaemic attack referral 
Stroke/CVA annual review 
Referral to stroke clinic 
Seen in stroke clinic 
Delivery of rehabilitation for stroke 
Suspected stroke 
Infarction - cerebral 
Cerebrovascular disease 
Cerebral infarction NOS 
Intracerebral haemorrhage 
CVA - cerebral artery occlusion 
CVA - Cerebrovascular accident unspecified 
Stroke due to cerebral arterial occlusion 
CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
Evacuation of intracerebral haematoma NEC 
Cerebral arterial occlusion 
Left sided cerebral infarction 
Cerebral infarct due to thrombosis of precerebral 
arteries 
Cerebral infarction due to embolism of cerebral arteries 
Sequelae of cerebral infarction 
Suspected cerebrovascular disease 
CVA unspecified 
H/O: CVA 
Left sided CVA 
Cerebrovascular disease NOS 
Right sided CVA 
Suspected cerebrovascular accident 
Cerebellar infarction 
Infarction of basal ganglia 
22 Cardiac arrest, 
cardiopulmonary resuscitation 
Cardiac arrest 
O/E - collapse -cardiac arrest 
Sudden cardiac death, so described 
Cardiac arrest-ventricular fibrillation 
Cardiac arrest with successful resuscitation 
Cardiopulmonary resuscitation 
23 Superficial vein thrombus Thrombosis of vein NOS 
Thrombophlebitis NOS 
Phlebitis and thrombophlebitis of the leg NOS 
Thrombosed haemorrhoids NOS 
Phlebitis and thrombophlebitis 
External thrombosed haemorrhoids 
Thrombosis of vein of leg 
Superficial vessel phlebitis and/or thrombophlebitis of 
leg 
Evacuation of thrombosed haemorrhoid 
Thrombophlebitis of a superficial leg vein NOS 
Other phlebitis and thrombophlebitis NOS 
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Phlebitis and thrombophlebitis NOS 
Superficial thrombophlebitis in pregnancy and the 
puerperium 
Thrombophlebitis after infusion 
Superficial phlebitis and thrombophlebitis of the leg NOS 
24 AF, SVT History of supraventricular tachycardia 
Paroxysmal atrial fibrillation 
ECG: supraventricular arrhythmia 
Paroxysmal atrial tachycardia 
Atrial fibrillation 
Atrial flutter 
Atrial fibrillation and flutter 
ECG: atrial fibrillation 
H/O: atrial fibrillation 
ECG: atrial flutter 
ECG: paroxysmal atrial tachy. 
Atrial fibrillation monitoring 
Atrial fibrillation and flutter NOS 
Atrial fibrillation resolved 
Excepted from atrial fibrillation qual indic: Inform dissent 
Atrial fibrillation annual review 
Atrial fibrillation monitoring first letter 
History of atrial flutter 
Persistent atrial fibrillation 
Permanent atrial fibrillation 
Supraventricular tachycardia NOS 
Paroxysmal supraventricular tachycardia 
Paroxysmal supraventricular tachycardia NOS 
25 Ectopics Ventricular ectopic beats 
Supraventricular ectopic beats 
Ventricular premature depolarization 
26 Arrhythmia requiring 
cardioversion/ablation/pacemaker 
[V]Cardiac pacemaker in situ 
[V]Fitting or adjustment of cardiac pacemaker 
Implantation of intravenous cardiac pacemaker system 
Direct current cardioversion 
Introduction of cardiac pacemaker system via vein 
Cardioversion and stimulation 
Internal electrode cardioversion 
Implantation of permanent intravenous cardiac 
pacemaker 
Implantation of cardiac pacemaker system NEC 
Seen by cardiac pacemaker technician 
H/O: cardiac pacemaker 
Implantation of internal cardiac defibrillator 
Other cardiac pacemaker system 
Other cardiac pacemaker system NOS 
Removal of cardiac pacemaker system NEC 
Implantation of dual chamber cardiac pacemaker system 
Percutaneous transluminal internal cardioversion NEC 
Renewal of cardioverter defibrillator 
Electrical cardioversion planned 
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Patient with internal cardiac defibrillator pacemaker 
Percut transluminal ablation of heart conducting system 
NEC 
Perc transluminal ablation of atrial wall for atrial flutter 
Percutaneous transluminal ablation of atrial wall 
Percutaneous transluminal ablation of atrial wall NEC 
Percutaneous transluminal ablation of atrioventricular 
node 
Open ablation of atrioventricular node 
27 Vascular atherosclerotic 
events/occlusions/surgery (non-
coronary) 
External cardioversion NEC 
Embolism and thrombosis of the femoral artery 
Arterial embolism and thrombosis 
Embolisation of arteriovenous abnormality 
Embolism and thrombosis of the axillary artery 
Ischaemic optic neuropathy 
Ischaemic toe 
Ischaemic foot 
Retinal vascular occlusion NOS 
Retinal arterial branch occlusion 
Carotid artery occlusion 
Femoral artery occlusion 
Central retinal artery occlusion 
Iliac artery occlusion 
Percutaneous transluminal angioplasty of artery NEC 
Other bypass of femoral artery or popliteal artery NOS 
Endarterectomy of carotid artery NEC 
Aorto biiliac graft 
Percutaneous transluminal angioplasty of femoral artery 
Insertion of iliac artery stent 
Percutaneous transluminal angioplasty of iliac artery 
Other bypass of popliteal artery 
Other artery operations 
Carotid, cerebral and subclavian artery operations 
Other bypass of femoral artery 
Operation on artery NEC 
Endarterectomy of femoral artery NEC 
Other bypass of femoral artery or popliteal artery 
Percutaneous transluminal angioplasty of renal artery 
Repair of popliteal artery NEC 
Percutaneous transluminal angioplasty of carotid artery 
Percutaneous transluminal angioplasty of brachial artery 
Percutaneous transluminal embolisation of renal artery 
Endarterectomy of common iliac artery NEC 
Endarterectomy of iliac artery NEC 
Repair of iliac artery NEC 
Reconstruction of iliac artery NOS 
Percutaneous transluminal insertion of stent femoral 
artery 
Dissection of artery 
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28 Secondary hypertension 
including gestational/pre-
eclampsia 





Pre-eclampsia or eclampsia with pre-existing 
hypertension 
29 TIA Stroke/transient ischaemic attack monitoring first letter 
Stroke/transient ischaemic attack monitoring 
administration 
Stroke/transient ischaemic attack monitoring second 
letter 
Stroke/transient ischaemic attack monitoring third letter 
Transient cerebral ischaemia 
Transient ischaemic attack 
Transient ischaemic attack clinical management plan 
[V]Personal history of transient ischaemic attack 
Suspected transient ischaemic attack 
30 Venous occlusions (not 
superficial) 
Other venous embolism and thrombosis 
Percutaneous transluminal embolisation of vein 
Central retinal vein occlusion 
Retinal venous branch occlusion 
Branch retinal vein occlusion 
Retinal vein thrombosis 
Portal vein thrombosis 
Nonpyogenic venous sinus thrombosis 
 
Appendix Table 5: Read codes used to compose other health disorder sub-group 
categories 
Epilepsy 
1 epilepsy Epilepsy 
Grand mal (major) epilepsy 
Petit mal (minor) epilepsy 
Temporal lobe epilepsy 
Fit (in known epileptic) NOS 
H/O: epilepsy 
Traumatic epilepsy 
Epileptic seizures - myoclonic 
Epileptic seizures - tonic 
Grand mal seizure 
[X]Epileptic psychosis NOS 
Epilepsy monitoring 
O/E - petit mal fit 




Epilepsy medication review 
Jacksonian, focal or motor epilepsy 
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Epilepsy NOS 
Locl-rlt(foc)(part)idiop epilep&epilptic syn seiz locl onset 
Other forms of epilepsy NOS 
Complex partial epileptic seizure 
Excepted from epilepsy quality indicators: Patient unsuitabl 
Excepted from epilepsy quality indicators: Informed dissent 
Patient on maximal tolerated anticonvulsant therapy 
Suspected epilepsy 
Epilepsy resolved 
2 to 4 seizures a month 
Epileptic seizures - clonic 
Daily seizures 
1 to 7 seizures a week 
Epilepsy control good 
Epilepsy does not limit activities 
Epilepsy confirmed 
Epileptic seizures - atonic 
Generalised convulsive epilepsy 
Follow-up epilepsy assessment 
Epilepsy treatment changed 
1 to 12 seizures a year 
Partial epilepsy with impairment of consciousness 
Epilepsy screen administration 
Epilepsy screen invite 1 
Epilepsy screen invite 2 
Epilepsy monitoring NOS 
Many seizures a day 
O/E - Jacksonian fit 
Simple partial epileptic seizure 
Generalised convulsive epilepsy NOS 
Exception reporting: epilepsy quality indicators 
Emergency epilepsy treatment since last appointment 
Epilepsy society member 
Seen in epilepsy clinic 
No epilepsy drug side effects 
[X]Dissociative convulsions 
Epilepsy monitoring call first letter 
Epilepsy monitoring call second letter 
Contraceptive advice for patients with epilepsy 
Pre-conception advice for patients with epilepsy 
Contraceptive advice for patients with epilepsy declined 
Pregnancy advice for patients with epilepsy declined 
Pre-conception advice for patients with epilepsy declined 





Had a fit 
Fit - had one, symptom 
O/E - a seizure 
Last fit 
Convulsion - symptom 
Fit frequency 
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Seizure free >12 months 
Trigger factor for seizure 
No seizures on treatment 
[D]Convulsion NOS 
O/E - a fit 
Post-ictal state 
Respiratory 












Late onset asthma 
Asthma unspecified 
Exercise induced asthma 
Intrinsic asthma 
Seen in asthma clinic 
Hay fever with asthma 
Exercise induced asthma 
Extrinsic asthma with asthma attack 
Extrinsic (atopic) asthma 
Asthma limiting activities 
Asthma prophylactic medication used 
Asthma management plan given 
Asthma disturbing sleep 
Pollen asthma 
Asthma attack NOS 
Asthma monitored 
Number of asthma exacerbations in past year 
Airways obstruction reversible 
Change in asthma management plan 
Step up change in asthma management plan 
Asthma annual review 





Refuses asthma monitoring 
Excepted from asthma quality indicators: Patient unsuitable 





Asthma - currently dormant 
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Asthma not disturbing sleep 
Asthma not limiting activities 
Asthma disturbs sleep frequently 
Asthma follow-up 
Hay fever with asthma 
Asthma NOS 
Asthma monitoring admin. 
Asthma control step 2 
Asthma control step 1 
Asthma monitoring due 
Allergic bronchitis NEC 
Step down change in asthma management plan 
Asthma control step 3 
Exception reporting: asthma quality indicators 
Referral to asthma clinic 
Asthma monitoring by nurse 
Asthma treatment compliance unsatisfactory 
Asthma treatment compliance satisfactory 
Asthma monitoring check done 
Asthma control step 5 
Asthma control step 4 
Occupational asthma 
Asthma causes daytime symptoms 1 to 2 times per week 
Asthma restricts exercise 
Asthma monitor 3rd letter 
Asthma monitor 2nd letter 
Asthma monitor 1st letter 
Mixed asthma 
Health education - asthma 
Asthma never causes daytime symptoms 
Asthma causes daytime symptoms most days 
Asthma never restricts exercise 
Asthma sometimes restricts exercise 
Asthma control step 0 
DNA - Did not attend asthma clinic 
Asthma monitoring admin.NOS 
Asthma monitoring by doctor 
Asthma causing night waking 
Asthma monitor phone invite 
Asthma night-time symptoms 
Asthma causes daytime symptoms 1 to 2 times per month 
Hyperreactive airways disease 
Asthma monitor verbal invite 
Asthma never disturbs sleep 
Asthma limits walking up hills or stairs 
Asthma limits walking on the flat 
Asthma disturbs sleep weekly 
Asthma causes night symptoms 1 to 2 times per month 
Asthma monitor offer default 
Asthma daytime symptoms 
Extrinsic asthma NOS 
Attends asthma monitoring 
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Asthma accident and emergency attendance since last visit 
Asthma control test 
Patient has a written asthma personal action plan 
Health education - asthma self management 
Asthma review using Roy Colleg of Physicians three questions 
Asthma trigger - seasonal 
Asthma trigger - pollen 
Asthma causes symptoms most nights 
Asthma causes night time symptoms 1 to 2 times per week 
Asthma trigger - respiratory infection 
Asthma limits activities 1 to 2 times per month 
Asthma trigger - exercise 
Asthma limits activities 1 to 2 times per week 
Asthma trigger - warm air 
Asthma trigger - animals 
Asthma never causes night symptoms 
Asthma trigger - cold air 
Asthma trigger - airborne dust 
Asthma trigger - damp 
Asthma trigger - emotion 
Asthma trigger - tobacco smoke 
Asthma limits activities most days 
Chronic asthma with fixed airflow obstruction 
2 severe asthma Severe asthma attack 
Severe asthma 
Status asthmaticus NOS 
Emergency admission, asthma 
Extrinsic asthma without status asthmaticus 
Emergency asthma admission since last appointment 




Acute viral bronchitis unspecified 
Laryngotracheobronchitis 
Acute wheezy bronchitis 
Acute bronchitis NOS 




Simple chronic bronchitis 
Mucopurulent chronic bronchitis NOS 
Aspergillus bronchitis 




Recurrent wheezy bronchitis 
6 COPD or 
emphysema 
Emphysema 
Chronic obstructive airways disease 
Chronic obstructive pulmonary disease 
Acute exacerbation of chronic obstructive airways disease 
Chronic obstructive airways disease NOS 
Chronic obstructive pulmonary disease monitoring 
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Severe chronic obstructive pulmonary disease 
Moderate chronic obstructive pulmonary disease 
Mild chronic obstructive pulmonary disease 
Admit COPD emergency 
Excepted from COPD quality indicators: Patient unsuitable 
Excepted from COPD quality indicators: Informed dissent 
Chronic obstructive pulmonary disease annual review 
COPD follow-up 
COPD self-management plan given 
Chronic obstructive pulmonary disease follow-up 
Exception reporting: COPD quality indicators 
Chronic obstructive pulmonary disease monitoring admin 
Emergency COPD admission since last appointment 
COPD accident and emergency attendance since last visit 
Suspected chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease leaflet given 
Chronic obstructive pulmonary disease monitoring by nurse 
Chronic bullous emphysema 
Number of COPD exacerbations in past year 
Chronic obstructive pulmonary disease monitoring 1st letter 
Emphysema NOS 
Chronic obstructive pulmonary disease monitoring 2nd letter 
Chronic obstructive pulmonary disease monitoring 3rd letter 
DNA - Did not attend COPD clinic 
Chronic obstructive pulmonary disease NOS 
Chronic obstructive pulmonary disease monitor phone invite 
Chronic obstructive pulmonary disease monitoring verb invite 
Health education - chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease clini management plan 
Multiple COPD emergency hospital admissions 
Very severe chronic obstructive pulmonary disease 
At risk of chronic obstructive pulmonary diseas exacerbation 
Chronic obstructive pulmonary disease assessment test 
Issue of chronic obstructive pulmonary disease rescue pack 
Chronic obstructive pulmonary disease 3 monthly review 
Chronic obstructive pulmonary disease 6 monthly review 
History of chronic obstructive pulmonary disease 
Referral to COPD community nursing team 
COPD self-management plan agreed 
COPD self-management plan review 
Has chronic obstructive pulmonary disease care plan 
Chronic obstructive pulmonary disease rescue pack declined 
Chronic obstructive pulmon dis wr self managem plan declined 
Chronic obstruct pulmonary disease management plan declined 
Chron obstruct pulmonary dis wth acute exacerbation, unspec 
Diabetes 
1 Diabetes Non-insulin dependent diabetes mellitus 
Follow-up diabetic assessment 
Diabetes mellitus 
Type 2 diabetes mellitus 
Glycosuria 
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Insulin dependent diabetes mellitus 
Diabetic retinopathy 
Insulin treated Type 2 diabetes mellitus 
Type 1 diabetes mellitus 
Insulin dependent diabetes mellitus 
Diabetes mellitus with ketoacidosis 
Diabetic on oral treatment 
Diabetic neuropathy 
Diabetic - poor control 
Seen in diabetic clinic 
Hypoglycaemic coma 
Diabetic nephropathy 
Gestational diabetes mellitus 
Preproliferative diabetic retinopathy 
Proliferative diabetic retinopathy 
Diabetic monitoring 
Diabetic maculopathy 
Non-insulin dependent diabetes mellitus 
NIDDM - Non-insulin dependent diabetes mellitus 
Diabetic annual review 
Attending diabetes clinic 
H/O: diabetes mellitus 
Admit diabetic emergency 
Background diabetic retinopathy 
Diabetic on diet only 
Referral to diabetologist 
Diabetes mellitus with neuropathy 
Referral to diabetes nurse 
Non-insulin dependent diabetes mellitus - poor control 
Pt advised re diabetic diet 
Gestational diabetes mellitus 
Seen by diabetic liaison nurse 
Diabetes management plan given 
Diabetic on insulin 
Unstable diabetes 
DNA - Did not attend diabetic clinic 
[X]Hyperglycaemia, unspecified 
O/E - diabetic maculopathy present both eyes 
Diabetes monitoring admin. 
Hb. A1C - diabetic control 
Seen in diabetic eye clinic 
Advanced diabetic maculopathy 
Type 1 diabetes mellitus with nephropathy 
Dietary advice for diabetes mellitus 
Type 1 diabetes mellitus with ketoacidosis 
Non proliferative diabetic retinopathy 
Seen in diabetic foot clinic 
Diabetic peripheral neuropathy screening 
Excepted from diabetes qual indicators: Patient unsuitable 
Conversion to insulin 
Under care of diabetic foot screener 
O/E - left eye background diabetic retinopathy 
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Excepted from diabetes quality indicators: Informed dissent 
Diabetes mellitus during pregnancy/childbirth/puerperium 
O/E - right eye background diabetic retinopathy 
Diabetes medication review 
Pan retinal photocoagulation for diabetes 
Diabetic retinopathy NOS 
Refer to diabetic foot screener 
Under care of diabetes specialist nurse 
Referral to diabetes nurse 
Diabetes monitoring 3rd letter 
Patient on maximal tolerated therapy for diabetes 
Refer, diabetic liaison nurse 
Diabetic foot examination not indicated 
Diabetic retinopathy screening refused 
Diabetes care by hospital only 
Diabetes: practice programme 
Type 2 diabetes mellitus with nephropathy 
Diabetes: shared care programme 
Patient offered diabetes structured education programme 
Diabetic monitoring NOS 
Initial diabetic assessment 
Diabetic - good control 
Diabetic diet 
Diabetic weight reducing diet 
O/E - right eye proliferative diabetic retinopathy 
O/E - right eye preproliferative diabetic retinopathy 
O/E - no right diabetic retinopathy 
O/E - left eye proliferative diabetic retinopathy 
O/E - right eye diabetic maculopathy 
O/E - left eye preproliferative diabetic retinopathy 
O/E - no left diabetic retinopathy 
O/E - left eye diabetic maculopathy 
Diabetes clinic administration 
Diabetes monitor. check done 
Diabetes monitoring 1st letter 
Diabetes monitoring 2nd letter 
Fundoscopy - diabetic check 
Attends diabetes monitoring 
Referral to diabetic liaison nurse 
HbA1 - diabetic control 
Diabetes mellitus, adult onset, no mention of complication 
Maturity onset diabetes 
Diabetes mellitus with neurological manifestation 
Diabetic treatment changed 
Diabetes mellitus with renal manifestation 
Autonomic neuropathy due to diabetes 
O/E - Right diabetic foot at risk 
H/O: insulin therapy 
Self monitoring of blood glucose 
Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
Diabetic - follow-up default 
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Annual diabetic blood test 
Insulin treated Type 2 diabetes mellitus 
Diabetic retinopathy screening 
Type 1 diabetes mellitus with retinopathy 
Type 2 diabetes mellitus with persistent microalbuminuria 
Type 2 diabetes mellitus with retinopathy 
IDDM-Insulin dependent diabetes mellitus 
Diabetic retinopathy screening not indicated 
Diabetic foot examination declined 
Referral to diabetic eye clinic 
Diabetic retinopathy screening offered 
Injection sites - diabetic 
Diabetes monitored 
Diabetic lipid lowering diet 
Diabetes monitoring default 
Diabetic foot examination 
Type II diabetes mellitus 
Ischaemic ulcer diabetic foot 
Diabetic stabilisation 
Dietary advice for type II diabetes 
Diabetic diet - poor compliance 
Type 2 diabetes mellitus with persistent proteinuria 
Diabetic diet - good compliance 
O/E - Left diabetic foot at risk 
O/E - Right diabetic foot at low risk 
O/E - Left diabetic foot at low risk 
Diabetic Charcot arthropathy 
Foot abnormality - diabetes related 
Exception reporting: diabetes quality indicators 
Diabetic on insulin and oral treatment 
Diabetic 6 month review 
Did not attend diabetic retinopathy clinic 
Diabetes monitor.phone invite 
O/E - Left diabetic foot at moderate risk 
O/E - Right diabetic foot at moderate risk 
O/E - Right diabetic foot at high risk 
O/E - Left diabetic foot at high risk 
Diabetes monitor.verbal invite 
Diabetes monitoring admin.NOS 
[V]Dietary counselling in hypoglycaemia 
Perceived control of insulin-dependent diabetes 
Patient diabetes education review 
Type 2 diabetes mellitus with ketoacidosis 
Seen in community diabetes specialist clinic 
Private referral to diabetologist 
O/E - Left diabetic foot - ulcerated 
O/E - Right diabetic foot - ulcerated 
Diabetic patient unsuitable for digital retinal photography 
Insulin lipohypertrophy 
Understands diet - diabetes 
Seen in diabetic nurse consultant clinic 
Type 1 diabetes mellitus with hypoglycaemic coma 
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Type 1 diabetes mellitus with retinopathy 
Diabetes mellitus NOS with ketoacidosis 
Referral to diabetes structured education programme 
Diabetes care plan agreed 
O/E - diabetic maculopathy absent both eyes 
Diabetic crisis monitoring 
Type 1 diabetes mellitus with ophthalmic complications 
Type 2 diabetes mellitus without complication 
Type II diabetes mellitus with retinopathy 
Diabetic foot risk assessment 
O/E - left eye stable treated prolif diabetic retinopathy 
Patient held diabetic record issued 
Referral to diabetic register 
Discharge by diabetic liaison nurse 
Referral for diabetic retinopathy screening 
Referral to community diabetes specialist nurse 
Insulin dose changed 
Diabetes type 2 review 
Diabetes type 1 review 
Attended DAFNE diabetes structured education programme 
DESMOND diabetes structured education programme completed 
XPERT diabetes structured education programme completed 
Referral to DESMOND diabetes structured education programme 
Referral to DAFNE diabetes structured education programme 
Diabetes structured education programme declined 
Referral to XPERT diabetes structured education programme 
Attended XPERT diabetes structured education programme 
Referral to diabetes special interest general practitioner 
Did not attend XPERT diabetes structured education programme 
Did not complete DESMOND diabetes structured educat program 
Diabetes screening invitation 
Did not attend DESMOND diabetes structured education program 
Latent autoimmune diabetes mellitus in adult 
Other hypoglycaemia 
Diabetic foot screen 
Insulin treatment initiated 
Insulin initiation - enhanced services administration 
Diabetic dietary review 
Diabetic dietary review declined 
Type II diabetic dietary review 
Suspected diabetes mellitus 
Diabetic erectile dysfunction review 
Diabetic assessment of erectile dysfunction 
Type I diabetic dietary review 
Hypoglycaemic management discussed 
Referral to DESMOND structured programme declined 
Insulin alert pat information booklet information discussed 
Insulin passport completed 
Insulin passport given 
Insulin alert patient information booklet given 
Provision of diabetes clinical summary 
Type 1 diabetic dietary review 
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Insulin passport checked 
Referral to community diabetes clinic 
Proteinuric diabetic nephropathy 
O/E - Left diabetic foot at increased risk 
O/E - Right diabetic foot at increased risk 
Referral to community diabetes specialist nurse declined 
Declined diabetic retinopathy screening 
Diabetic retinopathy screening administrative status 
Hypoglycaemia education 
Erectile dysfunction due to diabetes mellitus 
Provision of written information about diabetes and driving 
Referral to DAFNE diabetes structured educn prog declined 
Education about diabetes and driving 
Diabetes Year of Care annual review 
Diabetic foot care education 
2 Diabetes with 
eye involvement 
Diabetic retinopathy 
Preproliferative diabetic retinopathy 
Proliferative diabetic retinopathy 
Diabetic maculopathy 
Background diabetic retinopathy 
O/E - diabetic maculopathy present both eyes 
Seen in diabetic eye clinic 
Advanced diabetic maculopathy 
Non proliferative diabetic retinopathy 
O/E - left eye background diabetic retinopathy 
O/E - right eye background diabetic retinopathy 
Pan retinal photocoagulation for diabetes 
Diabetic retinopathy NOS 
O/E - right eye proliferative diabetic retinopathy 
O/E - right eye preproliferative diabetic retinopathy 
O/E - left eye proliferative diabetic retinopathy 
O/E - right eye diabetic maculopathy 
O/E - left eye preproliferative diabetic retinopathy 
O/E - left eye diabetic maculopathy 
Type 1 diabetes mellitus with retinopathy 
Type 2 diabetes mellitus with retinopathy 
Referral to diabetic eye clinic 
Did not attend diabetic retinopathy clinic 
Type 1 diabetes mellitus with retinopathy 
Type 1 diabetes mellitus with ophthalmic complications 
Type II diabetes mellitus with retinopathy 
O/E - left eye stable treated prolif diabetic retinopathy 
3 Diabetes with 
poor control 
Diabetes mellitus with ketoacidosis 
Diabetic - poor control 
Hypoglycaemic coma 
Admit diabetic emergency 
Non-insulin dependent diabetes mellitus - poor control 
Unstable diabetes 
Hb. A1C - diabetic control 
Type 1 diabetes mellitus with ketoacidosis 
HbA1 - diabetic control 
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Diabetic diet - poor compliance 
[V]Dietary counselling in hypoglycaemia 
Type 2 diabetes mellitus with ketoacidosis 
Type 1 diabetes mellitus with hypoglycaemic coma 
Diabetes mellitus NOS with ketoacidosis 
Diabetic crisis monitoring 
Other hypoglycaemia 





Diabetes mellitus with neuropathy 
Type 1 diabetes mellitus with nephropathy 
Type 2 diabetes mellitus with nephropathy 
Diabetes mellitus with neurological manifestation 
Diabetes mellitus with renal manifestation 
Autonomic neuropathy due to diabetes 
Type 2 diabetes mellitus with persistent microalbuminuria 
Type 2 diabetes mellitus with persistent proteinuria 
Diabetic Charcot arthropathy 
O/E - Left diabetic foot - ulcerated 
O/E - Right diabetic foot - ulcerated 
Diabetic assessment of erectile dysfunction 
Proteinuric diabetic nephropathy 
Erectile dysfunction due to diabetes mellitus 
 
Appendix Table 6: Read codes used to compose CPRD-derived lifestyle factors 
History of heavy alcohol intake 
1 Heavy alcoholic Heavy drinker - 7-9u/day 
Very heavy drinker - >9u/day 
Suspect alcohol abuse - denied 
Increasing risk drinking 
Feels should cut down drinking 
Higher risk drinking 
Alcohol intake above recommended sensible limits 
Heavy drinker 
Very heavy drinker 
Binge drinker 
Hazardous alcohol use 
Harmful alcohol use 
Alcohol misuse 
Alcohol units consumed on heaviest drinking day 
Drinks in morning to get rid of hangover 
Alcoholics anonymous 
Disqualified from driving due to excess alcohol 
H/O: alcoholism 
Alcohol induced hallucinations 
Replaces meals with drinks 
Alcohol dependence resolved 
O/E - breath - alcohol smell 
SADQ - Severity of alcohol dependence questionnaire 
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Clinical Institute Withdrawal Assessment for Alcohol, revisd 
Alcohol disorder monitoring 
Alcohol abuse monitoring 
Delivery of rehabilitation for alcohol addiction 
Alcohol detoxification 
Alcohol harm reduction programme 
Advised to contact primary care alcohol worker 
Specialist alcohol treatment service signposted 
Aversion therapy - alcoholism 
Admitted to alcohol detoxification centre 
Referral to community alcohol team 
Referral to community drug and alcohol team 
Referral to specialist alcohol treatment service 
Referral to alcohol brief intervention service 
Declined referral to specialist alcohol treatment service 
Extended interven for excessive alcohol consumption declined 
Referral to community alcohol team declined 
Refer to MH services deferred until alcohol misuse resolved 
Police:venesect-alcohol 
Police:venesect-alcohol 
Alcohol misuse - enhanced services administration 
Alcohol consumption counselling 
Alcohol misuse - enhanced service completed 
Alcohol counselling by other agencies 
Brief intervention for excessive alcohol consumptn completed 
Extended intervention for excessive alcohol consumptn complt 
Withdrawn from alcohol detoxification programme 
Under care of community alcohol team 
Hospital attendance related to personal alcohol consumption 
Alcohol-induced pseudo-Cushing's syndrome 
Alcoholic psychoses 
Alcohol withdrawal delirium 
Alcohol amnestic syndrome 
Korsakov's alcoholic psychosis 
Korsakov's alcoholic psychosis with peripheral neuritis 
Alcohol amnestic syndrome NOS 
Other alcoholic dementia 
Alcoholic dementia NOS 
Chronic alcoholic brain syndrome 
Alcohol withdrawal hallucinosis 
Pathological alcohol intoxication 
Alcoholic paranoia 
Other alcoholic psychosis 
Alcohol withdrawal syndrome 
Other alcoholic psychosis NOS 
Alcoholic psychosis NOS 
Alcohol dependence syndrome 
Alcoholism 
Alcohol problem drinking 
Acute alcoholic intoxication in alcoholism 
Alcohol dependence with acute alcoholic intoxication 
Acute alcoholic intoxication, unspecified, in alcoholism 
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Continuous acute alcoholic intoxication in alcoholism 
Episodic acute alcoholic intoxication in alcoholism 
Acute alcoholic intoxication in remission, in alcoholism 
Acute alcoholic intoxication in alcoholism NOS 
Chronic alcoholism 
Unspecified chronic alcoholism 
Continuous chronic alcoholism 
Episodic chronic alcoholism 
Chronic alcoholism in remission 
Chronic alcoholism NOS 
Alcohol dependence syndrome NOS 
Nondependent alcohol abuse 
Hangover (alcohol) 
Intoxication - alcohol 
Nondependent alcohol abuse, unspecified 
Nondependent alcohol abuse, continuous 
Nondependent alcohol abuse, episodic 
Nondependent alcohol abuse in remission 
Nondependent alcohol abuse NOS 
[X]Mental and behavioural disorders due to use of alcohol 
[X]Mental & behav dis due to use alcohol: acute intoxication 
[X]Acute alcoholic drunkenness 
[X]Mental and behav dis due to use of alcohol: harmful use 
[X]Mental and behav dis due to use alcohol: dependence syndr 
[X]Alcohol addiction 
[X]Chronic alcoholism 
[X]Mental and behav dis due to use alcohol: withdrawal state 
[X]Men & behav dis due alcohl: withdrawl state with delirium 
[X]Delirium tremens, alcohol induced 




[X]Alcoholic psychosis NOS 
[X]Mental and behav dis due to use alcohol: amnesic syndrome 
[X]Korsakov's psychosis, alcohol induced 
[X]Alcoholic dementia NOS 
[X]Chronic alcoholic brain syndrome 
[X]Men & behav dis due to use alcohol: oth men & behav dis 
[X]Ment & behav dis due use alcohol: unsp ment & behav dis 
Alcoholic encephalopathy 
Cerebellar ataxia due to alcoholism 
Alcoholic polyneuropathy 
Alcoholic myopathy 
Oesophageal varices in alcoholic cirrhosis of the liver 
Maternal care for (suspected) damage to fetus from alcohol 
[D]Alcohol blood level excessive 
Alcohol deterrent poisoning 
Alcohol causing toxic effect 
Other alcohol causing toxic effect 
Alcohol causing toxic effect NOS 
[X]Toxic effect of other alcohols 
467 | P a g e  
 
Accidental poisoning by alcohol NOS 
Adverse reaction to alcohol deterrents 
[X]Accident poisoning/exposure to alcohol 
[X]Accident poison/exposure to alcohol at home 
[X]Acc poison/expos alcohol school/pub admin area 
[X]Accid pois/expos alcohol in sport/athletic area 
[X]Accid poison/expos alcohol in street/highway 
[X]Accid poison/expos alcohol trade/service area 
[X]Accid pois/expos to alcohol other spec place 
[X]Accid poison/expos to alcohol unspecif place 
[X]Intent self poison/exposure to alcohol 
[X]Int self poison/exposure to alcohol at home 
[X]Int self poison alcohol other spec place 
[X]Intent self poison alcohol unspecif place 
[X]Poisoning/exposure, ? intent, to alcohol 
[X]Poison/exposure ?intent, to alcohol at home 
[X]Pois/exp ?intent alcohol school/pub admin area 
[X]Pois/expos ?intent alcohol in street/highway 
[X]Pois/expos ?intent to alcohol unspecif place 
[X]Alcohol deterrents caus adverse effects in therapeut use 
[X] Adverse reaction to alcohol deterrents 
[X]Evid of alcohol involv determind by level of intoxication 
Alcohol detoxification 
Alcohol withdrawal regime 
Planned reduction of alcohol consumption 
Alcohol reduction programme 
Alcoholism counselling 
Advice to change alcoholic drink intake 
Advice to change alcohol intake 
Alcohol dependence scale 
ADS - Alcohol dependence scale 
Alcohol use disorders identification test 
SADQ - Severity of alcohol dependence questionnaire 
Short alcohol dependence data 
SADD - Short alcohol dependence data 
HoNOS item 3 - alcohol/drug problem 
[V]Personal history of alcoholism 
[V]Problems related to lifestyle alcohol use 
[V]Alcohol rehabilitation 
[V]Alcohol abuse counselling and surveillance 
[V]Blood-alcohol and blood-drug test 
2 Ex drinker - heavy  Ex-heavy drinker - (7-9u/day) 
Ex-very heavy drinker-(>9u/d) 
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Appendix to Chapter 4 
Appendix Table 7: Do comorbidities increase the risk of unemployment or work disability in a person with MSK disease? 




Design MSD population 



























Work disability or disability pension 
Abrai’do-Lanza 
(2006) (12) 




















Age, sex, education, 
family income, Latino 
ethnicity, duration of 
illness, physician visit 
for arthritis 6 months 
ago, limitations in 








does a health 
problem 
prevent 
working a job 
or limit the 
type or amount 


















52 (41) Age, sex, marital 
status, education, 
occupation type, 
duration of disease, 
rheumatoid factor, 
total radiographic 
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score, ADL difficulty 
score. 
P-value and 

















Age, sex, education, 
profession, presence 
of peripheral arthritis, 








OR: 3.15 (1.96 
to 5.09)  
Castillo-Ortiz 
(2016) (9) 




216 43.56 ± 
12.7 























Age, sex, ethnicity, 
urbanization, season, 
family type, calendar 





















the first year 
after diagnosis. 
(public register) 













Age, sex, ethnicity, 
urbanization, season, 
family type, calendar 











than one year 
HR: 1.3 (1.1 to 
1.4) 



























50.2 ± 8.2 
167 
(45.8) 

































69 (29.5) Age, education, 
current or former 
smoker, initial job as a 
professional/manager, 
























69 (29.5) Age, sex, education, 
current or former 
smoker, initial job as a 
professional/manager, 
















~261 Range 25 
to 74  







how many days 
out of the past 
30 “totally 
unable to work 


















out of the past 
30 that 
respondents  
had to “cut 
back on work 
or how 













0-2:  0.9 (0.3)  





(ASAS criteria)  
3370 43 ± 14 2221 
(34.1) 
Age, sex, ASDAS, 
















(95% CI).  















Age, gender, mHAQ, 













(95% CI).  
All countries 
1.44 (1.25 to 
1.68) 
































with a high 
educational 
attainment 
1.58 (0.34 to 
7.38) 
Participants 
with a low 
educational 
attainment 
1.52 (1.00 to 
2.29) 




disc and chronic 
low back pain 
treated with 






82 41 (25 – 
54) 
40 (48.8) Education, duration of 
sick leave (<12 
months vs >12 
months), Oswestry 










(95% CI).  





moderate to high 
disease activity 




Baseline HAQ and 



































22 (14) Age, age of onset, 














(ASAS criteria)  
3370 43 ± 14 2221 
(34.1) 










(95% CI).  









1,414 45 to 64 
years 
NR Age, sex, and highest 
level of education 
Comorbid 
conditions 
(one, two or 























2.86)   
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0.80 (0.70 to 
0.91) 
Return to work 
Nordin (2002) 
(350) 













Age, sex, type of 


























group, country region, 
sickness absence 









time from the 




(0.71 to 1.23) 
Women: 1.00 
(0.88 to 1.13) 









of medication for MSD 
pain or hospitalisation 











































Return to full 
employment 
within 1 year of 
surgery and still 
working on last 
follow up 
(follow-up for 2 
years after 
surgery).  





CS Psoriatic arthritis 
(rheumatologist-
confirmed) 
186 50.5 ± 
10.7 
74 (39.8) Age, sex, duration of 
PsA, education, PASI, 




labour at work, work 
schedule control, and 

















(95% CI)  
2.31 (1.19, 
4.50) 




Cohort Knee Pain (knee 
pain on most 













Age, type of work, 




























167,068 >18 years 111,707 
(67.2) 






weight status (BMI 
categorisation), 
smoking status, 
drinking status, time 














Self report: “Do 
arthritis or joint 
symptoms now 
affect whether 
you work, the 
type of work 
you do, or the 
amount of 
work you do?’’ 
Odds ratio 






(ASAS criteria)  
3370 43 ± 14 2221 
(34.1) 
















(95% CI).  
1.42 (1.26–
1.61) 








and defined as 
hip, knee, or foot 
pain for 1 day or 
more during the 
past year) 





Age, sex, severity of 
lower limb pain, 














the past 4 
weeks, if you 
work, have you 
taken part in 
paid or 
voluntary 
work as and 
when you have 
wanted?’’- 
answered 
some/a little or 










CS Knee Pain (knee 
pain on most 
days in the past 
month) 
129 Range 45 
to 75 
years 
64 (37.4) Age, sex, maximum 
















scale. A ten 
item scale 
evaluating loss 
of work hours 
or 
interruptions, 
change in type 







1 to 3: 3.49 
(0.84 to 14.46) 
4 or more: 4.44 
(1.02 to 19.32). 
478 | P a g e  
 
permanent 
change of work 
hours over 6 
months  
 
Appendix Table 8: Psychiatric disease and MSK disease related work disability 




Design MSD population 




















































































OR: 4.26 (2.06 to 
8.81)   

















6677 18 to 59 
years 







































6677 Range 18 to 
59 years 


























HR: 1.9 (1.8 to 
2.0) 











1987 for RA, Tan 
et al criteria for 
SLE and ICD-10 
for other IRD) 






















with a sick 
leave of at 
least 4 weeks 
OR 
unemployed 
and unable to 
do their 
usual activities 










OR: 1.6 (1.1 to 
2.3)  




Cohort  RA (biologics 
register- 
ACR, 1987) 

















LTSA (Time to 
lose 15 days of 





















: 46.1 ± 11.1 
Severe 
impairment







: 188 (93.1) 
Severe 
impairment
: 76 (87.4) 




































joints in past 
12m and 
treated for the 
condition by a 
healthcare 
587 Range 18 to 
64 years 





















days in the 
past 12 
months were 
you unable to 




standard error of 







18.7 (6.3) <0.01 





























7.4 (9.6) >0.05 
 
The additive 
effect of mental 
comorbidities on 
work days lost 
was  














pain in past 12m 
and treated for 






631 Range 18 to 
64 years 




























days in the 
past 12 
months were 
you unable to 










standard error of 











39.7 (7.4) <0.001  
Chronic Back 
trouble and 
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Interview: DSM-





5.4 (10.0) >0.05 
 
The additive 
effect of mental 
comorbidities on 
work days lost 
was  






































































CS  Arthritis and 
related 
conditions 
382 Range 15 to 
54 
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(checklist- self 
reported in the 









days unable to 
work out of 
past 30).   













on effect of 
mental disorder 
and arthritis 





Cohort  Musculoskeletal 
pain (self-













multiplied by 10: 



























1.55 (0.95 to 
2.55) 








































m Y: 44.7 ± 
10.2 
Absenteeis
m Y: 68.2% 







in the past 
week (self 
“The presence of 
major 
depression 
486 | P a g e  
 
pain diagnosed 
by a health care 
professional and 







and migraine).  
Absenteeis
m N:52.8 ± 
17.4 
Absenteeis












from work in 
the last week, 
mainly due to 
illness or 
disability) 
emerged as the 
strongest 
predictor among 
all the variables 
examined. 
Persons with a 
MDE in the past 
12 months were 
2.9 times (95% 
CI 2.825 to 
2.915) more 
likely to be 
absent from 





Unemployment status or job loss 
De Buck (2006) 
(354) 











(Tan et al. 
1982), or 
scleroderma.) 
































: 46.1 ± 11.1 
Severe 
impairment







: 188 (93.1) 
Severe 
impairment
: 76 (87.4) 

















that they have 
a job or paid 
work) 












1,414 45 to 64 
years 
NR Age, sex, and 






















1,414 45 to 64 
years 
NR Age, sex, and 












Odds ratio (95% 
CI)  
3.46 (1.92–6.23) 
Time to return to work 
Anderson 
(2016) (345) 


















Out of work for 
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use of physical 





longer than 1 
year, daily 
opioid load 
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representation, 
type of fusion 
surgery, 
instrumentation








as a result of 
their injury for 

















































1.18 (0.76–1.86)  












as a result of 
their injury for 












































OR (95% CI)  
At admission: 
1.21 (0.89–1.64) 





































body in pain, 
baseline neck 






Time to claim 
closure 
(similar to 






















14,170 Men: 43.1 ± 
10.2 
Women: 


















MSD pain or 
hospitalisation 















from the initial 
day of work 
absence until 





Men: 0.82 (0.74 
to 0.91) 
Women: 0.86 
(0.82 to 0.90) 




Cohort  RA (biologics 
register- 
ACR, 1987) 


















work (time to 
regain ≥16 
























disability in daily 
activities, 
occupational 







work at 2 
years (self-
report: any 
work).   
Beta 0.43  
R2 change 0.16  
Fchange: 
9.00***  











CS  Arthritis (self-
reported) 
167,068 >18 years 111,707 
(67.2) 











you been told by 
a doctor that 







)- Self report: 




OR (95% CI).  
1.51 (1.41–1.60) 
















type of work 
you do, or the 
amount of 
work you do?’’ 
Kessler (2003) 
(335) 




reported in the 
past 12 months) 
382 Range 15 to 
54 

















work loss days 
and number of 
days out of the 
past 30, when 
able to work 
but needed to 
cut back on 
what (they) 
did or did not 
get as much 

















on effect of 
mental disorder 
and arthritis 





CS  Arthritis and 
related 
382 Range 15 to 
54 












reported in the 












cut back on 
work or did 
less than usual 
out of past 
30).   
 









on effect of 
mental disorder 
and arthritis 







and defined as 
hip, knee, or 
foot pain for 1 
day or more 
during the past 
year) 
716 Range 50 to 
59 years 
392 (54.7) Age, sex, 
severity of 

















the past 4 
weeks, if you 
work, have 
you taken part 
in paid or 
voluntary 





OR (95% CI) 
Anxiety Non-
case (0–7): 1 
Possible/probabl
e case (8–21): 
0.95 (0.57, 1.56) 
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some/a little 






and defined as 
hip, knee, or 
foot pain for 1 
day or more 
during the past 
year) 
716 Range 50 to 
59 years 
392 (54.7) Age, sex, 
severity of 

















the past 4 
weeks, if you 
work, have 
you taken part 
in paid or 
voluntary 






or none of the 
time.  
Odds ratio (95% 
CI) 
Depression Non-
case (0–7): 1 
Possible/probabl
e case (8–21): 
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Appendix Table 9: Cardiovascular comorbidity and MSK disease related work disability 




Design MSD population 




























Work disability or disability pension 
Al Dhanhani 
(2009) (344) 
Cohort  Systemic Lupus 
Erythematosus 
(ACR criteria tan 
et al, 1982) 
432 35.9 ± 
13.6 




























45 ± 11 753 (72) Year of biologics-
start, disease 










the Prescribed Drug 
Register) 
LTSA (Time to 
lose 15 days of 







HR: 1.25 (0.85 
to 1.85) 
Sickness absence 
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Age, sex, and 
educational level 
Obesity (self-
reported height and 
weight: BMI ≥ 30 
kg/m2) 
Any sickness 
absence in the 
year prior (self-
report: 1-365 
days vs 0 days) 
OR (95% CI) 
1.37 (1.10 to 
1.71) 
















in follow up time, 
work-relatedness 




records: BMI ≥ 30.0) 
Return to work 
after a follow up 













53 ± 8 601 (80) Year of biologics-
start, disease 










the Prescribed Drug 
Register) 
Return to work 
(time to regain 








HR: 0.90 (0.56 
to 1.45) 
Unemployment status or job loss 
Schofield (2014) 
(352) 




1,414 45 to 
64 
years 
NR Age, sex, and 
highest level of 
education 

























1,414 45 to 
64 
years 
NR Age, sex, and 























1,414 45 to 
64 
years 
NR Age, sex, and 











































(self-report: (BMI  




Self report: “Do 
arthritis or joint 
symptoms now 
affect whether 
you work, the 
type of work you 
do, or the 














Age, sex, severity 
of lower limb pain, 
Obesity (self-
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and defined as 
hip, knee, or 
foot pain for 1 
day or more 














the past 4 
weeks, if you 
work, have you 
taken part in 
paid or 
voluntary 
work as and 
when you have 
wanted?’’- 
answered 
some/a little or 




20 to 24.9 
kg/m2): 1  





Appendix Table 10: Diabetes and MSK disease related work disability 




Design MSD population 















(%) in the 
Study 







Work disability or disability pension 
Al Dhanhani 
(2009) (344) 
Cohort Systemic Lupus 
Erythematosus 
432 35.9 ± 
13.6 
379 (88) Age at diagnosis, Female 







OR (95% CI) 
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(ACR criteria tan 












Unemployment status or job loss 
Schofield (2014) 
(352) 




1,414 45 to 64 
years 


















Appendix Table 11: Respiratory disease and MSK disease related work disability 




Design MSD population 





Age in years; 
Median 
(IQR)/ Mean 
± SD/ Mean 
Number of 
Females (%) 











Unemployment status or job loss 
Schofield (2014) 
(352) 




1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 


























1,414 45 to 64 
years 
NR Age, sex, and 

















Appendix Table 12: Other disease and MSK disease related work disability 




Design MSD population 


























association (95%CI)  
Unemployment status or job loss 
Schofield (2014) 
(352) 




1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
Diseases of the eye and 
adnexa (survey- ICD-10 
codes) 





Odds ratio (95% CI)  
Arthritis only: 
reference 
Diseases of the eye 








1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
Diseases of the skin and 
subcutaneous tissue 
(survey- ICD-10 codes) 





Odds ratio (95% CI)  
Arthritis only: 
reference 
502 | P a g e  
 










1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
Diseases of the 
digestive system 
(survey- ICD-10 codes) 





Odds ratio (95% CI)  
Arthritis only: 
reference 
Diseases of the 








1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
Diseases of the nervous 
system (survey- ICD-10 
codes)  





Odds ratio (95% CI)  
Arthritis only: 
reference 









1,414 45 to 64 
years 
NR Age, sex, and 




and metabolic disorders 
(survey- ICD-10 codes) 



















1,414 45 to 64 
years 
NR Age, sex, and 




(survey- ICD-10 codes) 













CS Arthritis (ICD-10 
codes “arthritis 
1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
Diseases of the 
genitourinary system 
(survey- ICD-10 codes) 
Not being in the 
labour force 
Odds ratio (95% CI)  
Arthritis only: 
reference 




 (survey- self 
report) 
 









1,414 45 to 64 
years 
NR Age, sex, and 
highest level of 
education 
“Other” comorbidity 
(survey- ICD-10 codes) 
 















and defined as 
hip, knee, or foot 
pain for 1 day or 
more during the 
past year) 
















Cognitive and Alertness 
behaviour 
subscale of the 
Functional Limitations 
Profile: No impairment 







the past 4 weeks, 
if you work, have 
you taken part in 
paid or voluntary 
work as and 
when you have 
wanted?’’- 
answered some/a 
little or none of 
the time.  
Odds ratio (95% CI) 
Cognitive impairment  
None (0): 1 
Cognitive impairment 
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Appendix Table 13: Newcastle-Ottawa Score: cross-sectional studies 
Reference  Outcome: 
Assessmen
























ABRAI´DO-LANZA (2006) (12) 1 1 0 2 1 1 0 6/10 
Agaliotis (2017) (363) 1 0 0 2 2 1 1 7/10 
Buist-Bouwman (2005)(364) 1 1 0 1 1 1 0 5/10 
CASTILLO-ORTIZ (2016)(9)  1 0 0 2 2 1 0 6/10 
Csupak (2018) (358) 1 1 0 2 2 1 1 8/10 
Hudson (2009) (13)  1 1 0 2 2 1 0 7/10 
Joshi (2015)(365) 1 1 0 2 1 1 0 6/10 
Kausto (2017) (366) 2 1 0 2 1 1 0 7/10 
Kennedy (2014)(334) 1 1 0 2 2 1 0 7/10 
Kessler (2001)(199) 1 1 0 1 2 1 0 6/10 
Kessler (2003)(335) 1 1 0 1 2 1 1 7/10 
Loewe (2004)(336) 1 1 1 1 1 1 0 6/10 
Munce (2007)(337) 1 1 0 1 2 1 0 6/10 
Nikiphorou (2018)(361) 1 1 0 2 2 1 0 7/10 
Panopalis (2007)(338) 2 0 0 2 2 1 0 7/10 
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Callahan (1992)(339) 1 1 0 2 1 1 0 6/10 
Van den Berg (2017) (340) 1 0 0 2 1 1 0 5/10 
Van der Zee-Neuen (2017)(341) 1 1 1 2 2 1 0 8/10 
 
Appendix Table 14: Newcastle-Ottawa Score: case-control studies 
Reference Selection 



















controls on the 
basis of the 




















0 0 1 0 1 0 1 0 3/9 
 
Appendix Table 15: Newcastle-Ottawa Score: cohort studies 
Reference Selection 
Representati















that outcome of 
interest was not 




cohorts on the 


















Agaliotis (2013) (343) 0 1 1 1 1 0 1 1 6/9 
Al Dhanhani (2009) (344)  0 1 1 1 2 0 1 0 7/9 
Anderson (2016)(345) 0 1 1 1 2 1 1 0 7/9 
Boonen (2001)(11) 1 1 0 1 1 0 0 1 5/9 
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Brede (2012)(346) 1 1 1 1 2 0 1 0 7/9 
Furunes (2018)(359) 0 1 0 0 2 0 1 1 5/9 
Kuijer (2017)(347) 0 1 1 0 1 0 1 1 5/9 
Lee (2017) (348) 0 1 0  1 1 0 1 0 4/9 
Manders (2014)(349) 0 1 1 1 2 1 1 0 7/9 
Melkevik (2018)(360) 0  1 0 0 1 1 1 1 5/9 
Nordin (2002)(350) 1 1 1 1 1 1 0 0 6/9 
Olofsson (2016)(351)  1 1 1 1 1 1 1 0 7/9 
Schofield (2014)(352)  0 1 1 0 1 1 1 1 6/9 
Ward (2001)(10) 0 1 0 1 2 0 1 1 6/9 
Webers (2018)(362)  1 1 1 1 2 0 1 1 8/9 
Wilkie (2013)(353) 0 1 0 1 2 0 1 0 5/9 
De Buck (2006)(354) 1 1 1 1 0 0 1 1 6/9 
Schade (1999)(355) 1 1 1 1 0 0 1 1 6/9 
Cote (2001)(356) 1 1 0 1 1 1 1 0 7/9  
Hansen (2016)(357)  1 0 1 0 1 1 1 0 5/9 
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Appendix to Chapter 5 
Appendix Table 16: Strata of SOC-10 sub-major occupational groups among people with 















Corporate managers and directors Level 
4 
18 (3.6) 5 (2.3) 13 (4.7) 
Science, research, engineering, and technology 
professionals 
9 (1.8) 7 (3.2) 2 (0.7) 
Health professionals 28 (5.7) 2 (0.9) 26 (9.5) 
Teaching and educational professionals 48 (9.7) 18 (8.2) 30 (11.0) 
Business, media and public service professionals 14 (2.8) 9 (4.1) 5 (1.8) 
Other managers and proprietors Level 
3 
15 (3.0) 5 (2.3) 10 (3.7) 
Science, engineering, and technology associate 
professionals 
9 (1.8) 5 (2.3) 4 (1.5) 
Health and social care associate professionals 10 (2.0) 4 (1.8) 6 (2.2) 
Protective service occupations 7 (1.4) 6 (2.7) 1 (0.4) 
Culture, media, and sports occupations 3 (0.6) 2 (0.9) 1 (0.4) 
Business and public service associate 
professionals 
15 (3.0) 8 (3.6) 7 (2.6) 
Skilled agricultural and related trades 9 (1.8) 8 (3.6) 1 (0.4) 
Skilled metal, electrical and electronic trades 16 (3.2) 16 (7.3) 0 (0.0) 
Skilled construction and building trades 15 (3.0) 14 (6.4) 1 (0.4) 
Textiles, printing, and other skilled trades 13 (2.6) 9 (4.1) 4 (1.5) 
Administrative occupations Level 
2 
65 (13.2) 18 (8.2) 47 (17.2) 
Secretarial and related occupations 12 (2.4) 1 (0.5) 11 (4.0) 
Caring personal service occupations 34 (6.9) 5 (2.3) 29 (10.6) 
Leisure, travel and related personal service 
occupations 
13 (2.6) 3 (1.4) 10 (3.7) 
Sales occupations 30 (6.1) 5 (2.3) 25 (9.1) 
Customer service occupations 5 (1.0) 2 (0.9) 3 (1.1) 
Process, plant and machine operatives 16 (3.2) 12 (5.5) 4 (1.5) 
Transport and mobile machine drivers and 
operatives 
19 (3.9) 19 (8.6) 0 (0.0) 
Elementary trade and related occupations Level 
1 
10 (2.0) 8 (3.6) 2 (0.7) 
Elementary administration and service 
occupations 
53 (10.7) 27 (12.3) 26 (9.5) 
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Appendix Table 17: Strata of SOC-10 sub-major occupational groups among case 












11 Corporate managers and directors Level 
4 
2 (3.1) 13 (4.9) 3 (1.8) 
21 Science, research, engineering, and 
technology professionals 
2 (3.1) 5 (1.9) 2 (1.2) 
22 Health professionals 4 (6.3) 12 (4.6) 12 (7.2) 
23 Teaching and educational professionals 3 (4.7) 33 (12.5) 12 (7.2) 
24 Business, media and public service 
professionals 
1 (1.6) 8 (3.0) 5 (3.0) 
12 Other managers and proprietors Level 
3 
3 (4.7) 7 (2.7) 5 (3.0) 
31Science, engineering, and technology associate 
professionals 
0 (0.0) 6 (2.3) 3 (1.8) 
32 Health and social care associate professionals 0 (0.0) 4 (1.5) 6 (3.6) 
33 Protective service occupations 1 (1.6) 6 (2.3) 0 (0.0) 
34 Culture, media, and sports occupations 1 (1.6) 2 (0.8) 0 (0.0) 
35 Business and public service associate 
professionals 
1 (1.6) 10 (3.8) 4 (2.4) 
51 Skilled agricultural and related trades 4 (6.3) 1 (0.4) 4 (2.4) 
52 Skilled metal, electrical and electronic trades 1 (1.6) 6 (2.3) 9 (5.4) 
53 Skilled construction and building trades 0 (0.0) 8 (3.0) 7 (4.2) 
54 Textiles, printing, and other skilled trades 2 (3.1) 9 (3.4) 2 (1.2) 
41 Administrative occupations Level 
2 
5 (7.8) 34 (12.9) 26 (15.7) 
42 Secretarial and related occupations 0 (0.0) 9 (3.4) 3 (1.8) 
61 Caring personal service occupations 4 (6.3) 17 (6.4) 13 (7.8) 
62 Leisure, travel and related personal service 
occupations 
1 (1.6) 9 (3.4) 3 (1.8) 
71 Sales occupations 7 (10.9) 15 (5.7) 8 (4.8) 
72 Customer service occupations 0 (0.0) 3 (1.1) 2 (1.2) 
81 Process, plant and machine operatives 1 (1.6) 7 (2.7) 8 (4.8) 
82 Transport and mobile machine drivers and 
operatives 
3 (4.7) 4 (1.5) 3 (1.8) 
91 Elementary trade and related occupations Level 
1 
3 (4.7) 4 (1.5) 3 (1.8) 
92 Elementary administration and service 
occupations 
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Appendix Table 18: Strata of SOC-10 sub-major occupational groups among people with 


















Corporate managers and directors Level 
4 
18 (3.6) 8 (3.5) 10 (3.8) 
Science, research, engineering, and technology 
professionals 
9 (1.8) 3 (1.3) 6 (2.3) 
Health professionals 28 (5.7) 14 (6.1) 14 (5.3) 
Teaching and educational professionals 48 (9.7) 11 (4.8) 37 (14.0) 
Business, media and public service professionals 14 (2.8) 7 (3.0) 7 (2.7) 
Other managers and proprietors Level 
3 
15 (3.0) 8 (3.5) 10 (3.8) 
Science, engineering, and technology associate 
professionals 
9 (1.8) 3 (1.3) 6 (2.3) 
Health and social care associate professionals 10 (2.0) 1 (0.4) 9 (3.4) 
Protective service occupations 7 (1.4) 4 (1.7) 3 (1.1) 
Culture, media, and sports occupations 3 (0.6) 2 (0.9) 1 (0.4) 
Business and public service associate 
professionals 
15 (3.0) 8 (3.5) 7 (2.7) 
Skilled agricultural and related trades 9 (1.8) 4 (1.7) 5 (1.9) 
Skilled metal, electrical and electronic trades 16 (3.2) 7 (3.0) 9 (3.4) 
Skilled construction and building trades 15 (3.0) 14 (6.1) 1 (0.4) 
Textiles, printing, and other skilled trades 13 (2.6) 6 (2.6) 7 (2.7) 
Administrative occupations Level 
2 
65 (13.2) 22 (9.6) 43 (16.3) 
Secretarial and related occupations 12 (2.4) 4 (1.7) 8 (3.0) 
Caring personal service occupations 34 (6.9) 16 (7.0) 18 (6.8) 
Leisure, travel and related personal service 
occupations 
13 (2.6) 7 (3.0) 6 (2.3) 
Sales occupations 30 (6.1) 15 (6.5) 15 (5.7) 
Customer service occupations 5 (1.0) 3 (1.3) 2 (0.8) 
Process, plant and machine operatives 16 (3.2) 8 (3.5) 8 (3.0) 
Transport and mobile machine drivers and 
operatives 
19 (3.9) 12 (5.2) 7 (2.7) 
Elementary trade and related occupations Level 
1 
10 (2.0) 6 (2.6) 4 (1.5) 
Elementary administration and service 
occupations 
53 (10.7) 32 (13.9) 21 (8.0) 
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Appendix to Chapter 6  










OR (95% CI) 
Managers, directors and senior 
officials 
82 (8.3) 49 (9.9) 33 (6.7) 0.65 (0.41 to 
1.03) 
Professional occupations 198 (20.0) 99 (20.0) 99 (20.0) 1.00 (0.73 to 
1.36) 
Associate professional and technical 
occupations 
91 (9.2) 47 (9.5) 44 (8.9) 0.93 (0.61 to 
1.43) 
Administrative and secretarial 
occupations 
168 (17.0) 91 (18.4) 77 (15.6) 0.82 (0.59 to 
1.14) 
Skilled trades occupations 98 (9.9) 45 (9.1) 53 (10.7) 1.21 (0.79 to 
1.84) 
Caring, leisure, and other service 
occupations 
86 (8.7) 39 (7.9) 47 (9.5) 1.24 (0.79 to 
1.96) 
Sales and customer service 
occupations 
74 (7.5) 39 (7.9) 35 (7.1) 0.88 (0.54 to 
1.44) 
Process, plant and machine operatives 71 (7.2) 36 (7.3) 35 (7.1) 0.97 (0.57 to 
1.62) 
Elementary occupations 105 (10.6) 42 (8.5) 63 (12.8) 1.58 (1.04 to 
2.40) 













OR (95% CI) 




39 (4.0) 21 (4.3) 18 (3.6) 0.86 (0.46 to 
1.61) 
21 Science, research, 
engineering, and 
technology professionals 
26 (2.6) 17 (3.4) 9 (1.8) 0.53 (0.24 to 
1.19) 
22 Health professionals 55 (5.6) 27 (5.5) 28 (5.7) 1.04 (0.59 to 
1.82) 
23 teaching and  
educational professionals 
80 (8.1) 32 (6.5) 48 (9.7) 1.52 (0.96 to 
2.39) 
24 business, media and 
public service professionals 
37 (3.7) 23 (4.7) 14 (2.8) 0.61 (0.31 to 
1.18) 




43 (4.4) 28 (5.7) 15 (3.0) 0.48 (0.24 to 
0.96) 
31 Science, engineering, and 
technology associate 
professionals 
16 (1.6) 7 (1.4) 9 (1.8) 1.29 (0.48 to 
3.45) 
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32 Health and social care 
associate professionals 
20 (2.0) 10 (2.0) 10 (2.0) 1.00 (0.42 to 
2.40) 
33 Protective service 
occupations 
10 (1.0) 3 (0.6) 7 (1.4) 2.33 (0.60 to 
9.02) 
34 Culture, media, and 
sports occupations 
7 (0.7) 4 (0.8) 3 (0.6) 0.75 (0.17 to 
3.35) 
35 Business and public 
service associate 
professionals 
38 (3.9) 23 (4.7) 15 (3.0) 0.64 (0.33 to 
1.24) 
51 Skilled agricultural and 
related trades 
19 (1.9) 10 (2.0) 9 (1.8) 0.90 (0.37 to 
2.21) 
52 Skilled metal, electrical 
and electronic trades 
32 (3.2) 16 (3.2) 16 (3.2) 1.00 (0.50 to 
2.00) 
53 Skilled construction and 
building trades 
25 (2.5) 10 (2.0) 15 (3.0) 1.56 (0.67 to 
3.59) 
54 Textiles, printing, and 
other skilled trades 










0.94 (0.66 to 
1.33) 
42 Secretarial and related 
occupations 
34 (3.4) 22 (4.5) 12 (2.4) 0.50 (0.23 to 
1.07) 
61 Caring personal service 
occupations 
63 (6.4) 29 (5.9) 34 (6.9) 1.20 (0.71 to 
2.04) 
62 Leisure, travel and 
related personal service 
occupations 
23 (2.3) 10 (2.0) 13 (2.6) 1.33 (0.56 to 
3.16) 
71 Sales occupations 64 (6.5) 34 (6.9) 30 (6.1) 0.86 (0.50 to 
1.47) 
72 Customer service 
occupations 
10 (1.0) 5 (1.0) 5 (1.0) 1.00 (0.29 to 
3.45) 
81 Process, plant and 
machine operatives 
30 (3.0) 14 (2.8) 16 (3.2) 1.17 (0.54 to 
2.52) 
82 Transport and mobile 
machine drivers and 
operatives 
41 (4.2) 22 (4.5) 19 (3.9) 0.85 (0.45 to 
1.62) 




17 (1.7) 7 (1.4) 10 (2.0) 1.43 (0.54 to 
3.75) 
92 Elementary 
administration and service 
occupations 
88 (8.9) 35 (7.1) 53 
(10.7) 
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Appendix Table 21: Association between structural heart disease and health-related job 
loss, across total study population and by gender 











OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
No structural heart 
disease 
494 (100.0) 487 (98.6) 1.00 1.00 
Structural heart disease 0 (0) 7 (1.4) NR NR 
Men 
No structural heart 
disease 
220 (100.0) 213 (96.8) 1.00 1.00 
Structural heart disease 0 (0.0) 7 (3.2) NR NR 
Women 
No structural heart 
disease 
274 (100.0) 274 (100.0) 1.00 1.00 
Structural heart disease 0 (0.0) 0 (0.0) NR NR 
Appendix Table 22: Association between cardiac arrhythmias and health-related job loss, 
across total study population and by gender 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
No arrhythmias 493 (99.8) 487 (98.6) 1.00 1.00 
Cardiac 
arrhythmias 
1 (0.2) 7 (1.4) 7.00 (0.86 to 
56.89) 
6.83 (0.83 to 56.47) 
Men 
No arrhythmias 220 
(100.0%)  
214 (97.3) 1.00 1.00 
Cardiac 
arrhythmias 
0 (0.0) 6 (2.7) NR NR 
Women 
No arrhythmias 273 (99.6) 273 (99.6) 1.00 1.00 
Cardiac 
arrhythmias 
1 (0.4) 1 (0.4) 1.00 (0.06 to 
15.99) 
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Appendix Table 23: Association between psychiatric-level mental health problems and 
health-related job loss, by age at HRJL 










OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Aged <50  
No psychiatric-level 
MHPs 
63 (98.4) 63 (98.4) 1.00 1.00 
Psychiatric-level MHPs 1 (1.6) 1 (1.6) 1.00 (0.06 to 
15.99) 
0.72 (0.04 to 11.86) 
Aged 50 - <60 
No psychiatric-level 
MHPs 
263 (99.6) 258 (97.7) 1.00 1.00 
Psychiatric-level MHPs 1 (0.38)                                                      6 (2.3) 6.00 (0.72 to 
49.84) 




166 (100.0) 165 (99.4) 1.00 1.00 
Psychiatric-level MHPs 0 (0.0) 1 (0.6) NE NE 
Appendix Table 24: Association between peripheral atherosclerotic disease and health-
related job loss, by age at HRJL 
Variable Number of 
“exposed” 
controls, n (%) 
Number of 
“exposed” 




OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No PAD 64 (100.0) 63 (98.4) 1.00 1.00 
PAD 0 (0.0) 1 (1.6) NE NE 
Aged 50 - <60 
No PAD 263 (99.6) 257 (97.4) 1.00 1.00 
PAD 1 (0.4) 7 (2.7) 7.00 (0.86 to 
56.89) 
7.12 (0.82 to 61.51) 
Aged >60 
No PAD 166 (100.0) 163 (98.2) 1.00 1.00 
PAD 0 (0.0) 3 (1.8) NE NE 
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Appendix Table 25: Association between cardiac arrhythmias and health-related job loss, 
by age at HRJL 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
Aged <50  
No arrhythmias 64 (100.0) 64 (100.0) 1.00 1.00 
Cardiac 
arrhythmias 
0 (0.0) 0 (0.0) NE NE 
Aged 50 - <60 
No arrhythmias 264 (100.0) 259 (98.1) 1.00 1.00 
Cardiac 
arrhythmias 
0 (0.0) 5 (1.9) NE NE 
Aged >60 
No arrhythmias 165 (99.4) 164 (98.8) 1.00 1.00 
Cardiac 
arrhythmias 
1 (0.6) 2 (1.2) 2.00 (0.18 to 
22.06) 
2.58 (0.23 to 29.12) 
Appendix Table 27: Association between structural heart disease and health-related job 
loss, by age at HRJL 










HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
OR (95% CI) 
Aged <50  
No structural heart 
disease 
64 (100.0) 64 (100.0) 1.00 1.00 
Structural heart disease 0 (0.0) 0 (0.0) NE NE 
Aged 50 - <60 
No structural heart 
disease 
264 (100.0) 261 (98.9) 1.00 1.00 
Structural heart disease 0 (0.0) 3 (1.1) NE NE 
Aged >60 
No structural heart 
disease 
166 (100.0) 162 (97.6) 1.00 1.00 
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Appendix Table 27: Association between epilepsy and health-related job loss, by age at 
HRJL 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No epilepsy 64 (100.0) 62 (96.9) 1.00 1.00 
Epilepsy 0 (0.0) 2 (3.1) NE NE 
Aged 50 - <60 
No epilepsy 261 (98.9) 260 (98.5) 1.00 1.00 
Epilepsy 3 (1.1) 4 (1.5) 1,50 (0.25 to 8.98) 2.08 (0.30 to 14.57) 
Aged >60 
No epilepsy 166 (100.0) 165 (99.4) 1.00 1.00 
Epilepsy 0 (0.0) 1 (0.6) NE NE 
Appendix Table 28: Association between association between chronic MSD and health-











OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No chronic MSD 60 (93.8) 55 (85.9) 1.00 1.00 
Chronic MSD 4 (6.3) 9 (14.1) 2.25 (0.69 to 
7.31) 
2.55 (0.63 to 10.33) 
Aged 50 - <60 
No chronic MSD 217 (82.2) 195 (73.9) 1.00 1.00 
Chronic MSD 47 (17.8) 69 (26.1) 1.59 (1.06 to 
2.41) 
1.58 (1.04 to 2.41) 
Aged >60 
No chronic MSD 135 (81.3) 108 (65.1) 1.00 1.00 
Chronic MSD 31 (18.7) 58 (34.9) 2.42 (1.42 to 
4.13) 
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Appendix Table 29: Association between musculoskeletal pain and health-related job loss, 









HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No MSD pain  56 (87.5) 41 (64.1) 1.00 1.00 
MSD pain 8 (12.5) 23 (35.9) 4.00 (1.50 to 10.66) 4.40 (1.48 to 13.08) 
Aged 50 - <60 
No MSD pain  222 (84.1) 182 (68.9) 1.00 1.00 
MSD pain 42 (15.9) 82 (31.1) 2.48 (1.59 to 3.88) 2.33 (1.46 to 3.71) 
Aged >60 
No MSD pain  128 (77.1) 118 (71.1) 1.00 1.00 
MSD pain 38 (22.9) 48 (28.9) 1.48 (0.85 to 2.57) 1.51 (0.85 to 2.67) 
Appendix Table 30: Association between primary-care-level mental health problems and 










HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol 
use.  
OR (95% CI) 
Aged <50  
No primary-care-level 
MHP 
59 (92.2) 44 (68.8) 1.00 1.00 
Primary-care-level 
MHP 
5 (7.8) 20 (31.3) 16.00 (2.12 to 
120.65) 
29.70 (2.78 to 
317.56) 
Aged 50 - <60 
No primary-care-level 
MHP 
233 (88.3) 182 (68.9) 1.00 1.00 
Primary-care-level 
MHP 




154 (92.8) 139 (83.7) 1.00 1.00 
Primary-care-level 
MHP 
12 (7.2) 27 (16.3) 2.36 (1.17 to 4.78) 2.04 (0.98 to 4.25) 
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Appendix Table 31: Association between sleep disturbance and health-related job loss, by 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
Aged <50  
No sleep 
disorders 
61 (95.3) 58 (90.6) 1.00 1.00 
Sleep disorders 3 (4.7) 6 (9.4) 2.00 (0.50 to 8.00) 2.71 (0.46 to 16.05) 
Aged 50 - <60 
No sleep 
disorders 
256 (97.0) 246 (93.2) 1.00 1.00 




163 (98.2) 153 (92.2) 1.00 1.00 
Sleep disorders 3 (1.8) 13 (7.8) 4.33 (1.23 to 15.21) 4.34 (1.18 to 15.97) 
Appendix Table 32: Association between severe mental health disorders and health-









HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
OR (95% CI) 
Aged <50  
No severe MHPs 63 (98.4) 57 (89.1) 1.00 1.00 
Severe MHPs 1 (1.6) 7 (10.9) NE NE 
Aged 50 - <60 
No severe MHPs 258 (97.7) 240 (90.9) 1.00 1.00 
Severe MHPs 6 (2.3) 24 (9.1) 4.00 (1.64 to 9.79) 4.00 (1.49 to 10.76) 
Aged >60 
No severe MHPs 163 (98.2) 160 (96.4) 1.00 1.00 
Severe MHPs 3 (1.8) 6 (3.6) 2.50 (0.49 to 
12.89) 
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Association with HRJL, 
unadjusted. 
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No hypertension 61 (95.3) 55 (85.9) 1.00 1.00 
Hypertension 3 (4.7) 9 (14.1) 3.00 (0.81 to 11.08) 3.52 (0.77 to 16.01) 
Aged 50 - <60 
No hypertension 219 (83.0) 194 (73.5) 1.00 1.00 
Hypertension 45 (17.1) 70 (26.5) 1.86 (1.19 to 2.92) 1.90 (1.19 to 3.04) 
Aged >60 
No hypertension 130 (78.3) 112 (67.5) 1.00 1.00 
Hypertension 36 (21.7) 54 (32.5) 1.78 (1.07 to 2.97) 1.64 (0.97 to 2.76) 











HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
Aged <50  
No heart 
failure 
64 (100.0) 63 (98.4) 1.00 1.00 
Heart failure 0 (0.0) 1 (1.6) NE NE 
Aged 50 - <60 
No heart 
failure 
257 (97.4) 251 (95.1) 1.00 1.00 




159 (95.8) 136 (81.9) 1.00 1.00 
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Appendix Table 35: Association between ischaemic heart disease and health-related job 
loss, by age at HRJL 
Variable Prevalence 
among 
controls, n (%) 
Prevalence 
among cases, n 
(%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
   No IHD 64 (100.0) 63 (98.4) 1.00 1.00 
     IHD 0 (0.0) 1 (1.6) NE NE 
Aged 50 - <60 
   No IHD 254 (96.2) 250 (94.7) 1.00 1.00 
     IHD 10 (3.8) 14 (5.3) 1.40 (0.62 to 3.15) 1.25 (0.55 to 2.88) 
Aged >60 
   No IHD 155 (93.4) 151 (91.0) 1.00 1.00 
     IHD 11 (6.6) 15 (9.0) 1.40 (0.62 to 3.15) 1.23 (0.52 to 2.93) 










Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Aged <50  
No asthma 60 (93.8) 60 (93.8) 1.00 1.00 
Asthma 4 (6.3) 4 (6.3) 1.00 (0.25 to 4.00) 1.12 (0.24 to 5.17) 
Aged 50 - <60 
No asthma 244 (92.4) 234 (88.6) 1.00 1.00 
Asthma 20 (7.6) 30 (11.4) 1.67 (0.88 to 3.16) 1.94 (0.99 to 3.81) 
Aged >60 
No asthma 60 (93.8) 60 (93.8) 1.00 1.00 
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Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
Aged <50  
No 
COPD 
64 (100.0) 64 (100.0) 1.00 1.00 
COPD 0 (0.0) 0 (0.0) NE NE 
Aged 50 - <60 
No 
COPD 
261 (98.9) 257 (97.4) 1.00 1.00 




164 (98.8) 158 (95.2) 1.00 1.00 
COPD 2 (1.2) 8 (4.8) 4.00 (0.85 to 18.84) 6.12 (1.14 to 32.74) 
Appendix Table 38: Association between cerebrovascular accident and health-related job 









Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of 
heavy alcohol use.  
OR (95% CI) 
Aged <50  
No CVA 64 (100.0) 64 (100.0) 1.00 1.00 
CVA 0 (0.0) 0 (0.0) NE NE 
Aged 50 - <60 
No CVA 262 (99.2) 254 (96.2) 1.00 1.00 
CVA 2 (0.8) 10 (3.8) 5.00 (1.10 to 22.82) 5.76 (1.19 to 27.79) 
Aged >60 
No CVA 164 (98.8) 159 (95.8) 1.00 1.00 
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OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Aged <50  
No diabetes 64 (100.0) 59 (92.2) 1.00 1.00 
   Any diabetes 0 (0.0) 5 (7.8) NE NE 
Aged 50 - <60 
No diabetes 248 (93.9) 233 (88.3) 1.00 1.00 
   Any diabetes 16 (6.1) 31 (11.7) 2.25 (1.14 to 
4.44) 
2.07 (1.03 to 4.19) 
Aged >60 
No diabetes 151 (91.0) 142 (85.5) 1.00 1.00 
   Any diabetes 15 (9.0) 24 (14.5) 1.90 (0.88 to 
4.09) 
1.77 (0.81 to 3.87) 
Appendix Table 40: Association between psychiatric-level mental health problems and 
health-related job loss, by “type” of HRJL 






cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No psychiatric-level 
MHPs 
228 (99.1) 227 (98.7) 1.00 1.00 
Psychiatric-level MHPs 2 (0.9) 3 (1.3) 1.50 (0.25 to 
8.98) 
1.63 (0.25 to 10.59) 
Partly due to a health problem 
No psychiatric-level 
MHPs 
264 (100.0) 259 (98.1) 1.00 1.00 
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Appendix Table 41: Association between peripheral atherosclerotic disease and health-
related job loss, by “type” of HRJL 






cases, n (%) 
Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No PAD 229 (99.6) 226 (98.3) 1.00 1.00 
PAD 1 (0.4) 4 (1.7) 4.00 (0.45 to 35.79) 2.43 (0.25 to 23.94) 
Partly due to a health problem 
No PAD 264 (100.0) 257 (97.4) 1.00 1.00 
PAD 0 (0.0) 7 (2.7) NE NE 
Appendix Table 42: Association between cardiac arrhythmias and health-related job loss, 
by “type” of HRJL 












OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No arrhythmias 230 
(100.0) 
224 (97.4) 1.00 1.00 
Cardiac 
arrhythmias 
0 (0.0) 6 (2.6) NE NE 
Partly due to a health problem 
No arrhythmias 263 (99.6) 263 (99.6) 1.00 1.00 
Cardiac 
arrhythmias 
1 (0.4) 1 (0.4) 1.00 (0.06 to 
15.99) 
0.85 (0.05 to 14.22) 
Appendix Table 43: Association between structural heart disease and health-related job 
loss, by “type” of HRJL 
Variable Number of 
“exposed” 
controls, n (%) 
Number of 
“exposed” 
cases, n (%) 
Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No structural 
heart disease 
230 (100.0) 226 (98.3) 1.00 1.00 
Structural heart 
disease 
0 (0.0) 4 (1.7) NE NE 
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Partly due to a health problem 
No structural 
heart disease 
264 (100.0) 261 (98.9) 1.00 1.00 
Structural heart 
disease 
0 (0.0) 3 (1.1) NE NE 
Appendix Table 44: Association between COPD and health-related job loss, by “type” of 
HRJL 









Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No COPD 230 (100.0) 220 (95.7) 1.00 1.00 
COPD 0 (0.0) 10 (4.4) NE NE 
Partly due to a health problem 
No COPD 259 (98.1) 259 (98.1) 1.00 1.00 
COPD 5 (1.9) 5 (1.9) 1.00 (0.29 to 3.45) 1.28 (0.32 to 5.13) 
Appendix Table 45: Association between epilepsy and health-related job loss, by “type” of 
HRJL 






cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of 
heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No epilepsy 229 (99.6) 226 (98.3) 1.00 1.00 
Epilepsy 1 (0.4) 4 (1.7) 4.00 (0.45 to 35.79) 5.83 (0.62 to 54.96) 
Partly due to a health problem 
No epilepsy 262 (99.2) 261 (98.9) 1.00 1.00 
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Appendix Table 46: Association between chronic MSD and health-related job loss, by 










OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No chronic 
MSD 
203 (88.3) 168 (73.0) 1.00 1.00 
Chronic MSD 27 (11.7) 62 (27.0) 2.75 (1.65 to 4.59) 2.71 (1.60 to 4.57) 
Partly due to a health problem 
No chronic 
MSD 
209 (79.2) 190 (72.0) 1.00 1.00 
Chronic MSD 55 (20.8) 74 (28.0) 1.48 (0.99 to 2.20) 1.47 (0.98 to 2.22) 
Appendix Table 47: Association between musculoskeletal pain and health-related job loss, 







cases, n (%) 
Association with 
HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy alcohol 
use.  
OR (95% CI) 
Mainly due to a health problem 
No MSD pain  186 (80.9) 151 (65.7) 1.00 1.00 
MSD pain 44 (19.1) 79 (34.4) 2.13 (1.39 to 3.26) 2.01 (1.30 to 3.12) 
Partly due to a health problem 
No MSD pain  220 (83.3) 190 (72.0) 1.00 1.00 
MSD pain 44 (16.7) 74 (28.0) 2.36 (1.44 to 3.89) 2.42 (1.44 to 4.07) 
Appendix Table 48: Association between primary-care-level mental health problems and 











OR (95% CI) 
Association with HRJL, 
adjusted for 
education level, single 
status, history of 
heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No primary-care-level 
MHPs 
214 (93.0) 161 (70.0) 1.00 1.00 
Primary-care-level 
MHPs 
16 (7.0) 69 (30.0) 6.89 (3.42 to 
13.86) 
6.93 (3.37 to 14.25) 
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Partly due to a health problem 
No primary-care-level 
MHPs 
232 (87.9) 204 (77.3) 1.00 1.00 
Primary-care-level 
MHPs 
32 (12.1) 60 (22.7) 2.22 (1.36 to 
3.63) 
2.08 (1.24 to 3.46) 
Appendix Table 49: Association between sleep disturbance and health-related job loss, by 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No sleep 
disorders 
224 (97.4) 211 (91.7) 1.00 1.00 
Sleep disorders 6 (2.6) 19 (8.3) 3.60 (1.34 to 9.70) 3.57 (1.27 to 10.04) 
Partly due to a health problem 
No sleep 
disorders 
256 (97.0) 246 (93.2) 1.00 1.00 
Sleep disorders 8 (3.0) 18 (6.8) 2.43 (1.01 to 5.86) 2.18 (0.89 to 5.33) 
Appendix Table 50: Association between severe mental health disorders and health-
related job loss, by “type” of HRJL 
Variable Prevalence 
among 





HRJL, unadjusted.  
OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No severe MHPs 225 (97.8) 210 (91.3) 1.00 1.00 
Severe MHPs 5 (2.2) 20 (8.7) 4.75 (1.62 to 13.96) 4.29 (1.42 to 12.92) 
Partly due to a health problem 
No severe MHPs 259 (98.1) 247 (93.6) 1.00 1.00 
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Appendix Table 51: Association between hypertension and health-related job loss, by 











OR (95% CI) 
Association with 
HRJL, adjusted for 
education level, 
single status, history 
of heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No hypertension 189 (82.2) 177 (77.0) 1.00 1.00 
Hypertension 41 (17.8) 53 (23.0) 1.44 (0.88 to 2.36) 1.34 (0.80 to 2.22) 
Partly due to a health problem 
No hypertension 221 (83.7) 184 (69.7) 1.00 1.00 
Hypertension 43 (16.3) 80 (30.3) 2.32 (1.49 to 3.62) 2.26 (1.44 to 3.55) 
 
Appendix Table 52: Association between heart failure and health-related job loss, by 










HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No heart 
failure 
224 (97.4) 208 (90.4) 1.00 1.00 
Heart failure 6 (2.6) 22 (9.6) 5.00 (1.71 to 14.63) 4.34 (1.46 to 12.95) 
Partly due to a health problem 
No heart 
failure 
256 (97.0) 242 (91.7) 1.00 1.00 
Heart failure 8 (3.0) 22 (8.3) 3.00 (1.28 to 7.06) 3.42 (1.38 to 8.44) 
Appendix Table 53: Association between ischaemic heart disease and health-related job 











OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, 
history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
   No IHD 221 (96.1) 216 (93.9) 1.00 1.00 
   Ischaemic Heart 
Disease 
9 (3.9) 14 (6.1) 1.56 (0.67 to 
3.59) 
1.32 (0.56 to 3.12) 
Partly due to a health problem 
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   No IHD 252 (95.5) 248 (93.9) 1.00 1.00 
   Ischaemic Heart 
Disease 
12 (4.6) 16 (6.1) 1.36 (0.63 to 
2.97) 
1.34 (0.61 to 2.97) 











HRJL, unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education 
level, single status, history 
of heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No asthma 218 (94.8) 208 (90.4) 1.00 1.00 
Asthma 12 (5.2) 22 (9.6) 2.03 (0.99 to 4.18) 2.18 (1.05 to 4.55) 
Partly due to a health problem 
No asthma 245 (92.8) 239 (90.5) 1.00 1.00 
Asthma 19 (7.2) 25 (9.5) 1.41 (0.76 to 2.64) 1.51 (0.79 to 2.87) 
Appendix Table 55: Association between cerebrovascular accident and health-related job 









Association with HRJL, 
unadjusted.  
OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of heavy 
alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No CVA 229 (99.6) 218 (94.8) 1.00 1.00 
CVA 1 (0.4) 12 (5.2) 12.00 (1.56 to 92.29) 13.49 (1.71 to 106.34) 
Partly due to a health problem 
No CVA 261 (98.9) 259 (98.1) 1.00 1.00 
CVA 3 (1.1) 5 (1.9) 1.67 (0.40 to 6.97) 2.09 (0.46 to 9.60) 




controls, n (%) 
Prevalence 





OR (95% CI) 
Association with HRJL, 
adjusted for education level, 
single status, history of 
heavy alcohol use.  
OR (95% CI) 
Mainly due to a health problem 
No diabetes 219 (95.2) 204 (88.7) 1.00 1.00 
   diabetes 11 (4.8) 26 (11.3) 2.88 (1.29 to 
6.43) 
2.48 (1.08 to 5.70) 
Partly due to a health problem 
No diabetes 244 (92.4) 230 (87.1) 1.00 1.00 
528 | P a g e  
 
   diabetes 20 (7.6) 34 (12.9) 2.00 (1.05 to 
3.80) 
1.79 (0.93 to 3.44) 
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Appendix to Chapter 7  























MSDs (chronic or 
recent pain) 
x x x 89 (50.3) 6 (60.0) 31 (60.8) 111 (51.2) 24 (41.4) 22 (43.1) 39 (42.9) 7 (58.3) 
Chronic MSD X x 76 (31.5) 48 (27.1) 4 (40.0) 21 (41.2) 63 (29.0) 12 (20.7) 11 (21.6) 27 (29.7) 5 (41.7) 
MSD pain X 76 (34.9) X 76 (31.5) 5 (50.0) 17 (33.3) 72 (33.2) 17 (29.3) 16 (31.4) 20 (22.0) 3 (25.0) 
Primary care MHP 89 (23.2) 48 (22.0) 59 (24.5) x 6 (60.0) 37 (72.6) 34 (15.7) 9 (15.5) 9 (17.7) 17 (18.7) 3 (25.0) 
Psychiatric MHP 6 (1.6) 4 (1.8) 5 (2.1) 6 (3.4) x 2 (3.9) 3 (1.4) 1 (1.7) 1 (2.0) 1 (1.1) 1 (8.3) 
Sleep disorders 31 (8.1) 21 (9.6) 17 (7.1) 37 (20.9) 2 (20.0) x 5 (2.3) 6 (10.3) 3 (5.9) 4 (4.4) 1 (8.3) 
Hypertension 111 (29.0) 63 (28.9) 72 (29.9) 34 (19.2) 3 (30.0) 5 (9.8) x 23 (39.7) 27 (52.9) 46 (50.6) 9 (75.0) 
Heart failure 24 (6.3) 12 (5.5) 17 (7.1) 9 (5.1) 1 (10.0) 6 (11.8) 23 (10.6) x 26 (51.0) 14 (15.4) 0 (0.0) 
Ischaemic heart 
disease 
22 (5.7) 11 (5.1) 16 (6.6) 9 (5.1) 1 (10.0) 3 (5.9) 27 (12.4) 26 (44.8) X 14 (15.4) 2 (16.7) 
Diabetes 39 (10.2) 27 (12.4) 20 (8.3) 17 (9.6) 1 (10.0) 4 (7.8) 46 (21.2) 14 (24.1) 14 (27.5) x 5 (41.7) 
Peripheral 
atherosclerosis 
7 (1.8) 5 (2.3) 3 (1.2) 3 (1.2) 1 (10.0) 1 (2.0) 9 (4.2) 0 (0.0) 2 (3.9) 5 (5.5) X 
Cardiac arrythmias 3 (0.8) 2 (0.9) 2 (0.8) 1 (0.6) 1 (10.0) 0 (0.0) 3 (1.4) 2 (3.5) 3 (5.9) 2 (2.2) 0 (0.0) 
Venous thrombus 1 (0.3) 1 (0.4) 1 (0.4) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Structural heart 
disease 
2 (0.5) 1 (0.5) 1 (0.4) 1 (0.6) 0 (0.0) 0 (0.0) 4 (1.8) 4 (6.9) 3 (5.9) 0 (0.0) 0 (0.0) 
CVA 8 (2.1) 3 (1.4) 7 (2.9) 4 (2.3) 0 (0.0) 1 (2.0) 8 (3.7) 5 (8.6) 2 (3.9) 3 (3.3) 1 (8.3) 
Epilepsy 4 (1.0) 2 (0.9) 3 (1.2) 2 (1.1) 1 (10.0) 0 (0.0) 1 (0.5) 2 (3.5) 1 (2.0) 0 (0.0) 0 (0.0) 
Asthma 34 (8.9) 19 (8.7) 21 (8.7) 14 (7.9) 0 (0.0) 6 (11.8) 21 (9.7) 6 (10.3) 5 (9.8) 6 (6.6) 0 (0.0) 
COPD 8 (2.1) 5 (2.3) 5 (2.1) 6 (3.4) 0 (0.0) 3 (5.9) 3 (1.4) 3 (5.2) 1 (2.0) 1 (1.1) 0 (0.0) 
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Appendix Table 58:  frequency of comorbidity pairs 
 Cardiac 
arrhythmias 
Venous thrombus Structural heart 
disease 
CVA Epilepsy Asthma COPD 
MSDs (chronic or recent pain) 3 (37.5) 1 (100.0) 2 (28.6) 8 (38.1) 4 (40.0) 34 (43.6) 8 (40.0) 
Chronic MSD 2 (25.0) 0 (0.0) 1 (14.3) 3 (14.3) 2 (20.0) 19 (24.4) 5 (25.0) 
MSD pain 2 (25.0) 1 (100.0) 1 (14.3) 7 (33.3) 3 (30.0) 21 (26.9) 5 (25.0) 
Primary care MHP 1 (12.5) 1 (100.0) 1 (14.3) 4 (19.1) 2 (20.0) 14 (18.0) 6 (30.0) 
Psychiatric MHP 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Sleep disorders 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0) 6 (7.7) 3 (15.0) 
Hypertension 3 (37.5) 0 (0.0) 4 (57.1) 8 (38.1) 1 (10.0) 21 (26.9) 3 (15.0) 
Heart failure 2 (25.0) 0 (0.0) 4 (57.1) 5 (23.8) 2 (20.0) 6 (7.7) 3 (15.0) 
Ischaemic heart disease 3 (37.5) 0 (0.0) 3 (42.9) 2 (9.5) 1 (10.0) 5 (6.4) 1 (5.0) 
Diabetes 2 (25.0) 0 (0.0) 0 (0.0) 3 (14.3) 0 (0.0) 6 (7.7) 1 (5.0) 
Peripheral atherosclerosis 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0) 0 (0.0) 0 (0.0) 
Cardiac arrythmias x 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Venous thrombus 0 (0.0) x 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Structural heart disease 1 (12.5) 0 (0.0) x 2 (9.5) 0 (0.0) 0 (0.0) 0 (0.0) 
CVA 0 (0.0) 0 (0.0) 2 (28.6) x 0 (0.0) 1 (1.3) 0 (0.0) 
Epilepsy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) x 0 (0.0) 0 (0.0) 
Asthma 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0) x 12 (60.0) 
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Appendix Table 59: clusters formed from total population cluster analysis using chronic MSDs to define MSDs  
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6  Cluster 7 Cluster 8 Cluster 9 Cluster 10 
Total 404 (40.9) 140 (14.2) 59 (6.0) 41 (4.2) 14 (1.4) 13 (1.3) 44 (4.5) 141 (14.3) 113 (11.4) 11 (1.1) 
Chronic musculoskeletal 
disorders 
0 (0.0) 50 (35.7) 13 (22.0) 2 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 40 (28.4) 113 (100.0) 0 (0.0) 
Hypertension 0 (0.0) 139 (99.3) 35 (59.3) 24 (58.5) 0 (0.0) 4 (30.8) 13 (29.6) 2 (1.4) 0 (0.0) 0 (0.0) 
Primary care mental 
health problems 
0 (0.0) 19 (13.6) 6 (10.2) 3 (7.3) 4 (28.6) 3 (23.1) 3 (6.8) 139 (98.6) 0 (0.0) 0 (0.0) 
Diabetes 0 (0.0) 2 (1.4) 59 (100.0) 11 (26.8) 0 (0.0) 2 (15.4) 0 (0.0) 10 (7.1) 7 (6.2) 0 (0.0) 
Asthma 0 (0.0) 5 (3.6) 2 (3.4) 3 (7.3) 3 (21.4) 0 (0.0) 44 (100.0) 9 (6.4) 11 (9.7) 1 (9.1) 
Heart failure 0 (0.0) 7 (5.0) 4 (6.8) 27 (65.9) 14 (100.0) 0 (0.0) 0 (0.0) 2 (1.4) 3 (2.7) 1 (9.1) 
Ischaemic heart disease 0 (0.0) 6 (4.3) 0 (0.0) 38 (92.7) 0 (0.0) 0 (0.0) 0 (0.0) 6 (4.3) 1 (0.9) 0 (0.0) 
Sleep disorders 0 (0.0) 0 (0.0) 1 (1.7) 1 (2.4) 2 (14.3) 0 (0.0) 1 (2.3) 34 (24.1) 1 (0.9) 11 (100.0) 
Cerebrovascular accident 0 (0.0) 2 (1.4) 0 (0.0) 2 (4.9) 1 (7.1) 13 (100.0) 1 (2.3) 0 (0.0) 2 (1.8) 0 (0.0) 
COPD 0 (0.0) 1 (0.7) 0 (0.0) 1 (2.4) 2 (14.3) 0 (0.00) 8 (18.2) 5 (3.6) 2 (1.8) 0 (0.0) 
Peripheral atherosclerotic 
disease 
0 (0.0) 3 (2.1) 5 (8.5) 0 (0.0) 0 (0.0) 1 (7.7) 0 (0.0) 2 (1.4) 0 (0.0) 0 (0.0) 
Psychiatric care mental 
health problems 
0 (0.0) 1 (0.7) 1 (1.7) 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 5 (3.6) 0 (0.0) 0 (0.0) 
Epilepsy 0 (0.0) 1 (0.7) 0 (0.0) 1 (2.4) 1 (7.1) 0 (0.0) 0 (0.0) 2 (1.4) 1 (0.9) 0 (0.0) 
Arrythmias 0 (0.0) 0 (0.0) 1 (1.7) 4 (9.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 
Structural heart disease 0 (0.0) 1 (0.7) 0 (0.0) 5 (12.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) 
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Appendix Table 60: clusters formed from total population cluster analysis using recent MSD pain to define musculoskeletal disorders 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6  Cluster 7 Cluster 9 
Total  396 (40.1) 163 (16.5) 56 (5.7) 42 (4.3) 106 (10.7) 150 (15.2) 14 (1.4) 45 (4.6) 
Musculoskeletal pain 0 (0.0) 59 (36.2) 9 (16.1) 5 (11.9) 10 (9.4) 150 (100.0) 5 (35.7) 0 (0.0) 
Hypertension 0 (0.0) 161 (98.8) 29 (51.8) 6 (14.3) 4 (3.8) 4 (2.7) 0 (0.0) 12 (26.7) 
Primary care mental health 
problems 
0 (0.0) 23 (14.1) 2 (3.6) 12 (28.6) 106 (100.0) 33 (22.0) 0 (0.0) 0 (0.0) 
Diabetes 0 (0.0) 27 (16.6) 16 (28.6) 42 (100.0) 4 (3.8) 0 (0.0) 0 (0.0) 2 (4.4) 
Asthma 0 (0.0) 4 (2.5) 4 (7.1) 0 (0.0) 8 (7.6) 15 (10.0) 2 (14.3) 45 (100.0) 
Heart failure 0 (0.0) 2 (1.2) 44 (78.6) 0 (0.0) 6 (5.7) 5 (3.3) 1 (7.1) 0 (0.0) 
Ischaemic heart disease 0 (0.0) 6 (3.7) 35 (62.5) 1 (2.4) 3 (2.8) 5 (3.3) 0 (0.0) 1 (2.2) 
Sleep disorders 0 (0.0) 1 (0.6) 1 (1.8) 0 (0.0) 35 (33.0) 0 (0.0) 14 (100.0) 0 (0.0) 
Cerebrovascular accident 0 (0.0) 1 (0.6) 4 (7.1) 3 (7.1) 4 (3.8) 1 (0.7) 0 (0.0) 0 (0.0) 
COPD 0 (0.0) 3 (1.8) 3 (5.4) 0 (0.0) 4 (3.8) 3 (2.0) 0 (0.0) 7 (15.6) 
Peripheral atherosclerotic disease 0 (0.0) 7 (4.3) 2 (3.6) 1 (2.4) 2 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) 
Psychiatric care mental health 
problems 
0 (0.0) 1 (0.6) 0 (0.0) 1 (2.4) 3 (2.8) 3 (2.0) 0 (0.0) 0 (0.0) 
Epilepsy 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.0) 0 (0.0) 0 (0.0) 
Arrythmias 0 (0.0) 1 (0.6) 4 (7.1) 1 (2.4) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) 
Structural heart disease 0 (0.0) 2 (1.2) 4 (7.1) 0 (0.0) 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 
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Appendix Table 61: total population demographics (chronic MSD only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6  Cluster 7 Cluster 8 Cluster 9 Cluster 10 
Total 404 (40.9) 140 (14.2) 59 (6.0) 41 (4.2) 14 (1.4) 13 (1.3) 44 (4.5) 141 (14.3) 113 (11.4) 11 (1.1) 

























Sex (m) 161 (39.9) 76 (54.3) 38 (64.4) 35 (85.4) 4 (28.6) 8 (61.5) 19 (43.2) 48 (34.0) 39 (34.5) 5 (45.5) 
Ethnicity (white) 395 (97.8) 138 (98.6) 58 (98.3) 40 (97.6) 13 (92.9) 13 (100.0) 43 (97.7) 139 (98.6) 111 (98.2) 11 (100.0) 
Married/Civil 
partnership 
278 (69.9) 100 (71.4) 46 (79.3) 27 (65.9) 6 (42.9) 9 (69.2) 26 (60.5) 90 (64.3) 80 (70.8) 7 (63.6) 
   Single 30 (7.5) 7 (5.0) 4 (6.9) 7 (17.1) 2 (14.3) 3 (23.1) 4 (9.3) 13 (9.3) 4 (3.5) 2 (18.2) 
   Divorced 71 (17.8) 24 (17.1) 3 (5.2) 6 (14.6) 3 (21.4) 1 (7.7) 11 (25.6) 31 (22.1) 20 (17.7) 2 (18.2) 
   Widowed 19 (4.8) 9 (6.4) 5 (8.6) 1 (2.4) 3 (21.4) 0 (0.0) 2 (4.7) 6 (4.3) 9 (8.0) 0 (0.0) 
University degree 98 (24.3) 30 (21.4) 7 (11.7) 7 (17.1) 1 (7.1) 3 (23.1) 14 (31.8) 35 (24.8) 22 (19.5) 5 (45.5) 
   Vocational 
qualifications/higher 
professional 
162 (40.1) 61 (43.6) 23 (39.0) 17 (41.5) 2 (14.3) 3 (23.1) 17 (38.6) 46 (32.6) 49 (43.4) 3 (27.3) 
    High school 
qualifications 
77 (19.1) 24 (17.1) 13 (22.0) 5 (12.2) 9 (64.3) 3 (23.1) 6 (13.6) 28 (19.9) 16 (14.2) 1 (9.1) 
 No qualifications 67 (16.6) 25 (17.9) 16 (27.1) 12 (29.3) 2 (14.3) 4 (30.8) 7 (15.9) 32 (22.7) 26 (23.0) 2 (18.2) 
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Appendix Table 62: total population demographics (musculoskeletal pain only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6  Cluster 7 Cluster 9 
Total 396 (40.1) 163 (16.5) 56 (5.7) 42 (4.3) 106 (10.7) 150 (15.2) 14 (1.4) 45 (4.6) 
Age at HRJL, y, median 
(IQR) 
57.48 (52.42 – 
60.28) 
59.13 (55.82 – 
61.22) 
61.36 (58.72 – 
63.66) 
59.54 (55.18 – 
61.49) 
56.84 (51.72 – 
59.86) 
55.98 (51.71 – 
61.03) 
57.41 (50.47 – 
61.15) 
58.08 (55.37 – 
59.86) 
Sex (m) 149 (37.6) 92 (56.4) 43 (76.8) 25 (59.5) 34 (32.1) 62 (41.3) 7 (50.0) 18 (40.0) 
Ethnicity (white) 389 (98.2) 161 (98.8) 54 (96.4) 42 (100.0) 104 (98.1) 146 (97.3) 14 (100.00) 43 (95.6) 
Married/Civil partnership 270 (68.9) 117 (72.2) 37 (66.1) 32 (76.2) 69 (65.7) 103 (69.6) 10 (71.4) 27 (61.4) 
   Single 24 (6.1) 11 (6.8) 8 (14.3) 3 (7.1) 8 (7.6) 14 (9.5) 2 (14.3) 3 (6.8) 
  Widowed 26 (6.6) 9 (5.6) 4 (7.1) 3 (7.1) 5 (4.7) 3 (2.0) 0 (0.0) 4 (9.1) 
   Divorced 72 (18.4) 25 (15.4) 7 (12.5) 4 (9.5) 23 (21.9) 28 (18.9) 2 (14.3) 10 (22.7) 
University degree 94 (23.7) 33 (20.3) 7 (12.5) 7 (16.7) 23 (21.7) 33 (22.0) 6 (42.9) 16 (35.6) 
   Vocational 
qualifications/higher 
professional 
159 (39.9) 68 (41.7) 24 (42.9) 16 (38.1) 30 (28.3) 67 (44.7) 5 (35.7) 14 (31.1) 
    High school 
qualifications 
77 (19.4) 30 (18.4) 11 (19.6) 8 (19.1) 23 (21.7) 25 (16.7) 1 (7.1) 5 (11.1) 
 No qualifications 67 (16.9) 32 (19.6) 14 (25.0) 11 (26.2) 30 (28.3) 25 (16.7) 2 (14.3) 10 (22.2) 
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Appendix Table 63: multimorbid population demographics (chronic MSD only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 5 
Total 88 (32.2) 35 (12.8) 109 (39.9) 32 (11.7) 
Age at HRJL, y, median (IQR) 57.30 (54.12 to 60.17) 61.13 (58.50 to 62.44) 59.63 (56.42 to 61.27) 57.43 (53.96 to 61.37) 
Sex (m) 29 (33.0) 29 (82.9) 61 (56.0) 14 (43.8) 
Ethnicity (white) 87 (98.9) 34 (97.1) 106 (97.3) 30 (93.8) 
Married/Civil partnership 51 (58.6) 25 (71.4) 85 (78.7) 18 (58.1) 
   Single 11 (12.6) 6 (17.1) 6 (5.6) 6 (19.4) 
   Divorced 19 (21.8) 3 (8.6) 11 (10.2) 6 (19.4) 
   Widowed 6 (6.9) 1 (2.9) 6 (5.6) 1 (3.2) 
University degree 18 (20.5) 5 (14.3) 17 (15.6) 6 (18.8) 
   Vocational qualifications/higher professional 29 (33.0) 13 (37.1) 44 (40.4) 13 (40.6) 
    High school qualifications 21 (23.9) 5 (14.3) 19 (17.4) 5 (15.6) 
    No qualifications 20 (22.7) 12 (34.3) 29 (26.6) 8 (25.0) 
Cases 68 (77.3) 21 (60.0) 78 (71.6) 23 (71.9) 
 
Appendix Table 64: multimorbid population constituent health disorders (chronic MSD only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 5 
Total 88 (32.2) 35 (12.8) 109 (39.9) 32 (11.7) 
Chronic musculoskeletal disorders 44 (50.0) 1 (2.9) 80 (73.4) 1 (3.1) 
Hypertension 21 (23.9) 22 (62.9) 84 (77.1) 13 (40.6) 
Primary care mental health 
problems 
85 (96.6) 3 (8.6) 7 (6.4) 12 (37.5) 
Diabetes 8 (9.1) 11 (31.4) 47 (43.1) 2 (6.3) 
536 | P a g e  
 
Asthma 2 (2.3) 3 (8.6) 18 (16.5) 30 (93.8) 
Heart failure 8 (9.1) 26 (74.3) 13 (11.9) 3 (9.4) 
Ischaemic heart disease 5 (5.7) 33 (94.3) 7 (6.4) 1 (3.1) 
Sleep disorders 35 (39.8) 1 (2.9) 2 (1.8) 4 (12.5) 
Cerebrovascular accident 4 (4.6) 2 (5.7) 8 (7.3) 1 (3.1) 
COPD 2 (2.3) 1 (2.9) 3 (2.8) 13 (40.6) 
Peripheral atherosclerotic disease 2 (2.3) 0 (0.0) 9 (8.3) 0 (0.0) 
Psychiatric care mental health 
problems 
5 (5.7) 0 (0.0) 2 (1.8) 0 (0.0) 
Epilepsy 2 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Arrythmias 0 (0.0) 1 (2.9) 2 (1.8) 0 (0.0) 
Structural heart disease 1 (1.1) 4 (11.4) 1 (0.9) 0 (0.0) 
Venous thrombus 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 
 
Appendix Table 65: multimorbid population demographics (musculoskeletal pain only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
Total 95 (32.5) 36 (12.3) 35 (12.0) 110 (37.7) 12 (4.1) 
Age at HRJL, y, median (IQR) 59.10 (55.37 – 61.72) 59.18 (54.88 – 61.01) 60.09 (58.39 – 62.36) 56.04 (51.99 – 60.00) 61.23 (58.21 – 63.99) 
Sex (m) 56 (59.0) 23 (63.9) 30 (85.7) 35 (85.7) 75 (68.2) 
Ethnicity (white) 91 (95.8) 36 (100.0) 34 (97.1) 109 (99.1) 10 (83.3) 
Married/Civil partnership 70 (73.7) 29 (82.9) 23 (65.7) 64 (58.7) 4 (36.4) 
   Single 7 (7.4) 1 (2.9) 6 (17.1) 15 (13.8) 3 (27.3) 
  Widowed 6 (6.3) 3 (8.6) 1 (2.9) 6 (5.5) 1 (9.1) 
   Divorced 12 (12.6) 2 (5.7) 5 (14.3) 24 (22.0) 3 (27.3) 
University degree 12 (12.6) 4 (11.1) 6 (17.1) 27 (24.6) 2 (16.7) 
   Vocational qualifications/higher 
professional 
44 (46.3) 12 (33.3) 14 (40.0) 34 (30.9) 5 (41.7) 
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  High school qualifications 20 (21.1) 9 (25.0) 5 (14.3) 25 (22.7) 3 (25.0) 
  No qualifications 19 (20.0) 11 (30.6) 10 (28.6) 24 (21.8) 2 (16.7) 
Cases 64 (67.4) 26 (72.2) 24 (68.6) 90 (81.8) 6 (50.0) 
 
Appendix Table 66: multimorbid population constituent health disorders (recent musculoskeletal pain only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
Total 95 (32.5) 36 (12.3) 35 (12.0) 110 (37.7) 12 (4.1) 
Musculoskeletal pain 74 (77.9) 0 (0.0) 6 (17.1) 59 (53.6) 3 (25.0) 
Hypertension 73 (76.8) 26 (72.2) 20 (57.1) 27 (24.6) 0 (0.0) 
Primary care mental health 
problems 
2 (2.1 11 (30.6) 3 (8.6) 103 (93.6) 1 (8.3) 
Diabetes 16 (16.8) 36 (100.0) 12 (34.3) 4 (3.6) 0 (0.0) 
Asthma 26 (27.4) 1 (2.8) 1 (2.9) 14 (12.7) 10 (83.3) 
Heart failure 13 (13.7) 4 (11.1) 24 (68.6) 8 (7.3) 3 (25.0) 
Ischaemic heart disease 10 (10.5) 1 (2.8) 34 (97.1) 4 (3.6) 0 (0.0) 
Sleep disorders 0 (0.0) 0 (0.0) 1 (2.9) 43 (39.1) 0 (0.0) 
Cerebrovascular accident 7 (7.4) 3 (8.3) 2 (5.7) 4 (3.6) 0 (0.0) 
COPD 2 (2.1) 0 (0.0) 1 (2.9) 5 (4.6) 11 (97.7) 
Peripheral atherosclerotic disease 3 (3.2) 5 (13.9) 2 (5.7) 2 (1.8) 0 (0.0) 
Psychiatric care mental health 
problems 
2 (2.1) 1 (2.8) 0 (0.0) 5 (4.6) 0 (0.0) 
Epilepsy 3 (3.2) 0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 
Arrythmias 1 (1.1) 0 (0.0) 3 (8.6) 0 (0.0) 0 (0.0) 
Structural heart disease 3 (3.2) 0 (0.0) 4 (11.4) 0 (0.0) 0 (0.0) 
Venous thrombus 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
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Appendix Table 67: multimorbid men population demographics (chronic MSD only) 
 Cluster 1 Cluster 4 Cluster 5 Cluster 6 
Total 21 (15.1) 54 (38.9) 37 (26.6) 17 (12.2) 
Age at HRJL, y, median (IQR) 56.07 (51.71 to 
62.03) 
58.84 (56.05 to 
60.72) 
61.13 (58.67 to 
63.47) 
59.10 (55.82 to 
63.47) 
Ethnicity (white) 21 (100.0) 54 (100.0) 35 (94.6) 16 (94.1) 
Married/Civil partnership 15 (71.4) 41 (77.4) 21 (56.8) 13 (76.5) 
   Single 2 (9.5) 3 (5.7) 9 (24.3) 2 (11.8) 
   Divorced 3 (14.3) 7 (13.2) 5 (13.5) 2 (11.8) 
   Widowed 1 (4.8) 2 (3.8) 2 (5.4) 0 (0.0) 
University degree 4 (19.1) 11 (20.4) 11 (29.7) 4 (23.5) 
   Vocational qualifications/higher 
professional 
7 (33.3) 22 (40.7) 13 (35.1) 12 (70.6) 
    High school qualifications 4 (19.1) 8 (14.8) 6 (16.2) 0 (0.0) 
 No qualifications 4 (19.1) 11 (20.4) 11 (29.7) 4 (23.5) 
Cases 18 (85.7) 39 (72.2) 23 (62.2) 12 (70.6) 
 
Appendix Table 68: multimorbid men population constituent health disorders (chronic MSD only) 
 Cluster 1 Cluster 4 Cluster 5 Cluster 6 
Total 21 (15.1) 54 (38.9) 37 (26.6) 17 (12.2) 
Chronic musculoskeletal 
disorders 
14 (66.7) 26 (48.2) 3 (8.1) 7 (41.2) 
Hypertension 1 (4.8) 52 (96.3) 23 (62.2) 7 (41.2) 
Primary care mental health 
problems 
19 (90.5) 13 (24.1) 0 (0.0) 1 (5.9) 
Diabetes 5 (23.8) 24 (44.4) 13 (35.1) 0 (0.0) 
539 | P a g e  
 
Asthma 3 (14.3) 1 (1.9) 3 (8.1) 16 (94.1) 
Heart failure 1 (4.8) 4 (7.4) 26 (70.3) 0 (0.0) 
Ischaemic heart disease 2 (9.5) 1 (1.9) 31 (83.8) 0 (0.0) 
Sleep disorders 11 (52.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Cerebrovascular accident 0 (0.0) 6 (11.1) 2 (5.4) 1 (5.9) 
COPD 2 (9.5) 1 (1.9) 1 (2.7) 7 (41.2) 
Peripheral atherosclerotic 
disease 
2 (9.5) 6 (11.1) 0 (0.0) 0 (0.0) 
Psychiatric care mental health 
problems 
0 (0.0) 2 (3.7) 0 (0.0) 0 (0.0) 
Epilepsy 0 (0.0) 1 (1.9) 0 (0.0) 0 (0.0) 
Arrythmias 0 (0.0) 1 (1.9) 2 (5.4) 0 (0.0) 
Structural heart disease 1 (4.8) 2 (3.7) 4 (10.8) 0 (0.0) 
Venous thrombus 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 
Appendix Table 69: multimorbid men population demographics (recent musculoskeletal pain only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Total 64 (41.6) 31 (20.1) 36 (23.4) 19 (12.3) 
Age at HRJL, y, median (IQR) 59.29 (55.98 – 
61.29) 
60.09 (58.39 – 
62.36) 
55.90 (50.44 – 
60.05) 
59.45 (54.19 – 
63.70) 
Ethnicity (white) 63 (98.4) 30 (96.8) 36 (100.0) 18 (94.7) 
Married/Civil partnership 48 (76.2) 18 (58.1) 24 (66.7) 14 (73.7) 
   Single 5 (7.9) 6 (19.4) 6 (16.7) 1 (5.3) 
  Widowed 3 (4.8) 1 (3.2) 1 (2.8) 1 (5.3) 
   Divorced 7 (11.1) 6 (19.4) 5 (13.9) 3 (15.8) 
University degree 11 (17.2) 6 (19.4) 9 (25.0) 2 (10.5) 
   Vocational qualifications/higher 
professional 
28 (43.8) 12 (38.7) 11 (30.6) 13 (68.4) 
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    High school qualifications 15 (23.4) 5 (16.1) 7 (19.4) 1 (5.3) 
 No qualifications 10 (15.6) 8 (25.8) 9 (25.0) 3 (15.8) 
Cases 44 (68.8) 21 (67.7) 29 (80.6) 12 (63.2) 
 
Appendix Table 70: multimorbid men population constituent health disorders (recent musculoskeletal pain only) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Total 64 (41.6) 31 (20.1) 36 (23.4) 19 (12.3) 
Musculoskeletal pain 40 (62.5) 4 (12.9) 16 (44.4) 9 (47.4) 
Hypertension 47 (73.4) 17 (54.8) 14 (38.9) 8 (42.1) 
Primary care mental health 
problems 
1 (1.6) 1 (3.2) 36 (100.0) 1 (5.3) 
Diabetes 28 (43.8) 11 (35.5) 7 (19.4) 1 (5.3) 
Asthma 0 (0.0) 1 (3.2) 3 (8.3) 18 (94.7) 
Heart failure 10 (15.6) 21 (67.7) 2 (5.6) 1 (5.3) 
Ischaemic heart disease 3 (4.7) 30 (96.8) 1 (2.8) 2 (10.5) 
Sleep disorders 3 (4.7) 0 (0.0) 9 (25.0) 0 (0.0) 
Cerebrovascular accident 6 (9.4) 2 (6.5) 1 (2.8) 1 (5.3) 
COPD 1 (1.6) 1 (3.2) 2 (5.6) 7 (36.8) 
Peripheral atherosclerotic disease 7 (10.9) 1 (3.2) 2 (5.6) 0 (0.0) 
Psychiatric care mental health 
problems 
2 (3.1) 1 (3.2) 1 (2.8) 0 (0.0) 
Epilepsy 1 (1.6) 1 (3.2) 0 (0.0) 0 (0.0) 
Arrythmias 2 (3.1) 2 (6.5) 0 (0.0) 0 (0.0) 
Structural heart disease 3 (4.7) 4 (12.9) 0 (0.0) 0 (0.0) 




541 | P a g e  
 
Appendix Table 71: multimorbid women population demographics (chronic MSD only) 
 Cluster 1 Cluster 2 
Total 71 (53.0) 59 (44.0) 
Age at HRJL, y, median (IQR) 59.86 (56.42 – 61.48) 56.80 (52.65 – 60.00) 
Ethnicity (white) 69 (97.2) 58 (98.3) 
Married/Civil partnership 51 (71.8) 38 (65.5) 
   Single 5 (7.0) 6 (10.3) 
   Divorced 10 (14.1) 11 (19.0) 
   Widowed 5 (7.0) 3 (5.2) 
University degree 11 (15.5) 7 (11.9) 
   Vocational qualifications/higher professional 27 (38.0) 19 (32.2) 
    High school qualifications 13 (18.3) 15 (25.4) 
 No qualifications 20 (28.2) 18 (30.5) 
Cases 51 (71.8) 44 (74.6) 
 
Appendix Table 72: multimorbid women population constituent health disorders (chronic MSD only) 
 Cluster 1 Cluster 2 
Total 71 (53.0) 59 (44.0) 
Chronic musculoskeletal disorders 46 (64.8) 25 (42.4) 
Hypertension 55 (77.5) 5 (8.5) 
Primary care mental health problems 18 (25.4) 55 (93.2) 
Diabetes 23 (32.4) 2 (3.4) 
Asthma 17 (23.9) 10 (17.0) 
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Heart failure 4 (5.6) 10 (17.0) 
Ischaemic heart disease 6 (8.5) 7 (11.9) 
Sleep disorders 2 (2.8) 28 (47.5) 
Cerebrovascular accident 3 (4.2) 3 (5.1) 
COPD 0 (0.0) 4 (6.8) 
Peripheral atherosclerotic disease 2 (2.8) 0 (0.0) 
Psychiatric care mental health 
problems 
0 (0.0) 4 (6.8) 
Epilepsy 1 (1.4) 3 (5.1) 
Arrythmias 1 (1.4) 1 (1.7) 
Structural heart disease 0 (0.0) 0 (0.0) 
Venous thrombus 0 (0.0) 1 (1.7) 
Appendix Table 73: multimorbid women population demographics (musculoskeletal pain only) 
 Cluster 1 Cluster 2 
Total 67 (48.6) 62 (44.9) 
Age at HRJL, y, median (IQR) 59.06 (55.24 – 61.21) 56.28 (52.35 – 60.00) 
Ethnicity (white) 65 (97.0) 61 (98.4) 
Married/Civil partnership 47 (70.2) 36 (59.0) 
   Single 4 (6.0) 7 (11.5) 
  Widowed 6 (9.0) 4 (6.6) 
   Divorced 10 (14.9) 14 (23.0) 
University degree 6 (9.0) 15 (24.2) 
   Vocational qualifications/higher professional 25 (37.3) 19 (30.7) 
    High school qualifications 16 (23.9) 16 (25.8) 
 No qualifications 20 (29.9) 12 (19.4) 
Cases 49 (73.1) 50 (80.7) 
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Appendix Table 74: multimorbid women population constituent health disorders (recent musculoskeletal pain only) 
 Cluster 1 Cluster 2 
Total 67 (48.6) 62 (44.9) 
Musculoskeletal pain 38 (56.7) 34 (54.8) 
Hypertension 54 (80.6) 4 (6.5) 
Primary care mental health problems 20 (29.9) 61 (98.4) 
Diabetes 19 (28.4) 3 (4.8) 
Asthma 20 (29.9) 6 (9.7) 
Heart failure 2 (3.0) 7 (11.3) 
Ischaemic heart disease 6 (9.0) 5 (8.1) 
Sleep disorders 3 (4.5) 28 (45.2) 
Cerebrovascular accident 2 (3.0) 3 (4.8) 
COPD 2 (3.0) 2 (3.2) 
Peripheral atherosclerotic disease 2 (3.0) 0 (0.0) 
Psychiatric care mental health problems 0 (0.0) 4 (6.5) 
Epilepsy 0 (0.0) 2 (3.2) 
Arrythmias 1 (1.5) 1 (1.6) 
Structural heart disease 0 (0.0) 0 (0.0) 
Venous thrombus 0 (0.0) 1 (1.6) 
 
Appendix Table 75: musculoskeletal disorder population cluster demographics  
 Cluster 1 Cluster 2 Cluster 4 Cluster 5 Cluster 8 
Total 96 (25.1) 25 (6.5) 86 (22.5) 10 (2.6) 159 (41.5) 
Age at HRJL, y, median (IQR) 59.72 (55.98 
– 61.39) 
59.45 (56.07 – 
61.85) 
55.99 (52.36 – 
60.07) 
60.59 (57.26 – 
62.13) 
58.10 (53.36 – 
60.99) 
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Ethnicity (white) 94 (97.9) 23 (92.0) 85 (98.8) 10 (100.0) 156 (98.1) 
Married/Civil partnership 70 (72.9) 20 (80.0) 53 (62.4) 7 (70.0) 109 (69.4) 
   Single 5 (5.2) 1 (4.0) 10 (11.8) 0 (0.0) 9 (5.7) 
  Widowed 7 (7.3) 2 (8.0) 5 (5.9) 0 (0.0) 9 (5.7) 
   Divorced 14 (14.6) 2 (8.0) 17 (20.0) 3 (30.0) 30 (19.1) 
University degree 14 (14.6) 4 (16.0) 17 (19.8) 0 (0.0) 35 (22.0) 
   Vocational 
qualifications/higher 
professional 
42 (43.8) 12 (48.0) 29 (33.7) 4 (40.0) 70 (44.0) 
    High school qualifications 18 (18.8) 3 (12.0) 21 (24.4) 3 (30.0) 23 (14.5) 
 No qualifications 22 (22.9) 6 (24.0) 19 (22.1) 3 (30.0) 31 (19.5) 
Cases 60 (62.5) 17 (68.0) 72 (83.7) 7 (70.0) 69 (43.4) 
 
Appendix Table 76: musculoskeletal disorder population cluster constituent health disorders  
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 Cluster 7 Cluster 8 
Total 96 (25.1) 25 (6.5) 3 (0.8) 86 (22.5) 10 (2.6) 1 (0.3) 3 (0.8) 159 (41.5) 
Chronic musculoskeletal 
disorders 
59 (61.5) 16 (64.0) 2 (66.7) 43 (50.0) 5 (50.0) 1 (100.0) 2 (66.7) 90 (56.6) 
Recent MSD pain 58 (60.4) 14 (56.0) 1 (33.3) 60 (69.8) 7 (70.0) 1 (100.0) 2 (66.7) 98 (61.6) 
Hypertension 84 (87.5) 9 (36.0) 1 (33.3) 17 (19.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Primary care mental health 
problems 
8 (8.3) 2 (8.0) 0 (0.0) 79 (91.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Diabetes 32 (33.3) 2 (8.0) 0 (0.0) 3 (3.5) 1 (10.0) 0 (0.0) 1 (33.3) 0 (0.0) 
Asthma 0 (0.0) 24 (96.0) 0 (0.0) 9 (10.5) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Heart failure 10 (10.4) 0 (0.0) 0 (0.0) 5 (5.8) 9 (90.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Ischaemic heart disease 12 (12.5) 3 (12.0) 0 (0.0) 2 (2.3) 5 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Sleep disorders 1 (1.0) 0 (0.0) 0 (0.0) 30 (34.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Cerebrovascular accident 3 (3.1) 1 (4.0) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 3 (100.0) 0 (0.0) 
COPD 0 (0.0) 1 (4.0) 3 (100.0) 4 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 




4 (4.2) 0 (0.0) 0 (0.0) 3 (3.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Psychiatric care mental health 
problems 
1 (1.0) 0 (0.0) 0 (0.0) 4 (4.7) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Epilepsy 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 3 (30.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Arrythmias 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 1 (100.0) 0 (0.0) 0 (0.0) 
Structural heart disease 2 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Venous thrombus 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Appendix to Chapter 8 
Appendix Table 77: A description of participants with MSDs for SOC-10 sub-major occupational categories, stratified by type of MSD 
Demographic variable Prevalence among 
participants with any 
MSDs, n (%) 
Prevalence among 
participants with 
chronic MSDs, n (%) 
Prevalence among 
participants with MSD 
pain, n (%) 
Corporate managers and directors 14 (3.7) 9 (4.1) 8 (3.3) 
Science, research, engineering, and 
technology professionals 
6 (1.6) 5 (2.3) 4 (1.7) 
Health professionals 20 (5.2) 10 (4.6) 16 (6.6) 
Teaching and educational professionals 30 (7.8) 16 (7.3) 17 (7.1) 
Business, media and public service 
professionals 
15 (3.9) 11 (5.1) 9 (3.7) 
Other managers and proprietors 11 (2.9) 4 (1.8) 8 (3.3) 
Science, engineering, and technology 
associate professionals 
7 (1.8) 5 (2.3) 4 (1.7) 
Health and social care associate professionals 9 (2.4) 7 (3.2) 3 (1.2) 
Protective service occupations 3 (0.8) 1 (0.5) 2 (0.8) 
Culture, media, and sports occupations 0 (0.0) 0 (0.0) 0 (0.0) 
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Business and public service associate 
professionals 
14 (3.7) 6 (2.8) 9 (3.7) 
Skilled agricultural and related trades 8 (2.1) 4 (1.8) 5 (2.1) 
Skilled metal, electrical and electronic trades 12 (3.1) 4 (1.8) 10 (4.2) 
Skilled construction and building trades 7 (1.8) 3 (1.4) 6 (2.5) 
Textiles, printing, and other skilled trades 11 (2.9) 6 (2.8) 6 (2.5) 
Administrative occupations 45 (11.8) 26 (11.9) 28 (11.6) 
Secretarial and related occupations 14 (3.7) 6 (2.8) 11 (4.6) 
Caring personal service occupations 28 (7.3) 16 (7.3) 16 (6.6) 
Leisure, travel and related personal service 
occupations 
7 (1.8) 3 (1.4) 6 (2.5) 
Sales occupations 35 (9.1) 25 (11.5) 19 (7.9) 
Customer service occupations 7 (1.8) 3 (1.4) 5 (2.1) 
Process, plant and machine operatives 13 (3.3) 9 (4.1) 6 (2.5) 
Transport and mobile machine drivers and 
operatives 
22 (5.7) 14 (6.4) 16 (6.6) 
Elementary trade and related occupations 5 (1.3) 2 (0.9) 5 (2.1) 
Elementary administration and service 
occupations 
36 (9.4) 21 (9.6) 20 (8.3) 
Appendix to Chapter 9  
Appendix Table 78: Examining the preliminary main effects model for statistical interactions, including participants with any MSD.  
  Effect estimates in the 
preliminary main 
effects model 






Any MSD 1.86 (1.35 to 2.56) 1.87 (1.33 to 2.64) 2.03 (-2.25 to 6.31) 0.97 (0.41 to 2.29) 




Primary level MHP 3.49 (2.26 to 5.40) 3.54 (1.98 to 6.31) 
Hypertension Any MSD 1.86 (1.35 to 2.56) 1.72 (1.24 to 2.40) 1.54 (-0.40 to 3.49) 2.02 (0.89 to 4.62) 
hypertension 1.58 (1.07 to 2.32) 1.30 (0.83 to 2.02) 
Heart failure Any MSD 1.86 (1.35 to 2.56) 1.85 (1.34 to 2.56) 5.29 (-9.15 to 19.72) 1.25 (0.27 to 5.72) 
Heart failure 5.02 (2.14 to 11.77) 4.67 (1.77 to 12.35) 
Asthma Any MSD 1.86 (1.35 to 2.56) 1.75 (1.25 to 2.44) 4.02 (-2.21 to 10.26) 2.24 (0.68 to 7.35) 
Asthma   2.18 (1.24 to 3.82) 1.64 (0.82 to 3.29) 
CVA Any MSD 1.86 (1.35 to 2.56) 1.87 (1.36 to 2.58) 0.16 (-13.26 to 13.57) 0.66 (0.05 to 9.32) 
CVA 3.88 (1.17 to 12.94) 4.33 (1.05 to 17.78) 
Epilepsy Any MSD 1.86 (1.35 to 2.56) 1.84 (1.34 to 2.54) NE NE 
Epilepsy 5.74 (1.02 to 32.45) 4.25 (0.66 to 27.39) 
Diabetes Any MSD 1.86 (1.35 to 2.56) 1.99 (1.43 to 2.78) -1.40 (-4.34 to 1.55) 0.43 (0.14 to 1.33) 
Diabetes 1.93 (1.06 to 3.52) 2.84 (1.27 to 6.39) 
 
Appendix Table 79: Examining the preliminary main effects model for statistical interactions, including participants with chronic MSDs.  
  Effect estimates in the 
preliminary main 
effects model 








Chronic MSD 1.69 (1.19 to 2.41) 1.93 (1.31 to 2.84) -1.87 (-5.31 to 1.57) 0.41 (0.16 to 1.05) 
Primary care MHP 3.58 (2.32 to 5.54) 4.50 (2.70 to 7.51) 
Hypertension Chronic MSD 1.69 (1.19 to 2.41) 1.47 (0.98 to 2.19) 2.09 (-0.67 to 4.84) 1.94 (0.81 to 4.68) 
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Hypertension 1.66 (1.13 to 2.42) 1.38 (0.88 to 2.16) 
Heart failure Chronic MSD 1.69 (1.19 to 2.41) 1.73 (1.20 to 2.49) -1.05 (-9.78 to 7.68) 0.54 (0.09 to 3.41) 
Heart failure 4.50 (1.94 to 10.45) 5.08 (2.01 to 12.85) 
Asthma Chronic MSD 1.69 (1.19 to 2.41) 1.62 (1.12 to 2.35) 2.21 (-3.23 to 7.64) 1.71 (0.42 to 7.00) 
Asthma  1.80 (1.02 to 3.20) 1.60 (0.83 to 3.07) 
CVA Chronic MSD 1.69 (1.19 to 2.41) 1.72 (1.21 to 2.46) -4.84 (-13.45 to 3.77) 0.15 (0.01 to 2.86) 
CVA 4.12 (1.23 to 13.77) 5.60 (1.42 to 22.10) 
Diabetes Chronic MSD 1.69 (1.19 to 2.41) 1.95 (1.33 to 2.86) -2.53 (-5.13 to 0.07) 0.24 (0.07 to 0.82) 
Diabetes 2.01 (1.10 to 3.67) 3.01 (1.48 to 6.13) 
 
Appendix Table 80: Examining the preliminary main effects model for statistical interactions, including participants with recent musculoskeletal pain 
  Effect estimates in the 
preliminary main 
effects model 






Primary care level 
MHP 
MSD pain 2.14 (1.48 to 3.09) 1.93 (1.30 to 2.86) 7.13 (-2.04 to 16.30) 1.97 (0.74 to 5.24) 
Primary care 
MHP 
3.41 (2.24 to 5.20) 2.89 (1.79 to 4.66) 
Hypertension MSD pain 2.14 (1.48 to 3.09) 2.21 (1.45 to 3.37) 0.32 (-1.88 to 2.52) 0.88 (0.38 to 2.04) 
Hypertension 1.56 (1.07 to 2.28) 1.61 (1.04 to 2.49) 
Heart failure MSD pain 2.14 (1.48 to 3.09) 3.42 (2.24 to 5.22) 7.72 (-12.40 to 27.84) 1.68 (0.30 to 9.54) 
549 | P a g e  
 
Heart failure 3.82 (1.78 to 8.10) 3.49 (1.56 to 7.80) 
CVA MSD pain 2.14 (1.48 to 3.09) 2.12 (1.47 to 3.06) NE NE 
CVA 3.93 (1.13 to 13.63) 2.95 (0.79 to 11.00) 
Epilepsy MSD pain 2.14 (1.48 to 3.09) 2.14 (1.48 to 3.09) NE NE 
Epilepsy 5.92 (1.06 to 33.17) 5.73 (1.00 to 32.66) 
Diabetes MSD pain 2.14 (1.48 to 3.09) 2.22 (1.52 to 3.25) -0.63 (-4.29 to 3.03) 0.56 (0.15 to 2.14) 
Diabetes 2.04 (1.14 to 3.63) 2.32 (1.20 to 4.50) 
 
